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Abstract 
Cellular changes occur during osteoarthritis (OA), which lead to an alteration in phenotype 
of the resident cartilage cell, the chondrocyte, and subsequent destruction of the tissue. 
Many of these changes are unknown. I hypothesise these changes may be due in part to 
microRNAs (miRNAs), small non-coding RNAs that regulate the expression of a discrete 
repertoire of genes through base-specific interactions within the target genes 
3’untranslated region. A previous screen in our laboratory has identified a number of 
miRNAs differentially expressed in OA cartilage.  
The objectives of this study were; (1) to investigate the genetic association of the most 
extensively studied cartilage miRNA (miR-140), and its targets, with OA, and (2) to assess 
the function of other, differentially expressed, and less well studied miRNAs, in 
development signalling pathways, namely miR-125b and miR-324-5p, but focusing on miR-
324-5p.  
Here I identified; (1) SNPs within the miR-140 locus and a predicted, OA-associated, miR-
140 target, that may affect function; and (2) miR-125b and miR-324-5p as regulators of 
Hedgehog (Hh) signalling, likely to play a role in skeletal development. miR-324-5p 
regulates Hh signalling in human and mouse, yet the mechanism appears unconserved. In 
humans, miR-324-5p targets SMO and GLI1. Using Stable Isotope Labelling with Amino 
acids in Cell culture (SILAC) mass spectrometry and whole-genome microarrays, I 
identified novel miR-324-5p targets, and validated Glypican1 (Gpc1) as a direct target of 
miR-324-5p and a regulator of Hh signalling in mouse. In addition to regulation of Hh, miR-
324-5p regulates Wnt signalling, in which it forms a negative feedback loop. 
Together, this body of work demonstrates how miRNAs, their targets and their function 
can be linked in their expression and association with OA.   
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Chapter 1 Introduction 
1.1 Osteoarthritis 
Arthritis is a disease of the joint which involves reduced joint function and pain. 
Osteoarthritis (OA) is the most common form of arthritis, with the majority of over 65 year 
olds showing radiographic evidence of the disease [1]. OA can be divided into two main 
groups; primary OA, which has no known cause and mainly effects older people, and 
secondary OA, which has a known cause such as trauma or developmental defects, and 
tends to affect younger people than primary OA [2]. OA can affect joints such as the hip, 
knee, spine and hands, with each having slightly different disease characteristics, and as 
such can be considered as separate diseases. There are a number of risk factors for OA 
development such as age, obesity, mechanical injury and genetics [3]. 
OA involves joint space narrowing, subchondral bone thickening, subchondral cyst 
formation, osteophyte formation, cartilage calcification, vascular invasion and changes in 
ligaments, muscles, nerves, meniscus and synovium, but is epitomized by the loss of 
articular cartilage [1, 4]. OA is a major cause of pain and disability and can lead to social 
isolation, depression [5], and can even increase the risk of mortality [6]. The number of 
people with OA is set to rise due to obesity and the aging population, increasing the 
burden on society which currently requires 1-2.5% of gross national product [7]. 
There are no OA disease modifying drugs. Currently management for OA involves exercise, 
lifestyle changes, non steroidal anti-inflammatory drugs (NSAIDS) and analgesics. NSAIDS 
which selectively target cyclooxygenase 2 (COX2), an enzyme responsible for mediating 
inflammation and pain, have been used in the treatment of OA and were effective in 
reducing pain and inflammation, but do not target the cause or progression of the disease 
[8]. In 2004, one of these drugs was withdrawn from use due to increased risk of heart 
attack and stroke [9]. In addition to NSAIDs, injections of corticosteroids, MMP inhibitors 
[10], IL-1β inhibitors [11] and glucosamine and chondroitin sulfate therapeutic agents [12] 
have been used treat OA but with mixed results [13]. More recently, autologous implants 
(where mesenchymal cells are extracted from bone marrow and differentiated in vitro are 
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implanted back into the patient) have been used to treat secondary OA, but again this 
approach has had mixed results [14]. As there are currently no OA disease modifying drugs 
it means joint replacement surgery and pain management are often the only option for 
patients suffering from OA [15]. 
1.2 The joint structure 
There are a number of tissues which make up the joint including articular cartilage, 
synovial fluid, tendon, ligament and subchondral bone. In the knee there is also fat pad, 
menisci and the patella. Surrounding the joint is the fibrous capsule and synovial 
membrane. All these tissues are essential for the pain free and frictionless articulation of 
joints. The tissues are all linked, with damage in one adversely affecting the others, all 
having the potential to contribute to the pain and joint destruction seen in OA. 
1.2.1 Articular cartilage 
Articular cartilage covers the ends of long bones, is load bearing, essential for smooth pain 
free joint movement [16], and maintained by a single cell type, the chondrocyte [17]. In 
healthy cartilage the matrix is constantly being turned over by the chondrocyte, in a 
balance of catabolic and anabolic activity. Articular cartilage is avascular, alymphatic and 
aneuronal, meaning the chondrocyte obtains its nutrients from the surrounding synovial 
fluid. The cartilage extracellular matrix (ECM) predominately consists of proteoglycan and 
collagen. Aggrecan is the most abundant proteoglycan in the cartilage, it consists of a 
protein core with three globular domains (G1, G2 and G3) and glycosaminoglycan (GAG) 
chains. G1 binds to hyaluronic acid (via link protein) and there are many GAG chains 
between G2 and G3, which consist of chondroitin sulphate and keratin sulphate [18]. The 
GAG on aggrecan is negatively charged which attracts water and is surrounded by a 
collagen network. The most abundant collagen in articular cartilage is type II collagen. The 
combination of the hydrostatic pressure created by aggrecan and structure of collagen 
means the cartilage is firm and resists compression. 
The articular cartilage can be divided into four zones; the superficial zone, which has the 
most organised and highest collagen content, providing a smooth surface for articulation 
[19]; the middle zone, which is less organised; the deep zone, which has a high 
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proteoglycan content; and the calcified zone, which is a layer of calcified cartilage that lies 
directly on the subchondral bone. 
1.2.2 Subchondral bone 
The subchondral bone can be split into two zones, the subchondral bone plate which lies 
directly beneath the calcified zone of articular cartilage, and the trabecular bone which is 
beneath the subchondral bone plate. Both are primarily composed of collagen type I and 
mineralised with inorganic crystals of hydroxyapatite. The two main types of cell within 
the bone are osteoblasts which form bone, and osteoclasts which resorb bone. 
1.2.3 Joint capsule, synovial membrane and synovial fluid 
Surrounding the joint is the joint capsule. The joint capsule is lined by the synovial 
membrane, which is responsible for fighting infection and secreting synovial fluid. The 
synovial fluid provides the chondrocyte with nutrients and also contains lubricin to reduce 
joint friction, and mesenchymal progenitor cells which are prepared to mediate joint 
repair. 
Other joint tissues include; the fat pad which acts as a cushion and is a source of 
adipokines and mesenchymal progenitor cells; the menisci, which are made from fibrous 
cartilage and maintain joint stability; ligaments, which are mainly composed of type I 
collagen and attach bone to bone to also stabilise the joint; and the tendons, which are 
also predominately composed of type I collagen and attach muscle to bone to allow for 
joint movement. 
1.3 Joint maintenance 
A number of factors can influence the activity of the chondrocyte including growth factors 
and mechanical loading, which can both potentiate each other in their activation of matrix 
degrading enzymes [20]. This means the response to these factors needs to be finely 
regulated in order maintain the anabolic and catabolic balance of the chondrocyte, and 
ultimately maintain healthy cartilage. 
Metalloproteinases (MPs) are a subtype of protease [21]. Matrix metalloproteinases 
(MMPs) and A Disintegrin And Metalloproteinase with Thrombospondin Motifs 4 and 5 
(ADAMTS-4 and 5) are both subtypes of MPs [21]. MPs are essential during skeletal 
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development and joint maintenance [16]. Different MPs can cleave different parts of the 
ECM, collagenases such as MMP1, 8 and 13 can cleave collagen while aggrecanases, such 
as ADAMTS-4 and 5 can degrade aggrecan. MMPs and ADAMTS are regulated by tissue 
inhibitors of metalloproteinases (TIMPs)[22].  
1.4 OA risk factors  
Age is the main risk factor for OA. From a biochemical point of view there is less aggrecan 
in old cartilage than young [4, 23], meaning the cartilage becomes softer and weaker, 
increasing susceptibility to injury. During aging there is also an accumulation of advanced 
glycation end products (AGEs) [4]. However not all old people get OA, indicating other 
factors must also play a role. 
Other risk factors for OA include obesity, gender, mechanical injury, abnormal joint 
loading, nutrition, and genetics. Mechanical injury and abnormal joint loading can both 
follow one another. Likewise muscle strength, leg length inequality, abnormal joint 
morphology and misalignment of the joint can all lead to abnormal joint loading and 
increased chance of mechanical injury. Abnormal joint loading such as static compression 
has been found to cause the degredation of cartilage, and is thought to contribute to OA 
[24]. 
Obesity is a risk factor for OA [25, 26], due in part to increased loading. However obesity 
can also increase the incidence of OA in non loading joints such as the hand [26], 
suggesting other factors in obese individuals must also play a role in increasing the 
incidence of OA. Indeed, adipokines such as leptin produced by adipose tissue, can up 
regulate and activate MMPs [27]. 
Interestingly, females tend to have an increased risk and severity of OA [28], possibly due 
to differences in levels of hormones [29], or due to differences in cartilage thickness, with 
females tending to have thinner cartilage than males [30]. In addition, the Chinese more 
resistant to hand OA [31] and hip OA [32], although Chinese woman are more susceptible 
to knee OA [33], suggesting ethnicity/genetics are important for OA pathogenesis. 
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Twin studies have identified genetics as contributing to the susceptibility of OA [34]. More 
specifically genes which contribute to OA susceptibility such as GDF5 were found during 
hypothesis-lead candidate gene studies [35]. Studies to find additional susceptibility genes 
for OA now use hypothesis-free approaches. Linkage studies compare the genomes of 
effected siblings and attempt to identify regions of DNA associated with OA, regions on 
chromosomes 2 [36], 4 [37], 6 [37], 11 [38], and 16 [37] have all been associated with OA. 
More recently genome wide association scans (GWAS), have attempted to identify 
additional signals associated with OA. Because many regions of DNA are in linkage 
disequilibrium, the number of SNPs needed to be genotyped to scan the whole genome is 
considerably less than the total number of SNPs in the genome. OA GWAS studies have 
been performed in by UK [39], Japanese [40] and Dutch [41] groups. The UK study 
identified 8 susceptibility signals either within or close to GLT8D1, GNL3, ASTN2, 
FILIP1/SENP6, KLHDC5/PTHLH, CHST11, TP63, FTO and SUPT3H/CDC5L [39]. 
Understanding why some people are more susceptible to OA than others will increase our 
understanding of the molecular mechanisms involved in OA. 
1.5 OA pathology 
OA is a disease that can affect multiple components of the joint. However, it is not 
completely clear which joint component the initiating factor occurs in. In reality, it is likely 
to be a combination of factors from different joint tissues with a large intra-individual 
variability. Nevertheless, as the disease progresses the number of tissues involved in the 
disease increases until the joint no longer functions. The structural changes within the 
joint lead to an altered biochemical environment which further contributes to the loss of 
articular cartilage. 
MMPs are essential during skeletal development and in joint maintenance, but their 
deregulation is recognised as a major contributor to OA. Mice lacking MMP13 are 
somewhat resistant to cartilage erosion [42] and mice lacking ADAMTS5 are also resistant 
to cartilage loss [43], indicating MMP13 and ADAMTS5 are involved in OA pathogenesis.  
MMP13 (and MMP1) have been found to be increased in OA, leading to the degradation 
of type II collagen in OA [16]. There is also an imbalance in the level of MMPs and TIMPs, 
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which leads to ECM destruction and release of matrix fragments. The matrix fragments 
have been suggested to cause an inflammatory response in the synovium, which then 
responds by secreting MMPs and cytokines, further contributing to a vicious cycle of the 
inflammation and ECM degradation. Chondrocytes respond to the increased levels of 
MMPs, cytokines and growth factors with a change to a more hypertrophic phenotype 
[44], a chondrocyte phenotype also seen during skeletal development (Section 1.6), 
suggesting an attempt to re-initiate developmental signalling pathways. Although the 
chondrocytes do lay down new matrix they are unable to replicate the ECM that was laid 
down during development. This altered ECM may further contribute to the disease. During 
OA the cartilage become rough, thins and eventually can be absent from some parts of 
the joint. There is also vascular invasion of the cartilage from the subchondral bone [45]. 
From a biochemical point of view, there is cleavage of type II collagen and loss of 
proteoglycan, initially at the surface, as the disease progresses the loss of proteoglycan 
continues and the organisation of the collagen becomes affected throughout the cartilage 
[45]. 
As for the chondrocytes themselves, in healthy cartilage they have low activity, in OA the 
chondrocytes become ‘activated’, causing proliferation, increased secretion of 
proinflammatory cytokines, increased secretion of catabolic factors, increased secretion of 
anabolic factors, changes in chondrocyte gene expression [46], and changes in metabolic 
activity leading to altered ECM remodelling, and eventual erosion and fibrillation of the 
cartilage. Interestingly, there is also increased chondrocyte cell death and senescence in 
OA [47]. Studies have shown developmental pathways such as Hh (Hedgehog) [48], 
wingless-type MMTV integration site family members (Wnt) [49] and TGFβ (transforming 
growth factor β) [50] are involved in OA and contribute to cartilage breakdown. At the 
same time, there is thickening of the subchondral plate, formation of boney out growths 
at the joint margin called osteophytes and formation of bone cysts due to the action of 
osteoclasts. 
Many of these changes are now quite well understood and are often said to be 
reminiscent of skeletal development [51]. However the mechanisms leading to this altered 
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gene expression is less well understood. In brief, the articular cartilage in OA is likely to 
become damaged, the chondrocyte then responds by re-instating developmental 
pathways in an attempt to repair the cartilage, the chondrocyte is unsuccessful and this 
may contribute further to the disease. 
1.6 Development 
Pathways such as Hedgehog (Hh) and wingless-type MMTV integration site family 
members (Wnt) signalling  play a role in development, and adult tissue homeostasis. 
Defects in Hh and Wnt signalling have been shown to cause developmental abnormalities, 
and are often altered in diseases such as OA. The reinitiation/alteration of these signalling 
pathways is likely to be a failed attempt of the chondrocyte to initiate repair mechanisms. 
During development varying amount of different types of morphogen elicit a wide range 
of cellular responses to produce the patterning of tissues. 
1.6.1 Digit formation 
The formation of each digit is dependent on an increasing concentration of Sonic 
Hedgehog (Shh), with the thumb being able to form independent of Shh and little finger 
being highly dependent on the presence of Shh [52]. The separation of the digits is also a 
tightly regulated process. It is thought bone morphogenic proteins (BMPs) induce 
apoptosis in the interdigit space, and Noggin prevents BMP induced apoptosis within the 
digits [53]. 
1.6.2 Endochondral ossification  
The development of longitudinal bones (endochondral ossification) involves a number of 
different cell populations, and tight regulation of signalling pathways. During 
endochondral ossification pluripotent mesenchymal cells differentiate into chondrocytes 
and lay down a cartilage model that extends from the growth plate which will eventually 
be degraded and turned into bone by osteoblasts. 
The process involves the signalling of many morphogens including TGF-β [54], BMPs, 
fibroblast growth factor (FGF), parathyroid hormone related peptide (PTHrP), WNTs [54] 
and Indian hedgehog (IHH), which lead to the activation of a number of transcription 
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factors such as Sox9 [55], Runx2 [56] and Gli1 [57]. Briefly MSCs proliferate, condense 
then undergo chondrogenic differentiation via up regulation of Sox9/5/6 activity [58] and 
make a cartilage model, they then undergo hypertrophy and terminally differentiate [59]. 
Vascularisation of the cartilage then occurs which brings in osteoclasts which lay down 
bone [59]. The chondrocytes at the ends of long bones are prevented from undergoing 
hypertrophy and completing this process, meaning cartilage remains [59]. These 
chondrocytes then function to maintain this functional cartilage layer, known as articular 
cartilage, which is essential for smooth pain free joint movement. 
IHH and PTHrP form a negative feedback loop to regulate chondrocyte hypertrophy. IHH is 
secreted by prehypertrophic chondrocytes to maintain chondrocyte proliferation and 
induce hypertrophic chondrocyte differentiation. IHH also induces the expression of PTHrP 
from the periarticular chondrocytes. PTHrP inhibits hypertrophic differentiation, to 
maintain the cartilage at the ends of long bones [60]. BMPs also have a role in 
endochondral ossification [61]. Cbfa1/Runx2 [62] and Osterix [63] are essential for 
osteoblast formation. 
1.6.3 Intramembranous ossification 
Unlike endochondral ossification, intramembranous ossification does not involve cartilage. 
Mesenchymal cells differentiate into osteoblasts which secrete bone matrix, blood vessels 
then infiltrate the bone and leads to the formation of bone marrow. 
1.7 Hedgehog signalling 
The Hh pathway was first discovered in Drosophila. It gained the name ‘hedgehog’ 
because when the Hh gene was mutated the fly developed spikes on the anterior half of 
its body [64]. Since then three Hh morphogens; Sonic (Shh), Desert (Dhh) and Indian (Ihh) 
Hedgehog have been discovered in mammals and have been shown to play roles in the 
proliferation and differentiation of cells. 
1.7.1 Hedgehog signal transduction 
The Hh signalling pathway is largely conserved throughout species and has important roles 
in embryonic and cartilage development [65, 66]. The pathway involves a cell organelle 
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called the primary cilia. In mammals the three homologous of the Hh signalling molecule; 
Shh, Dhh, and Ihh [67], are all thought to signal through the same pathway. The Hh 
pathway consists of the receptor Patched (Ptch1), signal transducer Smoothened (Smo) 
and the Gli transcription factors. Ptch1 is the transmembrane receptor for the Hh ligand 
and is required for signal transduction, Smo is a seven transmembrane signal transducer 
which signals through the Gli transcription factors. In mammals there are three Gli 
transcription factors (Gli1-3), interestingly active Gli1 leads to the expression of Hh target 
genes including Gli1 itself [67]. Shh, Ihh and Dhh all have the ability to bind to the 
membrane receptor Ptch1, causing a loss of the inhibition on the Hh signal transducer 
SMO, allowing accumulation of the active Hh transcription factor Gli1. 
Inactive state: In the absence of a stimulatory Hh ligand, Ptch1 is localised to the cilia and 
prevents Smo from activating the pathway by stopping it from entering the primary cilium 
[68]. These circumstances allow the phosphorylation and degradation of Gli proteins. Gli 
proteins are cleaved into small repressors, a process that also occurs in, and requires, the 
primary cilium [69]. Glycogen synthase kinase 3 (GSK3) and Protein kinase A (PKA) are 
both thought to play a role in the inhibition of Hh signalling [70](Figure 1.1). 
Active state: A Hh ligand is able to overcome the inhibition by GSK3 and PKA by binding to 
the membrane receptor Ptch1, upon interacting with the Hh ligand, Ptch1 moves away 
from the cell surface, diminishing this inhibition and allowing activation of the pathway 
activator Smo [71], which then relocalises to the membrane of the primary cilia [68]. Ptch1 
contains a sterol sensing domain and has been associated with vesicle trafficking. This 
allows Smo to be released from intracellular vesicles and enter the primary cilia (a process 
involving oxysterols)[68], the presence of Smo in the primary cilia prevents 
phosphorylation and degradation of Gli proteins, allowing the full length active form of 
Gli1 to remain and increase in concentration. The active form of Gli then moves to the 
nucleus where it initiates the transcription of Hh response genes, including Gli1 [67], Hhip 
and Ptch1, in feedback loops to further activate the pathway and also prevent the spread 
of the Hh signal [72]. As Gli1 is also a Hh response gene, it can be used as an indicator of 
active Hh signalling. 
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In addition to activation of Hh signal through ligand binding, it is also possible to activate 
Hh signalling using synthetic compounds that directly antagonize Smo, such as 
Purmorphamine (Pur), a purine derivative [73] and Smoothened agonist (SAG) [74]. 
1.7.2 Hedgehog in development and OA  
Of all cytokines involved in chondrogenesis and osteogenesis, Ihh plays a particularly 
interesting role [75]. Ihh is first expressed in the cartilaginous condensation [60] and is 
produced in the prehypertrophic and hypertrophic zones, which forms a gradient that 
opposes that of PTHrP, to regulate hypertrophy. PTHrP is secreted from resting 
chondrocytes and functions to inhibit chondrocyte differentiation, meaning proliferation 
decreases as the chondrocytes move away from the growth plate. Ihh increases 
chondrocyte hypertrophy via the Wnt and BMP pathways [76]. Ihh causes the 
proliferation of columnar chondrocytes and prevents the differentiation of proliferating 
chondrocytes [77]. Ihh also signals to preosteoblasts in the adjacent pericardium [75] to 
aid Runx2 and Osterix in osteoblast differentiation [78]. The role of Ihh continues 
postnatally to maintain growth plate and trabecular bone [79]. 
The role of Ihh in skeletal development was illustrated by in mice, Ihh-/- mice have 
abnormal bone growth and all skeletal structures are reduced in size [80], while Smo 
knockout in cartilage decreases chondrocyte proliferation [81]. In humans, defects in Hh 
can cause polydactyl [82]. Ihh protein is more abundant in OA cartilage compared to 
normal [83]. More recently, Lin et al. found surgical induction of OA in mice initiates Hh 
signalling, and the inhibition of Hh signalling causes a reduction in OA severity, in 
surgically-induced OA-mice [48]. More specifically, Hh signalling was suggested to 
contribute to OA severity through Runx2 regulation of ADAMTS5 [48]. 
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Figure 1.1 Simplified schematic of the Hh signalling pathway 
 
Figure 1.1 Simplified schematic of the Hh signalling pathway. (A) In the absence of Hh 
ligand, Ptch1 inhibits Smo by preventing it from entering the primary cilia (inhibitory 
arrow) meaning Smo cannot activate Gli1 (PKA/CKIα/GSK3β cause Gli1 degradation). (B) 
The binding of Hh to Ptch1 relieves its inhibitory effect on Smo, allowing Smo to enter the 
primary cilia and allowing the activation of the transcriptional activator Gli1 (and prevent 
Gli1 degradation by PKA/CKIα/GSK3β) and thus cause Hh target gene expression including 
that of Gli1 and Ptch1. 
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1.7.3 Primary cilia 
The primary cilium is an important cell organelle for Hh signalling and is found on almost 
all growth arrested cells. Its importance in Hh signalling was first noticed in 2003, where a 
mouse mutant in Wimple (IFT172, required for primary cilia formation) was found to have 
defective Hh signalling [84]. Since then many of the Hh signalling components such as Gli 
[69], Smo [85] and Ptch1 [68] have been found to localise to the primary cilium. 
The structure of the primary cilium relates to its function. The primary cilium extends into 
the extracellular space, allowing for the detection of environmental stimuli. They have a 
high surface area to volume ratio, allowing for a high number of membrane receptors to 
be expressed. At the base of the cilium lies the basal body. It is centriole derived, and 
organises the cilium microtubules [86]. The entry of proteins from the cell body to the 
primary cilium is tightly regulated, by a region at its base, called the transition zone, 
allowing for compartmentalization of signalling molecules [87]. The Hh signalling pathway 
utilises this compartmentalization. Primary cilia bending causes an increase in intracellular 
Ca2+, an example of this is where urine passes over the cilia in the kidney cells [88], this 
effect is abolished by removal of the primary cilia [89]. The primary cilium has also been 
shown to play a role in sensing mechanical stimuli in the cartilage ECM surrounding the 
chondrocyte [90]. 
The primary cilium is constructed at the tip, away from the site of protein synthesis within 
the cell, they therefore need, and utilise, a process known as intra flagella transport (IFT) 
[91], to transport proteins from the basal body to the site of construction. As well as 
functioning in construction, IFT also regulates the signalling events that go on within the 
primary cilium. The IFT can move proteins at speeds of up to 1µm per second, meaning 
the primary cilium is efficient in cell signalling [92]. A study by McGlasham et al. in 2008 
showed the length and number of primary cilia in cartilage are increased during OA [93], 
possibly due to IL1 [94]. This may lead to the altered Hh signalling and sensitivity to 
mechanical stimuli seen in OA. 
There are a number of proteins associated with, and involved in primary cilia and 
cilliogenesis, such as BBS and IFT proteins. In humans, defects in BBS proteins have been 
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associated with obesity, loss of the sense of smell, mental retardation/learning disorders, 
diabetes, male infertility, kidney failure and sight loss. Mutations in IFT proteins have been 
associated with abnormal developmental phenotypes in mice, many of which are possibly 
related to altered Hh signalling pathway activity [69, 84, 95]. 
1.8 Wnt signalling 
The Wnt family of ligands consists of 19 ligands, traditionally said to be either canonical or 
non canonical. Similar to Hh, the Wnt pathway also plays a role in bone development [96]. 
Wnt is actually regulated by Ihh during osteoblast formation [97]. In addition, Ihh is also 
regulated by canonical Wnt signallng [98]. The order of Hh and Wnt activation can 
determine the differentiation of osteoblasts and the differentiation of chondrocytes [99]. 
1.8.1 Wnt signal transduction 
Canonical: In the absence of Wnt ligand, Axin, Gsk3, APC and CKI aid to degrade β-catenin 
[100]. In the presence of Wnt, Wnt binds a Frizzled receptor which leads to the 
recruitment of the LRP5/6 (low density lipoprotein) co-receptor, this then prevents 
Axin/Gsk3 phosphorylation of β-catenin leading to its stabilisation. β-catenin then 
accumulates in the nucleus and interacts with lymphoid-binding factor (LEF) and T-cell 
factors (TCF) to cause the expression of a number of Wnt target genes, including Runx2 
[100] (Figure 1.2). 
Non canonical: In addition to canonical Wnt signalling there are also a non-canonical Wnt 
signalling pathways such as the Wnt/calcium pathway and the planar cell polarity pathway 
(PCP) [101]. Unlike canonical Wnt signalling, these pathways do not require LRP and 
instead require ROR. The calcium signalling of the non canonical Wnt signalling can inhibit 
the canonical Wnt pathway [102]. 
1.8.2 Wnt in development and OA 
The importance of canonical Wnt signalling in human development is shown by a naturally 
occurring loss of functional LRP5 causing decreased bone mass [103], the opposite is also 
true in that gain of function leads to increased bone mass [104]. Similar phenotypes are 
also observed in mice with abnormal Lrp5 [105]. Non canonical Wnt signalling requires 
ROR, therefore mutations in Ror2 in mice is likely to be indicative of loss of non canonical 
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Wnt signalling. Human mutations in ROR2 cause skeletal abnormalities such as 
brachadactyl type B, Robinow syndrome, spinal defects and a dysmorphic face [106, 107], 
with similar phenotypes observed in mice [108, 109]. A number of other Wnt signalling 
components have been shown to cause defects in bone development [96]. These studies 
show both the canonical and non-canonical Wnt signalling play a role in skeletogenesis. 
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Figure 1.2 Simplified schematic of canonical Wnt signalling 
 
Figure 1.2 Canonical Wnt signalling. (A) In the absence of Wnt ligand 
APC/Axin/CKIα/GSK3β mediate the phosphorylation and degradation of β-catenin. (B) In 
the presence of Wnt ligand, Wnt ligand binds to Frizzled (FZD), and with the recruitment 
of LRP5/6, DVL prevents APC/Axin/CKIα/GSK3β from phosphorylating β-catenin meaning it 
is stabilised and translocates to the nucleus causing the activation of Wnt target genes. 
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1.9 microRNAs 
I hypothesise miRNAs have a role in endrochondral osscification, chondrogenesis and OA, 
via regulation of the signalling pathways described. miRNAs are small (approximately 
22nt), single stranded, non-coding RNAs that modulate gene expression through base 
specific interactions within the target genes 3’untranslated region (UTR) to block 
translation [110]. The first miRNA was described in 1993 by Lee et al. [111] and since then, 
hundreds have been identified (www.mirbase.org). Each miRNA has the ability to regulate 
the expression of a large number of genes, and each gene is postulated to be regulated by 
many miRNAs [110]. 
miRNAs were originally mooted as providing ‘fine tuning’ to the control of gene 
expression. Recently, particularly through the generation of knockout and transgenic mice 
for specific miRNAs, it has become clear that they can be major regulators in development 
and play a significant role in various pathologies and defining cell phenotype. 
All known miRNAs are registered on miRBase (www.mirbase.org) [112]. miRBase is 
managed by The University of Manchester and contains information on miRNA stem loop 
sequence, deep sequencing data, genomic location, miRNA families, the mature sequence 
of both miRNAs encoded from the stem loop, any relevant references for each miRNA and 
links to other internet sites such as to the target prediction site PicTar (http://pictar.mdc-
berlin.de/). 
1.9.1 miRNA processing and mechanisms of action 
miRNAs are either transcribed from within genes, usually intronic, or from outside of 
genes (intergenic) where they have their own promoter. Several miRNAs can be encoded 
from the same RNA transcript and are called polycistronic miRNAs. Initial miRNA 
transcripts (pri-miRNAs) are transcribed in a 5’ to 3’ direction by the RNA polymerase II 
transcription factor and vary in size but always contain a stem-loop. 
Pri-miRNAs are then cleaved by the nuclear ribonuclease Drosha (which is a dsRNA-
specific RNase-III-type endonucluease and is associated with the RNA binding protein; 
DiGeorge syndrome critical region gene 8; DGCR8) in the nucleus [113], leaving only the 
stem loop and a one or two nt overhang. This molecule is called a pre-miRNA which is 
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around 80 nucleotides in length. Following processing to short stem-loop structures, the 
pre-miRNA is exported from the nucleus usually by Exportin 5 [114]. The cytoplasmic 
dsRNA-specific RNase-III-type endonucluease Dicer removes the stem-loop forming a 
miRNA duplex of about 21nt in length consisting of two arms of the loop (often named -5p 
and -3p respectively). After Dicer cleavage a two nt 3’ overhang remains (essential for the 
duplex to be incorporated into RISC). In a concerted process Dicer assigns miRNAs to one 
of a family of four Argonaute proteins [115]. 
Argonautes tightly bind to single stranded miRNAs in the core of the RISC complex, 
meaning only one of the miRNA strands is incorporated. The other strand is generally 
degraded, a choice based upon the intrinsic thermodynamic properties of the strands 
[116] and pri-miRNA sequence [117]. There are 4 different Ago proteins in humans, the 
reason for having more than one Ago protein is currently unclear, although each Ago 
protein may be sequence specific. Ago 1-4 can all be used for miRNAs [118]. Ago 2 also 
required for siRNA-triggered mRNA degradation [118]. 
The RISC complex then uses the miRNA as a guide to complementary base pair with the 
miRNA targets. The RISC-miRNA complex usually base pairs via the seed region 
(nucleotides 2-7) of the miRNA to target sites usually on the 3’UTR of target genes [119]. 
Both -5p and -3p miRNAs of the stem loop have to potential to be incorporated into the 
RISC complex and target their own discrete repertoire of genes. The miRNA:RISC:Target 
interaction then leads to the reduced translation and mRNA degradation of the target. 
[116, 120-122]. miRNAs themselves can be differentially expressed and can play a major 
role in defining cell phenotype and disease severity [110]. 
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Figure 1.3 miRNA processing pathway 
 
Figure 1.3 A schematic showing the main pathways involved in miRNA formation and 
function. miRNAs are transcribed by RNA polymerase II transcription into Pri-miRNAs, 
which are then cleaved by Drosha [113], leaving only the stem loop, called a pre-miRNA, 
which are exported from the nucleus usually by Exportin 5. Dicer then removes the stem-
loop forming a miRNA duplex. One of the miRNA strands is incorporated into RISC. The 
other strand is generally degraded. The RISC complex then uses the miRNA as a guide to 
complementary base pair with the miRNA targets. The RISC-miRNA complex usually base 
pairs via the seed region (nucleotides 2-7) of the miRNA to target sites usually on the 
3’UTR of target genes [119]. Both -5p and -3p miRNAs of the stem loop have to potential 
to be incorporated into the RISC complex and target their own discrete repertoire of 
genes and pathways. 
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1.9.2 miRNA regulation 
As well as regulating the expression of various genes, miRNAs themselves are subject to 
various regulatory mechanisms, similar to normal protein coding genes, miRNA expression 
can be controlled by their (or their host genes) promoter. In addition, miRNAs participate 
in a large regulatory network where they are both regulators and regulated by other 
mRNAs and even miRNAs [123]. It has been suggested many miRNA targets are actually 
‘pseudo targets’ whose function is to bind the miRNA and prevent its action on other ‘real’ 
miRNA targets [124]. Other types of RNA including coding mRNAs, pseudogenes and long 
non-coding RNAs can also act as competing endogenous RNAs (ceRNAs) to regulate the 
levels of miRNA available, causing altered expression of ‘real’ targets [125]. 
1.9.3 miRNA target prediction 
miRNAs target many gene transcripts to negatively regulate them, potentially meaning 
each miRNA is involved in a number of cellular processes. Following the identification of 
miRNAs, work to identify miRNA targets began and it was quickly realised miRNA target 
prediction was complex. miRNAs do not need to be fully complementary to their target. In 
2003 Stark et al. realized the importance of the seed region (nucleotides 2-8) in Drosophila 
[126]. Most miRNAs need to be fully complementary to their targets within the seed 
region, although this is not always the case [127]. There are a number of online target 
prediction programs for miRNAs, each has a different prediction algorithm and therefore 
each predicts a different repertoire of targets. 
TargetScan 
Targetscan (www.targetscan.org) is an online miRNA prediction software and was the first 
program to exploit the seed in its algorithm to predict vertebrate miRNA targets [128]. 
Originally Targetscan searched for 7mer seed regions and then took into consideration the 
rest of the miRNA-mRNA interaction [128]. Targetscan now searches for 8mer and 7mer 
seed matches, taking into account flanking by Adenosine, species conservation, and 
context, it also allows mismatches within the seed as long as there is compensatory 3’ 
pairing. The most recent release (6.0) takes into account target site abundance and 
includes all 3’UTRs from RefSeq [119, 129, 130]. 
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PicTar 
PicTar (http://pictar.mdc-berlin.de/), searches for miRNA targets within conserved regions 
of 3’UTRs. It also takes into account the expression of the miRNA and the potential target. 
It then calculates the free energy of the potential miRNA-Target duplexes in each species 
and gives them a combined score for all species. miRNAs with multiple alignments are also 
favoured. PicTar tends to predict fewer targets but is more specific than other target 
prediction algorithms [131]. 
DIANA-microT 
DIANA-microT (http://diana.cslab.ece.ntua.gr/microT/), uses a 9 nucleotide shifting 
window that moves along the 3’UTR. At each position it calculates the free energy and 
considers the number of consecutive complementary bases. For potential miRNA:Target 
interactions it then also considers species conservation. It also gives a signal:noise ratio 
(chosen miRNA binding to 3’UTR:random miRNA sequence binding to 3’UTR) [132]. 
miRanda 
The miRanda algorithm searches for complementary miRNA binding sites in 3’UTRs. Each 
potential site is then scored based on binding energy, position within the 3’UTR and 
species conservation, the score is penalized by mismatches and gaps in binding [133]. 
miRGen (http://www.diana.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets) and MicroCosm 
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) both use the miRanda 
algorithm. 
miRDB 
miRDB (http://mirdb.org/miRDB/l) was created by using SVM (support vector learning 
machine) analysis of thousands of targets impacted by miRNAs. The features of these 
targets are then combined with already well known miRNA target features to create the 
algorithm (MirTarget2). 
With ongoing experiments to validate miRNA targets additional information can be fed 
into the algorithms to improve the accuracy in which they predicted targets, with the 
eventually goal being to create a perfect algorithm. It remains to be seen what will come 
first, a perfect algorithm or validation of every target of every miRNA. Due to the sheer 
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number of miRNAs, miRNAs targets and the complexity of their interactions both at this 
stage seem unlikely. There is however an increasing number of validated miRNA targets. 
miRTarBase (validated targets) 
miRTarBase (http://miRTarBase.mbc.nctu.edu.tw/) is a database of ‘validated’ miRNA 
targets [134]. It also provides information on the validation technique (microarray, 
luciferase assay, western blot, proteomics, or real-time RT-PCR) as not all ‘validated’ 
targets on the database are validated via luciferase. It relies on manual surveying of the 
literature meaning a number of validated miRNA targets are likely to be missed. 
1.10 miRNAs in development 
The overall importance of miRNAs in development was demonstrated by Berstein et al. in 
2003, where the global deletion of the miRNA processing enzyme Dicer led to embryonic 
lethality in mice [135]. This demonstrated miRNAs are essential for mouse survival, but 
does not indicate whether or not miRNAs are involved in skeletogenesis. In addition 
conditional knockout of Dicer in Prx1 (a gene expressed in the developing skeleton) 
expressing cells also caused skeletal defects [136]. Kobayashi et al. used a ‘collagen II-Cre 
floxed Dicer’ mouse to produce a cartilage restricted, Dicer null mouse. The mice were 
viable, but lack virtually all cartilage miRNAs and display severe developmental defects 
[137]. More specifically there is a decrease in chondrocyte proliferation and a faster onset 
of hypertrophy [137]. Knockout of Dicer in the skeleton shows miRNAs have a role in 
skeletogenesis, bur does no indicate which.  
The most extensively studied miRNA in cartilage is miR-140, originally identified as being 
cartilage specific in Danio rerio [138]. Tuddenham et al. later showed miR-140 was also 
cartilage specific in the developing mouse [139]. Following differentiation of mesenchymal 
cells to cartilage the expression of miR-140 is increased [140]. This is because miR-140 is 
under the control of cartilage specific transcription factor Sox9 [141]. Due to the restricted 
expression of miR-140 to cartilage, it was likely it played a role in development. Miyaki et 
al. demonstrated this by creating a miR-140 null mouse [142]. miR-140 mice have shorter 
long bones and craniofacial deformities [142]. The exact mechanisms by which miR-140 
mediates its effects on skeletal development are not yet fully understood. miR-140 is 
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however known to directly target HDAC4 [143], CXCL12 [144], SMAD3 [145], DNPEP [146], 
VEGF [147] and SP1 [141], many of which have been shown to play a role in cartilage and 
OA. Taken together this suggests miR-140 plays a major role in skeletal development. 
The phenotype of the miR-140 null mouse [142] is less severe than the Col2-Cre:Dicerfl/fl 
mouse [137] suggesting miR-140 is not the only miRNA involved in skeletal development. 
In addition to miR-140, other miRNAs have been shown to regulate the migration and 
differentiation of the chondrocyte as well as directly regulating the matrix components 
secreted by the chondrocyte. Both miR-488 [148] and miR-34a [149] have been shown to 
regulate chondrocyte/mesenchymal cell migration. Following migration and condensation 
the chondrocyte transcription factor SOX9 is upregulated leading to type II collagen and 
aggrecan expression. miR-145 directly targets SOX9 expression decreasing chondrocyte 
differentiation (decreased Col2a1 and aggrecan) and increase hypertrophic differentiation 
(increased MMP13) [150]. miR-365 is a mechanosensitive miRNA and can induce 
chondrocyte differentiation by targeting HDAC4 [151], similar to miR-140. A number of 
miRNAs have been shown to regulate secreted matrix constituents including miR-675 
which is regulated by miR-145 and targets Col2a1 expression [152], miR-29a and miR-29b 
also regulate Col2a1 [153] and miR-1 regulates aggrecan expression [154]. In addition to 
those already mentioned, miR-455 is a cartilage specific miRNA which is expressed from 
the Col27a1 gene, regulates TGFβ signalling and may play a role in digit formation [155].  
1.11 miRNAs in OA 
The evident role of miRNAs in skeletal development and the role of developmental 
pathways in OA suggest miRNAs are involved in OA pathogenesis. Profiling miRNAs in 
healthy and OA cartilage attempted to determine the relative importance of each miRNA 
in OA [156]. Iliopoutos et al. showed miR-140 expression was decreased in OA, further 
suggesting a role of miR-140 in healthy cartilage maintenance [156]. They also found 
altered expression of miR-22 which targets PPARα and BMP7 leading to altered MMP13 
and aggrecan expression. In another screen of miRNAS in OA, Jones et al. found altered 
expression of miR-9, miR-98 and miR-146a which are involved in the regulation of IL-1 
[157]. IL-1 is a cytokine know to have a role in OA, in addition to the miRNAs mentioned 
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above there are a number of other miRNAs regulated by or involved in the regulation of 
IL-1 such as miR-34a [158], miR-199a-3p and miR-27b, the latter directly regulates MMP13 
[159]. miR-146a, miR-155, miR-181a, miR-223 are all increased in blood of OA patients. 
Their function is unknown but they may serve an important role in the future as 
biomarkers, enabling for tailored therapies. 
1.12 miRNA regulation of developmental pathways 
Many of the miRNAs which regulate skeletal development or are involved in OA work 
through developmental signalling pathways. In addition to those known to have a role in 
OA and development there are likely to be a number of other miRNAs which have been 
shown to regulate these pathways and may have a yet to be discovered role in skeletal 
development and OA. 
There is limited direct evidence for miRNAs regulating or being regulated by Wnt signalling 
to control skeletal development or OA. There are however a number of miRNAs which 
regulate Wnt and, due to Wnt involvement in development and OA, it would be surprising 
if these miRNAs did not have a role in either skeletal development or OA. miR-29b, miR-
101 and miR-124 have all been shown to increase canonical Wnt signalling by reducing the 
expression of GSK3β [160]. 
The role of miRNA regulation of Hh signalling in development has also been 
demonstrated. In a study which knocked out all miRNA in the developing eye, there was 
altered Notch and Hh signalling [161] and is a study which knocked out all epidermal 
miRNAs there was loss of Shh [162]. Conditional knockout of Dicer in Shh expressing cells 
shows miRNAs play a role in preventing cell death in the Shh dependent digit formation in 
mice, although they do not appear to play a role in digit patterning in Shh expressing cells 
[136]. In a separate study, which also used conditional knockout of Dicer in Shh expressing 
cells, miRNAs were shown to play a role in lung development and patterning [163]. 
In addition to the studies that show miRNAs in general have a role in Hh regulation of 
development, a number of studies have shown specific miRNAs are important in the Hh 
regulation of development. Deletion of the miR-199a~214 cluster leads to skeletal 
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abnormalities in mice [164] which is likely to involve Hh, as miR-214 may form a feedback 
loop with Hh signalling. Twist1 a Hh regulator, induces the expression of both miR-199a 
and miR-214, and miR-214 has been found to target SuFu, another Hh regulator in Danio 
renio (zebrafish) [165]. miR-199a is a regulator of Smad/TGFβ signalling by targeting 
Smad1 [166]. Hh signalling can induce the expression of the miR-17~92 cluster which are a 
group of miRNAs involved in skeletal development and are also thought to act through 
TGFβ signalling [167]. 
A screen has shown a number of miRNAs have been found to be differentially expressed 
by altered Hh signalling in zebrafish [168]. miR-29 expression is repressed by Hh in human 
cholangiocarcinoma cells [169] and miR-206 is repressed by Shh in lung explants [170]. 
miR-25 is Hh responsive and regulates TNF signalling [171]. 
As well as being regulated by Hh, a number of miRNAs have been show to regulate 
multiple components of the Hh signalling pathway in Drosophila [172], Danio renio [165] 
and mammals.  In humans the miR-302~367 cluster can indirectly regulate Shh signalling 
through CXCR4 repression [173]. miR-196 is a regulator of Hoxb8 and Shh in limb 
development [174]. miR-365 is a mechanosensitive miRNA in cartilage which increases the 
expression of Ihh by targeting HDAC4 [151]. Ferretti et al. showed miR-326, miR-125b and 
miR-324-5p can modulate the Hh pathway in cancer cells [127]. More specifically miR-326, 
miR-125b and miR-324-5p were predicted to suppress the pathway activator SMO, and 
miR-324-5p was also predicted to target the downstream transcription factor Gli1 in 
humans [127]. 
1.13 miRNA therapeutics 
miRNAs are showing excellent potential as disease biomarkers to improve disease 
diagnosis. There is also research going on into an anti-miRNA therapy for the treatment of 
Hepatitis C virus (HCV). HCV RNA forms an interaction with miR-122, which is essential for 
virus reproduction [175]. The use of a locked nucleic acid (LNA) to inactivate miR-122 has 
proven useful in the treatment of HCV infected Chimps [176, 177] and is paving the way 
for future miRNA therapeutics. 
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1.14 Aims and hypothesis 
Research has begun to investigate the effect of specific miRNAs in cartilage, but further 
work is required. With ongoing research, the role of each miRNA in cartilage is becoming 
clearer. To summarise, both miRNAs and developmental signalling pathways are 
important in cartilage development and OA. This project will focus on how miRNAs may 
act upon these signalling pathways to attenuate cartilage development and OA. This 
research will improve our understanding of OA biology, and may lead to anti/pro-miRNA 
therapy for OA. I hypothesise miRNAs have a role in endrochondral 
osscification/chondrogenesis and OA, via regulation of the signalling pathways described. 
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Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Anti-Human/mouse Gli1 (V812) rabbit polyclonal was purchased from Cell Signalling 
Technologies, New England Biolabs (NEB), Hitchin, UK. Anti-Human/mouse Smo (ab72130) 
was purchased from Abcam, Cambridge, UK.Anti-human/mouse Gpc1 (16700-1-AP) rabbit 
polyclonal was purchased from Protein Tech Group (Manchester, UK). Mouse monoclonal 
anti-acetylated tubulin (T-6793) was purchased from Sigma-Aldrich (Poole, UK). GAPDH 
was purchased from Chemicon International (Thermo Fisher, Uk). Alexa Fluor® 488 goat 
anti-mouse IgG, Alexa Fluor® 594 goat anti-mouse IgG, Alexa Fluor® 594 goat anti-rabbit 
IgG Alexa and Alexa Fluor® 488 goat anti-rabbit IgG antibodies were purchased from Life 
technologies (Paisley, UK). 
2.1.2 Cell lines 
2.1.2.1 C3H10T1/2 
C3H10T1/2 cells are mouse pluripotent mesenchymal cells, and are capable of 
differentiation into fat, cartilage and bone under the appropriate stimuli. The C3H10T1/2 
cell line was isolated by Reznikoff et al. in 1972 from a line of C3H mouse embryo cells 
[178]. Full details of this cell line can be found at the American Type Culture Collection 
(ATCC) company website (www.atcc.org). Cells were a gift from Professor Ian Clark, 
University of East Anglia, Norwich, UK. The cell line was cultured in minimum essential 
medium (MEM) culture medium by the method outlined below. Stimulation of C3H10T1/2 
cells with Ihh can activate the Hh signalling cascade [67]. Ihh and Bmp2 induces 
osteoblastogenesis as measured by alkaline phosphatase activity [179], and seeding in 
micromass followed by Bmp2 stimulation can induce chondrogenic differentiation as 
measured by alcian blue [180]. 
2.1.2.2 SW1353 
The SW1353 cell line was initiated from a primary grade II chondrosarcoma in the right 
humerus of a 72 year old Caucasian female in 1977. Cells were purchased from ATCC. The 
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cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM) culture medium by 
the method outlined below. 
2.1.3 Cell culture reagents 
DMEM medium was obtained from Invitrogen (Life technologies). Foetal bovine serum 
(FBS), MEM medium, penicillin-streptomycin solution (10000 U/ml and 10 mg/ml 
respectively), L-glutamine solution (200 mM), trypsin-EDTA solution (0.5g porcine trypsin 
and 0.2g EDTA per L), non-essential amino acid solution, Dimethyl sulphoxide (DMSO), 
Ampicillin sodium salt was obtained from Sigma-Aldrich Ltd. Phosphate buffered saline 
(PBS) was purchased from Lonza (Wokingham, UK). Tryptone, yeast extract and bacto-agar 
were purchased from Difco Laboratories (Detroit, MI, USA).  
2.1.5 Transfection reagents 
For small RNA transfections, cells were transfected with DharmaFECT® transfection 
reagents, siGENOME®/SMARTpool® small interfering RNA (siRNA) were purchased from 
Dharmacon (Cramlington, UK). For plasmid transfections cells were transfected with 
Fugene HD transfection reagent was purchased from Promega (Southampton, UK). 
2.1.6 Cytokines, growth factors and other stimuli 
Recombinant human Ihh, Recombinant Wnt3a, Recombinant BMP-2 were purchased from 
R&D systems (Abingdon, UK). Pur and SAG were purchased from (Calbiochem). All 
cytokines and agonists were stored at –80oC in buffer recommended by the supplier. 
2.1.7 Immunoblotting reagents 
Bovine serum albumin (BSA) (desiccate), Bradford reagent, N,N’,N’-
Tetramethylethylenediamine (TEMED), polyoxyethylene sorbitan monolaurate (Tween-20) 
and Kodak high-speed X-ray film were purchased from Sigma-Aldrich (Poole, UK). 
Ammonium persulphate (APS) was purchased from BDH Chemicals (Poole, UK). A 37.5:1 
mix of acrylamide/bis-acrylamide was purchased from Amresco (Solon, OH, USA). 
Immobilon-P polyvinylidene difluoride (PVDF) 0.45 µM membrane was purchased from 
Millipore (Watford, UK). Enhanced chemiluminescence (ECL), ECL-plus and ECL-advanced 
Western blot detection reagents were purchased from Amersham Biosciences (Little 
Chalfont, UK). PageRuler™ pre-stained protein ladder, GeneRuler was purchased from 
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Fermentas Life Sciences (York, UK). Marvel non-fat dry milk powder was obtained from 
Premier Foods (St. Albans, UK). 
2.1.6 Molecular biology reagents 
TaqGold was purchased from Life technologies. GeneRuler™ 100kb and 1kb DNA ladders, 
EcoRI, BSR1 and HindIII were purchased from Fermentas Life Sciences (York, UK). 
Deoxyribonucleotide triphosphate (dNTP) was purchased from Bioline (London, UK). 
pMIR-Report vector was purchased from Ambion (Southampton, UK). TITANIUM™ Taq 
DNA Polymerase was purchased from TaKaRa Biomedicals (Wokingham, UK). Phire Hot 
Start II polymerase was purchased from Thermo Scientific. Agarose (electrophoresis 
grade) was obtained from Life Technologies. RNase- and DNase-free H2O obtained from 
Sigma-Aldrich (Poole, UK) Real-time RT-PCR primers and probes were purchased from 
Sigma-Aldrich (Poole, UK). Probes library probes were purchased from Roche (Roche 
Diagnostics, Burgess Hill, UK). Moloney Murine Leukaemia Virus (M-MLV) was purchased 
from Life Technologies. TaqMan® Universal PCR Master Mix (2X) was purchased from Life 
Technologies (Foster City, CA, USA). VECTASHIELD mounting medium with DAPI was 
purchased from Vector Labs. -mercaptoethanol, Triton X-100 and Gelatin from cold 
water fish skin were obtained from Sigma-Aldrich (Poole, UK). 
2.1.7 Commercially available kits 
The Cells-to-cDNA™ II Kit was purchased from Ambion (Ambion (Europe) Ltd., Huntingdon, 
UK). QIAquick® GelExtraction Kit and QIAquick DNA extraction kit were purchased from 
Qiagen (Crawley, UK). E.Z.N.A Tissue DNA extraction kit was purchased from Omega Bio-
Tek (Norcross, GA, USA). BigDye Terminator v3.1 sequencing kit was purchased from Life 
Technologies. 
All other standard laboratory chemicals and reagents, unless otherwise indicated, were 
commercially available from Sigma-Aldrich Ltd, Fisher Scientific or BDH Chemicals. 
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2.2 Methods 
2.2.1 SNP genotyping assays 
2.2.1.1 Agarose Gel Electrophoresis 
Agarose gels are prepared in the range of 1 – 2% (w/v) by dissolving the required amount 
of agarose in 1x Tris-acetate-ethylenediamine tetraacetic acid (TAE) containing 0.04 M Tris 
(pH 8), 5.7% (v/v) glacial acetic acid and 0.001M EDTA, through boiling. Ethidium bromide 
was added to cooled agarose at a final concentration of 0.2 µg/ml. Gels were poured, 
allowed to set and the required amount of DNA in loading buffer (0.125 M (pH 6.8), 2% 
(w/v) SDS, 10% (v/v) glycerol and 0.001% (w/v) bromophenol blue) loaded. Bands were 
separated at 100V for approximately 40 min in TAE and visualised on a ChemiGenius II 
BioImager (Syngene, Cambridge, UK). 
2.2.1.2 Restriction Fragment Length Polymorphism (RFLP) 
PCR was carried out on 50ng genomic DNA extracted from the blood of OA cases and 
controls. PCR was performed using TaqGold, a mix was prepared consisting of the 
following 50ng DNA, 7.5pM forward and reverse miR-140 RFLP primers (Table 2.1) 
(0.075µl of 100nM stock), 1.5µl 10XPCR buffer, 0.2mM dNTPs, 0.08 units Taq Gold, 2mM 
Mg++ (1.2µl) and H2O to total 15µl. Thermo cycling conditions were as follows 95
oC for 
5min followed by 30 cycles of 95oC for 15s and 65oC for 30s and a final step of 72oC for 
7min. 
PCR products were then digested using BsrI restriction enzyme. Digested PCR products 
were then separated by size through agarose Gel Electrophoresis stained with ethidium 
bromide and visualised using UV light (see above). 
2.2.1.3 Sequencing the miR-140 region 
Genomic DNA of OA cases and controls was sequenced. PCR of the miR-140 region was 
performed as described for RFLP using miR-140 sequencing primers, both forward and 
reverse primers contained M13 primer binding sites (miR-140seq F and miR-140 seq R-
Table 2.1). Following PCR, 10µl the reaction was cleaned up. 2.4U Shrimp Alkaline 
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Phosphatase (SAP) (2.4µl of 1U/µl), Exo1 and 1.4µl of 10x buffer were added. Mineral oil 
was then overlaid. Samples were then heated to 37oC for 15min and then 80oC for 15min. 
Sequencing was performed on cleaned up PCR products generated from genomic DNA. 
Sequencing reactions consisting of the following; 6µl cleaned up PCR product, 0.5µl Big 
dye premix v3.1, 2µl 5x Big dye buffer, 1.2µl H2O, 0.3µM primer were then subject to the 
following thermal conditions 25 cycles of 96oC for 10s, 50oC for 5s, 60oC for 4min then 
cooled to 4C. The reaction was then diluted with 10µl H2O, mixed and briefly centrifuged. 
20µl of diluted sequencing reaction was then transferred to fresh 3100 sequencing plate 
containing 60µl 100% ethanol and 0.1µl pellet paint, mixed and briefly centrifuged before 
being incubated at room temperature for 1hr. The solution was centrifuged (1600g for 
45min) and supernatant discarded. The plate was inverted and briefly centrifuged on 
tissue paper to remove residual supernatant. 70µl 70% (v/v) ethanol was added was 
added to the pellet, vortexed and centrifuged (1600g for 15min). The supernatant was 
discarded and the plate inverted and briefly centrifuged on tissue paper to remove 
residual supernatant. 10µl MiliQ ultrapure H2O was then added to each sample, mixed and 
briefly centrifuged. 10µl HiDi formamide (Invitrogen) was added t o each sample, mixed 
and briefly centrifuged. Samples were sequenced on the ABI 3100 Genetic Analyzer, and 
analysed using SeqScape software (Applied Biosystems, Warrington, UK). 
2.2.1.4 ABI SNP Genotyping Assay 
The applied biosystems SNP Genotyping Assay have a PCR primer pair and work in a 
similar way to the TaqMan assay, but have two allele-specific TaqMan® MGB (minor 
groove binding) probes containing distinct fluorescent dyes (VIC and FAM). Amplifications 
were preformed in 5µl final volumes in optical plates, following the manufactured 
instructions. Amplifications were preformed in a thermal cycler (Bio-Rad), the plate was 
then transferred to the Prism 7900HT sequence detection system (ABI) to read 
fluorescence and call SNPs. 
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2.2.2 3’Untranslated region and Gpc1 overexpression cloning 
Cloning was performed using the infusion cloning system (Clontech). 3’UTR luciferase 
constructs were cloned from 3’UTRs of potential targets and pMIR-Report vector (Ambion, 
UK), which contains the luciferase reporter gene. Cloning was performed using the 
infusion cloning system. Transcriptional activation of the promoter generates luciferase 
enzyme from the reporter and results in the production of light when substrate is added. 
The intensity of the light produced is proportional to the amount of enzyme produced and 
therefore any effect of miRNAs on the 3’UTRs will be observed. Mouse Gpc1 
overexpression construct was cloned into HaloTag® Fusion (N-Terminal) expression vector 
purchased from promega.  
2.2.2.1 Infusion primer design 
3’UTR sequences were obtained from NCBI. Primers were designed using the Primer3 
software with the addition of vector specific 15-16nt infusion adaptors to the 5’ end of 
both the forward and reverse primers, for example 5’-AAAGCTGCGCACTAGT-3’ and 5’- 
ATCCTTTATTAAGCTT-3’ for pMIR-Report. Primers for infusion are shown in Table 2.1. 
2.2.2.2 PCR Amplification and purification 
The PCR was carried out using 4µl 5x Phire buffer, 0.2mM dNTPs, 50ng gDNA, 0.4µl Phire 
DNA polymerase (Thermo Scientific), 500nM forward and reverse primers and H2O in a 
20μl reaction mix according to the manufacturer’s instructions. Each primer pair PCR 
reaction was performed in quadruplicate, with each sample having a different annealing 
temperature (55OC, ~56.5OC, ~58OC and 60OC). PCR cycling were: 95°C for 1 min, 35 cycles 
of 95°C for 30 sec, gradient of 55-65 for 30 sec and 68°C for 2 min and then 68°C for 5 min. 
PCR products were visualised by gel electrophoresis as described. PCR reactions with 
single product of the correct size for each primer pair were combined and purified using 
Nucleospin extract II kit according to the manufactures protocol. 
2.2.2.3 Preparation of plasmid 
The pMIR-Report vector was digested with 10U HindIII and 10U SpeI in 50μl, in a reaction 
containing 5µl plasmid, 5µl 10x buffer M, (Roche), H2O to 50μl. The reaction was 
incubated at 37oC overnight before the digestion was then heat killed. The digested 
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plasmid was then run on a 1%TAE agarose gel as described above to verify correct 
digestion, and to perform gel extraction of the plasmid. 
Digested plasmid was extracted from the gel and purified using the QIAquick Gel 
extraction Kit according to manufacturer’s instructions. Briefly the required band was 
excised with as little gel as possible. Gel was dissolved in Buffer QG and the plasmid 
extracted and purified using QIAquick spin columns prior to elution in 30μL dH2O.  
2.2.2.4 Infusion cloning reaction  
PCR products of 3’UTRs containing infusion (Clontech) sequence were cloned into pMIR-
Report vector using infusion cloning. 10µl infusion reactions containing the following were 
created; 2µl 5x infusion HD enzyme premix, 1.5µl linearised vector (50ng/µl), 1µl Purified 
PCR amplicon (stock concentrations ~50ng/µl) and 5.5µl water. Reaction was incubated at 
50oC for 15min before being placed on ice. 
2.2.2.5 Infusion transformation 
2.5µl of the infusion reaction was added to 50µl Stellar Competent cells in 10ml falcons. 
Reactions were incubated on ice for 30 minutes prior to transformation by heat-shock at 
42°C for 45 seconds followed by incubation on ice for 1-2min.  500µl of S.O.C. medium 
was then added to each vial and cultures were shaken (220 rpm) at 37°C for 1 hour.  A 50-
75µl aliquot of each transformation was spread onto a pre-warmed agar plate containing 
100 µg/ml ampicillin (10.3g LB (easy mix), 7.5g Agar (bacto) and 500µl water was 
autoclaved then cooled before 100ug/ml Ampicilin was added).  Plates were incubated at 
37°C for 16 hours in order for colonies to develop. The next day individual colonies were 
selected and incubated in 3-5ml of LB supplemented with ampicillin (100μg/ml) (10.3g LB 
(easy mix), and 500µl water was autoclaved then cooled before 100ug/ml Ampicilin was 
added) at 37°C and 220rpm overnight in an orbital shaker. Standard aseptic technique was 
used throughout the cloning procedure. 
2.2.2.6 Small scale preparation of plasmid DNA  
A 1.5 ml aliquot of a bacterial culture was transferred to an Eppendorf and centrifuged for 
1min at 13,000 x g. The supernatant was discarded and cells resuspended in 100µl Buffer 
P1 (Qiagen) by vortexing. 200µl Buffer P2 (sodium hydroxide to lyse cells) (Qiagen) was 
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added to cells and mixed thoroughly by inverting 6 times. A 150µl aliquot of Buffer P3 
(Qiagen) was then added and mixed immediately by inverting 6 times. Lysates were 
centrifuged at 13,000g for 3 min and the supernatant removed to a new Eppendorf 
containing 1 ml 100% ethanol. Samples were vortexed for 10-15 sec to mix thoroughly and 
centrifuged for 10 min at 13000 xg. All ethanol was removed and pellets allowed to air-dry 
(~15min) before resuspension in 50µl dH2O. 
2.2.2.7 Restriction digests to check insertion 
A 2µl aliquot of each miniprep plasmid DNA was restriction endonuclease digested using 
the restriction enzyme HindIII and SpeI.  Plasmid DNA was combined with 5U HindIII and 
SpeI, 1.5µl 10x buffer M and 11µl dH2O in a 15µl reaction and incubated at 37°C for 1h. 
10µl of each digest was then run out on a 1% agarose gel to determine if it contained an 
insert of the correct size. 
2.2.2.8 Sequencing to check insertion 
10µl miniprep and 100µl 3.2pmol/µl primer was sent to life sciences for sequencing 
(http://www.lifesciences.sourcebioscience.com/genomic-services.aspx). Plasmids 
containing full insert and no errors were selected to study. 
2.2.2.9 Sub cloning and large scale preparation of plasmid DNA 
To create transfection quality plasmid, small scale plasmid preparations were re-
transformed and large scale preparation performed. 1µl Plasmid (mini prep) was added to 
25µl chemically competent DH5α (Invitrogen, Paisley, UK) in an Eppendorf and incubated 
on ice for 30min, before being heat shocked at 42oC for 30sec and returned to ice for 
2min. 500µl LB was added and cells incubate at 37C for 45-60min, 75-150µl was spread on 
a pre-warmed agar plate containing 100 µg/ml ampicillin and incubated overnight. The 
next day several colonies were selected and incubated in 5ml of LB supplemented with 
ampicillin (100μg/ml) at 37°C and 220rpm for 5h in an orbital shaker. The 5ml of grown 
culture was then transferred to 250ml of LB supplemented with ampicillin (100μg/ml) and 
grown at 37°C overnight in an orbital shaker at 220rpm. Plasmids were then extracted 
using Qiagen Maxiprep Kit (Qiagen) according to the manufacturers protocol. 
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2.2.2.10 Site directed mutagenesis 
To validate miRNA binding to 3’UTRs miRNA binding sites in 3’UTR were mutated. 
Positions complementary to positions 2, 3, 4 and 5 of the miRNA seed were mutated to 
the complementary sequence to ensure miRNA binding is disrupted. Primers were 
designed so they are complementary to the 3’UTR for 15 bp either side of the region to be 
mutated (Table 2.1). 
Mutagenesis was performed using the QuikChange II kit (Agilent, Berkshire, UK), according 
to the manufactures protocol. Briefly, a reaction mix totalling 50µl and contained 5µl of 
10x reaction buffer 50ng dsDNA template 125ng forward and reverse mutant primers, 
0.01mM dNTP mix, 2.5U Pfu Ultra HF DNA polymerase and H2O. Mix was then subject to 
the following cycling conditions; 95C for 30s, followed by 18 cycles of 95C for 30s, 55C for 
1min and 68C for 1min per kb of plasmid. The reaction was then placed on ice for 2min. 
1µl of Dpn1 restriction endonuclease enzyme was then added to each reaction, pipetted 
up and down and pulsed then incubated at 37C for 1hour. 
Following mutagenesis reaction the new mutated plasmid was transformed into XL1 Super 
Competent cells according to the manufactures protocol. Briefly 1µl of each sample was 
added to 50µl XL1 Super Competent cells in 15ml falcons, gently swirled to mix and 
incubated on ice for 30 min. The cells were then heat shocked at 42C for 45 sec and placed 
on ice for 2min. 500µl of N2X broth (preheated to 42C) was added to the sample before 
being incubated for 1h at 37 at 37C in the shaking incubator (220rpm) and spread on to 
Ampicillin containing agar. Mutated plasmids were grown up and sequenced as previously 
described. 
2.2.3 General cell culture 
C3H10T1/2 were maintained in MEM culture medium containing 2mM L-glutamine, 1% 
non-essential amino acids, 10% FCS, 100U/ml penicillin, and 100μg/ml streptomycin. 
SW1353 were maintained in DMEM culture medium, containing 2mM L-glutamine, 1% 
non-essential amino acids, 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin. Cells 
were grown in vented T75cm2 flasks, at 37ºC in 5% (v/v) CO2/humidified air until 
approximately 90% confluent. Cells were detached with trypsin and split into the 
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appropriate culture vessel for experimentation (either 96 (for RNA), 24 (for alkaline 
phosphatase assay) or 12 (protein for western) well plates and 6cm dish (protein for mass 
spectrometry) or into further T75cm2 flasks for continuation of the line every 2-3 days. 
For long term storage in liquid nitrogen, cells were detached with trypsin, pelleted by 
centrifugation at 200 x g for 5 minutes and resuspended in cryo-freezing medium (90% 
FCS with 10% DMSO), before being frozen slowly (1°C/min) in a cell freezing container 
overnight at -80°C prior to transfer to liquid nitrogen store. 
2.2.4 Cell stimulation 
Prior to stimulation, cells were plated in appropriate culture vessel at such a density to 
either ensure 80-90% confluence after 24h growing time or ensure appropriate 
confluence for transfection after 24h and then grown for a further 24h (either with or 
without transfection) depending on experiment type. Serum containing media was then 
aspirated off, and cells were washed twice in PBS to remove traces of serum, and then left 
for 16-20 hours in serum-free culture medium. Cells were then stimulated with 
recombinant Indian Hedgehog (R&D systems), Purmorphamine (Calbiochem), 
Recombinant BMP-2 (R&D systems) or smoothened agonist SAG (Calbiochem) for the time 
and concentration indicated in each figure. 
2.2.5 siRNA and miRNA transfection 
Pre-designed standard siGENOME SMARTpool siRNAs against Gli1, Gpc1, SMO and Ptch 
and siGENOME® Non-Targeting Pool #2 (siControl2) were purchased from Dharmacon 
(Cramlington, UK). The use of a SMARTpool maximises the chance of successful 
interference by providing four highly functional duplexes that target different regions of 
the target gene, while potentially minimising off-target effects due to the reduced 
concentration of each siRNA in the pool. 
C3H10T1/2 cells were cultured as above, and seeded in a 96, 48 or 12 well plate (density 
of 10,000 cells/cm2) and grown for 24h to reach around 50% confluence. Using 
Dharmafect transfection reagent (Dharmacon) cells were transfected for 24h (unless 
stated otherwise) with miRNAs and/or siRNAs (all 100nM). Control cells were also treated 
with Dharmafect alone and or miRNA or siRNA non-targeting control, miCon2 and siCon2 
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respectively (Dharmacon). Transfection was performed according to the manufacturer’s 
instructions with the desired siRNA concentration. Briefly, two tubes were prepared (tube 
1 and tube 2). In preparation of tube 1 mi/siRNAs were diluted to 20µM in 1 x 
DharmaFECT buffer. The appropriate volume of mi/siRNA (0.5µl per well for 96 well plate 
to give 100nM final) was added to the appropriate volume of H2O and MEM/DMEM media 
(without additional reagents) to dilute the mi/siRNA 20-fold and to 10 x the final 
concentration required and ensuring half the volume of tube 1 was media. Tube 2 was 
prepared by diluting the appropriate amount of DharmaFECT transfection reagent with 
media alone to dilute the DharmaFECT transfection reagent 50-fold and to 10 x the final 
concentration required. Tube 1 and 2 were left for 5 minutes at room temperature.  The 
contents of each tube were then combined and left for 20 minutes to form mi/siRNA 
containing liposomes. Sufficient serum-containing medium was then added to the mix to 
complete the desired volume of transfection medium for the culture vessel.  The culture 
medium was removed from the vessel by aspiration, and the appropriate volume of 
transfection medium was added to each well. After the 24h incubated at 37oC in 5% (v/v) 
CO2, transfected cells were washed with PBS and used in appropriate experiments. 
Appropriate scaling of volumes was used to transect different sized culture vessels. 
2.2.6 3’UTR Luciferase-miRNA co-transfection 
To assess the effect miRNAs have on 3’UTRs, 3’UTR luciferase constructs and the 
appropriate miRNA were co transfected into either SW1353s or C3H10T1/2 cells (for 
human and mouse 3’UTR constructs respectively). Cells were plated out in 48 well plates, 
After 24h cells were transfected with 3’UTR luciferase constructs using FUGENE® HD 
transfection reagent. 
Briefly a mix totalling 15µl per well and consisting of 200ng plasmid, 0.9µl Fugene HD and 
8.7µl NIL media per well was created and left to incubate for 15min at room temperature. 
At the same time Dharmafect transfection for miRNAs was also prepared (all 50nM). 
Briefly, two tubes were prepared (tube 1 and tube 2). In preparation of tube 1 miRNAs 
were diluted to 20µM in 1 x DharmaFECT buffer (Dharmacon, Lafayette, CO, USA). 0.75µl 
(per 48 well) miRNA (to give 50nM final) was added to 14.25µl (per48well) H2O and 15µl 
(per 48 well) 10T1/2nil media. Tube 2 was prepared by diluting 0.6µl (per48well) 
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DharmaFECT transfection reagent with 29.4µl (per 48well) 10T1/2nil media to dilute the 
DharmaFECT transfection reagent. Tube 1 and 2 were left for 5 minutes at room 
temperature. The 30µl of each tube were then combined (60µl) and left for 20 minutes to 
form miRNA containing liposomes. The 60µl DharmaFECT-miRNA mix and 15µl Fugene 
HD-plasmid mix were then both added to a fresh tube containing 225µl serum containing 
media (total 300µl), then gently mixed. The original media was then removed and 
replaced with the 300µl ‘DharmaFECT-miRNA-Fugene HD-plasmid mix’ and incubated at 
37ºC in 5% (v/v) CO2 for 24 hours. 
2.2.7 Luciferase assay 
Upon completion of the experiment (24h post transfection) cells were washed in PBS 
before the addition of 75µl 1 x reporter lysis buffer (Promega, Southampton, UK).  Plates 
were frozen containing the lysis buffer at -20ºC until ready for use. Following equilibration 
to room temperature, lysates were briefly mixed by gentle agitation. Then 10μl of cell 
lysate was transferred to a cross-talk free, white walled 96-well plates (PerkinElmer, 
Wellesley, MA, USA)  was mixed with 50μl of the luciferase substrate firefly luciferin 
(Promega, Southampton, UK), reconstituted in luciferase assay buffer according to the 
manufacturer’s instructions and read immediately using the Berthold MicroLumatPlus 
LB96V (Bundoora, Australia). 
2.2.8 Alkaline phosphatase assay 
C3H10T1/2 cells were cultured as previously described, and plated at 36,000 cells per well 
in 24 well plates. After 24 h cells were transfected as described. After 48 h the cells were 
stimulated as shown in serum containing medium for 5 days. Medium was refreshed after 
3 days. After 5 days of stimulation the cells were assessed for alkaline phosphatase 
activity. Briefly, cells were washed with PBS, 50mM HEPES pH 8.3 and fixed with 4% (w/v) 
paraformaldehyde for 5-10 min. 500µl alkaline phosphatase substrate (p-
nitrophenylphosphate (Alkaline Phosphate Yellow Liquid Substrate for ELISA’), Sigma 
Aldrich) was added. In the presence of active alkaline phosphatase, p-nitrophenol is 
produced whose levels can then be measured. After 15 min (or when the yellow had 
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developed), 100µl was removed and placed in a 96 well plate and absorbance read at 
405nm, using a TECAN plate reader and Xflor 4 software. 
2.2.9 Micro mass/ alcian blue assay 
C3H10T1/2 cells were cultured and transfected as previously described and indicated in 
each figure. Cells were trypsinised, counted, centrifuged, washed and resuspend at a 
concentration of 10x106/ml and plated into drops of 10µl, each containing 100,000 cells. 
Drops of cells were left to adhere for 2 h before appropriate medium was added. Micro 
mass cultures were cultured for the time indicated in each figure. After cell culture Alcian 
Blue was used as a marker of chondrogensis and extracted using Guanidinium 
hydrochloride (GHCl) to quantify. Alcian blue solution was prepared by adding 1 g Alcian 
blue to 100ml 0.1M HCl. Solution was mixed extensively at 37oC for 3days. 
2.2.10 Western blotting 
2.2.10.1Whole protein extraction 
Cells were plated into the appropriate culture vessel and after the desired culture 
conditions, medium removed and cells rinsed with ice-cold PBS. Lysis buffer (50mM Tris-
HCl, pH 7.4, 10% glycerol (v/v), 1mM EDTA, 1mM EGTA, 1mM Na3VO4, 5mM NaF, 10mM β 
glycerol phosphate, 5mM Na4P2O7, 1% Triton X-100 (v/v), 1μM microcystin-LF and 1 
Complete protease inhibitor Mini Protease Inhibitor Cocktail Tablet from (Roche 
Diagnostics) in a final volume of 50 ml) was prepared by adding 1µl  2-mercaptoethanol 
per ml lysis buffer. The PBS was then removed and replaced with ice-cold Lysis buffer 
(75μl/well for 24-well plate, 75μl/well for 12-well plate, 100μl/well for 6-well plate and 
150μl/6cm dish). The cells were scraped into the lysis buffer then transferred to a fresh 
Eppendorf on ice.  Samples were incubated for 20 minutes on ice, followed by 
centrifugation at 13,000 x g at 4oC for 3 minutes. The supernatant was then removed and 
stored immediately at -80oC, prior to protein quantification. 
2.2.10.2 Protein Quantification 
To determine protein concentration Bradford reagent (BioRad) was used. A 2mg/ml stock 
BSA protein standard solution (Pierce & Warriner, Chester, UK) was diluted to 0.4mg/ml 
BSA in distilled H2O (dH2O), and a series of standards from 0-4mg/ml added to a flat-
39 
 
bottomed 96-well plate. Cell lysates and equal quantities of cell lysis buffer to act as 
blanks, were added to the 96-well plate. Bradford assay reagent was then added to all the 
wells according to the manufacturer’s instructions. The samples were then gently mixed, 
left to stand for 5 minutes and the absorbance was read at 595nm using a Tecan Sunrise 
microplate absorbance reader. Protein concentrations were calculated and where possible 
protein equalized, prior to SDS-PAGE analysis. 
2.2.10.3 SDS-PAGE 
Cell lysates were thawed on ice and Laemmli sample buffer (0.1 M Tris-HCl, pH 6.8, 0.35 M 
SDS, 20% (v/v) glycerol, 0.01% (w/v) bromophenol blue and 5% (v/v) β-mercaptoethanol) 
added at a 5:1 ratio. Lysates were heated to 100°C for 5 min, cooled on ice and Proteins 
were then separated upon size by SDS-PAGE electrophoresis on appropriate 7.5 or 10% 
SDS-polyacrylamide gels at 180V for approximately 1 hour with pre-stained ladder 
SMO671 (Thermo). 
2.2.10.4 Immunoblotting 
Proteins were then transferred to PVDF membrane by electroblotting for 1-1.5 hours at 
1mA/cm2 in transfer buffer (20 mM Tris-HCl, 0.6 M glycine and 20% (v/v) methanol). 
Membranes were covered in blocking buffer (TBS-T (150 mM NaCl, 10 mM Tris-HCl, pH 7.5 
and 0.1% (v/v) Tween-20), 5% non-fat dry milk powder (w/v)) for 1 hour at room 
temperature. Membranes were subsequently washed 3 times in TBS-T prior to incubation 
with primary antibody (diluted accordingly in to the manufacturer’s instructions (1/1000 
unless otherwise stated)) solution overnight at 4°C with gentle agitation. Following 
incubation, membranes were washed 3 times for 5 minutes in TBS-T and incubated with a 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room 
temperature and washed a further three times in TBS-T for 5 minutes each as before. 
Secondary antibodies were diluted 1/2000 in a solution of 5% (w/v) milk powder in TBS-T. 
The membranes were washed 3 x 5 min in TBS-T before visualisation on high-speed Kodak 
X-ray film (Sigma-Aldrich) using Amersham ECL, ELC plus or ECL advanced (GE Healthcare) 
according to manufacturer’s instructions. Membranes were stripped of antibody in 
stripping buffer (1.5% (w/v) glycine, 0.1% (w/v) SDS and 1% (v/v) Tween 20) overnight 
with gentle agitation at room temperature.  The membranes were washed 3 times for 5 
40 
 
minutes each in TBS-T, reblocked in blocking buffer for 1 hour at room temperature and 
incubated with the desired primary antibody overnight as described above. GAPDH 
(Chemico International) or β-tubulin antibodies were used as a loading control. 
2.2.11 Real-time RT-PCR quantification of miRNAs and protein coding RNAs 
2.2.11.1 RNA extraction using Cells to cDNA II 
The Ambion Cells-to-cDNA II lysis buffer (Huntingdon, UK) lyses cells and inactivates 
RNases in a single step yielding a cell lysate that is competent for reverse transcription. 
This extraction method was used for cell numbers <1 x 104 seeded in a 96-well plate. Cell 
lysis was performed according to the manufacturer’s instructions. Briefly, after the desired 
period of growth factor/cytokine stimulation, cell monolayers were washed with ice-cold 
PBS and lysed directly by addition of 30µl Cells-to-cDNA™ II Cell Lysis Buffer. The 30µl lysis 
buffer was then transferred to an ice-cold 96-well PCR plate, which was incubated at 75oC 
for 15 min to inactivate RNases. 
2.2.11.2 Reverse transcription for protein coding genes following Cells to cDNA II 
Expression of Gli1, Smo, Ptch, Gpc1 and 18s. mRNA was performed as previously 
described [181]. An 8µl aliquot of each RNA sample was transferred to a new 96-well PCR 
plate for reverse transcription. RNA samples were combined with 0.625 mM dNTP and 0 .2 
µg p(dN)6 and incubated at 70°C for 5 min. Samples were cooled on ice followed by the 
addition of a reaction mix consisting of 10 mM DTT, 100 U M-MLV, 4µl 5X First-Strand 
Buffer (Invitrogen) and 1.5µl dH2O added to each sample giving a final reaction volume of 
20µl. The plate was then incubated at 37ºC for 50 min, followed by 70oC for 15 min. 
Samples were diluted by addition of 30µl dH2O (Sigma-Aldrich, Poole, UK) for target gene 
quantification, a further 1:10 dilution in H2O for quantification of 18S housekeeping gene, 
and stored at -20oC for further use. 5µl aliquots were used in PCR reactions. 
2.2.11.3 Reverse transcription for miRNAs following Cells to cDNA II 
MiRNA Reverse Transcription (Applied Biosystems) was performed according to the 
manufactures instructions, but in 15µl reactions. Briefly, 5µl total RNA sample was mixed 
with 0.15µl dNTPs (100mM), 1µl multiscribe (50U/µl), 1.5µl 10x RT buffer, 0.188µl RNase 
inhibitor, 4.162µl Nuclease free water and 3µl 5x miRNA specific RT Primer. The reaction is 
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then subject to the following thermal conditions, 16oC for 30 min, 42oC for 30 min, 85oC 
for 5 min then cooled to 4oC.  5µl of the above reaction was diluted 1/6 with 25µl H2O and 
4µl of this added to 10µl reaction real time reaction (total dilution of RT product into real-
time reaction was 15 fold). 
2.2.11.4 real-time RT-PCR of protein coding genes 
Primers for real-time RT-PCR were designed with Universal Probe library (Roche 
Diagnostics, Burgess Hill, UK). All primers were designed to span an intron-exon boundary 
to prevent amplification of any contaminating gDNA. 
PCR reactions for Roche probe library assays were prepared by combining 4µl diluted 
cDNA with 5µl of TaqMan® Gene Expression Master Mix (Applied Biosystems), 30nM of 
each primer and 15nM probe in a final volume of 10µl.  Cycling conditions were: 50°C for 2 
min, 95°C for 10 min and 40 cycles of; 95°C for 15 sec, 60°C for 1 min.  
TaqMan gene expression assays are made of a ready mix of primers and probe required 
for real-time RT-PCR detection that is based on the TaqMan® Probe-based real-time RT-
PCR system described above. 
2.2.11.5 real-time RT-PCR of miRNAs 
Real-time RT-PCR was carried out using Applied Biosystems assays for miRNAs. Individual 
miRNA RTs are performed separately along with a standard RNA RT for 18S. 4µl cDNA of 
the diluted miRNA RT reaction was added to each 10µl miRNA real-time RT-PCR reaction. 
Each reaction consists of the following; 5µl TaqMan® Gene expression mix (TGE), 0.5µl 
H2O, 0.5µl Assay (primer and probe for the studied miRNA), 4µl cDNA (1 in 6 diluted RT 
product). The reaction was then subject to the following thermal conditions; 95C for 10 
min followed by 40 cycles of 95oC for 15s and 60oC for 60s and read using the ABI PRISM 
7900HT Sequence Detection System (Applied Biosystems). 
2.2.12 Immunofluorescent cell imaging 
Cells were seeded into chamber slides and subject to the appropriate experimental 
conditions. Afterwards cell monolayers were washed twice in PBS for 5 min and fixed in 
4% (w/v) cold preparation of paraformaldehyde in PBS for 10 min at room temperature. 
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Cells were permebilised and blocked with PBG-Saponin solution (0.2% (v/v) fish skin 
gelatine, 0.5% (w/v) BSA and 0.5% (v/v) Triton-X-100 in PBS) for 10 min or PBG- Triton 
solution for 45 min at room temperature. Cells were incubated with primary antibody at a 
final concentration of 1 μg/ml for 45mins. Cells were then incubated with a secondary 
antibody (either; Alexa Fluor® 488 goat anti-mouse IgG, Alexa Fluor® 594 goat anti-mouse 
IgG, Alexa Fluor® 594 goat anti-rabbit IgG Alexa and Alexa Fluor® 488 goat anti-rabbit IgG) 
diluted 1:1000 (v/v). Cells were washed twice in between the antibody incubations with 
PBG-Saponin or PBG-Triton. Slides were washed twice in PBS and mounted in Vectashield 
with DAPI (Vactorlabs). Cells were visualised using confocal and fluorescent microscopy. 
Images were analysed using ImageJ analysis software (Wayne Rasband, NIH, USA). 
Individual cells were selected and the average quantity of red (acetylated alpha tubulin) 
and/or green (Smo) present in the cells (per area) calculated. The length of primary cilia 
was also calculated Using ImageJ. 
2.2.13 SILAC and mass spectrometry 
C3H10T1/2 cells were cultured for more than five population doublings (7 days of culture), 
in DMEM containing either isotopically labelled 13C L-Lysine-2HCl and 13C 15N L-Arginine-
HCl (Heavy), or normal Lysine and Arginine (light). Both heavy and light media contained 
dialysed FBS (all SILAC media, amino acids and FBS from Thermo Scientific). After 7 days of 
culture, the isotopic incorporation of the heavy amino acids was assessed. More than 99% 
of the peptides assessed by mass spectrometry contained heavy Arginine and Lysine. Both 
Heavy and light cells were plated out in 6cm dishes, after 24h the cells were around 50% 
confluent. Cells were then transfected in 2.5ml of media with 100nM of either miCon2 
(non-targeting miRNA mimic) or miR-324-5p mimic in the light and heavy cells respectively 
using 5µl Dharmafect transfection reagent 1 (DF1) (Dharmacon). After 24h of transfection 
cells were serum starved for a further 24hr. For stimulated SILAC experiments, both the 
light (miCon2) and heavy (miR-324-5p) were stimulated with 2µg/µl recombinant Ihh. For 
the unstimulated SILAC experiment, neither the light (miCon2) nor the heavy (miR-324-5p) 
were stimulated, instead cells were left in serum free media for a further 48hr, for 
continuity of experiments. All cells were then lysed using 150µl of lysis buffer, as 
described for immunoblotting. The Heavy and Light lysates were then mixed at a ratio of 
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1:1. Protein was boiled and separated upon size by SDS-PAGE, as described for western 
blot. Nanopure H2O was used in all gels and buffers to minimize contamination of keratin. 
Gel preparation, protein digestion, mass spectrometry and initial processing of data was 
performed by NEPAF (Newcastle).  Briefly, gels were then cut into 12 segments. Each 
segment was then digested with trypsin and peptides separated by liquid chromatography 
tandem mass spectrometry, (LC-MS/MS and analysed by mass spectrometry, search engine 
identifications performed using MASCOT (Matrix Science Company). Data was analysed 
using MaxQuant software as described by Cox et al. in 2009 [182]. Subsequent data 
analysis was performed in Microsoft Excel 2007 and is described in Chapter 5.  
2.2.14 Statistical analysis 
For real-time RT-PCR the relative amount of target gene and housekeeping gene were 
calculated using delta ct (2^(gene of interest ct-housekeeper ct)) or (2^gene of interest ct/2^house keeper ct). 
Data were normalised against the basal levels of genes, then plotted as the fold induction 
of gene expression over control levels. Fishers 2-tail exact and Chi squared tests were used 
to test the significance of categorical data, and were also used to calculate the significance 
of target enrichment in the sliding window and expanding window analysis of ordered 
gene lists in Chapter 5. Non-parametric Mann Whitney U test was used test the 
signigicance of the miRNA screen in chapter 4. Student’s two tailed t-test was used to 
calculate significance of pair wise data. Statistical differences between sample groups 
across independent experiments were calculated using one way analysis of variance 
(ANOVA) followed by a Bonferroni post test to account for multiple comparisons. 
Statistical differences were shown as p<0.05=*, p<0.01=** and p<0.001=***. 
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Table 2.1Table of primers 
 
 
 
 
Species Primer Sequence
Human miR140_RFLP_F AGACCTCTCCCGGTGTGGGC
Human miR140_RFLP_F  TCAGAGTCCTTTTGGGCTTG
Human miR140_seq_F TGTAAAACGACGGCCAGTGTGTGGGCATGTCTTCCCGC
Human miR140_seq_R CAGGAAACAGCTATGACCGAGTCCTTTTGGGCTTGAGC
Mouse GPC1_CDS_F GAGCTCAACCGCGGATATCTAGAATGGAACTCCGGACCCGAGGCT
Mouse GPC1_CDS_R CTGGAATTGGGCCCAAATCTAGATTACCGCCACCTGGGCCTGGCT
Mouse Serpine2_3UTR_F AAAGCTGCGCACTAGTGACGCAAGTGTTTCTGGTC
Mouse Serpine2_3UTR_R ATCCTTTATTAAGCTTGCAAATACTCGAGAGGGTTGTT
Mouse Gpc1_3UTR_F AAAGCTGCGCACTAGTGTCCCCAAAAGCCATGTAT
Mouse Gpc1_3UTR_R ATCCTTTATTAAGCTTAAAGCGGTAAGCAGCCTTTT
Mouse Anxa4_3UTR_F AAAGCTGCGCACTAGTAACTTCATTTTTCTGCACTGCT
Mouse Anxa4_3UTR_R ATCCTTTATTAAGCTTCTGAGGAATGTTCAGCACGA
HaloTag pHTN F GGACCTGATCGGCAGCGAG
HaloTag pHTN R GGTGTGAAATACCGCACAG
pmirReprot M13F TGTAAAACGACGGCCAGT
Mouse APP_mut324_F TAAAAATCGATGGGGctacCTTCTTGTGAACGTGG
Mouse APP_mut324_R CCACGTTCACAAGAAGgtagCCCCATCGATTTTTA
Mouse GLI1_mut324_F CATGAGGTGCCCAGGctacGGAGGTTTGGGCTGGG
Mouse GLI1_mut324_R CCCAGCCCAAACCTCCgtagCCTGGGCACCTCATG
Mouse GPC1_324_mut_site_1 F AGGAAGCCTGCAAGGctacCCAGTATGTTGCTGTC
Mouse GPC1_324_mut_site_1 R GACAGCAACATACTGGgtagCCTTGCAGGCTTCCT
Mouse GPC1_324_mut_site_2 F TCACCTGGCCATGGGctacCTGGGTGGCTGGTGAA
Mouse GPC1_324_mut_site_2 R TTCACCAGCCACCCAGgtagCCCATGGCCAGGTGA
Mouse GPC1_324_mut_site_3 F TTCCAGGGCCTAGGGctacCTGAGTTGCTATATCC
Mouse GPC1_324_mut_site_3 R GGATATAGCAACTCAGgtagCCCTAGGCCCTGGAA
Mouse Ptch1_pr56_F GGAAGGGGCAAAGCTACAGT
Mouse Ptch1_pr56_R TCCACCGTAAAGGAGGCTTA
Mouse Gpc1_pr79_F ATTGCCGAAATGTGCTCAA
Mouse Gpc1_pr79_R GGCCCCAGAACTTGTCAGT
Mouse Gli1 Applied Biosystems assay
Mouse Smo Applied Biosystems assay
Mouse miR-324-5p Applied Biosystems assay
Mouse miR-125b Applied Biosystems assay
Mouse 18S Applied Biosystems assay
Infusion cloning primers 
Sequencing primers 
Mutagenesis primers
Real time primers
miR-140 genotyping primers 
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Chapter 3 Genetic association of miR-140 and its targets 
3.1 Introduction 
3.1.1 miR-140 
miR-140 is one of the most studied miRNAs associated with OA and cartilage. Its 
expression was first shown to be cartilage specific in zebrafish [138] and then in mouse by 
Tuddenham et al. [139]. Tuddenham et al. also found miR-140 targets histone deacetylase 
4 (Hdac4), which represses Runx2, a transcription factor that controls chondrocyte 
hypertrophy and osteoblast differentiation [139]. miR-140 is also increased following 
differentiation of mesenchymal cells to cartilage [140] and plays a role in both cartilage 
development and maintenance [142]. miR-140 has been shown to decrease cartilage 
destruction and increase cartilage growth and development. Mice lacking miR-140 (miR-
140-/-) gain an OA like phenotype [142]. Conversely, mice overexpressing miR-140 are 
resistant to antigen-induced arthritis [142]. This is proposed to be because translation of 
ADAMTS5, a protease that mediates pathological aggrecan cleavage in cartilage [183], is 
inhibited by miR-140 [142]. miR-140 has been shown to be decreased in OA [156], which 
may contribute to some of the altered gene expression (including increased ADAMTS5) 
observed in OA [156]. Although a study in our laboratory, actually shows miR-140 
expression to be increase in OA [155]. miR-140 also decreases IL-1 induced MMP13 
production [140, 184], the same MMP family member believed to be involved in cartilage 
type II collagen cleavage [42]. 
3.1.2 SNPs and miRNAs 
Single nucleotide polymorphisms (SNPs) can create, destroy, or modify miRNA:target 
interactions. SNPs can occur in the 3’UTR of miRNA targets, in miRNA seeds, in miRNA 
stem loops and in miRNA flanking regions. The first SNP found in a 3’UTR (target) which 
was hypothesised to alter a miRNA binding was thought to contribute to Tourette’s 
syndrome [185]. Another interesting example of where a SNP in a 3’UTR creates a miRNA 
binding site is in Texel sheep where a mutation causes miRNA regulation of myostatin 
(GDF8) in muscle, leading to muscle hypertrophy and meaty sheep [186]. SNPs in 3’UTRs 
can also disrupt miRNA binding sites, such as the miR-433 binding site in FGF2, which may 
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contribute to Parkinson’s disease [187] and the miR-433 binding site in HDAC6, which may 
cause a chondrodysplasia [188]. 
SNPs in the miRNA coding region can also alter the function of miRNAs. SNPs within the 
mature miRNA can change the repertoire of miRNA targets, especially if the SNP occurs in 
the miRNA seed [189]. Although SNPs in the stem loop do not directly change the mature 
miRNA sequence, they can change how the miRNA is processed, leading to altered miRNA-
5p to miRNA-3p expression ratio [190], meaning SNPs outside of the mature miRNA can 
alter the expression of targets. miRNAs are processed from larger pieces of RNA meaning 
it is likely SNPs in miRNA flanking regions can also alter miRNA function by either changing 
RNA structure, meaning the miRNAs are processed differently, or changing a transcription 
regulation site. Studies have shown SNPs in miRNAs, their targets and in particular seed 
regions, are rare [189], as they are under negative selection [191], although some are 
under positive selection [192]. 
3.1.3 Previous data on SNPs in miR-140 
SNP rs7205289 (A/C), which is in very close proximity to miR-140 is thought to influence 
the processing of miR-140 and is associated with cleft palate in the Chinese population 
[190]. rs7205289 is a ‘C’ to ‘A’ transition, ‘A’ being the minor allele, having a prevalence of 
11.6% in the control Chinese population, with cleft pallet being associated with an 
increase in this allele (OR=0.55, p=0.001) [190].  The SNP is located at the miR-140 Drosha 
cleavage site (Figure 3.1) and the A allele is predicted to alter the processing of the stem 
loop to the mature miRNA, decreasing miR-140-5p and increasing miR-140-3p [190]. miR-
140-5p has been shown to regulate Pdgf signalling, a pathway involved in cleft palate 
[193]. The function of miR-140-3p is less well understood. Interestingly, miR-140 is 
transcribed from within WWP2, a gene which is also required for palatogenesis [194]. As 
miR-140 is an important miRNA in OA and SNP rs7205289 may affect miR-140 processing, 
it is plausible SNP rs7205289 is associated with OA. In addition, the region of chromosome 
16 where miR-140 is located has been suggested to be a possible susceptibility loci for OA 
[195], and WWP2 is also involved in cartilage biology by interacting with the cartilage 
transcription factor Sox9 [194]. The aim of this Chapter was to determine if any SNPs 
which may alter miR-140 function are associated with OA. 
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Specific aims 
Aim 1: Determine if SNPs in 3’UTRs can alter targeting by miR-140. 
Aim 2: Determine if rs7205289 is associated with OA. 
Aim 3: Identify additional SNPs in and around miR-140. 
Aim 4: Determine if rs2102066 (identified in Aim 3) is associated with OA. 
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Figure 3.1 SNP locations in miR-140 
 
Figure 3.1 The stem loop structure of miR-140. RNA is transcribed from chromosome 16. 
Green lettering indicates miR-140 (miR-140-5p). Red lettering indicates the miR-140-3p 
strand. miRNA stem loop can be split into four sections, terminal loop, upper stem 
(contains mature miRNAs), lower stem and basal segments. Blue arrows indicate the 
Drosha cleavage site and green arrows indicate the Dicer cleavage site. Red square 
indicates SNP rs7205289 (A/C) and the purple square indicated the approximate position 
of rs2102066 (G/A). 
 
AA AG GG Total p-val AG + GG AA Total  p-val AG+AA GG Total  p-val G A Total p-val
n % n % n % n % n % n % n % n % n %
Male control 267 57.4 165 35.5 33 7.1 465 Ref. 198 42.6 267 57.4 465 Ref. 432 92.9 33 7.1 465 Ref. 231 24.8 699 75.2 930 Ref.
Male hip 144 51.8 103 37.1 31 11.2 278 0.109 134 48.2 144 51.8 278 0.136 247 88.8 31 11.2 278 0.057 165 29.7 391 70.3 556 0.041
Male knee 72 62.1 37 31.9 7 6.0 116 0.657 44 37.9 72 62.1 116 0.363 109 94.0 7 6.0 116 0.686 51 22.0 181 78.0 232 0.364
Male hip and knee 10 41.7 12 50.0 2 8.3 24 0.305 14 58.3 10 41.7 24 0.129 22 91.7 2 8.3 24 0.819 16 33.3 32 66.7 48 0.187
Total male hip and hip and knee 154 51.0 115 38.1 33 10.9 302 0.089 148 49.0 154 51.0 302 0.081 269 89.1 33 10.9 302 0.065 181 30.0 423 70.0 604 0.027
Total male knee and hip and knee 82 58.6 49 35.0 9 6.4 140 0.951 58 41.4 82 58.6 140 0.809 131 93.6 9 6.4 140 0.785 67 23.9 213 76.1 280 0.757
Total male OA 226 54.1 152 36.4 40 9.6 418 0.347 192 45.9 226 54.1 418 0.317 378 90.4 40 9.6 418 0.183 232 27.8 604 72.2 836 0.165
Female control 194 54.5 134 37.6 28 7.9 356 Ref. 162 45.5 194 54.5 356 Ref. 328 92.1 28 7.9 356 Ref. 190 26.7 522 73.3 712 Ref.
Female hip 239 52.0 192 41.7 29 6.3 460 0.409 221 48.0 239 52.0 460 0.471 431 93.7 29 6.3 460 0.386 250 27.2 670 72.8 920 0.825
Female knee 94 53.4 74 42.0 8 4.5 176 0.282 82 46.6 94 53.4 176 0.813 168 95.5 8 4.5 176 0.151 90 25.6 262 74.4 352 0.697
Female hip and knee 27 64.3 12 28.6 3 7.1 42 0.469 15 35.7 27 64.3 42 0.227 39 92.9 3 7.1 42 0.869 18 21.4 66 78.6 84 0.300
Total female hip and hip and knee 266 53.0 204 40.6 32 6.4 502 0.542 236 47.0 266 53.0 502 0.663 470 93.6 32 6.4 502 0.399 268 26.7 736 73.3 1004 0.997
Total female knee and hip and knee 121 55.5 86 39.4 11 5.0 218 0.928 97 44.5 121 55.5 218 0.875 207 95.0 11 5.0 218 0.629 108 24.8 328 75.2 436 0.612
Total female OA 360 53.1 278 41.0 40 5.9 678 0.927 318 46.9 360 53.1 678 0.438 638 94.1 40 5.9 678 0.075 358 26.4 998 73.6 1356 0.427
Total control 461 56.2 299 36.4 61 7.4 821 Ref. 360 43.8 461 56.2 821 Ref. 760 92.6 61 7.4 821 Ref. 421 25.6 1221 74.4 1642 Ref.
Total OA 586 53.5 430 39.2 80 7.3 1096 0.735 510 46.5 586 53.5 1096 0.722 1016 92.7 80 7.3 1096 0.290 590 26.9 1602 73.1 2192 0.580
Total just Hip 383 51.9 295 40.0 60 8.1 738 0.715 355 48.1 383 51.9 738 0.533 678 91.9 60 8.1 738 0.406 415 28.1 1061 71.9 1476 0.535
Total just knee 166 56.8 111 38.0 15 5.1 292 0.834 126 43.2 166 56.8 292 0.550 277 94.9 15 5.1 292 0.574 141 24.1 443 75.9 584 0.568
Total hip and knee 37 56.1 24 36.4 5 7.6 66 0.999 29 43.9 37 56.1 66 0.989 61 92.4 5 7.6 66 0.965 34 25.8 98 74.2 132 0.976
Total hip and hip and knee 420 52.2 319 39.7 65 8.1 804 0.286 384 47.8 420 52.2 804 0.114 739 91.9 65 8.1 804 0.622 449 27.9 1159 72.1 1608 0.142
Total knee and hip and knee 203 56.7 135 37.7 20 5.6 358 0.834 155 43.3 203 56.7 358 0.665 338 94.4 20 5.6 358 0.441 175 24.4 541 75.6 716 0.721
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Gender, N (%)
Total Male Female 
n (%) n (%) n (%)
Cases 1096 418 38 678 62
Controls 821 465 57 356 43
Total 1917 883 46 1034 54
Type,
Hip only 738 67 278 67 460 68
Knee only 292 27 116 28 176 26
Hip and Knee 66 6 24 6 42 6
Hip only + Hip and Knee 804 302 502
Knee only + Hip and Knee 358 140 218
Genotype Allele
AA AG GG A G
n % n % n % p-val n % n % p-val 
Total control 461 56.2 299 36.4 61 7.4 1221 74.36 421 25.64
Total Cases 586 53.5 430 39.2 80 7.3 0.735 1602 73.08 590 26.92 0.580
Hip only 383 51.9 295 40.0 60 8.1 0.715 1061 71.88 415 28.12 0.535
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Hip and Knee 37 56.1 24 36.4 5 7.6 0.999 98 74.24 34 25.76 0.976
Hip only + Hip and Knee 420 52.2 319 39.7 65 8.1 0.286 1159 72.08 449 27.92 0.142
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Figure 13. 
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3.2 Results 
3.2.1 rs35592567 within OA associated gene TP63, may affect targeting by 
miR-140                                                             
Firstly, I investigated SNPs in the targets and predicted targets of miR-140. To determine if 
there were any SNPs that disrupted validated miR-140 targets I used miRTARBASE (list of 
validated targets; http://mirtarbase.mbc.nctu.edu.tw/) [134] and miRNASNP (list of SNPs 
in predicted miRNA targets; www.bioguo.org/miRNASNP/ ) [189] databases. According to 
miRTARBASE there were 8 partially or fully validated targets for miR-140-5p and miR-140-
3p and according to miRNASNP there were 72 and 70 SNPs which led to the loss and gain 
of miR-140-5p targets and 120 and 160 SNPs which led to the loss and gain of miR-140-3p 
targets respectively. There were no SNPS which led to the loss of any of the 8 validated 
miR-140 targets, I therefore turned our attention to predicted miR-140-5p and miR-140-
3p targets that SNPs may alter miRNA binding. Interestingly one (TP63) of the 72 predicted 
miR-140-5p targets which were predicted to be disrupted by a SNP (rs35592567), has 
been associated with OA (rs12107036 was signal SNP in the study (arcOGEN) that found 
the association of TP63 with OA) [39]. The major C allele at rs35592567 has a frequency of 
around 80% and was predicted to allow miR-140-5p to target TP63, whereas the minor T 
allele was not predicted to allow miR-140-5p to target TP63 (Figure 3.2). 
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Figure 3.2 Schematic showing rs35592567 may disrupt miR-140-5p binding to TP63 3’UTR 
 
Figure 3.2 Schematic showing rs35592567 may disrupt miR-140-5p binding to TP63 3’UTR. 
miR-140-5p seed sequence is highlighted in red. rs35592567 minor allele is highlighted in 
red and underlined. 
human TP63 wt(A)  5’-AUAGUAAGCAUAGAAACCACUA -3’
|| :| :    :||||||||
miR-140-5p        3’-GAUGGUAUCCCAUUUUGGUGAC -5’
|| :| :    :|||||| |
human TP63 mt(T)  5’-AUAGUAAGCAUAGAAACCAUUA -3’
x
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3.2.2 rs7205289, which is at the miR-140 Drosha cleavage site is not detected 
in Northern Europeans 
Secondly, I wanted to investigate SNPs within the miR-140 locus. rs7205289 is a SNP found 
in the miR-140 stem loop in the Chinese population [190]. To determine if the minor ‘A’ 
allele at rs7205289 was present in Northern Europeans, PCR followed by restriction 
fragment length polymorphism (RFLP) with restriction enzyme BsrI, was used. PCR was 
used to amplify a 390bp amplicon which included the rs7205289 SNP. When there is a C 
allele (major allele) at rs7205289 there is no BsrI restriction site, when there is an A allele 
(minor allele) at rs7205289 there is a BsrI restriction site. Genomic DNA from 91 male 
Northern European hip OA suffers and 87 male Northern European controls, who took 
part in the arcOGEN study cohort [39], were tested. Of the 178 northern Europeans tested 
none had the minor ‘A’ allele (Figure 3.3B). To confirm this data and to identify additional 
SNPs in and around the genomic region encoding miR-140, the region was sequenced in 
the same 178 individuals. All individuals tested were GG at rs7205289, confirming the 
RFLP data (Figure 3.3C) and suggesting rs7205289 is not polymorphic in the Western 
population. 
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Figure 3.3 rs7205289 is not present in northern Europeans 
 
Figure 3.3 rs7205289 is not present in Northern Europeans. (A) Schematic showing RFLP 
assay on 390bp amplicon, the additional BsrI restriction site (not affected by rs7205289) 
means wild-type (WT) alleles are cleaved once into 335bp and 55bp fragments, A allele at 
rs7205289 is cleaved three times into 200bp, 135bp and 55bp fragments. rs7205289 is 
indicated by red cross. (B) RFLP gel showing all alleles are WT (C allele). (C) Sequencing 
confirmed all tested alleles were WT (C allele). 
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3.2.3 Initial data shows rs2102066, which is 10nt downstream of miR-140 
stem-loop, is present in Northern Europeans and may be associated with male 
hip OA 
Besides rs7205289, other SNPs may exist in the miR-140 region. Two additional SNPs, 
rs111366342 and rs112773205, are annotated within the miR-140 stem loop (miRNASNP) 
however I found neither were polymorphic. There are 10 annotated SNPs in the 1kb 
upstream of miR-140 and 17 annotated SNPs in the 1kb downstream of miR-140 
(miRNASNP). Our data shows one of these SNPs, rs2102066, which is only 10nt 
downstream of the miR-140 stem loop (purple square in Figure 3.1), is polymorphic. 
rs2102066 is a ‘A’ to ‘G’ transition, ‘G’ being the minor allele and according to Ensemble 
has a frequency of 26% in Europeans and 32% in British. Due to its close proximity to miR-
140, and the importance of miR-140 in cartilage, I hypothesised rs2102066 may be able to 
alter miR-140 processing and may be associated with OA.  
To genotype rs2102066 an ABI SNP genotyping assay was used, it uses PCR to amplify the 
genomic region of the SNP and contains two fluorescent probes, one to each of the alleles. 
Consistent with Ensemble data, the allelic frequency of the minor allele was found to be 
approximately 30% (Figure 3.4). Sequencing and the ABI genotyping assay gave identical 
results for all individuals genotyped by both methods. Analysis of the allele frequencies 
revealed the minor G allele was more common in male hip OA than in controls, 58 (31.9%) 
and 49 (28.2%) respectively (Figure 3.4), with homozygous GG being over 3 times more 
common in male hip OA (14 (5.4%)) than controls (4 (4.6%)), (p<0.05, fishers 2-tailed exact 
test) (Figure 3.4). This preliminary data suggested the minor G allele at rs2102066 may 
contribute to hip OA susceptibility in males. 
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Figure 3.4 rs2102066 is present in northern Europeans 
 
Figure 3.4 rs2102066 is present in Northern Europeans and is associated with male Hip 
OA. Relative fluorescent intensities of VIC and FAM with correspond to the A and G alleles 
respectively for the ABI SNP genotyping assay. The minor G allele is associated with OA. 
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3.2.4 rs2102066 is associated with male hip OA 
3.2.4.1 There is no significant association of rs2102066 with all OA  
Given the relatively small number of individuals genotyped (87 controls and 91 hip OA 
suffers), I was cautious about concluding rs2102066 was associated with OA. However the 
data described warranted further investigation. Using samples located in Newcastle as 
part of the arcOGEN study [39], I genotyped 1096 cases and 821 controls using the ABI 
SNP assay, which can be stratified as shown in (Figure 3.1)  
There was no significant difference in allelic frequencies of rs2102066 for OA compared to 
control (Table 3.2-upper third). Similarly there were no significant differences of 
genotypes for rs2102066 for OA compared to controls (Table 3.2-upper third). However, 
the frequency of the minor G allele was slightly higher in all OA individuals than controls, 
being 26.92% and 25.64% respectively (p=0.58) (Table 3.2-upper third). 
3.2.4.2 There is no significant association of rs2102066 with OA when stratified on 
joint affected 
Although the pathologies of hip and knee OA have many similarities there are some 
differences [196]. In addition, a number of studies have shown many genetic variations do 
not always have the same level of association with hip and knee OA [39]. Taken together, 
these studies suggest hip and knee OA are separate diseases, with shared features. For 
this reason, separate analysis of hip and knee OA was performed. Of the 1096 cases 
genotyped, 738 had hip only OA, 292 had knee only OA and 66 had hip + knee OA (Table 
3.1). This means 2192 alleles of OA sufferers were genotyped, 1476 of which belonged to 
hip only OA sufferers, 584 belonged to knee only OA sufferers and 132 belonged to hip 
and knee OA sufferers (Figure 3.1). 
There was no significant difference in allelic frequencies or genotypes of rs2102066 for 
any type (joint effected) of OA compared to control (Table 3.2-upper third). However, the 
frequency of the minor G allele was higher in hip only OA (28.12%), than in knee only OA 
(24.14%), although neither were significantly different from controls (25.64%) (Figure 3.2-
upper third). Similarly the frequency of the homozygous GG genotype was higher in hip 
only OA (8.1%), than in knee only OA (5.1%), but again neither were significantly different 
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from controls (7.4%) (Figure 3.2 upper third). These data show, compared to controls, the 
minor G allele is increased in hip OA and decreased in knee OA, possibly suggesting the 
minor G allele may promote hip OA and protect against knee OA. 
3.2.4.3 rs2102066 is associated with male hip OA 
Studies have shown differences in the genetics of OA in males and females [39], with 
females tending to have a greater heritability for OA than males [197]. For these reasons I 
stratified our data by gender. There was a slight association (not significant) of the minor 
G allele and the homozygous GG genotype with male OA (Table 3.2-middle third). 
When further stratified by gender and OA joint effected, there was a significant 
association of the minor G allele with male hip OA (OR 1.28, p=0.04, 95%CI= 1.01-1.62) 
Table 3.2-green). There was also an association (approaching significance) of the 
homozygous GG genotype with male hip OA (OR 1.64, p=0.06, 95% CI= 0.98-2.74) (Table 
3.2--yellow). There was no significant association of either allele or genotype with male 
knee OA, female hip OA or female knee OA (Table 3.2--lower third). There was also no 
significant association of any genotype with male knee, female hip or female knee (Table 
3.2).  
I have also genotyped individuals which have hip and knee OA, and although their 
genotypes and allelic ratios were not significantly different from controls, I wanted to add 
these individuals to the individuals with hip only OA and to individuals with knee only OA, 
to analyse the total number of hip OA sufferers and total number of knee OA sufferers 
respectively. This analysis showed a significant association of the minor G allele with male 
hip OA + hip & knee OA compared with controls (Figure 3.2 -green), but did not show any 
significant association for male knee OA, female knee OA or female hip OA (Figure 3.2).  
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Table 3.1 Demographic of individuals genotyped at rs2102066 
 
Table 3.2 SNP downstream of miR-140 is associated with male hip OA. 
 
 
n (%) n (%) n (%)
Cases (N=1096) 1096 418 38 678 62
Controls (N=821) 821 465 57 356 43
Total 1917 883 46 1034 54
Hip only 738 67 278 67 460 68
Knee only 292 27 116 28 176 26
Hip and Knee 66 6 24 6 42 6
Hip only + Hip and Knee 804 302 502
Knee only + Hip and Knee 358 140 218
Total Male Female 
Gender, N (%)
n % n % n % Total p-val n % n % Total  p-val n % n % Total  p-val n % n % Total p-val
Male control 267 57.4 165 35.5 33 7.1 465 198 42.6 267 57.4 465 432 92.9 33 7.1 465 231 24.8 699 75.2 930
Male hip 144 51.8 103 37.1 31 11.2 278 0.109 134 48.2 144 51.8 278 0.136 247 88.8 31 11.2 278 0.057 165 29.7 391 70.3 556 0.041
Male knee 72 62.1 37 31.9 7 6.0 116 0.657 44 37.9 72 62.1 116 0.363 109 94.0 7 6.0 116 0.686 51 22.0 181 78.0 232 0.364
Male hip and knee 10 41.7 12 50.0 2 8.3 24 0.305 14 58.3 10 41.7 24 0.129 22 91.7 2 8.3 24 0.819 16 33.3 32 66.7 48 0.187
Total male hip and hip and knee 154 51.0 115 38.1 33 10.9 302 0.089 148 49.0 154 51.0 302 0.081 269 89.1 33 10.9 302 0.065 181 30.0 423 70.0 604 0.027
Total male knee and hip and knee 82 58.6 49 35.0 9 6.4 140 0.951 58 41.4 82 58.6 140 0.809 131 93.6 9 6.4 140 0.785 67 23.9 213 76.1 280 0.757
Total male OA 226 54.1 152 36.4 40 9.6 418 0.347 192 45.9 226 54.1 418 0.317 378 90.4 40 9.6 418 0.183 232 27.8 604 72.2 836 0.165
Female control 194 54.5 134 37.6 28 7.9 356 162 45.5 194 54.5 356 328 92.1 28 7.9 356 190 26.7 522 73.3 712
Female hip 239 52.0 192 41.7 29 6.3 460 0.409 221 48.0 239 52.0 460 0.471 431 93.7 29 6.3 460 0.386 250 27.2 670 72.8 920 0.825
Female knee 94 53.4 74 42.0 8 4.5 176 0.282 82 46.6 94 53.4 176 0.813 168 95.5 8 4.5 176 0.151 90 25.6 262 74.4 352 0.697
Female hip and knee 27 64.3 12 28.6 3 7.1 42 0.469 15 35.7 27 64.3 42 0.227 39 92.9 3 7.1 42 0.869 18 21.4 66 78.6 84 0.300
Total female hip and hip and knee 266 53.0 204 40.6 32 6.4 502 0.542 236 47.0 266 53.0 502 0.663 470 93.6 32 6.4 502 0.399 268 26.7 736 73.3 1004 0.997
Total female knee and hip and knee 121 55.5 86 39.4 11 5.0 218 0.928 97 44.5 121 55.5 218 0.875 207 95.0 11 5.0 218 0.629 108 24.8 328 75.2 436 0.612
Total female OA 360 53.1 278 41.0 40 5.9 678 0.927 318 46.9 360 53.1 678 0.438 638 94.1 40 5.9 678 0.075 358 26.4 998 73.6 1356 0.427
Total control 461 56.2 299 36.4 61 7.4 821 360 43.8 461 56.2 821 760 92.6 61 7.4 821 421 25.6 1221 74.4 1642
Total OA 586 53.5 430 39.2 80 7.3 1096 0.735 510 46.5 586 53.5 1096 0.722 1016 92.7 80 7.3 1096 0.290 590 26.9 1602 73.1 2192 0.580
Total just Hip 383 51.9 295 40.0 60 8.1 738 0.715 355 48.1 383 51.9 738 0.533 678 91.9 60 8.1 738 0.406 415 28.1 1061 71.9 1476 0.535
Total just knee 166 56.8 111 38.0 15 5.1 292 0.834 126 43.2 166 56.8 292 0.550 277 94.9 15 5.1 292 0.574 141 24.1 443 75.9 584 0.568
Total hip and knee 37 56.1 24 36.4 5 7.6 66 0.999 29 43.9 37 56.1 66 0.989 61 92.4 5 7.6 66 0.965 34 25.8 98 74.2 132 0.976
Total hip and hip and knee 420 52.2 319 39.7 65 8.1 804 0.286 384 47.8 420 52.2 804 0.114 739 91.9 65 8.1 804 0.622 449 27.9 1159 72.1 1608 0.142
Total knee and hip and knee 203 56.7 135 37.7 20 5.6 358 0.834 155 43.3 203 56.7 358 0.665 338 94.4 20 5.6 358 0.441 175 24.4 541 75.6 716 0.721
GG G AAA AG GG AG + GG AA AG+AA
n % n % n % Total p-val n % n % Total  p-val n % n % Total  p-val n % n % Total p-val
Male control 267 57.4 165 35.5 33 7.1 465 198 42.6 267 57.4 465 432 92.9 33 7.1 465 231 24.8 699 75.2 930
Male hip 144 51.8 103 37.1 31 11.2 278 0.109 134 48.2 144 51.8 278 0.136 247 88.8 31 11.2 278 0.057 165 29.7 391 70.3 556 0.041
Male knee 72 62.1 37 31.9 7 6.0 116 0.657 44 37.9 72 62.1 116 0.363 109 94.0 7 6.0 116 0.686 51 22.0 181 78.0 232 0.364
Male hip and knee 10 41.7 12 50.0 2 8.3 24 0.305 14 58.3 10 41.7 24 0.129 22 91.7 2 8.3 24 0.819 16 33.3 32 66.7 48 0.187
Total male hip and hip and knee 154 51.0 115 38.1 33 10.9 302 0.089 148 49.0 154 51.0 302 0.081 269 89.1 33 10.9 302 0.065 181 30.0 423 70.0 604 0.027
Total male knee and hip and knee 82 58.6 49 35.0 9 6.4 140 0.951 58 41.4 82 58.6 140 0.809 131 93.6 9 6.4 140 0.785 67 23.9 213 76.1 280 0.757
Total male OA 226 54.1 152 36.4 40 9.6 418 0.347 192 45.9 226 54.1 418 0.317 378 90.4 40 9.6 418 0.183 232 27.8 604 72.2 836 0.165
Female control 194 54.5 134 37.6 28 7.9 356 162 45.5 194 54.5 356 328 92.1 28 7.9 356 190 26.7 522 73.3 712
Female hip 239 52.0 192 41.7 29 6.3 460 0.409 221 48.0 239 52.0 460 0.471 431 93.7 29 6.3 460 0.386 250 27.2 670 72.8 920 0.825
Female knee 94 53.4 74 42.0 8 4.5 176 0.282 82 46.6 94 53.4 176 0.813 168 95.5 8 4.5 176 0.151 90 25.6 262 74.4 352 0.697
Female hip and knee 27 64.3 12 28.6 3 7.1 42 0.469 15 35.7 27 64.3 42 0.227 39 92.9 3 7.1 42 0.869 18 21.4 66 78.6 84 0.300
Total female hip and hip and knee 266 53.0 204 40.6 32 6.4 502 0.542 236 47.0 266 53.0 502 0.663 470 93.6 32 6.4 502 0.399 268 26.7 736 73.3 1004 0.997
Total female knee and hip and knee 121 55.5 86 39.4 11 5.0 218 0.928 97 44.5 121 55.5 218 0.875 207 95.0 11 5.0 218 0.629 108 24.8 328 75.2 436 0.612
Total female OA 360 53.1 278 41.0 40 5.9 678 0.927 318 46.9 360 53.1 678 0.438 638 94.1 40 5.9 678 0.075 358 26.4 998 73.6 1356 0.427
Total control 461 56.2 299 36.4 61 7.4 821 360 43.8 461 56.2 821 760 92.6 61 7.4 821 421 25.6 1221 74.4 1642
Total OA 586 53.5 430 39.2 80 7.3 1096 0.735 510 46.5 586 53.5 1096 0.722 1016 92.7 80 7.3 1096 0.290 590 26.9 1602 73.1 2192 0.580
Total just Hip 383 51.9 295 40.0 60 8.1 738 0.715 355 48.1 383 51.9 738 0.533 678 91.9 60 8.1 738 0.406 415 28.1 1061 71.9 1476 0.535
Total just knee 166 56.8 111 38.0 15 5.1 292 0.834 126 43.2 166 56.8 292 0.550 277 94.9 15 5.1 292 0.574 141 24.1 443 75.9 584 0.568
Total hip and knee 37 56.1 24 36.4 5 7.6 66 0.999 29 43.9 37 56.1 66 0.989 61 92.4 5 7.6 66 0.965 34 25.8 98 74.2 132 0.976
Total hip and hip and knee 420 52.2 319 39.7 65 8.1 804 0.286 384 47.8 420 52.2 804 0.114 739 91.9 65 8.1 804 0.622 449 27.9 1159 72.1 1608 0.142
Total knee and hip and knee 203 56.7 135 37.7 20 5.6 358 0.834 155 43.3 203 56.7 358 0.665 338 94.4 20 5.6 358 0.441 175 24.4 541 75.6 716 0.721
GG G AAA AG GG AG + GG AA AG+AA
n % n % n % Total p-val n % n % Total  p-val n % n % Total  p-val n % n % Total p-val
Male 2 7 7 4 165 5 5 33 1 465 198 2 6 2 7 7 4 465 432 9 33 1 465 23 4 8 699 5 2 930
Male hip 144 1.8 103 7.1 31 11.2 278 .109 134 8.2 144 1.8 278 .136 247 88.8 31 11.2 278 .057 165 9.7 391 0.3 556 .041
Male knee 72 62.1 37 31.9 7 6.0 116 .657 44 37.9 72 62.1 116 .36 109 4.0 7 6.0 116 .68 51 2.0 181 8.0 232 .364
Male hip and knee 10 41.7 12 50.0 2 8.3 24 0.305 14 58.3 10 41.7 24 0.129 22 91.7 2 8.3 24 0.819 16 33.3 32 66.7 48 0.187
Total male hip and hip and knee 154 51.0 115 38.1 33 10.9 302 0.089 148 49.0 154 51.0 302 0.081 269 89.1 33 10.9 302 0.065 181 30.0 423 70.0 604 0.027
Total male knee and hip and knee 82 58.6 49 35.0 9 6.4 140 0.951 58 41.4 82 58.6 140 0.809 131 93.6 9 6.4 140 0.785 67 23.9 213 76.1 280 0.757
Total male OA 226 54.1 152 36.4 40 9.6 418 0.347 192 45.9 226 54.1 418 0.317 378 90.4 40 9.6 418 0.183 232 27.8 604 72.2 836 0.165
Female control 194 54.5 134 37.6 28 7.9 356 162 45.5 194 54.5 356 328 92.1 28 7.9 356 190 26.7 522 73.3 712
Female hip 239 52.0 192 41.7 29 6.3 460 0.409 221 48.0 239 52.0 460 0.471 431 93.7 29 6.3 460 0.386 250 27.2 670 72.8 920 0.825
Female knee 94 53.4 74 42.0 8 4.5 176 0.282 82 46.6 94 53.4 176 0.813 168 95.5 8 4.5 176 0.151 90 25.6 262 74.4 352 0.697
Female hip and knee 27 64.3 12 28.6 3 7.1 42 0.469 15 35.7 27 64.3 42 0.227 39 92.9 3 7.1 42 0.869 18 21.4 66 78.6 84 0.300
Total female hip and hip and knee 266 53.0 204 40.6 32 6.4 502 0.542 236 47.0 266 53.0 502 0.663 470 93.6 32 6.4 502 0.399 268 26.7 736 73.3 1004 0.997
Total female knee and hip and knee 121 55.5 86 39.4 11 5.0 218 0.928 97 44.5 121 55.5 218 0.875 207 95.0 11 5.0 218 0.629 108 24.8 328 75.2 436 0.612
Total female OA 360 53.1 278 41.0 40 5.9 678 0.927 318 46.9 360 53.1 678 0.438 638 94.1 40 5.9 678 0.075 358 26.4 998 73.6 1356 0.427
Total control 461 56.2 299 36.4 61 7.4 821 360 43.8 461 56.2 821 760 92.6 61 7.4 821 421 25.6 1221 74.4 1642
Total OA 586 53.5 430 39.2 80 7.3 1096 0.735 510 46.5 586 53.5 1096 0.722 1016 92.7 80 7.3 1096 0.290 590 26.9 1602 73.1 2192 0.580
Total just Hip 383 51.9 295 40.0 60 8.1 738 0.715 355 48.1 383 51.9 738 0.533 678 91.9 60 8.1 738 0.406 415 28.1 1061 71.9 1476 0.535
Total just knee 166 56.8 111 38.0 15 5.1 292 0.834 126 43.2 166 56.8 292 0.550 277 94.9 15 5.1 292 0.574 141 24.1 443 75.9 584 0.568
Total hip and knee 37 56.1 24 36.4 5 7.6 66 0.999 29 43.9 37 56.1 66 0.989 61 92.4 5 7.6 66 0.965 34 25.8 98 74.2 132 0.976
Total hip and hip and knee 420 52.2 319 39.7 65 8.1 804 0.286 384 47.8 420 52.2 804 0.114 739 91.9 65 8.1 804 0.622 449 27.9 1159 72.1 1608 0.142
Total knee and hip and knee 203 56.7 135 37.7 20 5.6 358 0.834 155 43.3 203 56.7 358 0.665 338 94.4 20 5.6 358 0.441 175 24.4 541 75.6 716 0.721
GG G AAA AG GG AG + GG AA AG+AA
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3.3 Discussion 
3.3.1 SNPs in 3’UTRs may change miR-140 targets 
SNPs can also occur in individual targets to change how a miRNA regulates that target. A 
number of SNPs have the potential to alter miR-140 binding to targets, with one of these 
targets (TP63) being associated with OA. I searched for SNPs which have the potential to 
alter miR-140 targets, as this miRNA is most highly expressed cartilage. Interestingly in a 
separate study, TP63 expression was not detected in either OA or NOF cartilage, but was 
detected in tendon, fat pad and osteophyte [39], perhaps suggesting the high miR-140 
expression in cartilage is leading to reduced TP63 expression.  
3.3.2 No SNPs found in miR-140 stem loop 
Our study did not find any polymorphic SNPs within the miR-140 stem-loop, although if I 
increased the number of samples there could be. Interestingly, rs7205289 has been found 
in the Chinese population [190], suggesting rs7205289 is population specific. In the 
Chinese population rs7205289 is associated with cleft pallet, with CA/AA at rs7205289 
contributing to cleft pallet [198], by controlling the processing of miR-140 [199]. 
3.3.3 rs2102066 is in miR-140 flanking region and is associated with male hip 
OA 
Due to the importance of miR-140 in cartilage and the previously identified OA association 
of the chromosome 16 region where miR-140 is located [37], it is not surprising, 
rs2102066, which is only 10nt downstream of the miR-140 stem-loop is associated with 
male hip. In addition, taken together with previous data, I have shown the genetics of hip 
OA and knee OA in males and females are different. 
3.3.4 rs2102066 may affect miR-140 processing by altering precursor RNA 
structure. 
SNPs within stem loops have previously been shown to alter miRNA processing by 
changing the RNA structure [190]. To our knowledge no SNP outside of the pre-miRNA has 
been shown to alter miRNA processing, but as miRNAs are processed from larger sections 
of RNA and rs2102066 is only 10nt downstream of the miR-140 stem-loop, I hypothesised 
the minor G allele at rs2102066, may alter miR-140 precursor RNA structure and 
processing. To test this I modelled the structure of miR-140 with each of the alleles, using 
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the Centroidfold RNA folding program (www.ncrna.org/centroidfold) (Figure 3.5). The 
minor G allele alters the structure of the miR-140 flanking region (Figure 3.5). 
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Figure 3.5 Model of miR-140 with and without SNP rs2102066 
 
Figure 3.5 Model of miR-140 with and without SNP rs2102066. Minor G allele may alter 
miR-140 flanking region structure. (A) miR-140 stem loop RNA +/- 1kb flanking RNA was 
inputted into Centroidfold RNA folding program (www.ncrna.org/centroidfold) set to 
McCaskill. Dicer and Drosha cleavage sites are indicated by green and blue arrows 
respectively. (B) Zoomed version of A. 
G
A
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Dicer 
Drosha
Dicer 
A. B.
A G
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3.3.5 Increased power may verify associations 
I genotyped 1096 OA and 821 controls and have found a significant association of the 
minor G allele with male hip OA. I found a number of other associations although none 
were significant. I therefore wanted to increase the number of individuals genotyped in 
the study. I have genotyped all of the samples available in Newcastle, however there are 
many more OA and control individuals in the arcOGEN cohort [39]. I do not easily have 
access to the whole of the cohort, but there has been a genotyping array performed on all 
of the samples [39]. ~500,000 SNPs were genotyped on the array, but unfortunately 
neither of our studied SNPs were included. I therefore wanted to find SNPs in high LD with 
both rs2102066 (in miR-140 flanking region) and rs35592567 (predicted to prevent miR-
140 binding to TP63), which were included on the array. According to SNAP (Broad 
institute-proxy search) [200], there are 13 SNPs in perfect LD with rs2102066, and 9 SNPs 
in perfect LD with rs35592567, unfortunately none of these were included on the array 
(Table 3.3). There were however a number SNPs in high LD with rs2102066 and 
rs35592567 (Table 3.3). 4 of the SNPs in high LD with rs2102066, and 1 of the SNPs in high 
LD with rs35592567 were included on the array (Table 3.3). The genotypes of these SNPs 
will be a good representation of the genotype of the rs2102066 and rs35592567 and can 
be used to indicate if these SNPs are associated with OA in the whole arcOGEN cohort. 
Haploview may be a useful tool to determine which alleles are in LD with each other. 
However, because none of the proxy SNPs are in perfect LD with the studied SNPs the 
exact genotype in OA and controls can only be estimated. A technique called imputation 
could be used for this type of analysis, which we are currently beginning. 
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Table 3.3 SNPs in LD with rs2102066 and rs35592567 
 
Table 3.3 SNPs in high LD with rs2102066 and rs35592567 according to SNAP (Broad 
institute-proxy search). Rsquared of 1 indicates SNPs are in perfect LD with both alleles at 
each SNP are always inherited with the alleles at the other SNP. Dprime of 1 indicates 
SNPs are in complete LD and one, but not both, of the alleles at each SNP will always be 
inherited with one of the alleles at the other SNP. 
 
SNP Proxy SNP Distance RSquared DPrime On array?
rs2102066 rs2102066 0 1 1
rs2102066 rs10048090 731 1 1
rs2102066 rs10048088 776 1 1
rs2102066 rs2270841 804 1 1
rs2102066 rs8048678 1108 1 1
rs2102066 rs8048590 1274 1 1
rs2102066 rs2270840 2069 1 1
rs2102066 rs1566452 3738 1 1
rs2102066 rs11864678 4612 1 1
rs2102066 rs1983015 6101 1 1
rs2102066 rs904804 6488 1 1
rs2102066 rs904805 6601 1 1
rs2102066 rs904806 6829 1 1
rs2102066 rs904807 7105 1 1
rs2102066 rs8049004 1303 0.961 1
rs2102066 rs2291961 1501 0.961 1
rs2102066 rs8052727 1812 0.961 1
rs2102066 rs12932078 1634 0.925 1
rs2102066 rs2270842 2907 0.925 1 yes 
rs2102066 rs1983016 3236 0.925 1 yes 
rs2102066 rs904803 3436 0.925 1
rs2102066 rs9302605 5393 0.925 1
rs2102066 rs4985461 6562 0.925 1
rs2102066 rs3748388 7355 0.925 1
rs2102066 rs1052429 8267 0.925 1 yes 
rs2102066 rs3762178 5329 0.922 0.96
rs2102066 rs12932286 1518 0.89 1
rs2102066 rs3762177 4872 0.89 1 yes 
rs2102066 rs7206222 223 0.885 1
rs2102066 rs8047818 639 0.857 1
rs2102066 rs7499251 10272 0.857 1
rs2102066 rs7184994 8996 0.826 1
rs35592567 rs35592567 0 1 1
rs35592567 rs11709791 1218 1 1
rs35592567 rs60960402 5416 1 1
rs35592567 rs1515487 7338 1 1
rs35592567 rs11713848 10226 1 1
rs35592567 rs73202009 16773 1 1
rs35592567 rs61064225 19144 1 1
rs35592567 rs73202033 29317 1 1
rs35592567 rs73202034 31379 1 1
rs35592567 rs73202036 32266 1 1
rs35592567 rs9840360 23811 0.941 1
rs35592567 rs58312266 32589 0.941 1
rs35592567 rs11708746 444 0.938 1
rs35592567 rs11708753 495 0.938 1 yes 
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3.4 Summary 
I have found a SNP (rs2102066) which is just downstream of the miR-140 (the most 
studied miRNA in cartilage) locus, and another SNP (rs35592567) in a predicted, OA-
associated, miR-140 target (TP63), are likely to affect miR-140 function and to be 
associated with OA. Increased sample size is needed to verify and test the association of 
rs2102066 and rs35592567 respectively. One must note, TP63 is only a predicted target of 
miR-140 and is yet to be validated, further work is continuing to validate TP63 as a miR-
140 target and test if rs35592567 can affect the miR-140-TP63 interaction. In addition, the 
creation of a constructs would be needed to investigate the role of rs2102066 on miR-140 
processing.  
If this shows rs2102066 is able to effect miR-140 processing and rs35592567 is able to 
affect miR-140 regulation of TP63, it will be interesting to test if having the minor allele at 
both of these SNPs further increases an individual’s susceptibility to OA, compared to only 
having one or none of the SNPs. 
There are a number of factors that need to be considered for rs2102066 and rs35592567 
in miR-140 biology in OA. Firstly, at the time blood was taken for genotyping, the controls 
did not have OA, however they may go on to develop the disease. Secondly, rs2102066 is 
located 10nt downstream of the miR-140 stem loop and may not affect miR-140. To our 
knowledge the function of a SNP 10nt downstream of any miRNA stem loop has not been 
characterised. However, if the SNP alters the secondary structure of the miRNA stem loop 
basal segments, then processing of the miRNA may be altered. This work increases our 
understanding of OA genetics, may partly explain how the expression of miR-140 becomes 
altered in OA and may also partly explain the genetic association of TP63 with OA. Taken 
together, this data may suggest both the miR-140 encoding region and a miR-140 target 
are associated with OA. 
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Chapter 4 miR-125b and miR-324-5p regulate Hh signalling  
4.1  Introduction 
4.1.1 miR-125b-5p and miR-324-5p are increased in end-stage osteoarthritic 
cartilage 
miR-140 has previously been shown to be differentially expressed in OA and is the most 
extensively studied miRNA in cartilage. In Chapter 3 I investigated possible genetic 
associations of miR-140 and its target with OA. In chapter 4 I aim to investigate the 
functions of other miRNAs differentially expressed in OA. To identify miRNAs differentially 
expressed during Osteoarthritis (OA), a TaqMan® low density array of 365 miRNAs was 
performed on RNA obtained from total hip replacements for either OA or fracture to the 
neck of femur (NOF) cartilage by Hannah Elliott (previous laboratory member). Data were 
normalised, using a published method [201]. A number of miRNAs were differentially 
expressed in OA cartilage compared to NOF (unpublished data), such as miR-455 [155]. 
Two differentially expressed miRNAs of particular interest were miR-125b-5p and miR-
324-5p as they have both previously been shown to regulate the Hh signalling pathway 
[127]. The Hh pathway is important for both cartilage developemt and maintance (Section 
1.7). 
In our labs study miR-125b-5p was significantly increased in the OA cartilage compared to 
NOF and miR-324-5p was only detectable in the OA cartilage (Figure 4.1). miR-125b-5p has 
previously been shown to target the 3’UTR of the Hh activator SMO, while miR-324-5p has 
been shown to target both the 3’UTR of SMO and the 3’UTR of the Hh transcription factor 
GLI1 [127].  
This chapter will start by investigating the structure, processing and evolutionary history 
of miR-125b-5p and miR-324-5p, I will then use a number of computational prediction 
methods to predict the targets and functions of miR-125b-5p and miR-324-5p and finally 
investigate the functions of miR-125b-5p and miR-324-5p, predominately focusing on their 
role in Hh signalling, which will form the main aim of this chapter. 
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Specific aims 
Aim 1: Determine the structure and processing of miR-125b and miR-324 
Aim 2: Investigate the evolutionary history of miR-125b and miR-324 
Aim 3: Predict targets and functions of miR-125b-5p and miR-324-5p 
Aim 4: Validate miR-125b-5p and miR-324-5p target human SMO and GLI1 3’UTRs 
Aim 5: Characterise Hh signalling in mouse C3H10T1/2 cell line 
Aim 6: Characterise miR-125b-5p and miR-324-5p effect on Hh signalling in mouse 
C3H10T1/2 cell line 
Aim 7: Identify factors controlling miR-125b-5p and miR-324-5p expression 
Aim 8: Determine the mechanism by which miR-125b-5p and miR-324-5p regulate Hh 
signalling in mouse 
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Figure 4.1 miR-125b-5p and miR-324-5p are increased in OA. 
 
 
Figure 4.1 miR-125b-5p and miR-324-5p are increased in OA. Real-time RT-PCR was used 
to identify miRNAs differentially expressed in OA and normal (NOF) cartilage. The 
expression of both miR-125b-5p and miR-324-5p are increased during end-stage OA, 
p<0.01 (**) and p<0.001 (***) respectively (non-parametric Mann Whitney U test). 
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4.2 Results 
4.2.1 Structure and processing of miR-125b and miR-324 stem-loops 
Mature miRNAs form from stem-loops, their processing involves cleavage by the enzymes 
Drosha and Dicer (Chapter 1), which determine mature miRNA sequences and ultimately 
their targets and functions. Cleavage sites are based on stem-loop sequence and 
structure, although the exact criteria are unknown. miRBase (the microRNA registry) 
contains annotation for all miRNA structures and sequences [112]. 
miR-125b was originally cloned from mouse brain [202], and can be encoded from two 
genomic loci, one on chromosome 9 and one on chromosome 16 for miR-125b-1 and miR-
125b-2 respectively. Each locus produces identical ‘-5p’ strands (miR-125b-5p) but 
different ‘-3p’ strands (miR-125b-1-3p and miR-125b-2-3p). Both ‘-3p’ antisense miRNAs 
have also been cloned [203]. Homology searches suggested both homologues of miR-125b 
are present in human [204], being encoded from chromosome 11 and chromosome 21 for 
miR-125b-1 and miR-125b-2 respectively, their expression was later validated in human 
BC-1 cells [205]. 
miR-324-5p was originally cloned from rat cerebro-cortical dissociated cultures of E18 rat 
embryos [206]. Expression of miR-324-5p and miR-324-3p was later verified in mouse 
[207], homology searches suggested miR-324 was also present in human [204], and it has 
now been cloned from human BC-1 cells [205]. miR-324 is encoded downstream of DVL2 
from chromosome 17 and chromosome 11 in human and mouse respectively. 
More recently, the use of high-throughput sequencing has allowed further investigation 
into miRNA sequence, structure and expression [208, 209] with data available on miRBase 
[112]. Alignment of sequencing reads for miR-125b shows mature miRNA sequences and 
stem-loop structure are in agreement with the miRBase annotation and miR-125b-5p is 
more highly expressed than the antisense strands (miR-125b-1-3p and miR-125b-2-3p) in 
mouse (Figure 4.2A and B) and human (Figure 4.2D and E). 
Similar to miR-125b-5p, the mature miR-324-5p sequence is as annotated in miRBase and 
is more highly expressed than the antisense ‘-3p’ strand for both mouse (Figure 4.2C) and 
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human (Figure 4.2F). The miR-324-3p mature sequence is different from miRBase 
annotation in human and mouse. In human, high-throughput sequencing shows miR-324-
3p actually starts 2nt downstream of the miRBase annotated miR-324-3p, meaning the 
‘actual’ human miR-324-3p seed is likely to be ‘CACUGCC’ rather than ‘CUGCCCC’ to 
(Figure 4.2F). The ‘actual’ human miR-324-3p sequence is also shown in Table 4.1. Mouse 
high-throughput sequencing shows two variants of mature miR-324-3p sequence, around 
half of the reads start at the miRBase predicted site, the other half start 2nt downstream, 
meaning there are two possible seeds; ‘CACUGCC’ (the mouse miRBase 
annotated/canonical miR-324-3p) and ‘CUGCCCC’ (non-canonical)(Figure 4.2 C). Canonical 
mouse miR-324-3p is shown as ‘mouse miR-324-3p’ and non-canonical mouse miR-324-5p 
is shown as ‘non-canonical miR-324-3p’ in Table 4.1. miRBase annotation used to describe 
the miR-125b and miR-324 stem-loops, the mature miRNAs, their antisense miRNAs and 
the sequences of each in human and mouse is also shown in Table 4.1.  
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Table 4.1 miR-125b and miR-324 annotation 
Description Sequence 
miRBase mouse miR-125b-1 stem-loop (Chr 9)   UGCGCUCCCCUCAGUCCCUGAGACCCUAACUUGUGAUGUUUACCGUUUAAAUCCACGGGUUAGGCUCUUGGGAGCUG 
miRBase human miR-125b-1 stem-loop (Chr 11)   UGCGCUCCUCUCAGUCCCUGAGACCCUAACUUGUGAUGUUUACCGUUUAAAUCCACGGGUUAGGCUCUUGGGAGCUGCGAGUCGUGCU 
miRBase mouse miR-125b-2 stem-loop (Chr 16)           GCCUAGUCCCUGAGACCCUAACUUGUGAGGUAUUUUAGUAACAUCACAAGUCAGGUUCUUGGGACCUAGGC 
miRBase human miR-125b-2 stem-loop (Chr 21) ACCAGACUUUUCCUAGUCCCUGAGACCCUAACUUGUGAGGUAUUUUAGUAACAUCACAAGUCAGGCUCUUGGGACCUAGGCGGAGGGGA 
miRBase mouse mature miR-125b-5p                 UCCCUGAGACCCUAACUUGUGA 
miRBase human mature miR-125b-5p                 UCCCUGAGACCCUAACUUGUGA 
miRBase mouse mature miR-125b-1-3p                                                         ACGGGUUAGGCUCUUGGGAGCU 
miRBase human mature miR-125b-1-3p                                                         ACGGGUUAGGCUCUUGGGAGCU 
miRBase mouse mature miR-125b-2-3p                                                        ACAAGUCAGGUUCUUGGGACCU 
miRBase human mature miR-125b-2-3p                                                      UCACAAGUCAGGCUCUUGGGAC 
  
miRBase mouse miR-324 stem-loop (Chr 11) AACUGACUAUGCCUCCUCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCCCCAGGUGCUGCUGGGGGUUGUAGUCUGAC 
miRBase human miR-324 stem-loop (Chr 17)   CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCCCCAGGUGCUGCUGGGGGUUGUAGUC 
miRBase mouse mature miR-324-5p                  CGCAUCCCCUAGGGCAUUGGUGU 
miRBase human mature miR-324-5p                  CGCAUCCCCUAGGGCAUUGGUGU 
miRBase mouse mature miR-324-3p                                                     CCACUGCCCCAGGUGCUGCU 
Non-canonical mouse mature miR-324-3p                                                       ACUGCCCCAGGUGCUGCUGG 
miRBase human mature miR-324-3p                                                       ACUGCCCCAGGUGCUGCUGG 
Actual human mature miR-324-3p                                                     CCACUGCCCCAGGUGCUGCUGG 
Table 4.1 Annotation used to describe miR-125b and miR-324 sequences. Bold indicates mature miRNA sequences, underlined indicates 
miRNA seed sequence. 
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Figure 4.2 Alignment of deep sequencing reads and stem-loop structures of miR-125b-1, 
miR-125b-2 and miR-324 in human and mouse 
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Figure 4.2 Alignment of deep sequencing reads and stem-loop structures of miR-125b-1, 
miR-125b-2 and miR-324 in human and mouse. Deep sequencing reads were obtained 
from miRBase and aligned with the total number of reads for each base (read counts) 
displayed on the y axis and the stem-loop sequence on the x axis. Stem-loop structures 
according to miRBase and predicted from deep sequencing alignment. Mature ‘-5p’ 
sequences in green, mature ‘-3p’ sequences in red as suggested by miRBase with reads 
not predicted by miRBase in black. Drosha and Dicer cleavage site shown by blue and 
green triangles respectively, as suggested by deep sequencing (large triangles) or as 
suggested by miRBase (darker small triangles) if different from deep seq. Non-canonical 
Dicer cleavage site for mouse miR-324-3p shown by orange triangle. (A) Deep sequencing 
reads and stem-loop for mouse miR-125b-1. (B) Deep sequencing reads and stem-loop for 
mouse miR-125b-2. (C) Deep sequencing reads and stem-loop for mouse miR-324-5p. (D) 
Deep sequencing reads and stem-loop for human miR-125b-1. (E) Deep sequencing reads 
and stem-loop for human miR-125b-2. (F) Deep sequencing reads and stem-loop for 
human miR-324-5p. 
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4.2.2 Evolution of miR-125b and miR-324 
miRNAs are generally encoded from genomic regions which are more conserved than the 
surrounding DNA [192]. In humans and mice miR-125b can be encoded from two genomic 
loci, a feature conserved in many species. Alignment of all miR-125b loci using Clustal 
OMEGA [210] (www.clustal.org), shows miR-125b is highly conserved between species 
(Figure 4.3). Phylogenic analysis of miR-125b sequences using Clustal2 Phylogeny 
(http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), separates them into 
three clades, named here as ‘a’ ‘b’ and ‘c’ (Figure 4.4). Times of divergence of species 
which possess miR-125b were extracted from Time Tree (www.timetree.org) and a 
phylogenic tree of these species created using Phylodendron 
(http://iubio.bio.indiana.edu/treeapp/) (Figure 4.5). Many of the species which possess 
miR-125b diverged around 800million years ago, indicating miR-125b is at least this old 
(See ‘#’ on Figure 4.5). Species which diverged from humans more than 661.2 million years 
ago only have one copy of miR-125b where as many species which diverge from humans 
less than 400.1 million years ago have two copies of miR-125b (Table 4.2), this suggests 
the two miR-125b loci seen in many species today have arisen from a single duplication 
between 400.1 and 661.2 million years ago (see ‘+’ on Figure 4.5). This is further 
supported by the fact that all species which contain two miR-125b loci have one miR-125b 
loci belonging to sequence phylogenic clade ‘b’ and one to clade ‘c’ (Table 4.2). Those 
species which contain only one miR-125b locus have miR-125b sequences belonging to 
clade ‘a’ (Table 4.2). This suggests a sequence not to dissimilar to those sequences in clade 
‘a’ duplicated to give rise to two miR-125b loci not to dissimilar to those in clade ‘b’ and 
‘c’. These sequences have since evolved independently giving rise to ‘bi’,’bii’,’biii’,’ci’, ‘cii 
etc (Figure 4.5 and Table 4.2). Interestingly zebrafish have 3 genomic loci for miR-125b 
(Table 4.2). Two of the three miR-125b loci are very similar and part of clade ‘bii’ 
suggesting they have arisen from a more recent second duplication in fish. It cannot be 
excluded that there are additional yet to be annotated miR-125b loci in other species. In 
addition, it cannot be excluded that miR-125b may have arisen from other miRNAs or 
other regions of genomic DNA. Genome wide searches for miR-125b sequences or similar 
sequences were unable to identify the origin of miR-125b.  
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Alignment of all miR-324 loci shows the majority of miR-324 stem-loops are conserved 
between species (Figure 4.3B). All species which possess a miR-324 stem-loop diverge 
within the last 100 million years (see ‘*’ in Figure 4.5) indicating miR-324 is relatively 
young in comparison to miR-125b, at around 100 million years old, and appears to be 
conserved in almost all placental animals (Figure 4.3C). A number of species which 
diverged after the occurrence of miR-324 have no annotated miR-324 sequence (Table 
4.2). This could be due to the loss of the miR-324 loci, but is more likely because miR-324 
is yet to be annotated. Genome wide searches for miR-324 sequences or similar 
sequences did not identify the origin of miR-324. Meaning it is unknown if miR-324 has 
arisen from another miRNA or if it has arisen from a ‘random’ piece of RNA. 
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Figure 4.3 miR-125b and miR-324 sequences. 
 
 
Figure 4.3 miR-125b and miR-324 sequences. miR-125b and miR-324 stem-loop sequences 
were obtained from miRBase and aligned using clustal OMEGA [210] (www.clustal.org). 
Green and red boxes represent the approximate position of the ‘-5p’ and ‘-3p’ mature 
miRNAs respectively. (A) Alignment of miR-125b sequences (B) Alignment of miR-324 
sequences. See Table 4.2 for list of species abbreviations. 
 
aca-mir-125b-1      ----------------------------------------------UGCGCCCCUCUCUG
age-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
bta-mir-125b-1      ----------------------------------------------CGCGCGCCUCUCAA
bfl-mir-125b        --------------------------------------GUGGAGGGCGUAUGUCACCCAG
cfa-mir-125b-1      ------------------------------------------------------------
ccr-mir-125b        ----------------------------------------------------------GG
dre-mir-125b-2      -----------------------------------------------GUGCCCCUCUCCU
eca-mir-125b        ----------------------------------------------UGCGCUCCUCUCAA
fru-mir-125b        -----------------------------------------------------CUCUCAU
ggo-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
hsa-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
lla-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
lca-mir-125b        --------------------------------------------ACCAGACUUUUCCUAG
mml-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mne-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mdo-mir-125b-2      ----------------------------------------------------------AA
mmu-mir-125b-2      ------------------------------------------------------GCCUAG
ola-mir-125b-1      ------------------------------------------AACCUGUACCUCUCUCAU
ptr-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
ppy-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
rno-mir-125b-1      ----------------------------------------------UGCGCUCCCCUCAG
sko-mir-125b        ---------------------------------------CUCUAUAUGUGUAUUACCUAA
sha-mir-125b        UCCAAAAUAUCCGUACUAUAGAAGAAAGAAUUCUACUGCAUCAAAUAAGACUUUUCCUAG
sma-mir-125b        -----------------------------------------------------------A
ssc-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
tni-mir-125b        -----------------------------------------------GUACCUCUCUCAU
xtr-mir-125b-2      ------------------------------------------------GACUUUUCCUAG
aca-mir-125b-2      ----------------------------------------------CAGACUUUUCCUAG
age-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
bta-mir-125b-2      ------------------------------------------------GACUUUUCCUAG
cfa-mir-125b-2      ------------------------------------------------------------
cgr-mir-125b        --------------------------------------------------CUUUUCCUAG
dre-mir-125b-1      ---------------UUCUGUUGCAGGUUGGCGGUUGGUCUGCAAAUGUGCCUCUCACAA
dre-mir-125b-3      ------------------------------CCCGUGCGGCCACCGCUGCACUCCUCCUGG
eca-mir-125b-2      -------------------------------------------------------CCUAG
gga-mir-125b        --------------------------------------------AUCAGACUUUUCCUAG
ggo-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
hsa-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
lla-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mml-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
mne-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
mdo-mir-125b-1      -------------------------------------------------ACUUUUCCUAG
mmu-mir-125b-1      ----------------------------------------------UGCGCUCCCCUCAG
ola-mir-125b-2      -----------------------------------GUAGACUCUGUCGUACUUCACCUGC
ppa-mir-125b        ----------------------------------------------UGCGCUCCUCUCAG
ptr-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
ppy-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
rno-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
sla-mir-125b        ----------------------------------------------UGCGCUCCUCUCAG
sja-mir-125b        -----------------------------------------------------------A
sme-mir-125b        ---------------------------------------------GCAAGUUAUUCGACA
ssc-mir-125b-1      ----------------------------------------------------CCUCUCAG
xtr-mir-125b-1      ----------------------------------------------UGCACCCCUCUCAA
aca-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUAGUUUUU-AAGUCCACGGGUUAGGCUCUUGGGA
age-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
bta-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
bfl-mir-125b        CUCCCAAGAUCCUAACCUGUGAGCCAUGGA-------CAUCACAAGUUAGGGUCUCAGGG
cfa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ccr-mir-125b        UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUGAAAAUCACAGGUUAAGCUCUUGGGA
dre-mir-125b-2      UCCCUGAGACCCUAACUUGUGACGUUCUGCUUCG-AUGUCCACGGGUUGGGUUCUCGGGA
eca-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
fru-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCACGGGUUGGGUUCUUGGGA
ggo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
hsa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
lla-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
lca-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mml-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mne-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mdo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mmu-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGUUCUUGGGA
ola-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUGCUCUG-AUGUGCACGGGUUGGGCUCUUGGGA
ptr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ppy-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
rno-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
sko-mir-125b        UCCCUGAGACCCUAACUUGUGAGAAUUACCCAGCA---UUCACAGGUUAGUGGCUUAGGA
sha-mir-125b        UCCCUGAGACCCUAACUUGUGAGAUU-UUUUAGCAAUAAUCACAGGUCAGGCUCUUGGGA
sma-mir-125b        UCCCUGAGACUGAUAAUUGCUCUUUUUAUCAUGAUAAG-----GGAGUUUGAUGAGAGCA
ssc-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
tni-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCACGGGUUGGGUUCUUGGGA
xtr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGAUUUUUUAGCAACAAUCACAAGUUAGGCUCUUGGGA
aca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUU--UUUAGUAACAAUCACAAGUCAGGCUCUUGGGA
age-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
bta-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAGCAUCACAAGUCAGGCUCUUGGGA
cfa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
cgr-mir-125b        UCCCUGAGACCCUAACUUGUGAGGGA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
dre-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUCCUGUU-AUGUGCACGGGUUAGGUUCUUGGGA
dre-mir-125b-3      UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUAAAAAUCACAGGUUAAGCUCUUGGGA
eca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUGGUAACAUCACAAGUCAGGCUCUUGGGA
gga-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUU-UUGUAGCAACAAUCACAAGUCAGGCUCUUGGGA
ggo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
hsa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
lla-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mml-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mne-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mdo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAGGCU-UUUCAGCGACAACCACAGGUCAGGCUCUUGGGA
mmu-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ola-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGCUCUCUUGAUAAAAAAUCACGGGUUAGGCUCUUGGGA
ppa-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUAACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ptr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
ppy-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
rno-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
sla-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
sja-mir-125b        UCCCUGAGACUGAUAAUUGCUCUAGUUAUUAUAUCAUUAA-UGAGUUUACAAUAAGGGCA
sme-mir-125b        UCCCUGAGAUCAUAAUAUGCCUGAGAUUUGAACGCAAACCGGUAGAUUAUUGUCUCAGAG
ssc-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
xtr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUAGCUUUAAAAAUCCACGGGUUAGGCUCUUGGGA
** .***     *  **                        ..           .* .
aca-mir-125b-1      GCUGUGAGUUGUGCCAC------------------------
age-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
bta-mir-125b-1      GCUGCGAGUCGCGCC--------------------------
bfl-mir-125b        AAUGGGG----------------------------------
cfa-mir-125b-1      GC---------------------------------------
ccr-mir-125b        CC---------------------------------------
dre-mir-125b-2      GCUGUGAGAGGCAC---------------------------
eca-mir-125b        GCUGCGAGUCGUGCC--------------------------
fru-mir-125b        GCUG-------------------------------------
ggo-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
hsa-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
lla-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
lca-mir-125b        CCUAGGCGGAGGGGA--------------------------
mml-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mne-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mdo-mir-125b-2      GC---------------------------------------
mmu-mir-125b-2      CCUAGGC----------------------------------
ola-mir-125b-1      GCUGCGAGGGGCACUCACACAUCU-----------------
ptr-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
ppy-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
rno-mir-125b-1      GCUGCGAGUCGUGC---------------------------
sko-mir-125b        AUUGGGUGGUGCAUUCAUA----------------------
sha-mir-125b        CCUAGGCGGAGGGGAACCAGCAGCUCUGGAC----------
sma-mir-125b        AUUAUUA------------------CUCUCAGGUGUA----
ssc-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
tni-mir-125b        GCUGCGAGGGGCGCUCACACAUC------------------
xtr-mir-125b-2      CCUAGGCGGAGGG----------------------------
aca-mir-125b-2      CCUAGGCGGAGGGGAACC-----------------------
age-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
bta-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
cfa-mir-125b-2      CCU--------------------------------------
cgr-mir-125b        CCUAGGCGGA-------------------------------
dre-mir-125b-1      GCUGAGAGGGGUGCUCUGUCAUCAGCCCGCCGGCGUCGGAA
dre-mir-125b-3      CCUGGGCAGAGGGCAAAAGCACUGG----------------
eca-mir-125b-2      CCUAGGC----------------------------------
gga-mir-125b        CCUAGGCGGAGGGGA--------------------------
ggo-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
hsa-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
lla-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mml-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mne-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mdo-mir-125b-1      CCUAGGCGGAGG-----------------------------
mmu-mir-125b-1      GCUG-------------------------------------
ola-mir-125b-2      CGCGGGCGGAGGGCACAAUCGAC------------------
ppa-mir-125b        GCUGCGAGUCGUAAU--------------------------
ptr-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
ppy-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
rno-mir-125b-2      CCUAGGCGGAGAGG---------------------------
sla-mir-125b        GCUGCGAGUCGUGCU--------------------------
sja-mir-125b        AUUAUUA------------------UUCUCAGGUGU-----
sme-mir-125b        UAAUUGAUAAAC-----UGCA--------------------
ssc-mir-125b-1      GCUGCGAGCCGUG----------------------------
xtr-mir-125b-1      GCUGUGAGUUGUGC---------------------------
aca-mir-125b-1      ----------------------------------------------UGCGCCCCUCUCUG
age-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
bta-mir-125b-1      ----------------------------------------------CGCGCGCCUCUCAA
bfl-mir-125b        --------------------------------------GUGGAGGGCGUAUGUCACCCAG
cfa-mir-125b-1      ------------------------------------------------------------
ccr-mir-125b        ----------------------------------------------------------GG
dre-mir-125b-2      -----------------------------------------------GUGCCCCUCUCCU
eca-mir-125b        ----------------------------------------------UGCGCUCCUCUCAA
fru-mir-125b        -----------------------------------------------------CUCUCAU
ggo-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
hsa-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
lla-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
lca-mir-125b        --------------------------------------------ACCAGACUUUUCCUAG
mml-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mne-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mdo-mir-125b-2      ----------------------------------------------------------AA
mmu-mir-125b-2      ------------------------------------------------------GCCUAG
ola-mir-125b-1      ------------------------------------------AACCUGUACCUCUCUCAU
ptr-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
ppy-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
rno-mir-125b-1      ----------------------------------------------UGCGCUCCCCUCAG
sko-mir-125b        ---------------------------------------CUCUAUAUGUGUAUUACCUAA
sha-mir-125b        UCCAAAAUAUCCGUACUAUAGAAGAAAGAAUUCUACUGCAUCAAAUAAGACUUUUCCUAG
sma-mir-125b        -----------------------------------------------------------A
ssc-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
tni-mir-125b        -----------------------------------------------GUACCUCUCUCAU
xtr-mir-125b-2      ------------------------------------------------GACUUUUCCUAG
aca-mir-125b-2      ----------------------------------------------CAGACUUUUCCUAG
age-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
bta-mir-125b-2      ------------------------------------------------GACUUUUCCUAG
cfa-mir-125b-2      ------------------------------------------------------------
cgr-mir-125b        --------------------------------------------------CUUUUCCUAG
dre-mir-125b-1      ---------------UUCUGUUGCAGGUUGGCGGUUGGUCUGCAAAUGUGCCUCUCACAA
dre-mir-125b-3      ------------------------------CCCGUGCGGCCACCGCUGCACUCCUCCUGG
eca-mir-125b-2      -------------------------------------------------------CCUAG
gga-mir-125b        --------------------------------------------AUCAGACUUUUCCUAG
ggo-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
hsa-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
lla-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
mml-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
mne-mir-125b-1      ----------------------------------------------UGCGCUCCUCUCAG
mdo-mir-125b-1      -------------------------------------------------ACUUUUCCUAG
mmu-mir-125b-1      ----------------------------------------------UGCGCUCCCCUCAG
ola-mir-125b-2      -----------------------------------GUAGACUCUGUCGUACUUCACCUGC
ppa-mir-125b        ----------------------------------------------UGCGCUCCUCUCAG
ptr-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
ppy-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
rno-mir-125b-2      --------------------------------------------ACCAGACUUUUCCUAG
sla-mir-125b        ----------------------------------------------UGCGCUCCUCUCAG
sja-mir-125b        -----------------------------------------------------------A
sme-mir-125b        ---------------------------------------------GCAAGUUAUUCGACA
ssc-mir-125b-1      ----------------------------------------------------CCUCUCAG
xtr-mir-125b-1      ----------------------------------------------UGCACCCCUCUCAA
aca-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUAGUUUUU-AAGUCCACGGGUUAGGCUCUUGGGA
age-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
bta-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
bfl-mir-125b        CUCCCAAGAUCCUAACCUGUGAGCCAUGGA-------CAUCACAAGUUAGGGUCUCAGGG
cfa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ccr-mir-125b        UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUGAAAAUCACAGGUUAAGCUCUUGGGA
dre-mir-125b-2      UCCCUGAGACCCUAACUUGUGACGUUCUGCUUCG-AUGUCCACGGGUUGGGUUCUCGGGA
eca-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
fru-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCACGGGUUGGGUUCUUGGGA
ggo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
hsa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
lla-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
lca-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mml-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mne-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mdo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mmu-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGUUCUUGGGA
ola-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUGCUCUG-AUGUGCACGGGUUGGGCUCUUGGGA
ptr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ppy-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
rno-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
sko-mir-125b        UCCCUGAGACCCUAACUUGUGAGAAUUACCCAGCA---UUCACAGGUUAGUGGCUUAGGA
sha-mir-125b        UCCCUGAGACCCUAACUUGUGAGAUU-UUUUAGCAAUAAUCACAGGUCAGGCUCUUGGGA
sma-mir-125b        UCCCUGAGACUGAUAAUUGCUCUUUUUAUCAUGAUAAG-----GGAGUUUGAUGAGAGCA
ssc-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
tni-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCACGGGUUGGGUUCUUGGGA
xtr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGAUUUUUUAGCAACAAUCACAAGUUAGGCUCUUGGGA
aca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUU--UUUAGUAACAAUCACAAGUCAGGCUCUUGGGA
age-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
bta-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAGCAUCACAAGUCAGGCUCUUGGGA
cfa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
cgr-mir-125b        UCCCUGAGACCCUAACUUGUGAGGGA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
dre-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUCCUGUU-AUGUGCACGGGUUAGGUUCUUGGGA
dre-mir-125b-3      UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUAAAAAUCACAGGUUAAGCUCUUGGGA
eca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUGGUAACAUCACAAGUCAGGCUCUUGGGA
gga-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUU-UUGUAGCAACAAUCACAAGUCAGGCUCUUGGGA
ggo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
hsa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
lla-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
mml-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mne-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
mdo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAGGCU-UUUCAGCGACAACCACAGGUCAGGCUCUUGGGA
mmu-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ola-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGCUCUCUUGAUAAAAAAUCACGGGUUAGGCUCUUGGGA
ppa-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUAACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
ptr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
ppy-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
rno-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA--UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
sla-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
sja-mir-125b        UCCCUGAGACUGAUAAUUGCUCUAGUUAUUAUAUCAUUAA-UGAGUUUACAAUAAGGGCA
sme-mir-125b        UCCCUGAGAUCAUAAUAUGCCUGAGAUUUGAACGCAAACCGGUAGAUUAUUGUCUCAGAG
ssc-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
xtr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUAGCUUUAAAAAUCCACGGGUUAGGCUCUUGGGA
** .***     *  **                        ..           .* .
aca-mir-125b-1      GCUGUGAGUUGUGCCAC------------------------
age-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
bta-mir-125b-1      GCUGCGAGUCGCGCC--------------------------
bfl-mir-125b        AAUGGGG----------------------------------
cfa-mir-125b-1      GC---------------------------------------
ccr-mir-125b        CC---------------------------------------
dre-mir-125b-2      GCUGUGAGAGGCAC---------------------------
eca-mir-125b        GCUGCGAGUCGUGCC--------------------------
fru-mir-125b        GCUG-------------------------------------
ggo-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
hsa-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
lla-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
lca-mir-125b        CCUAGGCGGAGGGGA--------------------------
mml-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mne-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mdo-mir-125b-2      GC---------------------------------------
mmu-mir-125b-2      CCUAGGC----------------------------------
ola-mir-125b-1      GCUGCGAGGGGCACUCACACAUCU-----------------
ptr-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
ppy-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
rno-mir-125b-1      GCUGCGAGUCGUGC---------------------------
sko-mir-125b        AUUGGGUGGUGCAUUCAUA----------------------
sha-mir-125b        CCUAGGCGGAGGGGAACCAGCAGCUCUGGAC----------
sma-mir-125b        AUUAUUA------------------CUCUCAGGUGUA----
ssc-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
tni-mir-125b        GCUGCGAGGGGCGCUCACACAUC------------------
xtr-mir-125b-2      CCUAGGCGGAGGG----------------------------
aca-mir-125b-2      CCUAGGCGGAGGGGAACC-----------------------
age-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
bta-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
cfa-mir-125b-2      CCU--------------------------------------
cgr-mir-125b        CCUAGGCGGA-------------------------------
dre-mir-125b-1      GCUGAGAGGGGUGCUCUGUCAUCAGCCCGCCGGCGUCGGAA
dre-mir-125b-3      CCUGGGCAGAGGGCAAAAGCACUGG----------------
eca-mir-125b-2      CCUAGGC----------------------------------
gga-mir-125b        CCUAGGCGGAGGGGA--------------------------
ggo-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
hsa-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
lla-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mml-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mne-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mdo-mir-125b-1      CCUAGGCGGAGG-----------------------------
mmu-mir-125b-1      GCUG-------------------------------------
ola-mir-125b-2      CGCGGGCGGAGGGCACAAUCGAC------------------
ppa-mir-125b        GCUGCGAGUCGUAAU--------------------------
ptr-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
ppy-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
rno-mir-125b-2      CCUAGGCGGAGAGG---------------------------
sla-mir-125b        GCUGCGAGUCGUGCU--------------------------
sja-mir-125b        AUUAUUA------------------UUCUCAGGUGU-----
sme-mir-125b        UAAUUGAUAAAC-----UGCA--------------------
ssc-mir-125b-1      GCUGCGAGCCGUG----------------------------
xtr-mir-125b-1      GCUGUGAGUUGUGC---------------------------
aca-mir-125b-1      ----------------------- --- ---- ------- UGCGCCCCUCUCUG
age-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
bta-mir-125b-1      ----------------------- --- ---- ------- CGCGCGCCUCUCAA
bfl-mir-125b        ----------------------- --- ----------GUGGAGGGCGUAUGUCACCCAG
cfa-mir-125b-1      ----------------------- --- ---- -------
ccr-mir-125b        ----------------------- --- ------------ GG
dre-mir-125b-2      ----------------------- --- ---- ------- GUGCCCCUCUCCU
eca-mir-125b        ----------------------- --- ------------ UGCGCUCCUCUCAA
fru-mir-125b        ----------------------- --- ------------ CUCUCAU
ggo-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
hsa-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
lla-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
lca-mir-125b        ----------------------- --- ------------ ACCAGACUUUUCCUAG
mml-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
mne-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
mdo-mir-125b-2      ----------------------- --- ---- ------- AA
mmu-mir-125b-2      ----------------------- --- ---- ------- GCCUAG
ola-mir-125b-1      ----------------------- --- ---- ------- AACCUGUACCUCUCUCAU
ptr-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
ppy-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
rno-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCCCUCAG
sko-mir-125b        ----------------------- --- -----------CUCUAUAUGUGUAUUACCUAA
sha-mir-125b        UCCAAAAUAUCCGUACUAUAGAAGAAAGAAUUCUACUGCA A U AGA UU U CUAG
sma-mir-125b        ----------------------- --- ------------ A
ssc-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
tni-mir-125b        ----------------------- --- ------------ GUACCUCUCUCAU
xtr-mir-125b-2      ----------------------- --- ---- ------- GACUUUUCCUAG
aca-mir-125b-2      ----------------------- --- ---- ------- CAGACUUUUCCUAG
age-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
bta-mir-125b-2      ----------------------- --- ---- ------- GACUUUUCCUAG
cfa-mir-125b-2      ----------------------- --- ---- -------
cgr-mir-125b        ----------------------- --- ------------ CUUUUCCUAG
dre-mir-125b-1      ---------------UUCUGUUGCAGGUUGGCGGUUGGUCUGCAAAUGUGCCUCUCA AA
dre-mir-125b-3      ----------------------- --- --CCCGUGCGGCCACCGCUGCACUCCUCCUGG
eca-mir-125b-2      ----------------------- --- ---- ------- CCUAG
gga-mir-125b        ----------------------- --- ------------ AUCAGACUUUUCCUAG
ggo-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
hsa-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
lla-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
mml-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
mne-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCUCUCAG
mdo-mir-125b-1      ----------------------- --- ---- ------- ACUUUUCCUAG
mmu-mir-125b-1      ----------------------- --- ---- ------- UGCGCUCCCCUCAG
ola-mir-125b-2      ----------------------- --- ---- --GUAGACUCUGUCGUACUUCACCUGC
ppa-mir-125b        ----------------------- --- ------------ UGCGCUCCUCUCAG
ptr-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
ppy-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
rno-mir-125b-2      ----------------------- --- ---- ------- ACCAGACUUUUCCUAG
sla-mir-125b        ----------------------- --- ------------ UGCGCUCCUCUCAG
sja-mir-125b        ----------------------- --- ------------ A
sme-mir-125b        ----------------------- --- ------------ GCAAGUUAUUCGACA
ssc-mir-125b-1      ----------------------- --- ---- ------- CCUCUCAG
xtr-mir-125b-1      ----------------------- --- ---- ------- UGCACCCCUCUCAA
aca-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUAGUUUUU-AAGUCCA GG UU GG CUUGG A
age-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
bta-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
bfl-mir-125b        CUCCCAAGAUCCUAACCUGUGAGCCAUGGA-------CAU A AAGUU GGG CU AG G
cfa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
ccr-mir-125b        UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUGAAAAUCA AG UU AG CUUGG A
dre-mir-125b-2      UCCCUGAGACCCUAACUUGUGACGUUCUGCUUCG-AUGUCCA GG UUGGGU CU GG A
eca-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
fru-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCA GG UUGGGU CUUGG A
ggo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
hsa-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
lla-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
lca-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
mml-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
mne-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
mdo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
mmu-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GGU CUUGG A
ola-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUGCUCUG-AUGUGCA GG UUGGG CUUGG A
ptr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
ppy-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
rno-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
sko-mir-125b        UCCCUGAGACCCUAACUUGUGAGAAUUACCCAGCA---UUCA AG UU GUGGCUUAG A
sha-mir-125b        UCCCUGAGACCCUAACUUGUGAGAUU-UUUUAGCAAUAAUCA AG UC GG CUUGG A
sma-mir-125b        UCCCUGAGACUGAUAAUUGCUCUUUUUAUCAUGAUAAG-----GGAGUUUGAUG GAGCA
ssc-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
tni-mir-125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-AUGUGCA GG UUGGGU CUUGG A
xtr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGAUUUUUUAGCAACAAUCA AA UU GG CUUGG A
aca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUU- UUUAGUAACAAUCA AA UC GG CUUGG A
age-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
bta-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAGCAUCA AA UC GG CUUGG A
cfa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
cgr-mir-125b        UCCCUGAGACCCUAACUUGUGAGGGA- UUUUAGUAACAUCA AA UC GG CUUGG A
dre-mir-125b-1      UCCCUGAGACCCUAACUUGUGACGUUUUCCUGUU-AUGUGCA GG UU GGU CUUGG A
dre-mir-125b-3      UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUAAAAAUCA AG UU AG CUUGG A
eca-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUGGUAACAUCA AA UC GG CUUGG A
gga-mir-125b        UCCCUGAGACCCUAACUUGUGAGGUU-UUGUAGCAACAAUCA AA UC GG CUUGG A
ggo-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
hsa-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
lla-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
mml-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
mne-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
mdo-mir-125b-1      UCCCUGAGACCCUAACUUGUGAGGCU-UUUCAGCGACAACCA AG UC GG CUUGG A
mmu-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
ola-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGCUCUCUUGAUAAAAAAUCA GG UU GG CUUGG A
ppa-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUAACCGUUU-AAAUCCA GG UU GG CUUGG A
ptr-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
ppy-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
rno-mir-125b-2      UCCCUGAGACCCUAACUUGUGAGGUA- UUUUAGUAACAUCA AA UC GG CUUGG A
sla-mir-125b        UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
sja-mir-125b        UCCCUGAGACUGAUAAUUGCUCUAGUUAUUAUAUCAUUAA-UGAGUUU AAUA GGGCA
sme-mir-125b        UCCCUGAGAUCAUAAUAUGCCUGAGAUUUGAACGCAAACCGGUAGAUU UG CUC GAG
ssc-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCA GG UU GG CUUGG A
xtr-mir-125b-1      UCCCUGAGACCCUAACUUGUGAUGUUUAGCUUUAAAAAUCCA GG UU GG CUUGG A
** .***     *  **                        ..     .  .
aca-mir-125b-1      GCUGUGAGUUGUGCCAC------ --- ---- --------
age-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
bta-mir-125b-1      GCUGCGAGUCGCGCC-------- --- ---- --------
bfl-mir-125b        AAUGGGG---------------- --- -------------
cfa-mir-125b-1      GC--------------------- --- ---- --------
ccr-mir-125b        CC--------------------- --- -------------
dre-mir-125b-2      GCUGUGAGAGGCAC--------- --- ---- --------
eca-mir-125b        GCUGCGAGUCGUGCC-------- --- -------------
fru-mir-125b        GCUG------------------- --- -------------
ggo-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
hsa-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
lla-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
lca-mir-125b        CCUAGGCGGAGGGGA-------- --- -------------
mml-mir-125b-2      CCUAGGCGGAGGGGA-------- --- ---- --------
mne-mir-125b-2      CCUAGGCGGAGGGGA-------- --- ---- --------
mdo-mir-125b-2      GC--------------------- --- ---- --------
mmu-mir-125b-2      CCUAGGC---------------- --- ---- --------
ola-mir-125b-1      GCUGCGAGGGGCACUCACACAUCU--- ---- --------
ptr-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
ppy-mir-125b-1      GCUGCGAGUCGUGCU-------- --- ---- --------
rno-mir-125b-1      GCUGCGAGUCGUGC--------- --- ---- --------
sko-mir-125b        AUUGGGUGGUGCAUUCAUA----------------------
sha-mir-125b        CCUAGGCGGAGGGGAACCAGCAGCUCUGGAC----------
sma-mir-125b        AUUAUUA------------------CUCUCAGGUGUA----
ssc-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
tni-mir-125b        GCUGCGAGGGGCGCUCACACAUC------------------
xtr-mir-125b-2      CCUAGGCGGAGGG----------------------------
aca-mir-125b-2      CCUAGGCGGAGGGGAACC-----------------------
age-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
bta-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
cfa-mir-125b-2      CCU--------------------------------------
cgr-mir-125b        CCUAGGCGGA-------------------------------
dre-mir-125b-1      GCUGAGAGGGGUGCUCUGUCAUCAGCCCGCCGGCGUCGGAA
dre-mir-125b-3      CCUGGGCAGAGGGCAAAAGCACUGG----------------
eca-mir-125b-2      CCUAGGC----------------------------------
gga-mir-125b        CCUAGGCGGAGGGGA--------------------------
ggo-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
hsa-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
lla-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
mml-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mne-mir-125b-1      GCUGCGAGUCGUGCU--------------------------
mdo-mir-125b-1      CCUAGGCGGAGG-----------------------------
mmu-mir-125b-1      GCUG-------------------------------------
ola-mir-125b-2      CGCGGGCGGAGGGCACAAUCGAC------------------
ppa-mir-125b        GCUGCGAGUCGUAAU--------------------------
ptr-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
ppy-mir-125b-2      CCUAGGCGGAGGGGA--------------------------
rno-mir-125b-2      CCUAGGCGGAGAGG---------------------------
sla-mir-125b        GCUGCGAGUCGUGCU--------------------------
sja-mir-125b        AUUAUUA------------------UUCUCAGGUGU-----
sme-mir-125b        UAAUUGAUAAAC-----UGCA--------------------
ssc-mir-125b-1      GCUGCGAGCCGUG----------------------------
xtr-mir-125b-1      GCUGUGAGUUGUGC---------------------------
aca-mir-125b-1      ------------------------------------------- --UGCGCCCCUCUCUG
age-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
bta-mir-125b-1      ------------------------------------------- --CGCGCGCCUCUCAA
bfl-mir-125b        --------------------------------------GUGGAGGGCGUAUGUCACCCAG
cfa-mir-125b-1      ------------------------------------------- --- ---- -------
ccr-mir-125b        ------------------------------------------- --- ----------GG
dre-mir-125b-2      ------------------------------------------- ---GUGCCCCUCUCCU
eca-mir-125b        ------------------------------------------- --UGCGCUCCUCUCAA
fru-mir-125b        ------------------------------------------- --- -----CUCUCAU
ggo-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
hsa-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
lla-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
lca-mir-125b        ------------------------------------------- ACCAGACUUUUCCUAG
mml-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
mne-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
mdo-mir-125b-2      ------------------------------------------- --- ---- -----AA
mmu-mir-125b-2      ------------------------------------------- --- ---- -GCCUAG
ola-mir-125b-1      ------------------------------------------AACCUGUACCUCUCUCAU
ptr-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
ppy-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
rno-mir-125b-1      ------------------------------------------- --UGCGCUCCCCUCAG
sko-mir-125b        ---------------------------------------CUCUAUAUGUGUAUUACCUAA
sha-mir-125b        UCCAAAAUAUCCGUACUAUAGAAGAAAGAAUUCUACUGCAUCAAAUAAGACUUUUCCUAG
sma-mir-125b        ------------------------------------------- --- -----------A
ssc-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
tni-mir-125b        ------------------------------------------- ---GUACCUCUCUCAU
xtr-mir-125b-2      ------------------------------------------- --- GACUUUUCCUAG
aca-mir-125b-2      ------------------------------------------- --CAGACUUUUCCUAG
age-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
bta-mir-125b-2      ------------------------------------------- --- GACUUUUCCUAG
cfa-mir-125b-2      ------------------------------------------- --- ---- -------
cgr-mir-125b        ------------------------------------------- --- --CUUUUCCUAG
dre-mir-125b-1      ---------------UUCUGUUGCAGGUUGGCGGUUGGUCUGCAAAUGUGCCUCUCACAA
dre-mir-125b-3      ------------------------------CCCGUGCGGCCACCGCUGCACUCCUCCUGG
eca-mir-125b-2      ------------------------------------------- --- ---- --CCUAG
gga-mir-125b        ------------------------------------------- AUCAGACUUUUCCUAG
ggo-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
hsa-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
lla-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
mml-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
mne-mir-125b-1      ------------------------------------------- --UGCGCUCCUCUCAG
mdo-mir-125b-1      ------------------------------------------- --- -ACUUUUCCUAG
mmu-mir-125b-1      ------------------------------------------- --UGCGCUCCCCUCAG
ola-mir-125b-2      -----------------------------------GUAGACUCUGUCGUACUUCACCUGC
ppa-mir-125b        ------------------------------------------- --UGCGCUCCUCUCAG
ptr-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
ppy-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
rno-mir-125b-2      ------------------------------------------- ACCAGACUUUUCCUAG
sla-mir-125b        ------------------------------------------- --UGCGCUCCUCUCAG
sja-mir-125b        ------------------------------------------- --- -----------A
sme-mir-125b        ------------------------------------------- -GCAAGUUAUUCGACA
ssc-mir-125b-1      ------------------------------------------- --- ----CCUCUCAG
xtr-mir-125b-1      ------------------------------------------- --UGCACCCCUCUCAA
aca mir 125b 1      UCCCUGAGACCCUAACUUGUGACGUU AGUUUUU-AAG CCACGGGUUAGGCUCUUGGGA
age mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
bta mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUUUA CGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
bfl mir 125b        CUCCCAAGAUCCUAACCU AGCCAU G ------- UCACAAGUUAGGGUCUCAGGG
cfa mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU AAAUCCACGGGUUAGGCUCUUGGGA
ccr mir 125b        UCCCUGAGACCCUAACUUGUGAGCUUUGUGUGCUGAAAAUCACAGGUUAAGCUCUUGGGA
dre mir 125b 2      UCCCUGAGACCCUAACUUGUGACGUUCUGCUU G-A GUCCACGGGUUGGGUUCUCGGGA
eca mir 125b        UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
fru mir 125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUGUG-A GUGCACGGGUUGGGUUCUUGGGA
ggo mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
hsa mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
lla mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
lca mir 125b        UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
mml mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
mne mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
mdo mir 125b 2      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU AAAUCCACGGGUUAGGCUCUUGGGA
mmu mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA UUUUAGUAAC UCACAAGUCAGGUUCUUGGGA
ola mir 125b 1      UCCCUGAGACCCUAACUUGUGACGUU UGCU G-A GUGCACGGGUUGGGCUCUUGGGA
ptr mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
ppy mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
rno mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
sko mir 125b        UCCCUGAGACCCUAACUUGUGAG AU ACCC GC ---UUCACAGGUUAGUGGCUUAGGA
sha-mir-125b        UCCCUG CCCUA UGUGAG U -UUUUAGCAAUA UCACAGGUCAGGCUCUUGGGA
sma mir 125b        UCCCUGAGACUGAUAAUUGCUCUUUUUAUCAUGAUAAG ----GGAGUUUGAUGAGAGCA
ssc mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
tni mir 125b        UCCCUGAGACCCUAACUUGUGACGUUGUGCUG G-A GUGCACGGGUUGGGUUCUUGGGA
xtr mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGAUUUUUUAGCAA A UCACAAGUUAGGCUCUUGGGA
aca mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUU--UUUAG AA A UCACAAGUCAGGCUCUUGGGA
age mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
bta mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA UUU AG AGC UCACAAGUCAGGCUCUUGGGA
cfa mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA UUUUAGUAACAUCACAAGUCAGGCUCUUGGGA
cgr mir 125b        UCCCUGAGACCCUAACUUGUGAGGGA UUU AG AAC UCACAAGUCAGGCUCUUGGGA
dre mir 125b 1      CC U AGACC UAACUUGUGA GUU UCCUG U-AUGUGCACGGGUUAGGUUCUUGGGA
dre mir 125b 3      UCCCUGAGAC UAACUU UG G UU UGUG UAAAAAUCACAGGUUAAGCUCUUGGGA
eca mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA UUUUGGUAAC UCACAAGUCAGGCUCUUGGGA
gga mir 125b        UCCCUGAGACCCUAACUUGUGAGGU -UUGUAGCAA A UCACAAGUCAGGCUCUUGGGA
ggo mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
hsa mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
lla mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
mml mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
mne mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
mdo mir 125b 1      UCCCUGAGACCCUAACUUGUGAGGCU UUU AGCGA A CCACAGGUCAGGCUCUUGGGA
mmu mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
ola mir 125b 2      UCCCUGAGACCCUAAC U UGAGCUCUC UGA A AAAAUCACGGGUUAGGCUCUUGGGA
ppa mir 125b        UCCCUGAGACCCUAACUUGUGAUGUUAA CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
ptr mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
ppy mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
rno mir 125b 2      UCCCUGAGACCCUAACUUGUGAGGUA--UUU AG AAC UCACAAGUCAGGCUCUUGGGA
sla mir 125b        UCCCUGAGACCCUAACUUGUGAUGUU A CG UU-AAAUCCACGGGUUAGGCUCUUGGGA
sja mir 125b        UCCCUGAGACUGAUAAUUGCUCUAGUUAUUAUAUCAUUA -UGAGUUUACAAUAAGGGCA
sme mir 125b        UCCCUGAGAUCAUAAUAUGCCUGAGAUUU AACGCAA CGGUAGAUUAUUGUCUCAGAG
ssc mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUUUACCGUUU-AAAUCCACGGGUUAGGCUCUUGGGA
xtr mir 125b 1      UCCCUGAGACCCUAACUUGUGAUGUU AGCUUUAAAAAUCCACGGGUUAGGCUCUUGGGA
** .***     *  **                        ..           .* .
aca-mir-125b-1      CU GAGU G GCC C------------------------
age-mir-125b-1      C CGAGU GCU--------------------------
bta-mir-125b-1      C CGAGU CGCC--------------------------
bfl-mir-125b        A UGGGG--- ------------------------
cfa-mir-125b-1      C------------ --------------------------
ccr-mir-125b        CC---------------------------------------
dre-mir-125b-2      CU GAGAGGCAC --------------------------
eca-mir-125b        C CGAGU GCC--------------------------
fru-mir-125b        CU ---------- --------------------------
ggo-mir-125b-1      C CGAGU GCU--------------------------
hsa-mir-125b-1      C CGAGU GCU--------------------------
lla-mir-125b-1      C CGAGU GCU--------------------------
lca-mir-125b        CCUAGGCGGAGGG A--------------------------
mml-mir-125b-2      CCUAGGCGGAGGG A--------------------------
mne-mir-125b-2      CCUAGGCGGAGGG A--------------------------
mdo-mir-125b-2      C------------ --------------------------
mmu-mir-125b-2      CCUAGGC ---------------------------------
ola-mir-125b-1      CU CGAG GG ACUCACACAU U-----------------
ptr-mir-125b-1      C CGAGU GCU--------------------------
ppy-mir-125b-1      C CGAGU GCU--------------------------
rno-mir-125b-1      C CGAGU GC --------------------------
sko-mir-125b        AUUGGG GGUGCAUUCAUA----------------------
sha-mir-125b        CCU GGCGGAGG G CC G GCUC GGAC----------
sma-mir-125b        AU A A----------- --CUC CAGGUGU ----
ssc-mir-125b-2      CCUAGGCGGAGGG A--------------------------
tni-mir-125b        CU CGAG GGCGCUCACACAU ------------------
xtr-mir-125b-2      CCUAGGCGGAGG ----------------------------
aca-mir-125b-2      CCUAGGCGGAGG G C-----------------------
age-mir-125b-2      CCUAGGCGGAGGG A--------------------------
bta-mir-125b-2      CCUAGGCGGAGGG A--------------------------
cfa-mir-125b-2      CCU--- ---------------------------------
cgr-mir-125b        CCUA GCGGA-------------------------------
dre-mir-125b-1      CU AGAGGGGUGCUC CAU A CCCGCCGG G C A
dre-mir-125b-3      CCUGGGCAGAG GC GCACUG ----------------
eca-mir-125b-2      CCUAGGC ---------------------------------
gga-mir-125b        CCUAGGCGGAGG G --------------------------
ggo-mir-125b-2      CCUAGGCGGAGGG A--------------------------
hsa-mir-125b-2      CCUAGGCGGAGGG A--------------------------
lla-mir-125b-2      CCUAGGCGGAGGG A--------------------------
mml-mir-125b-1      C CGAGU GCU--------------------------
mne-mir-125b-1      C CGAGU GCU--------------------------
mdo-mir-125b-1      CCUAGGCGGAGG-----------------------------
mmu-mir-125b-1      C ---------- --------------------------
ola-mir-125b-2      CGCGGGCGGA GGC C UCG ------------------
ppa-mir-125b        C CG GU AAU--------------------------
ptr-mir-125b-2      CCUAGGCGGAGGG A--------------------------
ppy-mir-125b-2      CCUAGGCGGAGGG A--------------------------
rno-mir-125b-2      CCUAGGCGGAGAG ---------------------------
sla-mir-125b        C CGAGU GCU--------------------------
sja-mir-125b        AU U A------------- ---- CU GGUGU-----
sme-mir-125b        UAAUUGA AA C-----UG A--------------------
ssc-mir-125b-1      C CGAG G- --------------------------
xtr-mir-125b-1      C GAGUUG GC---------------------------
hsa-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ptr-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ppy-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
mml-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
mmu-mir-324      AACUGACUAUGCCUCCUCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
rno-mir-324      --CUGACUAUGCCUCCUCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
bta-mir-324      AACUGGCUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ssc-mir-324      ------CUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUGAAGCUGGAGACCCACUGCC
cfa-mir-324      -----------------CGCAUCCCCUAGGGCAUUGGUGUGGAGCUGGAGACCCACUGCC
eca-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
***********************..******************
hsa-mir-324      CCAGGU CUGCUGGGGGUUGUAGUC----
ptr-mir-324      CAGGUGCUGCUGGGGGUUGUAGU-----
ppy-mir-324      CCAGGU CUGCUGGGGGUUGUAGUC----
mml-mir-324      CCAGGU CUGCUGGGGGUUGUAGUC----
mmu-mir-324      CCAGGU CUGCUGGGGGUUGUAGUCUGAC
3 4  CCAGGU CUGCUGGGGGUUGUAGUC----
bta 3 4 CCAGGUGCUGCUGGGGGUUGUAGUCUGAC
sc 3 4 CCAGGUGCUGCUGGGGGUUGUAGUCU--
cf 3 4 CCAGGU CUGCUGGGGGUUGU GUC----
eca 3 4    CAGGUGCUGCUGGGGGUUGUAGUC---
************************ 
hsa-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ptr-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ppy-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
mml-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
mmu-mir-324      AACUGACUAUGCCUCCUCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
rno-mir-324      --CUGACUAUGCCUCCUCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
bta-mir-324      AACUGGCUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
ssc-mir-324      ------CUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUGAAGCUGGAGACCCACUGCC
cfa-mir-324      -----------------CGCAUCCCCUAGGGCAUUGGUGUGGAGCUGGAGACCCACUGCC
eca-mir-324      --CUGACUAUGCCUCCCCGCAUCCCCUAGGGCAUUGGUGUAAAGCUGGAGACCCACUGCC
***********************..******************
hsa-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
ptr-mir-324      CCAGGUGCUGCUGGGGGUUGUAGU-----
ppy-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
mml-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
mmu-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUCUGAC
rno-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
bta-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUCUGAC
ssc-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUCU---
cfa-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
eca-mir-324      CCAGGUGCUGCUGGGGGUUGUAGUC----
************************ 
A. 
B. 
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Figure 4.4 Phylogeny analysis of miR-125b sequences 
 
Figure 4.4 Phylogeny analysis of miR-125b sequences. Following sequence alignment using 
Clustal OMEGA, phylogeny analysis was performed using ClustalW2 Phylogeny 
(http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/), with the following 
settings; tree format=Default, Distance correction=off (default), Exclude gaps-on (not 
default), clustering method=neighbour joining (default), P.I.M=off (default). Cluster 
grouping (clades) were named ‘a’,’b’ and ‘c’ for reference in the text. See Table 4.2 for list 
of species abbreviations. 
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Figure 4.5 Evolution of miR-125b and miR-324 
 
Figure 4.5 Evolution of miR-125b and miR-324. Information on the species which contain 
miR-125b and miR-324-5p stem-loops was obtained from miRBase. Times of divergence of 
each of these species were obtained from Time Tree (www.timetree.org). Species 
containing the stem-loops were arranged in a phylogenic tree using Phylodendron 
(http://iubio.bio.indiana.edu/treeapp/), and the time of divergence displayed on the x axis 
as an indicator of miRNA age. ‘*’ indicates miR-324 origin, ‘#’ indicates miR-125b origin, ‘+’ 
and ‘++’ indicates duplication of the miR-125b locus and ‘?’ where there is uncertainty of 
the time of divergence of two species. 
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Table 4.2 Evolution of miR-125b and miR-324-5p 
 
 
Table 4.2 Evolution of miR-125b and miR-324-5p. Table showing list of species which have 
an annotated miR-125b loci, the number of years (millions) since divergence from 
humans, the number of annotated miR-125b loci, the number of annotated miR-324 loci 
and the clade to which each miR-125b loci belongs in Figure 4.4. 
 
miR-125b loci type
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Homo sapiens hsa 0 2 bi ci 1
Pan troglodytes ptr 6.3 2 bi ci 1
Pan paniscus ppa 6.3 1 bi
Gorilla gorilla ggo 8.8 2 bi ci
Pongo pygmaeus ppy 15.7 2 bi ci 1
Macaca nemestrina mne 29 2 bi ci
Macaca mulatta mml 29 2 bi ci 1
Lagothrix lagotricha lla 42.6 2 bi ci
Ateles geoffroyi age 42.6 2 bi ci
Saguinus labiatus sla 42.6 1 bi
Lemur catta lca 74 1 ci
Cricetulus griseus cgr 92.3 1 ci
Mus musculus mmu 92.3 2 bi ci 1
Rattus norvegicus rno 92.3 2 bi ci 1
Bos taurus bta 94.2 2 bi ci 1
Sus scrofa ssc 94.2 2 bi ci 1
Canis familiaris cfa 94.2 2 bi ci 1
Equus caballus eca 94.2 2 bi ci 1
Monodelphis domestica mdo 162.6 2 cii bi
Sarcophilus harrisii sha 162.6 1 cii
Anolis carolinensis aca 296 2 bii cii
Gallus gallus gga 296 1 cii
Xenopus tropicalis xtr 371.2 2 biii cii
Tetraodon nigroviridis tni 400.1 1 bii
Fugu rubripes fru 400.1 1 bii
Oryzias latipes ola 400.1 2 bii ciii
Cyprinus carpio ccr 400.1 1 civ
Danio rerio dre 400.1 3 bii bii civ
Saccoglossus kowalevskii sko 661.2? 1 a
Branchiostoma floridae bfl 713.2? 1 a
Schistosoma japonicum sja 792.4 1 a
Schistosoma mansoni sma 792.4 1 a
Schmidtea mediterranea sme 792.4 1 a
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4.2.3 Predicted targets and functions of miR-125b-5p and miR-324-5p 
A number of prediction sites can be used to predict miRNA targets; each has a slightly 
different algorithm and therefore predicts a different repertoire of targets (Chapter 1). 
Figure 4.6 shows the number and cross-over of targets predicted by each prediction site 
for mouse miR-125b-5p (Figure 4.6A), mouse miR-324-5p (Figure 4.6B), human miR-125b-
5p (Figure 4.6C) and human miR-324-5p (Figure 4.6D). 
DAVID pathway analysis is an online tool used to provide functional analysis of large gene 
lists. It works by using a modified version of the Fishers exact test [211]. In this study I 
used the DAVID pathway analysis functional annotation chart. Pathway analysis was 
performed separately on the predicted targets of each prediction site. Where more than 
3,000 targets were predicted for a target prediction site, only the most highly scored 
3,000 targets were input into DAVID pathway analysis, as this is the limit of the tool. 
Pathways/terms were considered enriched if they have an EASE score (modified version of 
the Fishers exact test) >0.1 and a gene count of at least 2. Figure 4.7 shows the number 
and cross-over of terms/pathways considered to be enriched for each prediction site for 
mouse miR-125b-5p (Figure 4.7A), mouse miR-324-5p (Figure 4.7B), human miR-125b-5p 
(Figure 4.7C) and human miR-324-5p (Figure 4.7D). Venn diagrams for all terms/pathways, 
GO terms only and Kegg pathways analysis are shown.  
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Figure 4.6 Predicted targets of miR-125b-5p and miR-324-5p. 
 
Figure 4.6 Predicted targets of miR-125b-5p and miR-324-5p. The number and crossover 
of targets predicted by four online databases. (A) Predicted targets of mouse miR-125b-
5p. (B) Predicted targets of mouse miR-324-5p. (C) Predicted targets of human miR-125b-
5p. (D) Predicted targets of human miR-324-5p. (E) Common predicted targets of human 
and mouse miR-125b-5p. (F) Common predicted targets of human and mouse miR-324-5p. 
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Figure 4.7 Predicted functions of miR-125b-5p and miR-324-5p.  
 
Figure 4.7 Predicted functions of miR-125b-5p and miR-324-5p. Predicted targets for each 
online database were in put into DAVID pathway functional annotation chart, where more 
than 3000 targets were predicted only the top 3000 predicted target were input. Cut off 
for pathways being enriched was left at the DAVID default (0.1). The number and 
crossover of enriched pathways is shown. ‘All’ refers to all pathways and terms in the 
DAVID pathway analysis tool, which includes GO, Kegg and others.  (A) Pathway analysis of 
mouse miR-125b-5p predicted targets. (B) Pathway analysis of mouse miR-324-5p 
predicted targets. (C) Pathway analysis of human miR-125b-5p predicted targets. (D) 
Pathway analysis of human miR-324-5p predicted targets. 
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4.2.4 miR-324-5p but not miR-125b-5p targets human SMO and GLI1 3’UTRs 
In 2008, Ferretti et al. showed both miR-125b-5p and miR-324-5p regulate the Hh 
signalling pathway in human medulloblastoma [127]. The authors used luciferase 
constructs to show miR-125b-5p directly targets the Hh activator SMO, and miR-324-5p 
directly targets both SMO and the Hh transcription factor GLI1. To confirm this, luciferase 
reporter constructs were generated by cloning the human 3’UTR of either SMO or GLI1 
downstream of luciferase, placing luciferase under their control. In agreement with 
Ferretti et al., co-transfection of miR-324-5p with the constructs containing the SMO or 
GLI1 3’UTR reduces luciferase expression, indicating miR-324-5p can directly regulate 
human SMO and GLI1 3’UTRs (Figure 4.8A and B). Using site-directed mutagenesis we 
created constructs where the miR-324-5p binding site is no longer complementary to miR-
324-5p (Figure 4.8D and E). The extent to which miR-324-5p reduced the mutant construct 
luciferase was decreased compared to the wild-type construct (Figure 4.8A and B), 
indicating miR-324-5p exerts its action on the SMO and GLI1 3’UTR, through the binding 
sites proposed by Ferretti et al. Unexpectedly, miR-125b-5p significantly increased 
luciferase activity for the SMO wild-type and mutant 3’UTRs (Figure 4.8C and F), 
suggesting the human SMO 3’UTR is not a target of miR-125b-5p. 
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Figure 4.8 miR-324-5p and miR-125b-5p target components of the human Hh signalling 
pathway. 
 
Figure 4.8 miR-324-5p and miR-125b-5p target components of the human Hh signalling 
pathway. Cells were transfected with either GLI1wt, GLI1mt, SMOwt or SMOmt 3’UTR 
luciferase constructs (in pMIR-Report-Ambion) with either miCon, miR-324-5p or miR-
125b-5p. (A) miR-324-5p targets GLI1. (B) miR-324-5p targets SMO. (C) miR-125b-5p 
increases SMO 3’UTR luciferase. Schematic of miRNA interaction with wild-type (wt) 
(upper) and mutant (mt) (lower) 3’UTRs for (D) miR-324-5p:GLI, (E) miR-324-5p:SMO and 
(F) miR-125b-5p:SMO interactions. (G) Schematic of miR-125b-5p and miR-324-5p 
targeting Hh signalling in human. Data normalised to miCon for each plasmid and plotted 
as relative luciferase light units. All data are presented as mean + SEM, statistical 
difference were calculated using Student’s t-test, where, *p<0.05, **<0.01, ***p<0.001. 
Data combined from 5 independent experiments, each n=6. 
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4.2.5 Activation of Hh signalling in C3H10T1/2 
The Hh signalling pathway is known to be involved in cartilage formation, bone formation 
[178, 212] and OA [48]. I hypothesised that miR-125b-5p and miR-324-5p are also involved 
in these processes, especially given their altered expression in OA (Figure 4.1). Isolated 
human articular chondrocytes (HAC) are commonly used as an in vitro system to study the 
effects of molecules on chondrocytes and C3H10T1/2 cells are commonly used to the 
study the effects of molecules on osteoblastogeneisis and chondrogenesis. To test the 
ability of both cells to respond to Hh signalling I stimulated each cell type with Hh ligand 
(Ihh) for 48h. Gene expression analysis of the well characterised Hh response gene and 
transcription factor Gli1 confirmed both cell types had active Hh signalling (Figure 4.9). 
C3H10T1/2 had a more robust Hh response than HAC (Figure 4.9). Itherefore decided to 
use C3H10T1/2 cells to observe any modulatory effects of miR-125b-5p and miR-324-5p 
on Hh signalling. C3H10T1/2 is a mouse pluripotent mesenchymal cell-line, isolated from 
mouse embryonic C3H cells by Reznicoff et al. in 1973 [178]. In addition, C3H101/2 have a 
number of properties making them ideal for these studies. They are easily transfected 
and, under the correct stimuli, have the ability to undergo differentiation processes such 
as osteogenesis and chondrogenesis [180, 213]. 
In addition to activation of the Hh signalling pathway by ligands (Ihh, Shh and Dhh), it can 
also be activated by small molecule agonists of SMO such as Purmorphamine (Pur) [73] 
and SAG. [74] Following Ihh or Pur stimulation of C3H10T1/2 cells, Gli1 mRNA was 
robustly induced (Figure 4.10A) and increased in a time-dependent manner (Figure 4.10B 
and C). Similar to Gli1, Ptch is also a Hh response gene and part of the Hh signalling 
pathway, and as expected was also induced following Ihh and Pur stimulation, although to 
a lesser extent (3-4 fold) (Figure 4.10D), in a time dependent manner (Figure 4.10E and F). 
Ihh increased Gli1 protein expression as indicated by Immuno-blotting (Figure 4.10G). Part 
of Hh signalling activation also includes Smo relocalisation to the primary cilia. Following 
stimulation with Ihh, Smo increases around the primary cilium (Figure 4.10H). 
Quantification of the level of Smo, shows maximum localisation around the cilia following 
1h of Ihh stimulation (Figure 4.10I). 
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Figure 4.9 Hh response in HAC and C3H10T1/2 
 
Figure 4.9 Hh response in HAC and C3H10T1/2. (A) Human articular chondrocytes (HACs) 
were stimulated with 2μg/ml recombinant Indian hedgehog (Ihh) for 48h. Data combined 
from two patient donors, each n=4. (B) C3H10T1/2 cells were stimulated with 2μg/ml Ihh 
for 48h. Gli1 mRNA levels were then assessed using real time RT-PCR as described. Data 
from one n=4 experiment. All data are presented as mean + SD, statistical difference were 
calculated using Student’s t-test, where **<0.01, ***<0.001. 
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Figure 4.10 Activation of Hedgehog signalling in C3H10T1/2. 
 
 
Unstim Ihh Pur
0
50
100
150
200
***
**
R
e
la
ti
v
e
 G
li
1
 m
R
N
A
 /
1
8
S
Unstim Ihh Pur
0
1
2
3
4 ***
***
R
e
la
ti
v
e
 P
tc
h
 m
R
N
A
 /
1
8
S
Unstim 1 4 10  24
0
20
40
60
80
Ihh (h)
***
***
R
e
la
ti
v
e
 G
li
1
 /
1
8
S
Unstim 1 4 10  24
0
20
40
60
80
Pur (h)
***
***R
e
la
ti
v
e
 G
li
1
 /
1
8
S
Unstim 1 4 10  24
0
1
2
3
Ihh (h)
***
R
e
la
ti
v
e
 G
li
1
 /
1
8
S
Unstim 1 4 10  24
0
1
2
3
4
Pur (h)
***
***
***R
e
la
ti
v
e
 G
li
1
 /
1
8
s
Gll1 (160 kDa)
Unstim Ihh Unstim pur
170
130
100
70
55
40
35
15
kDa
170
130
100
70
55
40
35
15
kDa
Gll1 (160 kDa)
40
35
40
35
Gapdh (38 kDa)Gapdh (38 kDa)
A. B. C.
D.
G.
E. F.
86 
 
 
Figure 4.10 Activation of Hh signalling in C3H10T1/2. C3H10T1/2 cells stimulated with 
recombinant Ihh (2µg/ml) or Purmorphamine (Pur) (2uM) for 24h or the time shown. Real-
time RT-PCR was used to assess Gli1 and Ptch expression. Western blotting was used to 
assess Gli1 Protein. Acetylated α-tubulin and Smo immunostaining was used to assess Smo 
localisation around the primary cilia. (A) Ihh and Pur both increase Gli1 mRNA after 24h 
(data combined). (B) Ihh causes time dependent increase in Gli1 mRNA. (B) Pur causes 
time dependent increase in Gli1 mRNA. (D) Ihh and Pur increase Ptch mRNA after 24h 
(data combined). (E) Ihh causes time dependent increase in Ptch mRNA. (F) Pur causes 
time dependent increase in Ptch mRNA. (A-F) All data are presented as mean + SEM, 
statistical difference were calculated using ANOVA followed by a Bonferroni post test, 
where **<0.01, ***<0.001. Date from one representative experiment (n=6), of at least 
two independent experiments (G) Ihh and Pur increases Gli1 protein. Representative blot 
of at least 5 independent experiments (H) Ihh stimulation causes increased Smo 
localisation around the primary cilia. Representative cells are shown. Blue=DAPI, Green 
=SMO, Red= acetylated α-tubulin (I) Quantification of Smo localisation around the cilia 
with ImageJ (see materials and methods). Statistical difference were calculated using 
ANOVA followed by a Bonferroni post test, where **<0.01. Date combined from two 
independent experiments. 
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4.2.6 Inhibition of Hh signalling components in C3H10T1/2 
Ptch, Smo and Gli1 are key Hh signalling proteins. Depletion of these components with 
RNA interference should demonstrate the role of each in Hh signalling in C3H10T1/2. I 
therefore depleted each component with a pool of specific siRNAs (see materials and 
methods). As expected siRNA against Ptch, Smo and Gli1 all have the potential to alter Ihh 
and/or Pur induced Gli1 and Ptch expression (Figure 4.11), indicating all these 
components were involved in Hh signalling. There are however a number of additional 
effects of depleting these components on Hh signalling, some expected and some 
unexpected, these are described further in Appendix A.  
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Figure 4.11 RNA interference of Hedgehog signalling components. 
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Figure 4.11 RNA interference of Hh signalling components. C3H10T1/2 cells were 
transfected with non-targeting siCon or siRNA against Ptch, Smo and Gli1 for 24 h. Cells 
were then serum starved for 24h and either left unstimulated, stimulated for Ihh (2μg/ml) 
for 24h or stimulated with Purmorphamine (Pur) (2μM) for 24hr. Gli1, Ptch and Smo were 
assessed by real-time RT-PCR. Gli1 and Smo protein expression were assessed by 
Immunoblotting. (A) siRNA effect on basal Gli1 expression. (B) siRNA effect on Ihh induced 
Gli1 expression. (C) siRNA effect on Pur induced Gli1 expression. (D) siRNA effect on basal 
Ptch expression. (E) siRNA effect on Ihh induced Ptch expression. (F) siRNA effect on Pur 
induced Ptch expression. (G) siRNA effect on basal Smo expression. (H) siRNA effect on Ihh 
induced Smo expression. (I) siRNA effect on Pur induced Smo expression. Data combined 
from three independent experiments, each n=4. Data are presented as mean + SEM, 
statistical difference were calculated using ANOVA followed by a Bonferroni post test, 
where *p<0.05, **<0.01, ***<0.001. (J) Effect of siRNA on basal Gli1 and Smo protein. (K) 
Effect of siRNAs on Pur induced Gli1 and Smo protein levels. GAPDH was used as a loading 
control. 
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4.2.7 Hh signalling increases osteogenesis and chondrogenesis in C3H10T1/2 
Kinto et al. first showed Hh activation can induce osteoblast differentiation of C3H10T1/2 
[214]. Nakamura et al. then showed Ihh can synergise with Bmp2 in C3H10T1/2 to 
produce higher levels of alkaline phosphatase [179]. Indeed, I observed that stimulation of 
C3H10T1/2 with Bmp2 or Ihh increased alkaline phosphatase, and their combination 
produced a further increase, indicative of osteoblastogenesis (Figure 4.12). Since the 
original studies, Pur has been identified as an activator of Hh signalling and as expected 
increased alkaline phosphatase and caused a further increase when in combination with 
Bmp2 (Figure 4.12A). However siRNA against Gli1 did not reduce Bmp2 + Ihh induced 
alkaline phosphatase (Figure 4.12B). 
C3H10T1/2 can also undergo a type of chondrogenic differentiation when seeded into 
high density micromass cultures and stimulated with Bmp2 [180]. Chondrogenesis can be 
indicated by alcian blue, which stains glycosaminoglycans (GAG), and can be quantified by 
extracting alcian blue using guanidine hydrochloride (GHCl) and measuring absorbance at 
600nm (see materials and methods). As expected, Bmp2 increased alcian blue staining 
and the addition of Ihh to Bmp2 further increased alcian blue staining (Figure 4.13A and 
C). siRNA against Gli1 decreased basal (unstim), Bmp2 stimulated and Bmp2 + Ihh 
stimulated alcian blue (Figure 4.13B and D), indicating a role of Hh signalling in these 
micro masses, as previously suggested [215].  
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Figure 4.12 Effect of Hh signalling on Osteoblastogenesis. 
 
Figure 4.12 Effect of Hh signalling on Osteoblastogenesis. (A) C3H10T1/2 cells were 
seeded in mono-layer and were stimulated with either Ihh (2µg/ml), Bmp2 (100ng/ml) or 
Pur (2uM) either alone or in combination for 5 days. C3H10T1/2 cells were transfected 
with siCon or siGli1, then stimulated with Ihh (2µg/ml) and Bmp2 (100ng/ml) for 5 days. 
Alkaline phosphatase activity was used as a marker of osteogenesis. Relative alkaline 
phosphatase indicates relative absorbance at 405nm of alkaline phosphate yellow liquid 
substrate following incubation with cells. Data combined from three independent 
experiments, each n=3. All data are presented as mean + SEM, statistical difference were 
calculated using ANOVA followed by a Bonferroni post test, where **<0.01 and 
***<0.001. 
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Figure 4.13 Effect of Hh signalling on Chondrogenesis. 
 
Figure 4.13 Effect of Ihh signalling on chondrogenesis. C3H10T1/2 cells were either left 
untransfected or  pre transfected with either siCon or siGli1, seeded in micromasses and 
were stimulated with either Ihh (2µg/ml), Bmp2 (100ng/ml) either alone or in combination 
for 5 days. Alcian Blue was used as a marker of chondrogenesis. Alcian blue was quantified 
by extracting using GHCl and measuring absorbance at 600nm. (A) Bmp2 and Ihh effect on 
Alcian blue staining, (representative micromasses), (B) siGli1 effect on Alcian blue staining 
(representative micromasses). (C) Bmp2 and Ihh effect on extracted Alcian blue, data 
combined from 6 independent experiments, each n=2. (D) siGli1 effect on extracted Alcian 
blue, data combined from 2 independent experiments, each n=2. All data are presented as 
mean + SEM, statistical difference were calculated using ANOVA followed by a Bonferroni 
post test, where *p<0.05, **<0.01, ***<0.001. 
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4.2.8 miR-125b-5p and miR-324-5p regulate Hh signalling in C3H10T1/2 
Having established readouts of Ihh signalling, osteogenesis and chondrogenesis I next 
investigated the effects of miR-125b-5p and miR-324-5p on these processes. Our 
luciferase constructs suggest miR-324-5p directly regulates components of the Hh 
pathway in humans (Figure 4.8) and previous data by Ferretti et al. suggest both miR-
125b-5p and miR-324-5p are regulators of Hh signalling in humans [127]. I hypothesised 
that miR-125b-5p and miR-324-5p may regulate Hh signalling in mouse C3H10T1/2. Real-
time RT-PCR and western blot analysis of Gli1, showed pre transfection of either miR-
125b-5p or miR-324-5p inhibited Ihh induced Gli1 mRNA and protein expression 
respectively (Figure 4.14A and B), demonstrating miR-125b-5p and miR-324-5p can both 
regulate Hh signalling in the mouse C3H10T1/2 cell line. 
As shown in Figure 4.10H and I, Ihh stimulation causes Smo to move toward the primary 
cilia, with the greatest amount of Smo surrounding the primary cilium after 1h (Figure 
4.10H and I). I wanted to see if either miR-125b-5p or miR-324-5p have an effect on Smo 
localisation to the primary cilium, I choose 1h of stimulation to maximize any effect miR-
125b-5p and miR-324-5p may have. miR-125b-5p and miR-324-5p both reduced the total 
amount of Smo surrounding the primary cilia (Figure 4.14C) as quantified by ImageJ 
(Figure 4.14D), however, this may be due to a reduction in the overall level of Smo 
staining (Figure 4.14C). Interestingly preliminary data suggest miR-125b-5p but, not miR-
324-5p, reduces primary cilia length (Figure 4.14E). Regardless, these data overall provide 
further evidence for the involvement of miR-125b-5p and miR-324-5p in Hh signalling. 
miR-125b-5p and miR-324-5p inhibit Ihh induced Gli1 in C3H101/2 cells, (Figure 4.14). 
However, in Pur (2µM) treated cells, pre-transfection of miR-125b-5p increased, while 
pre-transfection of miR-324-5p did not consistently alter, Ihh induced Gli1 expression 
(Figure 4.15A). I then speculated this was due to differences in the way Ihh and Pur 
activate the Hh pathway and investigated this further. Both Ihh and Pur induce Hh 
pathway activity (Gli1 expression) in a similar time-dependent manner (Figure 4.10), 
indicating timing is unlikely to have a role in the differences in the effects of miR-125b-5p 
and miR-324-5p on Hh signalling. An interesting observation was that stimulation of 
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C3H10T1/2 cells with increasing concentrations of Pur and SAG caused increased Hh 
pathway activity, however at higher concentrations of both, Hh activity decreased (Figure 
4.15C-F), similar to previously reported observations [74, 216] and indicating a possible 
negative feedback loop; something not observed with the examined increasing 
concentrations of Ihh (Figure 4.15G). The addition of miR-125b-5p to Pur stimulated cells 
caused an increase in Hh pathway activity (Figure 4.15A), whereas the addition of miR-
125b-5p to Ihh stimulated cells caused a decrease in Hh activity (Figure 4.14). I therefore 
hypothesised miR-125b-5p disrupted this negative feedback loop and  allowed for the 
equivalent level of Hh signalling seen from lower level concentrations of Pur (see 
discussion). miR-125b-5p increased 1000nM SAG-induced Gli1 but did not increase 50nM 
SAG induced Gli1 (Figure 4.15H and I). This is likely to be because at 1000nM SAG miR-
125b-5p disrupts the negative feedback loop and allows high Hh, whereas at 50nM SAG 
there is little activation of the negative feedback loop meaning miR-125b-5p is unable to 
modulate Hh signalling. 
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Figure 4.14 miR-125b-5p and miR-324-5p inhibit Ihh induced Hh signalling in C3H10T1/2. 
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Figure 4.14 miR-125b-5p and miR-324-5p inhibit Ihh induced Hh signalling in C3H10T1/2. 
C3H10T1/2 were transfected with miCon, miR-125b-5p or miR-324-5p and stimulated with 
recombinant Indian hedgehog (Ihh) 2μg/ml for either 24h (A and B) or 1h (C and D). (A) 
Effect of miR-125b-5p and miR-324-5p on Gli1 mRNA, as measured by real-time RT-PCR, 
data combined from 8 independent experiments, each at least n=4. All data are presented 
as mean + SEM, statistical difference were calculated using ANOVA followed by a 
Bonferroni post test, where **<0.01, ***<0.001. (B) Effect of miR-125b-5p and miR-324-
5p on Gli1 protein, as measured by and immunoblotting. Representative blot of 5 
independent experiments. (C) Smo localisation around the primary cilia was visualised by 
staining with a Smo Ab and an acetylated α-tubulin Ab to show the primary cilia. (D) 
Images were quantified using Image J (see materials and methods). (E) Cilia length was 
also quantified using ImageJ (see materials and methods). (D and E) statistical differences 
were calculated using Stuvents ttest, where ***<0.001 
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Figure 4.15 miR-125b-5p and miR-324-5p have differing effects on Pur and SAG induced 
Gli1 in C3H10T1/2. 
 
 
Figure 4.15 miR-125b-5p and miR-324-5p have differing effects on Pur and SAG induced 
Gli1 in C3H10T1/2. (A) Gli1 protein following transfection with miR-125b-5p or miR-324-
5p, serum starving for 24h and stimulated with Pur (2µM) for 48 h. Representative blot 
from 3 independent experiments (B) Effect of miR-324-5p on Pur induced Gli1 mRNA, 
Representative data from two independent experiments, n=4. (C-G) C3H10T1/2 were 
stimulated with Pur, SAG or Ihh at the shown concentration for 48h and assessed for Gli1 
mRNA and protein. (H and I) C3H10T1/2 were transfected with miR-125b-5p or miR-324-
5p serum starved for 24h and stimulated with SAG (1000nM or 50nM) for 48 h. Gli1 was 
measured using immunoblotting. Statistical difference were calculated using ANOVA 
followed by a Bonferroni post test. 
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4.2.9 miR-125b-5p and miR-324-5p effect on alkaline phosphatase and alcian 
blue 
As activation of Hh signalling increased alkaline phosphatase (Figure 4.12), and miR-125b-
5p and miR-324-5p decreased Hh signalling (Figure 4.14), I wanted to test if inactivation of 
Hh signalling by miR-125b-5p and miR-324-5p alters the level of alkaline phosphatase 
production. Transfection of miR-125b-5p or miR-324-5p reduced Ihh + Bmp2 induced 
alkaline phosphatase (Figure 4.16). When I used Pur in place of Ihh I observed an increase 
in alkaline phosphatase with miR-125b-5p (Figure 4.16), similar to the effect observed for 
Gli1 mRNA and protein (Figure 4.15A). As expected miR-324-5p decreased Pur and Bmp2 
induced alkaline phophatase. 
The addition of Ihh to Bmp2 stimulated micromass cultures caused an increase in the level 
of alcian blue staining (Figure 4.13A and C), likewise pre transfection of siRNA against Gli1 
caused a decrease (Figure 4.13B and D). As miR-324-5p decreases Hh signalling (Figure 
4.14), I hypothesised miR-324-5p would affect alcian blue staining. To test this I 
transfected C3H10T1/2 cells with miR-324-5p and seeded these into micromass cultures. 
Unexpectedly, miR-324-5p did not consistently cause an increase or decrease in the 
amount of extracellular matrix produced, as indicated by alcian blue staining, for either 
cells stimulated with Bmp2, the combination of Bmp2 + Ihh, or unstimulated cells (Figure 
4.17A and B). 
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Figure 4.16 miR-125b-5p and miR-324-5p effect on osteoblastogenesis. 
 
Figure 4.16 miR-125b-5p and miR-324-5p effect on osteoblastogenesis. Alkaline 
phosphatase was used as a marker of bone formation, C3H10T1/2 cells were transfected 
with miR-125b-5p and miR-324-5p, then stimulated with Ihh (2µg/ml) + Bmp2 (100ng/ml) 
or Purmorphamine (Pur) (2uM) and Bmp2 (100ng/ml) for 5 days. P.Nitrophenol was 
measured to determine the level of alkaline phosphatase. Data combined data from 5 
independent experiments each n=3, All data are presented as mean + SEM, statistical 
difference were calculated using ANOVA followed by a Bonferroni post test, where 
*p<0.05. 
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Figure 4.17 miR-324-5p effect on chondrogenesis. 
 
Figure 4.17 miR-324-5p effect on chondrogenesis alcian blue was used as a marker of 
cartilage formation. (A) C3H10T1/2 cells were transfected with miR-324-5p then plated 
into micromass cultures, stimulated with Bmp2 (100ng/ml) and/or Ihh (2µg/ml) (B) alcian 
blue stain was extracted with GHCl and quantified as described previously. Data combined 
from 3 independent experiments, each n=2. All data are presented as mean + SEM, no 
statistical difference were found using Student’s t-test. 
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4.2.10  Retinoic acid but not Hh stimulation regulates miR-125b-5p and miR-
324-5p expression 
miRNAs are often part of feedback loops. miR-125b-5p and miR-324-5p regulate Hh 
signalling (Figure 4.14), therefore I hypothesised miR-125b-5p and miR-324-5p may be 
regulated by either Ihh or Pur stimulation. To test this I stimulated C3H10T1/2 with Ihh or 
Pur and measured miR-125b-5p and miR-324-5p expression using real-time RT-PCR. miR-
125b-5p expression was slightly decreased following Ihh and Pur stimulation (Figure 
4.18A). miR-324-5p was not significantly altered in expression by either Ihh or Pur 
stimulation (Figure 4.18B). 
Retinoic acid (RA) has previously been show to increase the expression of miR-125b-5p 
and miR-324-5p [127], I hypothesised it may have the same effect in C3H10T1/2. 
Unexpectedly, RA decreased miR-125b-5p and miR-324-5p expression, although its effect 
on miR-125b-5p was abolished following the addition of Ihh (Figure 4.18C and D). RA also 
inhibited Hh signalling (Figure 4.18E and F), opposite of the effect that would be expected 
from its effect on miR-324-5p. 
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Figure 4.18 Retinoic acid effects miR-125b-5p and miR-324-5p expression. 
 
Figure 4.18 Retinoic acid effects miR-125b-5p and miR-324-5p expression.C3H10T1/2 cells 
were stimulated with either Ihh (2µg/ml), Purmorphamine (Pur) (2µM), or Retinoic acid 
(RA) (2.5µM) or in combination for 48hr.  miR-125b-5p, miR-324-5p, Gli1 and Ptch were 
then assessed with real-time RT-PCR and normalised to 18S. (A) miR-125b-5p expression 
following Ihh and Pur stimulation. (B) miR-324-5p expression following Ihh and Pur 
stimulation. (C) miR-125b-5p expression following retinoic acid and Ihh stimulation. (D) 
miR-324-5p expression following retinoic acid and Ihh stimulation. (E) Gli1 expression 
following Retinoic acid and Ihh stimulation. (F) Ptch expression following Retinoic acid and 
Ihh stimulation. Data combined data from 2 independent experiments each n=5, All data 
are presented as mean + SEM, statistical difference were calculated using Student’s t-test, 
where *p<0.05, **<0.01 and ***<0.001. 
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4.2.11 miR-125b-5p and miR-324-5p targets are different in human and mouse 
miR-125b-5p and miR-324-5p can regulate Hh signalling in human [127] and mouse 
(Figure 4.14). Ferretti et al., and ourselves show miR-324-5p can directly regulate GLI1 and 
SMO in human (Figure 4.8). They suggest miR-125b-5p directly regulates SMO, although 
our results fail to support this observation (Figure 4.8C). 3’UTR sequences differ between 
species more than the corresponding protein coding sequence (CDS), therefore I aligned 
the human and mouse 3’UTR sequences and performed miR-125b-5p and miR-324-5p 
target searches to attempt to identify if miR-125b-5p can target mouse Smo and if miR-
324-5p can target both mouse Smo and Gli1 (Figure 4.19). The mouse target sites, which 
are equivalent to the target sites in human are shown in Figure 4.19C. The miR-125b-5p 
and miR-324-5p binding sites in the mouse Smo 3’UTR are completely unconserved which, 
due to the lack of seed binding (Figure 4.19C), suggests it is unlikely Smo is a target of 
either miR-125b-5p or miR-324-5p. The miR-324-5p binding site in the mouse Gli1 3’UTR is 
however similar to the human counterpart, although complementarity is reduced at the 3’ 
region of the miRNA. I hypothesised that mouse Gli1 is therefore a target of miR-324-5p. 
To test this I created a luciferase construct containing the mouse Gli1 3’UTR, however co-
transfection of miR-324-5p with this construct did not cause a reduction in the level of 
luciferase activity, indicating mouse Gli1 is not a target of miR-324-5p (Figure 4.19D). As 
subsequently expected, miR-324-5p was also unable to alter the level of luciferase 
following mutation of putative the miR-324-5p binding site (Figure 4.19D). The 
combination of 3’UTR alignment, target searches and luciferase constructs shows miR-
125b-5p and miR-324-5p are unable to directly target the 3’UTRs of Smo and Gli1 in 
mouse (Figure 4.19), yet they both are regulators of Hh signalling in mouse  (Figure 4.14). 
To understand how miR-125b-5p and miR-324-5p regulates Hh in mouse, additional miR-
125b-5p and miR-324-5p targets need to be identified in mouse cell line C3H10T1/2. I 
hypothesise some of these targets may be involved in Hh signalling. 
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Figure 4.19 miR-324-5p targets differ in human and mouse 
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Figure 4.19 miR-324-5p targets differ in human and mouse. (A) Alignment of human and 
mouse Smo 3’UTRs, miR-125b-5p (pink) and miR-324-5p (green) binding sites are 
highlighted. (B) Alignment of human and mouse Gli1 3’UTRs, miR-324-5p  binding sites are 
highlighted in green. (C) Detailed view of miR-125b-5p and miR-324-5p potential binding 
sites in Smo and Gli1 3’UTRs. (D) pMIR-Report plasmid containing mouse either wild-type 
(wt) or mutant binding site (mt) Gli1 3’UTR downstream of luciferase was transfect into 
C3H10T1/2 cells with either miCon2 or miR-324-5p, data normalised to miCon and plotted 
as relative luciferase light units, statistical difference were calculated using Students t test. 
Data combined from 5 independent experiment for mutant and wild-type constructs 
respectively, each n=6.  (E) Schematic showing the mechanism miR-125b-5p and miR-324-
5p regulate Hh signalling in mouse is unknown. 
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4.3 Discussion 
4.3.1  miRNA screens in OA 
This work is based on miR-125b-5p and miR-324-5p being up regulated in OA. To identify 
miRNAs differentially expressed in OA, Dr. Hannah Elliott (previous laboratory member) 
screened end-stage OA femoral head cartilage and used NOF (Neck of femur fracture) 
cartilage as a control. Both end-stage OA and NOF cartilage have previously been used to 
identify differences between OA and healthy cartilage [217] and were the best available 
for the study. miR-125b and miR-324-5p may both have the potential to alter 
developmental pathways, and even the final ‘developed’ articular cartilage composition. 
However, using end-stage OA cartilage does not allow the dynamics of miRNA expression 
during the disease to be determined, for example the presence or absence of a miRNA 
both before or during OA, may contribute to OA onset and progression and would be 
missed by this study. In addition by using NOF cartilage as a control I may have 
inadvertently identified miRNAs differentially expressed during osteoporosis, a bone 
degrading disease which can lead to fracture of the neck of femur. 
To date there are two published screens of miRNA expression on OA cartilage, each 
observing different miRNA expression profiles to our laboratory’s screen (unpublished 
data and [155]) and from each other [156, 157]. These variations may be due to 
differences in the severity or stage of OA, different methods of RNA isolation, or 
differences in detection techniques. Neither miR-125b-5p nor miR-324-5p were found to 
be differentially expressed in the other screens. In our study miR-125b-5p was significantly 
increased and miR-324-5p was only detected in OA cartilage (Figure 4.1). The expression 
of miR-125b-5p was higher than miR-324-5p in the screened cartilage, consistent with 
deep sequencing data combined from many tissues (Figure 4.2). Deep sequencing in 
cartilage suggest miR-125b-5p is in the top 2%, and miR-324-5p is in the top 20% of most 
abundantly expressed miRNAs in cartilage (Prof Ian Clark, University of East Anglia, 
personal communication). miRNA expression level does not always correlate to potency, 
how stable a miRNA target is, how sensitive a target is to changes in gene expression, and 
the number of targets or pseudo targets a miRNA has, are all determinants of miRNA 
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potency [124, 125]. A miRNA may also act in concert with other miRNAs on the same 
target or pathway to potentiate their effects [218, 219]. 
4.3.2 miR-125b-5p and miR-324-5p sequence and evolution 
miR-125b is encoded from two loci (miR-125b-1 and miR-125b-2) in mouse and human, 
the mature miR-125b-5p sequences are identical in both loci but the -3p sequences are 
not, meaning the number of miR-125b-5p sequences will be the combined number from 
both loci, whereas the number of miR-125b-3p sequences will be different for each loci. 
The total expression of miR-125b-5p is far greater than for each of the miR-125b-3p 
sequences (Figure 4.2). The relative contribution to miR-125b-5p expression from each 
loci is unknown. A number of primates only have one loci for miR-125b, perhaps indicating 
redundancy between the loci in humans and mice as the miR-125b-5p mature sequences 
are identical. Danio rerio (zebra fish) have three loci for miR-125b, perhaps indicating its 
importance to that species. In humans and mice, where deep sequencing data is available, 
one might expect little or no function of miR-125b-1-3p and miR-125b-2-3p due to their 
low expression; deep sequencing data for Danio rerio is not available. miR-125b is an 
ancient miRNA, being present in most animals and suggesting it has a functional relevance 
in these animals. These functions however may be different as the repertoire of protein 
coding genes and their 3’UTRs will be different. 
miR-324-5p is expressed in fewer species than miR-125b-5p, but due to the rate at which 
3’UTRs evolve, may have divergent functions in these species. Deep sequencing data from 
human suggests the miR-324-3p sequence is different from that annotated in miRBase, 
resulting in a different seed sequence and implying target prediction sites for miR-324-3p 
are incorrect (Figure 4.2). It is not surprising that there are differences between miRBase 
and deep sequencing as this information is often gained from cloning miRNAs from one 
species with predictive homology searches performed in another. Deep sequencing data 
for mice illustrates there are both canonical and non-canonical versions of miR-324-3p, 
each of which will target its own repertoire of genes, perhaps having distinct functions, 
the relative expression of non-canonical and canonical ‘-3p’ may be tissue specific and 
dependent on expression of RNA binding proteins which alter miRNA processing. Deep 
sequencing also suggests miR-324-5p is up to 10 times more abundant than miR-324-3p in 
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mouse and humans (Figure 4.2). The differences in ‘-5p’ and ‘-3p’ expression may indicate 
the role of miR-324-5p is more important than that of miR-324-3p. 
4.3.3 Predicted targets and functions of miR-125b-5p and miR-324-5p 
There is little crossover between databases with only 63, 12, 71 and 15 targets being 
predicted by all databases for mouse miR-125b-5p, mouse miR-324-5p, human miR-125b-
5p and human miR-324-5p respectively (Figure 4.6). Due to the variation in miRNA targets 
predicted by each database it was not surprising there was also little crossover in the 
predicted functions of miR-125b-5p and miR-324-5p (Figure 4.7). Luciferase reporter 
constructs, functional assays and DAVID pathway analysis of a list of genes following over 
and under expression of miRNAs are required to further investigate and validate these 
functions. 
4.3.4 Validated targets and functions of miR-125b-5p and miR-324-5p 
Previous studies have shown miR-125b-5p and miR-324-5p are involved in a number of 
processes. miR-125b-5p is the more well studied of the two miRNAs, according to 
miRecords (mirecords.biolead.org/), evidence suggests miR-125b-5p targets 65 different 
genes including Snail, an important gene for cartilage and Smo [127]. Recently miR-125b 
has been shown to target important enzymes for cartilage such as ADAMTS-4 [220] and 
MMP13 [221]. miR-324-5p on the other hand only has two published validated targets; 
Smo and Gli1 [127]. 
Ferretti et al. used both luciferase constructs and functional studies to show miR-125b-5p 
and miR-324-5p regulate Hh signalling. The majority of our data confirms the findings by 
Ferretti et al. apart from our observation that miR-125b-5p increases human SMO 3’UTR 
luciferase (Figure 4.8C). This could suggest that miR-125b-5p may not target Smo or that 
miR-125b-5p may target other proteins in the cell, in addition to Smo, leading to the 
observed increase in luciferase, masking any inhibitory effect of mi125b on Smo. 
Transfection of miR-125b-5p with other luciferase constructs may clarify this. Ferretti et 
al, did not report miR-125b-5p to have this effect on the 3’UTR construct [127], however I 
used a construct with a CMV promoter and different cells. In agreement with Ferretti et al. 
[127], miR-324-5p targets GLI1 and SMO in human. In contrast to Ferretti et al, our data 
suggests human SMO is not a target of miR-125b-5p. Western blot analysis of Hh response 
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genes by Ferretti et al, show both miR-125b-5p and miR-324-5p are regulators of Hh 
signalling [127], although our data now casts doubt over the mechanism by which miR-
125b-5p acts in human. 
4.3.5 Hh signalling in C3H10T1/2 
The data in Figure 4.11 shows the effects of inhibiting components the Hh pathway on 
basal, Ihh induced and Pur induced Hh signalling. The data is described fully in Appendix A. 
In summary the data suggest the Hh activator Smo is always required for Hh signalling. 
Ptch inhibits basal levels of Hh signalling but is also required for Pur induced Hh signalling, 
and Gli1 is required for Ihh and Pur induction of itself, but not of Ptch. 
The Hh signalling pathway involves the primary cilium, and during stimulation Smo moves 
toward it. In contrast to other studies, Ihh stimulation in our experiments did not cause 
Smo and acetylated α-tubulin co-localisation, but instead does result in Smo localising 
near the primary cilium, perhaps at its base. Staining for basal body protein such as γ-
tubulin may verify this. To our knowledge unlike Shh and Pur, Ihh has not been shown to 
cause Smo localisation previously, which may suggest that Ihh signalling differs to Shh and 
Pur. 
4.3.6 miR-125b-5p and miR-324-5p in Hh signalling 
miR-125b-5p and miR-324-5p both reduce Ihh induced Hh signalling activity (Figure 4.14), 
although the level of Hh activity remains higher than basal levels, indicating miR-125b-5p 
and miR-324-5p are not 100% effective in diminishing Hh pathway activity in mouse 
C3H10T1/2. The addition of miR-125b-5p to Pur (2µM) stimulated cells actually caused an 
increase in Hh pathway activity (Figure 4.15). The reason for this is unclear, one 
hypothesis could be it acts in a similar way to the effect it has on the luciferase reporter of 
Smo; miR-125b-5p may target a transcription inhibitor, pathway inhibitor or protease 
which allows increased Hh activity. This hypothesis however does not explain why miR-
125b-5p is able to reduce Ihh induced Gli1 (Figure 4.14). I therefore hypothesised that 
abnormally high stimulation from Pur or SAG, results in the Hh pathway regulating itself 
by turning on a natural, unknown, protective, negative feedback loop and which could 
itself be sensitive to miR-125b-5p levels, resulting in decreased negative feedback and 
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therefore an increase in pathway activity (Figure 4.20B). To investigate this C3H10T1/2 
cells were stimulated with a wide range of Pur and SAG concentrations. High 
concentrations of both Pur and SAG are inhibitory to pathway activity indicating the 
negative feedback loop to protect the cell from high Hh signalling. At the concentration of 
Pur used generally is this study (2000nM/2µM) the pathway is beginning to be inhibited 
(Figure 4.15C and E), indicating the negative feedback loop is active. Our hypothesis 
suggests miR-125b-5p increases Hh activity due to inhibition of the negative feedback 
loop. In support of this, transfection of miR-125b-5p slightly decreased Hh activity in lower 
(50nM SAG) stimulated cells, similar to the effect on Ihh stimulation (Figure 4.15I), 
increased Hh activity in highly (1000nM SAG) stimulated cells (Figure 4.15H), similar to the 
effect on high Pur stimulation.  
The exact mechanism of how high levels of Pur can lead to activation of the regulator 
mechanism and how the regulatory mechanism can lead to reduced Gli1 is unknown. In 
Wnt signalling high levels of ligand are predominantly associated with activation of β-
catenin and low levels of ligand are predominantly associated with activation of Ca2+ 
signalling, with canonical β-catenin and non-canonical Ca2+ signalling being able to 
reciprocally inhibit each other [102]. A similar mechanism of high and low reciprocal 
inhibition may exist in Hh signalling.  
There was limited evidence for high concentrations of Ihh causing decreased Hh signalling. 
However preliminary data showed high concentrations (5µg/ml) of Ihh did not cause 
reduced Gli1 expression but did cause reduced Ptch1 expression (Figure 4.20C and D). This 
high Ihh induced reduction of Ptch may involve Smo, as Smo mRNA is also reduced with 
high Ihh concentration. This shows some sort of regulatory mechanism may be active in 
high Ihh stimulated cells but this mechanism may have differing effects on different Hh 
response genes. 
An alternative possibility is that high concentrations of Pur and SAG are toxic to the cells, 
with miR-125b-5p somehow preventing this toxicity. Supporting this notation, pathway 
analysis of predicted miR-125b-5p targets suggest miR-125b-5p may have a possible role 
as a negative regulator of apoptosis and cell death. The effect of miR-125b-5p on different 
111 
 
Hh stimuli is interesting and warrants further investigation, but will not form the focus of 
this study. 
miR-125b-5p, but not miR-324-5p, reduces the length of the primary cilia, possibly 
indicating an additional mechanism by which miR-125b-5p may regulate Hh signalling. The 
mechanism by which miR-125b-5p decreased primary cilia length is unknown, however 
miR-125b-5p is predicted to target components of the cytoskeleton, which may also have 
a role in cilia structure organisation. 
Gli1 is a widely used readout of active Hh signalling, and is also responsible for the 
transcriptional activation of a number of genes. Gli2 and Gli3 are however also important 
regulators of Hh-induced gene expression whose function differs from Gli1 [222]. 
Activation of Gli1, Gli2 and Gli3 may differ depending on the level of Hh activation [222]. 
Further work is needed to determine the role miR-324-5p has in the regulation of Gli2 and 
Gli3. Neither Gli2 nor Gli3 have a miR-324-5p seed binding site in mouse, suggesting any 
effect miR-324-5p has on them will be directed through miR-324-5p’s ability to inhibit Hh. 
Interestingly, Gli3 is predicted to have a miR-324-5p seed binding site in human, and 
preliminary data from our lab suggests its expression is also decreased following miR-324-
5p overexpression. 
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Figure 4.20 Role of miR-125b-5p and miR-324-5p in high and low Ihh and purmorphamine Hh signalling in mouse. 
 
Figure 4.20 Role of miR-125b-5p and miR-324-5p in high and low Ihh and Pur stimulated 
Hh signalling in mouse. (A) Role of miR-324-5p and miR-125b-5p in Ihh signalling. Non 
faint; increasing concentration of Ihh leads to increased Hh signalling. miR-324-5p 
regulates Gpc1 to reduce Ihh induced Hh signalling. miR-125b-5p regulates an unknown 
target to regulate Ihh induced Hh signalling. Faint; there is limited evidence for high 
concentrations of Ihh causing decreased Hh signalling. (B) Role of miR-324-5p and miR-
125b-5p in Pur induced Hh signalling. High concentrations of Pur cause the activation of a 
regulatory mechanism which functions to inhibit high Hh signalling. miR-125b-5p regulates 
and unknown target to decrease low Pur induced Hh signalling. miR-125b-5p also inhibits 
this regulatory mechanism to allow to higher levels of Hh signalling following high levels of 
Pur. Faint; Pur acts downstream of Gpc1 meaning miR-324-5p does not alter Pur induced 
Hh signalling. (C-E) Preliminarily data shows high concentrations (5µg/ml) of Ihh does not 
cause reduced Gli1 expression but does cause reduced Ptch1 expression, possibly via a 
mechanism involving Smo. This shows a regulatory mechanism may be active in high Ihh 
stimulated cells but this mechanism may have differing effects on different Hh response 
genes. Data from one experiment of n=4. All data are presented as mean + SEM, statistical 
difference were calculated using ANOVA followed by a Bonferroni post test, where 
*<0.05, **<0.01, ***<0.001. 
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4.3.7 miR-125b-5p and miR-324-5p in OA and cartilage 
Down regulation of miR-125b-5p and miR-324-5p allows high Hh signalling [127]. Ferretti 
et al. found these miRNAs are increased upon cell differentiation, inhibiting the Hh 
pathway and therefore holding the Glioma cells in their differentiated state [127]. miR-
125b-5p and miR-324-5p are increased in end-stage OA and may be holding chondrocytes 
in a hypertrophic state. miR-125b-5p and miR-324-5p may have been decreased at the 
inception of OA allowing high Hh and promoting a change in chondrocyte phenotype from 
a prehypertrophic type II collagen secreting cell into a hypertrophic type X collagen 
secreting chondrocyte. 
Interestingly, in end stage OA cartilage there is an increased expression of Ihh (high Hh 
signalling), and increased expression of miR-125b-5p and miR-324-5p. I predict miR-125b-
5p and miR-324-5p are up regulated in OA as part of an ineffective protective mechanism 
to decrease Hh pathway activity (Figure 4.21). In this study I show miR-125b-5p and miR-
324-5p regulate alkaline phosphatase, a marker of bone formation and although miR-324-
5p inhibited alcian blue in initial experiments, there were both increases and decreases in 
subsequent experiments indicating more work is needed to understand the role, if any, 
miR-324-5p has on chondrogenesis. Interestingly, miR-324-5p regulates Pur and Bmp 
induced alkaline phosphatase (Figure 4.16), yet miR-324-5p does not consistently regulate 
Pur induced Hh signalling (Figure 4.15), suggesting miR-324-5p might also play a role in 
Bmp signalling. Interestingly, miR-125b has been shown to regulate Smad4 [223]. These 
results indicate miR-125b-5p and miR-324-5p may play a role during development and OA. 
Retinoic acid is the oxidized form of vitamin A and can alter mi125b and miR-324-5p 
expression (Figure 4.18) and has previously been shown to have a role in cartilage. This 
suggests, retinoic acid may work in part by altering miR-125b-5p and miR-324-5p 
expression to affect Hh pathway activity and alter chondrocyte hypertrophy and eventual 
OA. I have shown RA to inhibit Hh signalling and the expression of miR-125b-5p and miR-
324-5p (Figure 4.18). This seems contradictory as one would expect deceased miR-125b-
5p and miR-324-5p to allow higher Hh signalling, suggesting as well as inhibiting active Hh 
signalling, miR-125b-5p and miR-324-5p may also be required for active Hh signalling. 
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Direct inhibition of miR-125b-5p and miR-324-5p will shed light on this. Further work is 
also need to show what induces miR-125b-5p and miR-324-5p expression during OA. 
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Figure 4.21 miR-125b-5p and miR-324-5p may play a role in OA pathogenesis. 
 
 
 
Figure 4.21 miR-125b-5p and miR-324-5p may play a role in OA pathogenesis. A schematic 
showing miR-125b-5p and miR-324-5p regulate the Hh pathway, to control OA 
pathogenesis. The mouse cells the mechanism by which miR-125b-5p and miR-324-5p 
regulate Hh signalling is not known. Retinoic acid may attenuate miR-125b-5p and miR-
324-5p expression levels to regulate Hh signalling and cartilage metabolism. 
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4.3.8 Different targets in human and mice 
3’UTR alignment, target searches and luciferase studies (Figure 4.19) suggest the 
mechanism by which miR-125b-5p and miR-324-5p regulate Hh signalling in human and 
mouse may differ. There is evidence that suggests miR-125b-5p and miR-324-5p act up 
stream of Smo in the mouse Hh pathway, and therefore not on Gli1 as in the human Hh 
pathway. Firstly miR-125b-5p and miR-324-5p are able to inhibit Smo translocation around 
the cilia. Secondly, miR-324-5p does not consistently alter Pur induced Hh signalling. 
Identification of mouse miR-125b-5p and miR-324-5p targets may show the mechanism by 
which miR-125b-5p and miR-324-5p regulate Hh in mouse differs from human. 
4.4 Summary 
miR-125b-5p and miR-324-5p are increased in OA (Figure 4.1). They are both the 
predominantly expressed miRNA from their stem-loops (Figure 4.2) and are both 
conserved in many species (Figure 4.3). Target prediction databases predict many targets 
(Figure 4.6) and functions (Figure 4.7) of miR-125b-5p and miR-324-5p although there is 
little consistency between the target prediction databases. In agreement with Ferretti et 
al [127], I show miR-324-5p can bind and regulate both the Hh transcription factor GLI1 
and the Hh activator SMO in human (Figure 4.8A and B). In contrast with Ferretti et al. I 
show miR-125b-5p increases human SMO luciferase (Figure 4.8C). I do however show miR-
125b-5p and miR-324-5p are both important regulators of Hh signalling (Figure 4.14) and 
osteogenesis (Figure 4.16). RA alters miR-125b-5p and miR-324-5p expression and may 
form a possible mechanism to alter miR-125b-5p and miR-324-5p expression in vivo 
(Figure 4.18). In contrast to suggestions by Ferretti et al. [127], our results indicate miR-
125b-5p and miR-324-5p do not regulate mouse Smo and Gli1 (Figure 4.19). To 
understand how miR-125b-5p and miR-324-5p regulates Hh in mouse, additional miR-
125b-5p and miR-324-5p targets need to be identified in mouse cell line C3H10T1/2. I 
hypothesise some of these targets may be involved in Hh signalling. 
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Chapter 5 Identification of novel miR-324-5p targets 
5.1 Introduction 
To elucidate the mechanism by which miR-324-5p regulates Hh in mouse I wanted to 
identify direct downstream targets of miR-324-5p which are required for Hh signalling. In 
addition to online target prediction websites (Chapter 4) there are a number of different 
approaches that can be used to identify miRNA targets, including proteome profiling 
[224], transcriptome profiling [225] and pull-down of various members of the miRNA-
RISC-mRNA complex [226, 227]. The advantage of experimental target identification is it 
avoids the inherent bias of computational target prediction. miRNAs function by inhibiting 
translation and/or causing mRNA degradation, leading to reduced protein and/or mRNA 
expression, because of this miRNA targets can be found by high-throughput analysis of 
mRNA (transcriptome microarrays or high-throughput sequencing (HT-seq)) and protein 
(proteomics) following miRNA overexpression [224, 225]. 
Transcriptome profiling can be used to quantify the relative expression of mRNA 
transcripts and has previously been used to identify miRNA targets [225]. In initial 
experiments, miRNAs were overexpressed and a significant enrichment of miRNA seed 
binding sites (of the miRNAs that was overexpressed) was found in mRNAs whose 
expression decreased, suggesting these mRNAs were targets [119]. In those studies the 
miRNAs were increased above physiological levels and would arguably lead to the miss-
identification of some targets which are not relevant at miRNA physiological levels. To 
avoid this some studies have used antisense oligonucleotides (antagomirs) to inhibit the 
action of the miRNA and observed increased expression of target mRNAs [228]. The 
increased expression of target mRNA following miRNA inhibition is often small, perhaps 
limiting the usefulness of miRNA inhibitors in target identification experiments. Advances 
in next generation sequencing techniques means RNA sequencing is likely to replace 
transcriptome microarrays in these types of experiments [229], their higher sensitivity 
may also be useful for miRNA inhibitor experiments. A number of miRNA targets have 
been shown to be decreased at a protein level but not an mRNA level [121, 230], 
transcriptome profiling will fail to identify these targets. Proteomic profiling however is 
able to identify this type of target. 
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There are a number of different types of quantitative proteomics. Stable Isotope Labelling 
with Amino acids in Cell culture (SILAC) proteomics has the ability to compare two 
populations of cells in the same mass spectrometry (MS) experiment and has previously 
been used to screen for miRNA targets [230]. Briefly, SILAC involves labelling one 
population of cells with heavy amino acids (Lysine and Arginine) and leaving the other 
population of cells unlabelled, the populations are then treated differently (transfection of 
miRNA of interest or control miRNA in this case), lysed, mixed at a ratio of 1:1, then 
analysed using MS. In order to achieve SILAC label incorporation cells need to undergo cell 
division. C3H10T1/2 divide relatively quickly, undergoing population doubling around 
every 18h [231], meaning cells can be readily labelled. Types of SILAC include ‘traditional’, 
‘pulse’, ‘super’ and ‘in vivo’. Traditional SILAC is as described above and has been used for 
miR-1 target identification [224]. In pulse-SILAC, cells are only transferred to labelled 
medium once treated or transfected, meaning it identifies differences in newly 
synthesized proteins, this technique has been used to identify miR-34a targets [232] and a 
slight variation used to detect miR-223 targets from a miR-233 knock-out mouse [233]. 
Super-SILAC involves pooling a number of heavy labelled cell-lines to investigate non 
dividing cells [234]. In-vivo-SILAC (the SILAC mouse) is now being developed and may 
prove useful for studying the effects of miRNAs in vivo experiments [235]. 
Ribosomal mRNA is an indicator of the level of translation [236]. Guo et al., analysed the 
amount of mRNA bound to ribosomes following miRNA overexpression to determine the 
effect a miRNA has on translation [121]. They found an enrichment of miRNA seed binding 
sites in genes whose translation was decreased, however they also used RNA sequencing 
of total mRNA and found almost all genes whose translation was decreased also had 
decreased total mRNA, suggesting for the majority of targets the miRNA functions to 
destabilise the mRNA rather than inhibit translation [121]. 
miRNAs target mRNAs through the action of a miRNA-RISC-mRNA complex, which is made 
up of many proteins including AGO proteins [237]. Pull-down of components of this 
complex followed by profiling of mRNA can identify direct miRNA targets. miRNA-mRNA 
complexes have been identified following the pull-down of labelled miRNAs, however 
initially the technique produced controversial results as there was no enrichment of 
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miRNA binding sites in the 3’UTRs [238]. A similar technique called LAMP (Labelled miRNA 
pull-down assay system) can be used to pull-down labelled miRNAs from an in vitro setting 
after being mixed with cell lysates [239]. Another miRNA pull-down called miR-TRAP assay 
involves cross linking with UV radiation to generate a covalent bond, allowing for a more 
stringent pull-down of miRNA targets, but involves pull-down from an in vitro setting 
[226]. The reverse can also be performed to identify miRNAs which target a specific 
mRNA, by pull-down of a labelled transcript and identifying the targeting miRNAs [227]. 
It is also possible to pull-down protein members of the RISC complex such as Ago1 [237] 
[240] and Ago2 [241] and profile the mRNA to detect targets. In 2009 Chi et al. published a 
miRNA target identification method where they cross-linked the mRNA and protein, 
meaning the interactions are stronger and more readily survive the IP process, this 
method is called HITS-CLIP (High-throughput sequencing of RNAs isolated by crosslinking 
immunoprecipitation) [242]. A modification of the HITS-CLIP method has allowed more 
precise mapping of miRNA-target interactions, this modified method is called PAR-CLIP 
(Photoactivatable-Ribonucleoside-Enhanced crosslinking and immunoprecipitation)[243]. 
HITS-CLIP and PAR-CLIP are both technically challenging and require a large amount of 
bioinformatic analysis to map the miRNA-RISC-mRNA interactions. 
Target identification strategies can feedback to further define properties of miRNA-target 
interactions. Previous target identification publications have shown that genes which have 
a conserved miRNA seed sequence binding site, are more likely to be miRNA targets [130]. 
In addition, the more base pairing that there is between the miRNA seed and its target, 
the more likely a gene is to be a miRNA target [119]. There are four different types of 
binding at the seed; 8mers, 7mer m8s, 7mer a1s and compensatory binding (Figure 5.1) 
[129]. 8mer target sites are an exact reverse complement match to positions 2-8 of the 
miRNA followed by an ‘A’ at position 1. 7mer m8 target sites also have an exact reverse 
complement match to positions 2-8, but do not have an ‘A’ at position 1. 7mer A1 sites 
have an exact reverse complement match to positions 2-7 of the miRNA, followed by an 
‘A’ at position 1. Compensatory binding is where seed miss matches are compensated for 
by additional binding at the 3’ end of the miRNA. 
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Here I will develop a strategy using proteome and transcriptome profiling to identify 
miRNA targets and use it to identify miR-324-5p targets required for Hh signalling. The 
main aim of this chapter is to identify miR-324-5p targets in mouse which have a possible 
role in Hh signalling. 
Specific aims 
Aim1: Determine if online target prediction programs identify mouse miR-324-5p targets 
involved in Hh signalling. 
Aim2: Develop a strategy to identify novel miRNA targets. 
Aim 3: Identify potential miR-324-5p targets which have a role in Hh signalling. 
Aim 4: Validate potential miR-324-5p targets identified in Aim3. 
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Figure 5.1 Different types of seed 
 
Figure 5.1 Different types of seed. miR-324-5p and hypothetical mRNA targets to illustrate 
different types of miRNA targets. Complementary bases are shown in red. Seed region is 
underlined and the first 8 bases of the miRNA are indicated by the numbers. (A) 8mer 
seed match. (B) 7mer m8 seed match. (C) 7mer a1 seed match. (D) 3’compensatory seed 
match. 
8mer seed match
87654321
miR-324-5p 3’-UGUGGUUACGGGAUCCCCUACGC -5’
....        ...|||||||
mRNA 5’-TACAACTGTAGACCAGGGATGCA -3’
7mer m8 seed match
87654321
miR-324-5p 3’-UGUGGUUACGGGAUCCCCUACGC -5’
....        ...|||||||
mRNA 5’-TACAACTGTAGACCAGGGATGCC -3’
7mer a1 seed match
87654321
miR-324-5p 3’-UGUGGUUACGGGAUCCCCUACGC -5’
....        ... ||||||
mRNA 5’-TACAACTGTAGACCACGGATGCA -3’
3’ Compensatory  
87654321
miR-324-5p 3’-UGUGGUUACGGGAUCCCCUACGC -5’
. |||||||..   .|| ||||
mRNA 5’-TAACCAATGAGACCAGGGATGCC -3’
D.
A.
B.
C.
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5.2  Results 
5.2.1 Online target prediction programs predict targets involved in Hh 
signalling 
3,061 different genes were predicted to be miR-324-5p targets by the four main online 
prediction programs analysed in Chapter 4, 11 of which are part of the Kegg Hh pathway 
(Figure 5.2A), representing 20.4% of the 54 genes listed in the Kegg Hh pathway, which is 
slightly higher than the percentage of all genes predicted to be miR-324-5p targets, 
~16.4% (3,061/~18,615) (p=0.44 fishers). Four genes were predicted to be a miR-324-5p 
targets by two or more databases and are part of the Kegg Hh pathway (Figure 5.2A) 
(Wnt7a, Csnk1g1, Rab23 and Bmp5). No targets predicted by three or more databases are 
part of the Kegg Hh pathway (Figure 5.2A). Due to the large number of predicted miR-324-
5p targets it is not surprising some predicted miR-324-5p targets are part of the Kegg Hh 
pathway (Figure 5.2). The large variation (outlined in Chapter 4), and unreliability of 
prediction [244], means it is unlikely all of these predicted miR-324-5p targets are real and 
due to the lack of comprehensiveness of the Hh kegg pathway it is likely a number of 
other predicted miR-324-5p targets may have a role in Hh. I therefore decided to develop 
a new strategy to identify miR-324-5p targets and determine if any are required for Hh 
signalling. 
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Figure 5.2 miR-324-5p is predicted to target parts of the Hh pathway 
 
Figure 5.2 miR-324-5p is predicted to target components of the Hh pathway. (A) 11 genes 
in the Hh Kegg pathway are predicted to be miR-324-5p targets by at least one target 
prediction program. 4 genes in the Hh Kegg pathway are predicted by two prediction 
programs. (B) Schematic showing the position of predicted targets in the Kegg Hh 
pathway. Colour indicates which prediction program predicted the target. Gene names 
shown are from the Kegg Hh pathway and not necessarily the exact predicted genes. All 
predicted genes are in the Kegg pathway list of genes (http://www.kegg.jp/) and are 
orthologs of the genes shown. 
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PicTar (all) 2 2 miRanda (all)
0 4
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0 0
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0
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#
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5.2.2 Development of a strategy to identify novel miR-324-5p targets 
Overexpression of miRNAs followed by transcriptome and proteome profiling has 
previously been used to screen for miRNA targets [225]. Our eventual goal is to identify 
direct miR-324-5p targets in Ihh stimulated cells. However as an initial proof of concept 
experiment I decided to identify miR-324-5p targets in unstimulated C3H10T1/2 cells to 
avoid the potent effect miR-324-5p has on Ihh signalling from masking direct miR-324-5p 
targets. 
5.2.2.1 Preparation of SILAC cells 
I decided to use SILAC to identify proteins whose expression decreased following miR-324-
5p overexpression. SILAC relies on the heavy cells being 100% labelled with heavy amino 
acids. To achieve this I passaged C3H10T1/2 cells 4 times at a split ratio of 1:5, which is the 
equivalent to >8 cell divisions and should give >99% incorporation of heavy amino acids 
(Figure 5.3). To check label incorporation I analysed heavy cells using MS, >99% of the 
peptides were heavy labelled. Unlabelled cells are referred to as ‘light’. 
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Figure 5.3 Preparation of SILAC cells 
 
Figure 5.3 Schematic showing labelling of C3H10T1/2 cells with heavy Arginine (13C6 
15N4-
Arg) and heavy Lysine (13C6-Lys) or light Arginine (
12C6 
14N4-Arg) and light Lysine (
12C6-Lys). 
C3H10T1/2 cells were maintained in normal DMEM medium and then split into either 
heavy or light SILAC DMEM at a ratio of 1:5. Cells were then split at a ratio of 1:5 every 2-3 
days, 3 more times before label incorporation was confirmed to be >99%. Cells were 
maintained in their respective SILAC DMEM medium until required, passaging every 2-3 
days at a ratio of 1:5. Approximate number of cell doublings and predicted heavy amino 
acid incorporation are shown in parentheses. 
*=Label incorporation check 
1/5 split 
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Normal C3H10T1/2 cells
1/5 split 
Light media
(12C6-Lys and 
12C6 
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(~2-3, 80%)
(~4-5, 96%)
(~7, 99.2%)
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(~11-12, >99.9%)
Predicted
1/5 split 
2-3 days
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5.2.2.2 SILAC 1 
In the first SILAC experiment (SILAC1), ‘heavy’ labelled mouse C3H10T1/2 cells were 
transfected with mature miR-324-5p and ‘light’ C3H10T1/2 were transfected with miCon 
(see materials and methods) (Figure 5.4A). Following data processing (see materials and 
methods), there were 1,735 proteins identified in SILAC1. Protein expression data was 
calculated from the ratio of miR-324-5p (heavy) to miCon (light) and converted into a log2 
value. Of the 1,735 proteins identified, 249 (14.4%) decreased, 159 (9.2%) increased, by a 
fold change of log2 0.2 and 1327 (76.5%) remained unchanged (Figure 5.4B) (From this 
point onwards a gene, protein or mRNA transcript will be referred to as increased when 
the fold change in expression is increased by >log2 0.2 and decreased when its expression 
is decreased by >log2 0.2, all other genes, proteins or mRNA transcripts will be referred to 
as unchanged). Log2 0.2 is equivalent to a 1.15 fold change, (see Appendix C for why a 
log2 0.2 cut off was chosen). 183 (10.5%) of the 1,735 genes whose protein was identified 
contain a miR-324-5p binding site in their 3’UTR, of which a greater number decreased 
than increased, 35 (19.1%) and 16 (8.7%) respectively (Figure 5.4C). 132 (72.1%) proteins 
whose genes contain a miR-324-5p seed binding site in their 3’UTR remained unchanged 
in expression (Figure 5.4C). A larger (1.48 fold, p=0.051) fraction of proteins whose 
expression decreased (35/249=14.0%) have a miR-324-5p seed binding site in their 3’UTR, 
than proteins whose expression either remained unchanged (132/1327=9.9%) or 
increased (16/159=10.0%) (Figure 5.4D).  
Of the 183 proteins identified whose genes 3’UTR contained a miR-324-5p seed binding 
site, 9 contained a conserved miR-324-5p seed binding site, a greater number of which 
decreased (three) than increased (one), five remained unchanged. The fraction of genes 
containing a conserved miR-324-5p seed binding site, was 3.01 fold higher in genes whose 
protein expression decreased (3/249), compared to genes whose protein either remained 
unchanged (5/1,327) or increased (1/159) (p=0.103). Additionally both ‘cumulative 
fraction’ (Figure 5.4E) and ‘normalised fraction’ (Figure 5.4F) plots showed a greater 
enrichment of conserved miR-324-5p seeds than non-conserved miR-324-5p seeds, in 
proteins whose expression decreased. See Appendix B for how ‘cumulative fraction’ and 
‘normalised fraction’ plots were made. 
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Of the 183 identified proteins whose gene contained a miR-324-5p seed binding site in 
their 3’UTR, 34 contained an 8mer, 70 contained a 7mer m8 and 92 contained a 7mer A1 
miR-324-5p seed binding site. The fraction of genes which contained an 8mer, 7mer m8 
and 7mer A1 type of miR-324-5p seed binding site is 1.86, 1.52 and 1.27 fold higher in 
genes whose protein expression decreased, compared to genes whose protein either 
remained unchanged or increased (p=0.123, p=0.169 and p=0.393) respectively. The 
cumulative fraction plot (Figure 5.4G) illustrates this. The normalised fraction plot (Figure 
5.4H) illustrates an enrichment of 8mer and 7mer m8 seeds, but not 7merA1 seeds. 
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Figure 5.4 SILAC 1 
 
Figure 5.4 SILAC 1. miR-324-5p targets are decreased at a protein level in miR-324-5p 
transfected heavy unstimulated cells. (A) Schematic showing experimental approach for 
SILAC 1. (B) Histogram showing expression changes of 1,735 proteins following miR-324-
5p transfection; 249 decreased, 159 increased by a fold change of log2 0.2 and 1327 
remained unchanged. (C) 183 of the 1,735 genes whose protein was identified contain a 
miR-324-5p binding site in their 3’UTR; 35 decreased, 16 increased and 132 did not alter 
by a fold change of log2 0.2. (D) Fraction of genes whose protein was identified which 
contain a miR-324-5p seed binding site; 14.1%, 10.0% and 9.9% of the genes whose 
protein expression decreased, increased and did not alter by a fold change of log2 0.2 
respectively, contain a miR-324-5p binding site. The fraction of genes containing a miR-
324-5p binding site is 1.48 fold higher in genes whose protein expression decreased 
compared to genes whose protein either remained unchanged in expression or increased 
(p=0.051). (E) Cumulative fraction of conserved and non conserved miR-324-5p seed 
binding sites. Of the 183 seed binding sites 9 are conserved, 3 of which are decreased. (F) 
Normalised fraction plot of conserved and non conserved miR-324-5p seed binding sites. 
(G) Cumulative fraction of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. (H) 
Normalised fraction plot of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. 
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5.2.2.3 SILAC2 
To eliminate any effect of heavy amino acids on protein expression, a second SILAC 
experiment (SILAC2) was performed, where the labels were reversed, ‘light’ cells were 
transfected with miR-324-5p and the ‘heavy’ cells with miCon (Figure 5.5A). There were 
1457 proteins identified in SILAC2. In SILAC2, protein expression data was calculated from 
the ratio of miR-324-5p (light) to miCon (heavy), then converted into a log2 fold change in 
expression. Similar to SILAC1, the majority of proteins remained unchanged in expression 
(827, 56.7%) and a larger number decreased (423, 29.0%), than increased (207, 14.2%) 
(Figure 5.5B). Interestingly, there are more genes whose protein expression either 
decreased or increased in SILAC2 (423+207) than in SILAC1 (249+159). 114 of the 1,457 
genes (7.8%) whose protein was identified in SILAC2, contain a miR-324-5p binding site in 
their 3’UTR, of which a larger number of proteins whose genes contain a miR-324-5p seed 
binding site were decreased (56 or 13.2%), than were increased (11 or 5.3%) (Figure 5.5C). 
Additionally the fraction of genes containing a miR-324-5p seed binding site was 2.57 fold 
higher in genes whose protein expression decreased 13.2% (56/423), compared to genes 
whose protein either increased 5.3% (11/207) or remained unchanged in expression 5.7% 
(47/827) (p=8.55x10-7) (Figure 5.5D). 
Of the 114 proteins whose genes contained a miR-324-5p seed binding site, 6 contained a 
conserved miR-324-5p binding site. Of these 4 decreased, 2 remained unchanged and 
none increased, meaning as in SILAC1 there is also a stronger enrichment of conserved 
miR-324-5p targets than non-conserved miR-324-5p targets, in proteins whose expression 
decreased. The fraction of genes which contained a conserved miR-324-5p seed binding 
site was 4.93 fold higher in genes whose protein expression decreased, compared to 
genes whose protein either remained unchanged or increased in expression (p=0.042) 
(Figure 5.5E and F). 
Of the 114 genes whose protein was identified in SILAC2 and contained a miR-324-5p 
binding site in their 3’UTR, 20, 50 and 55 of the genes contained an 8mer, 7mer m8 and 
7mer A1 miR-324-5p binding site respectively. The fraction of genes which contained an 
8mer, 7mer m8 and 7mer A1 miR-324-5p seed binding site was 2.02, 3.87 and 2.10 fold 
130 
 
higher in genes whose protein expression decreased compared to genes whose protein 
either remained unchanged or increased (p=0.113, p=9.15X10-7 and p=0.006) respectively. 
Suggesting 7mer m8 sites were more enriched than 8mer and 7mer A1 sites in genes 
whose protein expression decreased by >log2 0.2 (Figure 5.5G and H). 
131 
 
Figure 5.5 SILAC2 
 
Figure 5.5 SILAC 2. miR-324-5p targets are decreased at a protein level in miR-324-5p 
transfected light unstimulated cells. (A) Schematic showing experimental approach for 
SILAC 2. (B) Histogram showing expression changes of 1,457 proteins following miR-324-
5p transfection; 423 decreased, 207 increased by a fold change of log2 0.2 and 827 
remained unchanged (C) 114 of the 1,457 genes whose protein was identified contain a 
miR-324-5p binding site in their 3’UTR; 56 decreased, 11 increased and 47 did not alter by 
a fold change of log2 0.2. (D) Fraction of genes whose protein was identified which contain 
a miR-324-5p seed binding site; 13.2%, 5.3% and 5.7% of the genes whose protein 
expression decreased, increased and did not alter by a fold change of log2 0.2 
respectively, contain a miR-324-5p binding site. The fraction of genes containing a miR-
324-5p binding site is 2.57 fold higher in genes whose protein expression decreased 
compared to genes whose protein either remained unchanged in expression or increased 
(p=8.55x10-7). (E) Cumulative fraction of conserved and non conserved miR-324-5p seed 
binding sites. Of the 114 seed binding sites 6 are conserved, 4 of which are decreased. (F) 
Normalised fraction plot of conserved and non conserved miR-324-5p seed binding sites. 
(G) Cumulative fraction of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. (H) 
Normalised fraction plot of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. 
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5.2.2.4 Combine SILAC1 and SILAC2 
There were 1,227 proteins identified in both SILAC1 and SILAC2 experiments. Figure 5.6A 
shows data from SILAC1 correlates with data from SILAC2 (R2=0.4715). For example, 
79.4% of proteins decreased in SILAC1 and identified in SILAC2, were also decreased in 
SILAC2 with the addition of miR-324-5p (104/131) (Figure 5.6A). The average of both 
SILAC1 and SILAC2 was used to perform the seed analysis shown in Figure 5.6B-H. 
Following miR-324-5p transfection the majority (920/1227=75.0%) of proteins remained 
unchanged and a greater number decreased (198/1227=16.1%) than increased 
(109/1227=8.9%) (Figure 5.6B). 93 of the 1,227 genes (7.6%) whose protein was identified 
in SILAC1 and SILAC2 contained a miR-324-5p binding site in their 3’UTR. A larger number 
of proteins whose gene contained a miR-324-5p binding site were decreased 
(30/93=32.3%) than were increased (8/93=8.6%) (Figure 5.6C). The fraction of genes 
which contained a miR-324-5p seed binding site was a 2.74 fold higher in genes whose 
protein expression decreased (30/198=15.2%) compared to genes whose protein either 
increased (8/109=7.3%) or remained unchanged in expression (55/920=6.0%), (total not 
decreased; 63/1029=6.1%) (p=1.10x10-5) (Figure 5.6D). 
5 of the 93 proteins whose gene contained a miR-324-5p seed binding site, contained a 
conserved miR-324-5p seed binding site. 3 of these genes decreased, only 1 remained 
unchanged and only 1 increased, meaning there was a greater enrichment of conserved 
miR-324-5p targets than non conserved miR-324-5p targets in proteins whose expression 
decreased. The fraction of genes which contained a conserved miR-324-5p seed binding 
site was 7.9 fold higher in genes whose protein expression decreased (3/198) compared to 
genes whose protein either remained unchanged or increased in expression (2/1029) 
(p=0.008) (Figure 5.6E and F). 
Of the 93 genes whose proteins were identified in both SILAC1 and SILAC2 and contained 
a miR-324-5p binding site in their 3’UTR, 17, 38 and 46 contained an 8mer, 7mer m8 and 
7mer A1 miR-324-5p binding site respectively. The fraction of genes which contained an 
8mer, 7mer m8 and 7mer A1 miR-324-5p seed binding site is 3.73, 4.51 and 1.67 fold 
higher in genes whose protein expression decreased compared to genes whose protein 
133 
 
either remained unchanged in expression or increased, p=0.005, p=1.12X10-6 and p=0.144 
respectively, suggesting 7mer m8 sites are more enriched than both 8mer and 7mer A1 
sites, and 8mer sites are more enriched than 7mer A1 sites in genes whose protein 
expression decreased by >log2 0.2 (Figure 5.6G and H). Although there were some 
differences between SILAC1 and SILAC2, the similarities suggest there was a miR-324-5p 
transfection dependent enrichment of decreased proteins whose genes contain miR-324-
5p seed binding site. 
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Figure 5.6 SILAC1 and SILAC2 correlate 
 
Figure 5.6 SILAC 1 and SILAC 2 combined. (A) SILAC 1 data correlates with SILAC 2 data (R2 
=0.4715). Inset; numbers of proteins increased ‘U’, decreased ‘D’ and not changed ‘NC’ by 
log2 0.2 in SILAC1 (columns) and SILAC 2 (rows). (B) Histogram showing average 
expression changes of 1,227 proteins identified in SILAC 1 and SILAC 2 following miR-324-
5p transfection; 198 decreased, 109 increased by a fold change of log2 0.2 and 920 
remained unchanged (C) 93 of the 1,227 genes whose protein was identified contain a 
miR-324-5p binding site in their 3’UTR; 30 decreased and 8 increased by a fold change of 
log2 0.2, 55 remained unchanged. (D) Fraction of genes which contain a miR-324-5p seed 
binding site; 15.2%, 7.3% and 6.0% of the genes whose protein expression decreased, 
increased and remained unchanged respectively, contain a miR-324-5p binding site. The 
fraction of genes containing a miR-324-5p binding site is 2.74 fold higher in genes whose 
protein expression decreased compared to genes whose protein either remained 
unchanged in expression or increased (p=1.10x10-5). (E) Cumulative fraction of conserved 
and non conserved miR-324-5p seed binding sites. Of the 93 seed binding sites 5 are 
conserved, 3 of which are decreased. (F) Normalised fraction plot of conserved and non-
conserved miR-324-5p seed binding sites. (G) Cumulative fraction of 8mer, 7mer m8 and 
7mer a1 miR-324-5p seed binding sites. (H) Normalised fraction plot of 8mer, 7mer m8 
and 7mer a1 miR-324-5p seed binding sites. 
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5.2.2.5 Transcriptome microarray 1 (unstim) 
Recently Guo et al. showed the majority (>84%) of miRNA targets are reduced at mRNA, 
level as well as at the protein, level [121]. This meant transcriptome microarrays could be 
used to search for the majority of miRNA targets. Here a similar experiment to SILAC1 and 
SILAC2 was performed, but this time extracting the RNA for transcriptome analysis (Figure 
5.7A). I obtained mRNA expression data for 25,697 probes corresponding to 18,097 
different genes. Similar to protein expression the majority (18,367/25,697=71.5%) of 
mRNA probes changed less than log2 0.2 fold. In contrast to protein, a similar number of 
mRNAs were decreased and increased (3,708/25,697=14.4% and 3,622/25,697=14.1% 
respectively) (Figure 5.7B). 2,297 (8.9%) of the 25,697 probes I obtained mRNA expression 
data for were to genes which contained at least one miR-324-5p seed binding site, the 
majority (1,602/2,297=69.7%) of which remained unchanged in expression. A greater 
number of genes which contained miR-324-5p seed binding sites decreased (477/2,297) 
than increased (218/2,297) (Figure 5.7C), meaning the fraction of genes which contain a 
miR-324-5p seed binding site in their 3’UTR was 1.64 fold higher in genes whose 
expression decreased (477/3708=12.9%), compared to genes whose expression remained 
the same (1,602/18,367=8.7%) or increased (9218/3,622=6.0%) (p=1.34x10-19) (Figure 
5.7D). 
72 of the 2,297 mRNAs which contained a miR-324-5p seed binding site, contained a 
conserved miR-324-5p seed binding site, 24 of which decreased, 44 remained unchanged 
and only 4 increased, representing a 2.98 fold (p=4.85x10-6) fold enrichment in decreased 
mRNAs. Consistent with protein expression (SILAC) this was a greater enrichment than for 
mRNAs containing non-conserved miR-324-5p seed binding sites (Figure 5.7E and F). 
Of the 2,297 mRNAs which contained a miR-324-5p seed binding site 420 contained an 
8mer, 1,039 contained a 7mer m8 and 1,057 contained a 7mer A1. In contrast to SILAC1 
and 2, but as should be expected, 8mer seeds (1.88 fold, p=3.47x10-8) were more enriched 
than 7mer A1 (1.58 fold, p=4.49x10-9) and 7mer m8 seeds (1.52 fold, p=1.06x10-7) (Figure 
5.7G and H) in those genes whose expression decreased compared to genes whose 
expression either increased or remained unchanged following miR-324-5p transfection. 
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Figure 5.7 Transcriptome microarray 1 (unstim) 
 
Figure 5.7 Transcriptome microarray 1 (unstim). miR-324-5p targets are enriched with the 
decreased transcripts of miR-324-5p transfected unstimulated cells. (A) Schematic 
showing experimental approach for the unstimulated array. (B) Histogram showing 
expression changes of 25,697 transcripts corresponding to 18,097 genes, following miR-
324-5p transfection; 3,708 decreased, 3,622 increased by a fold change of log2 0.2 and 
18,367 remained unchanged. (C) 2,297 of the 25,697 identified transcripts contain a miR-
324-5p binding site in their 3’UTR; 477 decreased, 218 increased by a fold change of log2 
0.2 and 1,602 remained unchanged. (D) Fraction of transcripts which contain a miR-324-
5p seed binding site; 12.9%, 6.0% and 8.7% of transcripts decreased, increased and 
remained unchanged by a fold change of log2 0.2 respectively, contain a miR-324-5p 
binding site. The fraction of genes containing a miR-324-5p binding site is 1.64 fold higher 
in genes whose transcript decreased compared to genes whose transcript either remained 
unchanged in expression or increased (p=1.34x10-19). (E) Cumulative fraction of conserved 
and non-conserved miR-324-5p seed binding sites. Of the 2,297 seed binding sites 72 are 
conserved, 24 of which are decreased, 4 increased and 44 remained unchanged. (F) 
Normalised fraction plot of conserved and non conserved miR-324-5p seed binding sites. 
(G) Cumulative fraction of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. (H) 
Normalised fraction plot of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. 
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5.2.2.5 SILAC protein data correlates with array mRNA data 
Of the 18,097 different genes identified at the mRNA level, 1,299 also had proteomic 
expression data. Log2 fold changes in mRNA correlated with log2 fold change in protein 
following miR-324-5p transfection (R2=0.1948) (Figure 5.8A). 93 of the 1299 genes 
contained a miR-324-5p seed binding site in their 3’UTR, mRNA and protein data for these 
93 genes is shown in Figure 5.8B (R2=0.3089). 18 of these 93 decreased at a protein and 
mRNA level, representing a 3.67 fold (p=1.68x10-6) enrichment of miR-324-5p seed 
containing genes, in genes whose expression decreased at a protein and mRNA level, 
compared to other genes 975/1,207. This was a greater enrichment than in genes which 
decreased at only either an mRNA or protein level (1.6 fold and 2.7 fold respectively). 
Suggesting using both mRNA and protein data to predict miRNA targets is better than 
using either alone. The 18 potential targets whose protein decreased, mRNA decreased 
and contained a miR-324-5p seed binding site are shown in Figure 5.8C. 
138 
 
Figure 5.8 Combine SILAC 1 and 2 with unstim array 
 
Figure 5.8 SILAC 1 and SILAC 2 average combined with unstimulated array. (A) Change in 
protein expression correlates with change in mRNA expression following miR-324-5p 
transfection. 1,299 genes were identified at a protein and mRNA level, 92 of which 
decrease at a protein and mRNA level. (B) 93 genes were identified at a protein and mRNA 
level and also contain a miR-324-5p seed binding site, 18 of which decreased at an mRNA 
and protein level, meaning 74 out of 1206 genes lacking miR-324-5p seed binding sites 
also decrease. (C) Bar chart showing log2 fold change in protein and mRNA expression for 
18 potential targets following miR-324-5p transfection. 
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5.2.2.6 Target identification strategy and validation 
I created constructs where the 3’UTR of 2 potential targets were cloned down-steam of a 
luciferase reporter gene placing luciferase under the control of the predicted targets 
3’UTR. When co-transfected with miR-324-5p both of the potential targets had reduced 
luciferase expression (Figure 5.9A), indicating both of them were valid miR-324-5p targets. 
Our results indicate SILAC and transcriptome microarrays can be integrated to form an 
effective miRNA target identification strategy (outlined in Figure 5.9B). 
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Figure 5.9 Target identification strategy and validation 
 
Figure 5.9 Target identification strategy and validation. (A) C3H10T1/2 cells were 
transfected with either Anxa4 or App 3’UTR luciferase constructs (in pMIR-Report) with 
either miCon or miR-324-5p. Data combined from 3 independent experiments each n=6, 
data shown is mean and SEM, statistical difference was calculated using student t test 
where ***<0.001 and *<0.05. (B) Schematic showing miRNA target identification strategy. 
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5.2.3 Identification of potential miR-324-5p targets with a role in Hh signalling. 
Here I have outlined an effective, comprehensive strategy to identify novel miRNA targets, 
this was then employed to identify miR-324-5p targets responsible for regulating Hh 
signalling (the main aim of this Chapter and discussed in the following section). miRNA-
target interactions are dependent on both miRNA and target mRNA abundance [245]. 
Because I was searching for miR-324-5p targets responsible for loss of Hh signalling in Ihh 
stimulated cells, it is probably necessary to search for miR-324-5p targets in Ihh stimulated 
cells. The same experimental approach used in Chapter 4, was used here, as it is know 
miR-324-5p has the ability to inhibit Ihh induced Hh signalling in that experimental 
approach. 
5.2.3.1 SILAC3 (Ihh stimulated) 
To determine proteins whose expression decreased following miR-324-5p transfection in 
Ihh stimulated cells, a third SILAC experiment (SILAC3) was performed. In SILAC3, as in 
SILAC1, heavy labelled C3H10T1/2 cells were transfected with miR-324-5p and light 
C3H10T1/2 cells were transfected with miCon (Figure 5.10A). 2,086 proteins were 
identified, 1,604 of which remained unchanged, 255 decreased and 227 increased (Figure 
5.10B). Of the 2,086, 176 (8.4%) contained a miR-324-5p seed in their 3’UTR. Twice as 
many of these seed containing genes deceased at a protein level than increased, 36 
(20.5%) and 18 (10.2%) respectively (Figure 5.10C).  Similar to SILAC1 and SILAC2, there 
was a significant enrichment (1.99 fold, p=0.0005) of miR-324-5p binding sites in proteins 
whose expression decreased (36/255=14.1%) compared to proteins whose expression 
increased (18/227=7.9%) or remained unchanged (122/1604=7.6%) (Figure 5.10D). 
8 of the 176 proteins whose gene contained a miR-324-5p seed binding site, contained a 
conserved miR-324-5p seed binding site, 3 of which decreased, 4 remained unchanged 
and only 1 increased. Consistent with SILAC1 and SILAC2, there is a greater enrichment 
(4.35 fold, p=0.03) of proteins whose gene contained conserved miR-324-5p binging sites, 
than those which contained non-conserved miR-324-5p seed binding sites (Figure 5.10 E 
and F). 
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Of the 176 genes whose protein was identified in SILAC3 and contained a miR-324-5p 
binding site in their 3’UTR, 26 contained an 8mer, 70 contained a 7mer m8 and 92 
contained a 7mer A1 miR-324-5p binding site. The fraction of genes which contained an 
8mer, 7mer m8 and 7mer A1 miR-324-5p seed binding sites is 3.90, 3.03 and 1.19 fold 
higher in genes whose protein expression decreased compared to genes whose protein 
either remained unchanged or increased (p=0.0005, p=2.16X10-5 and p=0.568) 
respectively. Suggesting 8mer and 7mer m8 sites are more enriched than 7mer A1 sites in 
genes whose protein expression decreased (Figure 5.10G and H). 
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Figure 5.10 SILAC 3 (Ihh stimulated) 
 
Figure 5.10 SILAC 3 (Ihh stimulated). miR-324-5p targets are decreased at a protein level in 
miR-324-5p transfected heavy Ihh stimulated cells. (A) Schematic showing experimental 
set up for SILAC 3. (B) Histogram showing expression changes of 2,086 proteins following 
miR-324-5p transfection; 255 decreased, 227 increased by a fold change of log2 0.2 and 
1,604 remained unchanged. (C) 176 of the 1,086 genes whose protein was identified 
contain a miR-324-5p binding site in their 3’UTR; 36 decreased, 18 increased by a fold 
change of log2 0.2 and 122 remained unchanged. (D) Fraction of genes whose protein was 
identified which contain a miR-324-5p seed binding site; 14.1%, 7.9% and 7.6% of the 
genes whose protein expression decreased, increased and remained unchanged by a fold 
change of log2 0.2 respectively, contain a miR-324-5p binding site. The fraction of genes 
containing a miR-324-5p binding site is 1.99 fold higher in genes whose protein expression 
decreased compared to genes whose protein either remained unchanged in expression or 
increased (p=0.0005). (E) Cumulative fraction of conserved and non conserved miR-324-5p 
seed binding sites. Of the 176 seed binding sites 8 are conserved, 3 of which are 
decreased, 1 increased and 4 remained unchanged. (F) Normalised fraction plot of 
conserved and non conserved miR-324-5p seed binding sites. (G) Cumulative fraction of 
8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. (H) Normalised fraction plot 
of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. 
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5.2.3.2 Transcriptome microarray 2 (Ihh stimulated) 
To determine transcripts whose expression decreased following miR-324-5p transfection 
in stimulated cells a second transcriptome microarray was performed (transcriptome 
microarray 2 stim). In the stimulated transcriptome microarray, similar to SILAC3, 
C3H10T1/2 cells (normal) were transfected with miR-324-5p or miCon and stimulated with 
Ihh (Figure 5.11A). As with the unstimulated transcriptome microarray, mRNA expression 
data was obtained for 25,697 probes corresponding to 18,097 different genes (note: all 
transcriptome microarrays were performed and analysed simultaneously). Similar to the 
unstimulated microarray the majority (19,746/25,697=76.9%) of mRNAs remained 
unchanged in expression and a similar number of mRNAs were decreased and increased 
(2,975/25,697=11.6% and 2,958/25,697=11.5% respectively) (Figure 5.11B). Again as with 
the unstimulated array, 2,297 (8.9%) of the 25,697 probes I obtained mRNA expression 
data for, contained at least one miR-324-5p seed binding site. The majority (1,668/2,297) 
of which remained unchanged in expression. A greater number of the miR-324-5p seed 
containing genes decreased (409/2,297) than increased (220/2,297)(Figure 5.11C). The 
fraction of genes which contained a miR-324-5p seed binding site in their 3’UTR is 1.75 
fold higher in genes whose expression decreased (409/2,975=13.7%), than genes whose 
expression remained the same (1,668/19,764=8.4%) or increased (220/2,958=7.4%) 
(p=1.41x10-22) (Figure 5.11D). 
Of the 2,297 mRNAs which contained a miR-324-5p seed binding site, 72 contained a 
conserved miR-324-5p seed binding site, 19 of which decreased, 46 remained unchanged 
and only 7 increased. Consistent with all previous experiments, there was a greater 
enrichment (2.75 fold, p=8.37x10-5) of mRNAs that contained conserved miR-324-5p 
binding sites than mRNAs that contained non-conserved miR-324-5p seed binding sites in 
those mRNAs whose expression decreased (Figure 5.11E and F). 
Of the 2,297 mRNAs which contained a miR-324-5p seed binding site, 420, 1,039 and 
1,057 contained an 8mer, 7mer m8 and a 7mer A1 respectively. 8mer seeds (1.85 fold, 
p=6.41x10-7) and 7mer m8 seeds (2.03 fold, p=1.10x10-19) were more enriched than 7mer 
A1 seeds (1.42 fold, p=6.64x10-5) (Figure 5.11G and H), in those genes whose expression 
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decreased, compared to genes whose expression either increased or remained unchanged 
following miR-324-5p transfection. 
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Figure 5.11 Transcriptome microarray 2 (Ihh stimulated) 
 
Figure 5.11 Transcriptome microarray 2 (Ihh stimulated). miR-324-5p targets are 
decreased at an mRNA level in miR-324-5p transfected and Ihh stimulated cells. (A) 
Schematic showing experimental approach for the Ihh stimulated array. (B) Histogram 
showing expression changes of 25,697 transcripts corresponding to 18,097 genes, 
following miR-324-5p transfection; 2,975 decreased, 2,958 increased and 19,746 
remained unchanged. (C) 2,297 of the 25,697 identified transcripts contain a miR-324-5p 
binding site in their 3’UTR; 409 decreased, 220 increased by a fold change of log2 0.2 and 
1,668 remained unchanged. (D) Fraction of transcripts which contain a miR-324-5p seed 
binding site; 13.7%, 7.4% and 8.4% of transcripts decreased, increased and remained 
unchanged by a fold change of log2  0.2 respectively, contain a miR-324-5p binding site. 
The fraction of genes containing a miR-324-5p binding site is 1.76 fold higher in genes 
whose transcript decreased compared to genes whose transcript either remained 
unchanged in expression or increased (p=1.41x10-22). (E) Cumulative fraction of conserved 
and non conserved miR-324-5p seed binding sites. Of the 2,297 seed binding sites 72 are 
conserved, 19 of which are decreased, 7 increased and 46 remained unchanged. (F) 
Normalised fraction plot of conserved and non conserved miR-324-5p seed binding sites. 
(G) Cumulative fraction of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. (H) 
Normalised fraction plot of 8mer, 7mer m8 and 7mer a1 miR-324-5p seed binding sites. 
A.
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5.2.3.3 Combine SILAC3 (stim) and transcriptome microarray 3(stim) 
Of the 18,097 different genes identified on the array, 2,086 were also identified in SILAC3 
and the fold change in mRNA correlated with the fold change in protein (Figure 5.12A). 
176 of the genes contained a miR-324-5p seed binding site in their 3’UTR. mRNA and 
protein expression data for these 176 genes is shown in Figure 5.12B. 18 of the 176 genes 
are decreased at a an mRNA and protein level and can be considered as potential miR-
324-5p targets in Ihh stimulated cells according to our miRNA target identification strategy 
(Figure 5.12). 
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Figure 5.12 Combine SILAC 3 with Ihh stimulated array 
 
Figure 5.12 SILAC 3 combined with Ihh stimulated transcriptome array. (A) Change in 
protein expression correlates with change in mRNA expression following mR324-5p 
transfection. 2,086 genes were identified at a protein and mRNA level (B) 176 genes were 
identified at a protein and mRNA level and also contain a miR-324-5p seed binding site, 18 
of which decreased at an mRNA and protein level. (C) Bar chart showing log2 fold change 
in protein and mRNA expression for 18 potential targets following miR-324-5p 
transfection. 
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5.2.3.4 Potential targets which may have a role in Hh signalling 
Two strategies were used to identify which of potential targets were involved in Hh 
signalling. Firstly, the Hh Kegg pathway contains a number of genes which have previously 
been shown to be involved in Hh signalling. However, of the 18 potential targets none 
were part of the Hh KEGG pathway (Figure 5.13), although Hh Kegg pathway is not entirely 
comprehensive. Secondly, literature searches showed relatives of the potential target 
Glypican 1 (Gpc1) have previously been shown to play a role in Hh signalling [246, 247]. I 
therefore hypothesised Gpc1 was involved in Hh signalling and is a miR-324-5p target in 
mouse. The overall strategy used to identify potential miR-324-5p targets involved in Hh 
signalling is summarised in Figure 5.13. 
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Figure 5.13 Finding Gpc1 
 
Figure 5.13 Experimental flow used to identify Gpc1 as a miR-324-5p target with a possible 
role in Hh signalling. Numbers correspond to equivalent parts of the miRNA target 
identification strategy (Figure 5.8B) 
Appropriate C3H10T1/2 cells
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5.2.4 Validation of Gpc1 as a miR-324-5p target 
Gpc1 was identified in Ihh stimulated proteomics (SILAC 3) by 6 peptides, 5 of which 
decrease with the addition of miR-324-5p (Figure 5.14A). The array data showed Gpc1 
mRNA was decreased in both stimulated and unstimulated cells with the addition of miR-
324-5p (Figure 5.14B), indicating Gpc1 was a miR-324-5p target irrespective of Ihh 
stimulation. Immunoblotting of Gpc1 protein following miR-324-5p transfection was used 
to confirm miR-324-5p reduces Gpc1 at a protein level (Figure 5.14C). Real-time RT-PCR of 
Gpc1 mRNA following miR-324-5p transfection was used to confirm miR-324-5p reduced 
Gpc1 mRNA (Figure 5.14D). To validate Gpc1 as being a direct target of miR-324-5p, I 
created a construct where the mouse Gpc1 3’UTR was cloned downstream of a luciferase 
gene placing luciferase under the control of the Gpc1 3’UTR. Co-transfection of this 
construct with miR-324-5p showed miR-324-5p can reduce the amount of luciferase 
produced by this construct (Figure 5.14E), indicating Gpc1 was a direct miR-324-5p target 
in mouse. Further analysis of the mouse Gpc1 3’UTR showed it has 3 miR-324-5p seed 
matches (Figure 5.14F). Site directed mutagenesis of each of the 3 potential miR-324-5p 
binding sites indicated the most downstream site (site 3), which is a ‘12mer site’, was the 
only functional miR-324-5p binding site in the mouse Gpc1 3’UTR, as only when this site 
was mutated, was there a rescue of miR-324-5p mediated reduction of luciferase levels 
(Figure 5.14E). 
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Figure 5.14 Validation of Gpc1 as a direct miR-324-5p target 
 
Figure 5.14 Gpc1 is a miR-324-5p target in mouse. (A) Effect of miR-324-5p on Gpc1 
peptides identified in SILAC 3. (B) Effect of miR-324-5p on Gpc1 mRNA expression as 
identified in microarray 1 (unstim) and microarray 2 (Ihh stimulated). (C) Western blot 
analysis of Gpc1 protein following siGPC1 and miR-324-5p transfection. (D) real-time RT-
PCR analysis of Gpc1 mRNA following siGpc1 and miR-324-5p transfection. (E) pMIR-
Report plasmid containing either wild-type or mutant mouse Gpc1 3’UTR downstream of 
luciferase was transfect into C3H10T1/2 cells with either miCon2 or miR-324-5p, data 
normalised to miCon and plotted as relative luciferase light units, statistical difference 
were calculated using ANOVA. Data are combined from 5 independent experiments, each 
n=6-8. (F) Potential miR-324-5p binding site in wild-type and mutant Gpc1 3’UTRs. miRNA 
seed sequence is shown in red and underlined, mutated miR-324-5p seed binding site are 
shown in lower case. 
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5.3 Discussion 
The main aim of this chapter was to identify miR-324-5p targets in mouse which have a 
possible role in Hh signalling. 11 predicted mouse miR-324-5p targets were predicted to 
have a role in Hh signalling (Figure 5.2), but due to the unreliability of prediction 
algorithms, a strategy to identify miRNA targets was developed. C3H10T1/2 cells were 
transfected with mature miR-324-5p mimic, increasing miR-324-5p incorporation into RISC 
and its interaction with targets, ultimately caused miR-324-5p targets to have reduced 
expression. SILAC proteomics and transcriptome microarrays were then used to detect 
which genes had reduced protein and mRNA expression. To validate our experiments I 
analysed the 3’UTR of genes whose protein and mRNA expression decreased following 
miR-324-5p transfection and found these 3’UTRs had a significantly higher number of miR-
324-5p binding sites than the 3’UTRs of genes whose expression remained unchanged or 
increased; these genes were therefore considered as potential miR-324-5p targets. 
Literature searches found one potential target, Gpc1, had a possible role in Hh signalling 
(Chapter 6). Gpc1 was then validated as a direct miR-324-5p target. 
5.3.1 Analysis of target identification methodology 
5.3.1.1 Cell culture 
During strategy development, C3H10T1/2 cells were left unstimulated, keeping the 
experimental design a simple as possible and ensuring the majority of changes in gene 
expression were due to miR-324-5p overexpression rather than due to the blocking of Hh 
signalling. 
In the SILAC experiments heavy labelled lysine and arginine were used because the 
preparation of samples for MS involved the cleavage of proteins into peptides with 
trypsin, an enzyme that cleaves after lysines and arginines. This means every peptide will 
contain at least one heavy labelled amino acid. More specifically 13C6-Lys and 
13C6 
15N4-Arg 
were used to label cells as heavy, where the carbon in lysine and both the carbon and 
nitrogen in arginine contained one extra neutron in the nucleus. Lysine contains 6 carbons 
meaning any peptide that contained a lysine was 6 mass units heavier, while arginine 
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contains 6 carbons and 4 nitrogens meaning any peptide that contained an arginine was 
10 mass units heavier. Standard 12C6-Lys and 
12C6 
14N4-Arg were used in light media. 
Because two populations of cells are needed for SILAC experiments I wanted to avoid any 
differences between the populations being misinterpreted as real changes in expression 
or as miRNA targets. Labels in SILAC2 were therefore the reverse of the labels in SILAC1, 
miR-324-5p targets were enriched irrespective of label orientation. Proteins whose 
expression correlated with the label rather than the miRNA were likely to be due to 
stochastic variations between the experiments. Interestingly, a larger proportion of 
proteins changed in expression in SILAC2 than in SILAC1, this may be due to differences in 
transfection efficiency between the experiments, although this was not tested. 
5.3.1.2 Timing 
Some studies have shown miRNAs reduce protein and mRNA expression in as little as 4h 
[248, 249]. In our experiments I analysed much later (72h post transfection), meaning 
there was likely to be many secondary effects of miRNA targets, making it difficult to 
determine direct miR-324-5p targets from the indirect effects of targets. 
5.3.1.3 The potential targets 
18 potential targets were identified in unstimulated cells, luciferase constructs were made 
for 2 of these and both were validated as real miR-324-5p targets. This limited data 
suggests the strategy is effective, however it is likely some genes will have decreased in 
expression due to secondary effects of the miRNA and are not direct targets. During 
luciferase validation both the target (luciferase construct) and miR-324-5p itself were 
vastly increased in the cell, increasing the chance of miRNA-target interaction and 
probably leading to an over estimate of the number of physiologically relevant targets. 
5.3.1.4 Targets in Hh 
miRNA-target interactions are dependent on the miRNA and mRNA expression profile 
[245]. I wanted to identify miR-324-5p targets involved in Ihh signalling, therefore I 
stimulated the cells with Ihh, to ensure potential target mRNAs were present. The 
stimulation with Ihh was akin to that used in Chapter 4, where the mechanism by which 
miR-324-5p inhibits Ihh induction of Gli1 was unknown. Similar to the unstimulated cells 
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18 potential targets were identified in stimulated cells, although many of them were 
different (Figure 5.15). 
To assess if any potential miR-324-5p targets are required for Hh signalling, the list of 
potential targets identified in stimulated cells was compared to the list of genes in the 
Kegg Hh pathway. No potential miR-324-5p targets were part of the Hh kegg pathway 
meaning more detailed analysis and literature searches were required. Literature 
searches, showed some family members of one potential target, Gpc1, can regulate Hh 
signalling [246, 250-253] (discussed further in Chapter 6). I therefore hypothesised Gpc1 
could also regulate Hh signalling (Chapter 6). 
5.3.1.5 Gpc1 validation 
Gpc1 was only identified as a potential target in stimulated cells (SILAC3 and 
transcriptome microarray 2), as SILAC1 and 2 (unstim) did not identify Gpc1. Further 
experiments indicated Gpc1 was a target independent of stimulation (Figure 5.14E), 
perhaps suggesting Gpc1 was decreased with the addition of miR-324-5p in SILAC1 and 2, 
but just not detected, the reason this was unclear, but is possibly due to the inherent bias 
of proteomics to identify some peptides and not others. This was unlikely however as 
Gpc1 was identified by 6 peptides in SILAC 3 none of which were identified in either 
SILAC1 or SILAC2. An alternative possibility is Ihh stimulation ‘allowed’ Gpc1 protein to be 
identified, there is no evidence Gpc1 mRNA expression changed following Ihh stimulation 
(Figure 5.14E), but it is possible its cellular location did, meaning it became more 
abundant in extracts. Gpc1 location and its effects on Hh signalling warrants further 
investigation. Unfortunately, direct comparison of Gpc1 protein expression using 
immunoblotting on the actual lysates used in SILAC 1, 2 and 3 was not performed. In 
addition Gpc1 is a highly modified, membrane-bound, protein and its detection may be 
susceptible to slight variations in sample preparation between experiments. 
Of the 6 Gpc1 peptides in SILAC 3, 5 were decreased following miR-324-5p transfection 
(Figure 5.14A). The reason why one peptide increased following miR-324-5p transfection 
is unknown, although it may be due to miss identification of the peptide or stochastic 
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variation. Either way it was largely ignored as the reduction in Gpc1 protein was validated 
using immunoblotting. 
A luciferase construct was used to show miR-324-5p directly bound the Gpc1 3’UTR 
(Figure 5.14D). Further analysis of the mouse Gpc1 3’UTR showed it has 3 miR-324-5p 
seed matches (Figure 5.14F) referred here to as site one, site two and site three. Site 
directed mutagenesis of each of the 3 potential miR-324-5p binding sites indicated only 
the most downstrem site (site 3) is functional (Figure 5.14D). This is not surprising as there 
is more base pairing of this site with miR-324-5p (12mer) than site 1 (7mer) and site 2 
(8mer)(Figure 5.14). In addition site 3 is closer to the end of the 3’UTR than sites 1 and 2 
(Figure 5.14F), with sites closer to the ends of the 3’UTR having previously been shown to 
be more effective targets [218, 219]. 
5.3.1.6 Target ID in unstimulated cells vs. stim cells 
A total of 28 potential targets were identified in both the stimulated and unstimulated 
experiments, 18 of which were identified in the unstimulated experiments, 18 of which 
were identified in the stimulated experiments and 8 of which were identified in both 
(Figure 5.15), this indicated these 8 are miR-324-5p targets independent of stimulation. 
Similar to Gpc1, many of the other potential targets may also be stimulation independent. 
Equally, there are likely be a number of miR-324-5p targets which were not identified in 
either of the experiments, and a number of the identified potential targets may not be 
genuine targets. 
5.3.1.7 Summary of the methodology used 
Here I have created an effective miRNA target identification strategy (Figure 5.9B). 
Primarily it involves transfection of a mature miRNA of interest (or control) for 24h to 
increase the amount of that miRNA within the cell, this increases the amount of that 
miRNA within the RISC complex and subsequently increases the targeting effects of that 
miRNA. The cells are then treated in an appropriate way to ensure potential target 
transcripts are present. Proteomics (SILAC) and transcriptome microarrays are then 
performed on the protein and mRNA obtained from the transfected cells to detect those 
proteins and mRNAs whose expression decrease following miRNA transfection. The 
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enrichment of miRNA seed binding sites in the 3’UTR of genes whose protein and mRNA 
decreased is then validated. Luciferase constructs are used to validate individual targets 
before being investigated further. 
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Figure 5.15 Venn diagram of potential targets 
 
Figure 5.15 Venn diagram of potential targets. 18 potential targets were identified in the 
unstimulated experiments (SILAC1, SILAC2, unstimulated array) and 18 potential targets 
were identified in the stimulated experiments (SILAC3 and stimulated array). 8 potential 
targets were identified in both the unstimulated and stimulated experiments. 
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5.3.2 Analysis of what makes a good target 
5.3.2.1 Enrichment of miR-324-5p seed containing genes 
The transcriptome microarray and SILAC proteomics results showed miR-324-5p 
transfection reduced the expression of miR-324-5p targets. The conclusion is two fold. 
Firstly, a greater number of miR-324-5p seed containing genes decreased than increased 
following miR-324-5p transfection (Figure 5.4C, Figure 5.5C, Figure 5.6C, Figure 5.7C, 
Figure 5.8B, Figure 5.10C, Figure 5.11C and Figure 5.12B) and secondly of the genes whose 
expression decreased, a greater number than expected by chance contained a miR-324-5p 
seed binding site following miR-324-5p transfection (Figure 5.4D-F, Figure 5.5D-F, Figure 
5.6D-F, Figure 5.7D-F, Figure 5.10D-F and Figure 5.11D-F). 
5.3.2.2 Conserved sites are more enriched than non-conserved sites 
In all experiments (SILAC1, SILAC2, transcriptome microarray 1 (unstim), SILAC3 and 
transcriptome microarray 2 (stim)) there was a greater enrichment of conserved miR-324-
5p seed binding sites than non conserved miR-324-5p seed binding sites (Figure 5.4E & F, 
Figure 5.5E & F, Figure 5.6E & F, Figure 5.7E & F, Figure 5.10E & F and Figure 5.11E & F). In 
addition, there was a 2.73 fold enrichment of conserved miR-324-5p binding sites in the 
28 potential targets compared with miR-324-5p seed binding site containing genes not 
classified as a potential target. This suggested that generally the more species a given miR-
324-5p binding site is present in, the greater the chance of it being a real target. The 
reason why conserved seed binding sites are more likely to be real targets is probably 
linked to their evolution, but must also involve currently unknown mechanisms which 
allow increased binding to conserved targets. Robust miRNA-Target interactions would 
have been subject to a greater selection pressure than weak interactions and therefore 
have a greater chance of spreading through the gene pool. The effect the miRNA-Target 
interaction has on the organism will of course be determined either positive or negative 
selection pressure. Nevertheless a miRNA and target do need to interact in order for them 
to become conserved. 
5.3.2.3 Match at position 8 of the miRNA 
The most important region for miRNA-target interaction is known as the seed region as it 
is predicted to base pair with the target mRNA 3’UTR in the RISC complex [254]. There are 
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a number of different types of seed, the three main ones being 8mers, 7mer m8s and 
7mer A1s [129] and each has a different level of binding (Figure 5.1). 8mers, 7mer m8s 
and 7mer A1s all were all enriched in genes whose expression decreased, but 7mer A1s 
were consistently the least enriched (Figure 5.4G & H, Figure 5.5G & H, Figure 5.6G & H, 
Figure 5.7G & H, Figure 5.10G & H and Figure 5.11G & H). This was expected as they are 
the shortest type, and lack a match at position 8 (Figure 5.1C). Consistent with our results 
nucleotide number 8 has previously been shown to play a large role miRNA-mRNA 
interactions [255]. In contrast, Lewis et al. previously suggested nucleotide number 8 did 
not play a large role in determining if a gene is targeted, although they only analysed 
conserved miRNA seed binding sites [129]. In our experiments 8mers and 7mer m8s were 
found to be the most enriched but neither was consistently enriched more than the other 
(Figure 5.4G & H, Figure 5.5G & H, Figure 5.6G & H, Figure 5.7G & H, Figure 5.10G & H and 
Figure 5.11G & H), in contrast to previous studies [129] this suggest the ‘A’ at position 1 
(Figure 5.1A) does not always provide any additional benefit when positions 2-8 are 
complementary (Figure 5.1B).  
In addition, the consensus binding site for the whole of the miRNA was calculated to 
determine if regions outside of the seed are important. Consistent with analysis of 
enrichment of different seed types, there was a preceding ‘G’ (match at position 8) in 68% 
of the miR-324-5p 6mer seed binding sites in the 28 potential targets (Figure 5.16A), 
which was 1.86 fold higher than expected, further suggesting this base is beneficial for 
targets. Consensus sequence analysis of 7mers (Figure 5.16B), shows a slight preference 
for a ‘T’ (‘U’) to match the ‘A’ at position 9, and interestingly also at position 17 of the 
miRNA (Figure 5.16B). 
5.3.2.4 Positions in 3’UTR 
The position of the miRNA binding site within the 3’UTR has also been shown to be 
important for miRNA mediated reduction in gene expression [219]. The position of the 
miR-324-5p seed binding sites in the 28 potential targets seemed randomly distributed, 
and in contrast to previous studies [218, 219], showed no preference for the ends of the 
3’UTR (Figure 5.16C). 
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5.3.2.5 Number of miR-324-5p binding sites 
Some potential targets had more than one potential miR-324-5p seed binding site. 
Predicted targets whose protein and mRNA decreased (the potential targets) had an 
average of 1.52 seed binding sites per gene, where as all other genes whose 3’UTR 
contained a miR-324-5p seed binding site had an average of 1.25 seed binding sites per 
gene. This suggested having additional binding sites increases the likelihood of a gene 
being a miR-324-5p target. However, although a target may have many miR-324-5p seed 
binding sites not all of them need to be functional in order for a gene to be a target 
(Figure 5.14D). One potential target identified in Ihh stimulated cells is Serpine2 which had 
six consecutive miR-324-5p seed binding sites, strongly suggesting Serpine2 was a 324 
target. I validated Serpine2 as a target using luciferase (Figure 5.16D). Interestingly, the 
addition of miR-324-5p to the Serpine2 construct did not reduce luciferase to greater 
amount than for other validated targets (Figure 5.9A, Figure 5.14D, Figure 5.16D), 
suggesting having additional miR-324-5p seed binding sites does not influence how much 
a given target is reduced in expression (but may increase the probability of a gene being a 
miR-324-5p target). It has been suggested some miRNA targets bind to miRNAs to 
sequester the miRNA itself rather than to be regulated, these targets are called sponges 
[124]. Because Serpine2 has 6 7mer and 5 6mer miR-324-5p seed binding sites (Figure 
5.16D) it may function effectively in this way.  
5.3.2.6 Summary 
In summary a gene is required to contain a miR-324-5p seed in its 3’UTR and be reduced 
at a protein and mRNA expression in order for it to be classified as a potential miR-324-5p 
target. In addition our data has shown any gene that is conserved, has a match at position 
8 or has more than one miR-324-5p seed binding site has an increased the probability of a 
gene being a miR-324-5p target. Other studies, but not necessarily this one, have shown 
the position within the 3’UTR [218, 219], and additional binding away from the seed also 
increases the probability of a gene being a miR-324-5p target.  
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5.3.2. False positives and negatives 
There were however many genes that contained miR-324-5p seed binding sites that did 
not decrease and some genes which lack miR-324-5p seed binding sites did decrease. The 
reason why some miR-324-5p seed binding site containing genes do not decrease would 
have been partly due to the lack of the properties outlined above. Some miRNA seed 
containing genes might not be targets because they were detrimental to the organism and 
have evolved to escape the RISC complex, possibly by increased binding to RNA binding 
proteins [256, 257]. It is likely decreased genes which lack miRNA seed binding sites were 
due to secondary effects of real miRNA targets, although some miRNAs can interact with 
targets which lack a full seed binding site [127]. 
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Figure 5.16 What makes a good target? 
 
Figure 5.16 What makes a good target? (A) Consensus seed binding site analysis of 
surrounding 6mer binding sites in the 28 potential targets. (B) Consensus seed binding site 
analysis of surrounding 7mer binding sites in the 28 potential targets. (C) Relative position 
of all miR-324-5p seed binding sites in all 28 potential targets combined. (D) Serpine2 has 
6 7mer miR-324-5p binding sites (blue) and 5 6mer miR-324-5p binding sites (green)  and 
is a miR-324-5p target. Schematic shows miR-324-5p binding only to 7mer sites. Data 
combined from 3 independent experiments each n=6, data shown is mean and SEM, 
statistical difference was calculated using student t test where ***<0.001. 
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5.3.3 Analysis of online target prediction algorithms 
Online databases are a useful tool to aid with target identification, but when used alone 
offer little guidance as to which genes are real targets. For example, the combination of 
unstimulated SILAC and array experiments showed 8/93 proteins (Figure 5.6C) and 
218/2,297 mRNAs (Figure 5.7C), whose genes 3’UTR contained a miR-324-5p seed binding 
site actually increased in expression, strongly indicating they were not miR-324-5p targets, 
and would be falsely identified by any prediction program. Each prediction program has a 
slightly different algorithm and therefore predicts a different repertoire of targets. In an 
attempt to analyse which of the algorithms is the best, or more precisely which algorithm 
agreed most with our data, I analysed the number of predicted targets from each 
algorithm that decreased in transcriptome microarray 1 following miR-324-5p 
overexpression. The total number of probes on the array that were predicted to be a 
target by each algorithm is shown in Figure 5.17 along with the number of which 
decreased following miR-324-5p overexpression, the positive predictor value, the ‘fold 
better than by chance’ (how many fold higher, the fraction of predicted targets that 
decreased, is than the fraction of non-predicted targets that decreased) and the p-value 
for each program. Cumulative fraction plot, normalised fraction plot, sensitivity and 
specificity are shown in Figure 5.17. The cumulative fraction plot and normalised fraction 
plot indicated PicTar is the most specific algorithm (Figure 5.17C) and has the highest 
positive predictor value, however it predicted the fewest number of targets (Figure 5.17). 
TargetScan was the most sensitive program (Figure 5.17C) and predicted the largest 
fraction of targets (Figure 5.17A and B), TargetScan did however predict the largest 
number of targets (Figure 5.17). Consistent with previous studies [244, 258], there was an 
inverse relationship between sensitivity and specificity for all prediction programs, and no 
one program was best at both. Choosing which program to use should be dependent on 
the application it is being used for, for example the number of targets it is possible to 
further investigate. 
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Figure 5.17 Analysis of online target prediction algorithms 
 
Figure 5.17 Analysis of online prediction sites. (A) Cumulative fraction of genes predicted 
to be miRNA targets. (B) Normalised fraction of genes predicted to be targets by online 
prediction sites. (C) Sensitivity and specificity of online prediction sites. (D) Numbers show 
the total number of probes whose gene is a predicted target (out of 25,697 probes on the 
array) and number of predicted targets whose gene decreased (out of 996 decreased 
probes). The ‘fold better than by chance’ indicates how many fold higher, the fraction of 
predicted targets that decreased, is than the fraction of non-predicted targets that 
decreased. Positive predictor value (where ‘1’ is perfect prediction and ‘0’ is no prediction) 
and Fishers p-value for each prediction program is also shown. 
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5.3.4 miR-324-5p may regulate translation 
Traditionally miRNAs and RISC are thought to bind to their target mRNA causing either 
mRNA degradation, reducing the mRNA available for translation, or directly inhibit 
translation leaving the mRNA expression unaffected [110] (Figure 5.18A). For the vast 
majority of targets their reduction in protein correlates with the reduction in mRNA [121]. 
Recent data in Drosophila cells [248] and zebrafish [249] suggested the reduction in 
protein translation may actually precede the reduction in mRNA. More specifically they 
suggest the studied miRNAs function by reducing translation initiation and are not 
dependent on mRNA degradation [248, 249](Figure 5.18B). mRNA degradation does 
however still occurs for the majority of targets (due to decreased translation reducing 
mRNA stability) and correlates with protein expression at later time points as seen by Guo 
et al. [121]. With further validation in mammalian cells [259] these experiments will shed 
more light on how miRNAs function, in that miRNAs directly target protein translation 
with mRNA degradation being a secondary effect for the vast majority of targets. 
For a gene to be classified as a potential miR-324-5p target in our experiments it had to be 
decreased by log2 0.2 at an mRNA and protein level, however studies have shown up to 
16% of miRNA targets are only decreased at a protein level [121] and therefore such a 
target would not be classified as a potential target in this study. Here I used both 
microarray and proteomics meaning it was possible to distinguish between targets 
regulated at a protein and mRNA level, from targets only regulated a protein level. 30 
miR-324-5p seed containing genes whose mRNA and protein were identified decreased at 
a protein level. Of these, 18 (60%) also decreased at an mRNA level (Figure 5.18C), slightly 
lower than the 84% percentage suggested by the Bartel lab [121]. 40% of the miR-324-5p 
seed containing genes which decreased at a protein level did not decrease at an mRNA 
level (Figure 5.18C) suggesting miR-324-5p can regulate translation without altering 
mRNA. 
The reason why some targets were only decreased at a protein level is unclear. In the 
traditional model it would have been said the miRNA is targeting translation rather than 
mRNA degradation (Figure 5.18A). In the new model, where most miRNAs target 
translation, causing the mRNA to be degraded (due to less protection of RNA by 
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ribosomes) and a further reduction in translation (due to there being fewer transcripts) 
[248, 249], it is likely to be because the mRNA mediated reduction in translation does not 
destabilise the mRNA or reduce the protection by ribosomes. 
In an attempt to determine if this type of target was real (or existed in our data) I further 
analysed our data by investigating the enrichment of miR-324-5p targets in genes whose 
protein expression could not be explained by changes in mRNA expression (Figure 5.18D-
E). There was no enrichment of miR-324-5p seed binding sites in proteins whose 
expression decreased and their decrease could not be accounted for by a concomitant 
decrease in mRNA expression (fold change in protein expression/fold change in mRNA 
expression) (Figure 5.18D). Interestingly, and possibly opposing this, there was a 
significant enrichment of miR-324-5p seeds in genes whose protein expression decreased 
but whose mRNA expression changed less than log2 0.05 (Figure 5.18E). There was no 
enrichment of miR-324-5p seeds in genes whose mRNA decreased but did not also 
decrease at the protein level (their mRNA decrease cannot be accounted for by a 
reduction in protein; fold change mRNA expression/fold change protein expression) 
(Figure 5.18F). Taken together, these data suggested; A) there may have been some 
targets whose translation was regulated but there was no effect on mRNA, B) there was 
unlikely to have been targets where the miRNA affects mRNA but does not affect protein. 
This supports the hypothesis that the majority of miRNAs initially target translation and 
then depending on the type of target may or may not then lead to a reduction in mRNA 
[230]. Guo et al. concluded from their studies that 84% of miRNA targets were decreased 
due to mRNA destabilisation [121]. They performed their studies by comparing the total 
mRNA with ribosomal mRNA following miRNA overexpression. They found little difference 
in the level of mRNA being translated compared to the total mRNA and eluded (possibly 
incorrectly) to mRNA destabilisation preceding the reduced translation [121]. Taken 
together, the more recent data [248, 249], and the work by Guo et al. suggests miRNAs 
work by initially targeting translation and in 84% (60% in our study) of targets there is a 
subsequent reduction in mRNA. 
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Figure 5.18 miR-324-5p may regulate translation 
 
Figure 5.18 miR-324-5p may regulate translation (A) Traditional dogma of how miRs work, 
(B) New theory on how miRs work (C) Bar chart showing log2 fold change in protein and 
mRNA expression for 30 genes whose protein expression decreased following miR-324-5p 
transfection. Red line indicated log2 fold change 0.2. (D) No enrichment of miR-324-5p 
seed binding sites in proteins whose expression decreased and their decreased expression 
cannot be accounted for by the respective decrease in mRNA expression (fc protein 
expression/fc mRNA expression). Best p value is 0.088 at a fold change of log2 fc 0.18 (E) 
significant enrichment of miR-324-5p seeds in genes whose protein expression decreased 
but whose mRNA expression changed less than log2 0.05. Best p value is 0.0007 at a fold 
change of log2 fc -0.11  (F) No enrichment of miR-324-5p seeds in genes whose mRNA 
decreased and their mRNA decrease cannot be accounted for by a reduction in protein (fc 
mRNA expression/fc protein expression). The most significant enrichment is at a fold 
change of log2 fc -0.09 (p value is 0.08). 
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5.3.5 Estimate total number of miR-324-5p targets 
miRNAs exert their actions by targeting the 3’UTR of many targets. Our target 
identification strategy did not allow us to give the definite identity of all miR-324-5p 
targets. It does however allow us to estimate the total number of targets and give the 
identity of a fraction of these (only with a certain degree of confidence). 
During the strategy development around 5.7% (92-18=74, 74/1299=5.7%) of genes 
which lack miR-324-5p seed binding sites decreased following miR-324-5p 
overexpression (Figure 5.8), this strongly suggested they are a secondary effects of 
direct miR-324-5p targets. 19.35% (18/93) of miR-324-5p seed binding site containing 
genes decreased, this suggested 29.46% (5.7/19.35) of genes whose 3’UTR contains a 
miR-324-5p binding site and decreased at both an mRNA and protein level are 
decreased due to secondary effects of a real miRNA targets and just over 70% of the 
potential targets are real. This equated to just over 5 of the 18 potential targets being 
false positives, leaving 13 genuine miRNA targets. In this experiment (SILAC1, SILAC2 
and unstim array combined), 1,299 genes are identified, which equates to only around 
7% of the genome (1,299/18,615). I predicted 13 of the 1,299 are real targets, which 
would suggest ~185 targets in the whole genome. These calculations assumed a target 
needs to contain a miR-324-5p seed binding site in its 3’UTR and needs to be 
decreased log2 0.2 fold at an mRNA and protein level. This of course is not always the 
case. 
5.3.6 Assessment of strategy effectiveness  
Many groups use either SILAC or microarray to identify miRNA targets, by using both I 
was able to assess the relative effectiveness of each. Both the proteomics and 
microarray approaches enabled us to enrich for miR-324-5p targets (Figure 5.10 and 
Figure 5.11). However, a combination of both proteomics and microarray gave a 
greater enrichment than either alone. More precisely I observed a 1.6 fold enrichment 
using microarray, a 2.7 fold enrichment using the proteomics and a 3.7 fold 
enrichment of miR-324-5p seed binding site containing genes when both were 
combined. This suggested SILAC proteomics was more specific than transcriptome 
microarrays and their combination was more specific than both individually. More 
targets were enriched in the transcriptome microarrays than the proteomics, meaning 
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a greater number of potential targets could be generated from the array alone than 
the proteomics alone, although the certainty of any given target being real will be less. 
It is difficult to draw conclusions about the effectiveness of microarrays and SILAC in 
predicting targets. In order to properly assess the effectiveness of microarrays, SILAC 
and target prediction algorithms, the selection of genes used to make luciferase 
constructs should have been independent of any results obtained, independent on 
whether or not the gene contains a miR-324-5p seed sequence binding site and 
enough should have been made to gain statistical significance. If this were done a 
proper independent comparison of genes which decreased with real miR-324-5p 
targets could have been performed. However, this would have proven too costly and 
time consuming. Instead, only estimates of effectiveness could be made. 
I have shown transcriptome microarrays and SILAC proteomics can form an effective 
methodology to identify miRNA targets. However neither alone nor in combination are 
100% effective, in addition there are a number of other strategies that could have 
been chosen. In this section I will explore some of the benefits provided by these other 
strategies and what might benefit this strategy. 
5.3.7.1 miRNA inhibitors and target site protectors 
Transfection of miRNAs increased their concentration above their normal physiological 
level. Arguably this may have led to an over-estimate of the number of miRNA targets. 
The use of antagomirs (miRNA inhibitors) and a search for genes whose expression 
increased following their transfection may have given a more physiological indication 
of miRNA targets in these cells [228]. However attempting to decrease miR-324-5p and 
observing any effects is likely to have proven difficult. Target site protectors for each 
miRNA-target interaction could also be used to determine if a miRNA-target 
interaction was in fact functional at physiological levels [260]. 
5.3.7.2 Not only 3’UTR targets 
In addition to being decreased by log2 0.2 at an mRNA and protein level, a gene also 
needed to contain a miR-324-5p seed sequence binding site in its 3’UTR in order for it 
be considered as a potential target in this study. Genes which lack a full seed binding 
site in their 3’UTR have also been shown to be real miRNA targets [127]. In addition 
miRNAs can also target the 5’UTR or coding sequence of genes [261]. However, I 
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decided not to take types of targets into account as the vast majority of miRNAs act on 
the 3’UTR of genes [242]. 
5.3.7.3 Secondary effects 
Here I was searching for direct miRNA targets which can positively affect Hh signalling, 
in order to explain miR-324-5p inhibition of the pathway. It is possible miR-324-5p may 
regulate Hh signalling through the secondary effects of miR-324-5p. Due to the long 
72h post transfection time point chosen many of the secondary effects of the miRNA 
would be obtainable from this data. A downside of such a long time point is some real 
direct and indirect targets may have returned back to normal expression by 72h, 
meaning even though their expression changed they would not be identified. However 
in other studies we are able to measure sustained overexpression following 
transfection for up to 14days. To elucidate a mechanism by which a miRNA acts, all of 
the miRNA effects should be considered not only its perceived direct targets. 
5.3.7.4 Non traditional actions of miRNAs 
In a rare number of cases miRNAs can actually increase the expression of their target, 
possibly by recruiting transcription factors [261]. If this type of target was responsible 
for the miR-324-5p effect on Hh signalling, a negative regulator of Hh signalling should 
have been sought after. 
As well as binding mRNA, it is also possible for miRNAs to interact with receptors, such 
as Toll-like receptors (TLRs)[262, 263]. TLR7 and 8 preferentially bind miRNAs rich in 
GU at nucleotides 18-21[263], something which the miR-324-5p sequence contains 
(cgcauccccuagggcauuggugu). However further work is needed to determine if miRNAs 
with UGGU at nucleotides 18-21 or if miR-324-5p itself can bind TLR receptors. 
Interestingly, activation of TLR3 inhibits Shh induction of Hh signalling [264], indicating 
miRNAs may regulate Hh signalling through direct binding of TLRs. Both TLRs and 
miRNAs have been found in exosomes [263], suggesting they have the potential to 
interact. 
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5.3.7.5 Strengths and weaknesses of strategy used  
Although my strategy is effective at identifying miRNA targets in C3H10T1/2 cells, it is 
not necessarily going to be effective or practical for all miRNA target identification 
studies. This strategy is expensive, mainly due to the cost of culturing the cells in 13C6 
15N4-Arg and 
13C6-Lys labelled medium and the cost of enough mass spectrometry runs 
to allow sufficient coverage of the proteome. The strategy is also unlikely to work in 
cells which either do not divide or divide slowly. I have also been unable to avoid the 
bias of a miRNA needing a seed binding site, ideally decreased genes should be 
considered as potential targets irrespective of seed binding sites but then it would be 
too hard to distinguish between direct and indirect effects especially as I analysed my 
cells quite late (72h post-transfection). 
miRNA pull-down, or HITS/PAR-CLIP would have offered an alternative strategy, and 
may have increased the ratio of direct to indirect targets identified, but will still face 
many of the same problems as proteomics and transcriptomics. Interestingly, a 
strategy based on literature and computational analysis rather than experimental 
profiling would have been cheaper (although not necessarily less time consuming) and 
may have still been effective in determining targets which have a potential role in Hh 
signalling, although it is unlikely to have identified Gpc1. 
In my opinion the use of transcriptome microarray following both over and under 
expression of a miRNA combined with online prediction sites would be the most cost 
and time effective for a general miRNA target identification strategy. However, 
depending on the project context other strategies should also be considered, for 
example if miRNA and either mRNA or protein expression is already known, a 
computational approach looking for inverse correlations could be used. Due to the 
speed at which this field is moving my opinion on this is likely to quickly change.  
5.4 Summary 
The main aim of this chapter was to identify miR-324-5p targets in mouse which have a 
possible role in Hh signalling. Due the large number of predicted miR-324-5p targets, 
there were many predicted miR-324-5p targets involved in Hh signalling. However, due 
to the large variation and unreliability of prediction programs it was unlikely any given 
predicted miR-324-5p target is a real miR-324-5p target. For that reason I developed a 
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strategy to identify miRNA targets. I went on to assess the strengths and weaknesses 
of the strategy and employed it to identify miR-324-5p targets. More specifically I have 
identified Gpc1 as a miR-324-5p target which I believe to have a role in Hh signalling 
and may be involved in the mechanism by which miR-324-5p inhibits Hh signalling in 
mouse C3H10T1/2. 
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Chapter 6 Novel miR-324-5p target, Gpc1, regulates Hh 
6.1 Introduction 
miR-324-5p was increased in OA hip cartilage (Figure 4.1) and has previously been 
shown to regulate the Hh signalling pathway in humans by targeting the Hh pathway 
activator SMO and transcription factor GLI1 [127]. I have shown miR-324-5p regulation 
of Hh is conserved in mouse, yet the mechanism by which it does so is not (Chapter 4). 
In Chapter 5 I identified Gpc1 as a mouse miR-324-5p target and hypothesised it may 
play a role in Hh signalling and form part of the mechanism by which miR-324-5p 
regulates Hh signalling in mouse. 
6.1.1 Glypicans 
Gpc1 is a member of the Glypican family of heparin sulphate proteoglycans (HSPGs). In 
mouse there are 6 different Glypicans (1-6), and each has a homologue in human. The 
6 Glypicans can be divided into two groups; Gpc1/2/4/6 and Gpc3/5 [265]. There are 
only two Glypicans in Drosophila, Dally and Dally-like protein (dlp), which are thought 
to be homologues of Gpcs 3/5 and Gpcs 1/2/4/6 respectively [265]. The mammalian 
Glypicans 1/2/4/6 can be further subdivided into two groups Gpc1/2 and Gpc4/6. 
Interestingly a number of miRNAs are encoded from within close proximity to the 
Glypicans, which may be involved in similar processes (General discussion). Glypicans 
are anchored to the cell membrane by a Glycophosphatidylinositol (GPI) anchor which 
can be cleaved by an enzyme called Notum in mammals [266]. 
6.1.2 Glypicans can positively regulate Hh 
HSPGs have previously been shown to regulate a number of morphogens to produce 
many different types of morphogen gradient, for a review see [267]. The role of HSPGs 
in Hh signalling has been known for over 10 years. The addition of heparin, changes in 
the composition of PGs, and some of the enzymes involved in HSPG synthesis, can all 
alter Hh signalling [268-270]. 
Much of the work involving Glypicans in Hh signalling has been performed in 
Drosophila. In 2003 a group used RNAi to screen for genes involved in Drosophila Hh 
signalling and identified the Drosophila Glypican homologue Dally-like protein (dlp) 
[271]. Further investigation showed dlp plays a critical role in Hh signalling, either at 
the level of patched (ptc) or up stream of ptc [250], and may also contribute to the 
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movement of Hh ligand from the Hh producing cell to the Hh receiving cell. Dlp is 
required in Hh receiving cells for Hh signal transduction [251, 252]. More specifically, 
Glypicans are thought to contribute to the internalisation of Hh and Ptch [268], as dlp 
is often found with hh and ptc in endocytic vesicles [252]. Further evidence is 
suggested by Yan et al. for the role of dlp as a Hh co-receptor [272]. 
6.1.3 Glypicans can negatively regulate Hh 
As well as positively regulating Hh, some Glypicans have been shown to negatively 
regulate Hh signalling. Gpc3 can interact with Shh, causing the endocytosis and 
lysosomal degradation of Shh [246]. As mentioned previously, dlp also aids in the 
endocytosis of Hh ligand, yet is a positive regulator of Hh signalling. One crucial 
difference appears to be that unlike dlp, Gpc3 does not require Ptch for Hh ligand 
internalisation. In drosophila, dlp activates Hh signalling by removal of ptc from the 
membrane leading to active smo, where as in mouse, Gpc3 will act to endocytose Hh 
ligand without Ptch, leaving Ptch on the membrane and still able to inhibit Smo. It is 
suggested Gpc3 contributes to the degradation of Hh ligand in a similar way to what 
has previously been described for Ptch [273]. 
Recently a study has suggested Gpc1 to have a role in zebrafish Hh signalling. 
Depletion of Gpc1 in zebrafish causes developmental defects, and increased 
expression of Hh signalling target genes such as gli2a and ptch1 [274, 275]. The 
addition of cycopamine (a Hh antagonist) to these fish partially rescues the phenotype, 
and injection of Shh gave a similar phenotype to Gpc1 depletion [274], suggesting 
Gpc1 plays a negative role in Hh signalling, possibly acting as a sink for Hh ligand. 
Zebrafish Gpc1 is likely to be the ortholog of human and mouse Gpc1 as there are 6 
Gpcs and synteny in both species [274]. 
6.1.4 HS chains and GPI anchor 
Glypicans and other proteoglycans can regulate Hh signalling in both a positive and 
negative manner and exert much of their action though their negatively charged HS 
chains interacting with positively charged Na+ ions, H2O and morphogens [276]. HS-
GAG chains form on the serine residues in Ser-Gly sequences, of which Gpc1 has 3. HS 
chain formation is catalysed by a number of enzymes which sequentially add sugar 
residues to the non-reducing end of the growing chain [276]. The insertion sites for the 
HS chains are located close to the carboxyl terminus suggesting these chains are close 
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to the cell surface and may mediate interactions with molecules on the cell surface 
[276]. EXT family proteins then catalyse the HS polymerisation process by alternatively 
adding GlcA and GlcNAc residues. During the chain polymerisation process, a number 
of modifications take place, including sulphation [276]. It is possible to inhibit the 
formation of these chains with the addition of sodium chlorate, which reduces the 
amount of sulphate in HS GAG chains, impairing their synthesis and ability to function 
[277]. Sodium chlorate works by inhibiting ATP-sulphurylase, the first enzyme involved 
in the biosynthesis of 3’-phosphoadenosine 5’-phosphosulphate (PAPs), which are the 
active form of sulphate and sulphur donor in protein sulphation [278]. The addition of 
sodium chlorate to cells will show the function of HSPGs, although it has been reported 
Gpc3 core protein can also directly interact with Hh ligands [246]. 
The GPI anchor on glypicans is thought to play a role in the endocytosis of morphogens 
by acting as an endocytic signal [246, 252]. Notum, whose function is to cleave the GPI 
anchor [266], has itself been shown to be  involved in Hh signalling [279]. 
I hypothesised miR-324-5p regulates Hh signalling through a mechanism involving 
Gpc1. The main aim of this chapter is to investigate the role of Gpc1 in Hh signalling. 
Specific aims 
Aim 1: Determine if HSPGs are important for Hh signalling 
Aim 2: Determine the effect of Gpc1 depletion on Hh signalling 
Aim 3: Determine the effect of Gpc1 overexpression on Hh signalling 
Aim 4: Elucidate the mechanism by which Gpc1 regulates Hh signalling 
Aim 5: Compare the mechanisms by which miR-324-5p regulates Hh signalling in 
human and mouse 
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Figure 6.1 Figure showing schematic structure of Glypican1 
 
Figure 6.1 Structure of Glypicans (Gpc1). Gpc1 is attached to plasma membrane via 
Glycophosphatidylinositol (GPI) anchor. Heparin sulphate (HS) chains form near the C’ 
terminal of Gpc1. 
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6.2  Results 
6.2.1  Heparin Sulphate chains play a role in Hh signalling 
Since Gpc1 is a HSPG I therefore wanted to determine if HSPGs are important for Hh 
signalling in C3H10T1/2 cells. HSPGs exert much of their function through their HS 
chains. Sodium chlorate can inhibit HS chain formation [277]. Pre-treatment of cells 
with 2.5mM sodium chlorate for 48h decreased the level of Ihh (2µg/ml for 24h) 
induced Hh signalling (Figure 6.2A). HS chains chelate morphogen, therefore their lack, 
or lack of HSPG, would reduce morphogen levels. Consistent with this in my MS 
analysis of Hh signalling where I identified miR-324-5p targets (Chapter 5, SILAC3), I 
observed less Ihh in miR-324-5p transfected cells than in control transfected cells 
(Figure 6.2B). This was consistent for all seven of the peptides identified for Ihh. 
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Figure 6.2 Heparin sulphate plays a role in Hh signalling 
 
Figure 6.2 Effect of HS chain depletion on Hh signalling. (A) C3H10T1/2 cells were 
treated with Sodium chlorate (SC) for 48h at the concentration shown then serum 
starved and stimulated with Ihh (2μg /ml) for 24h. Data combined from 2 independent 
experiments, each n=3. Statistical differences were calculated using ANOVA followed 
by a Bonferroni post test, p<0.05=*. (B) Relative Ihh protein levels detected within cell 
lysates by mass spectrometry (SILAC3) following transfection of either miCon or miR-
324-5p for 24h as indicated, serum starvation for 24h and stimulation with Ihh 
(2μg/ml) for 24h. 
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6.2.2 Depletion of Gpc1 inhibits Hh signalling 
To test if Gpc1 was important for Hh signalling, C3H10T1/2 cells were transfected with 
siRNA against Gpc1 (siGpc1). As expected, and similar to miR-324-5p transfected cells, 
Gpc1 mRNA and protein was reduced in siGpc1 transfected cells (Figure 5.14). Similar 
to stimulation of siGli1 (Figure 6.3) and miR-324-5p (Figure 4.14) transfected cells, 
stimulation of siGpc1 transfected cells with Ihh resulted in less or no induction of Gli1 
mRNA or protein in comparison to siCon transfected cells (Figure 6.3), indicating Gpc1 
is required for Ihh signalling. In contrast to siGli1 (Figure 6.3), but similar to miR-324-5p 
(Figure 4.14) siGpc1 did not cause a reduction in basal Gli1 mRNA (Figure 6.3A). 
Again, consistent with miR-324-5p (Figure 4.16), but in contrast to siGli1 (Figure 6.4A), 
transfection of siGpc1 decreased Ihh and Bmp2 induced alkaline phosphatase (Figure 
6.4A). Also consistent with miR-324-5p (Figure 4.17) and in contrast with siGli1 (Figure 
4.13), siGpc1 did not cause a significant difference in Bmp2 or Bmp2 + Ihh induced 
alcian blue (Figure 6.4B). siGpc1 did however increase basal levels of alcian blue 
(Figure 6.4B). 
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Figure 6.3 Effect of Gpc1 depletion on Hh signalling 
 
Figure 6.3 Effect of Gpc1 depletion on Indian Hedgehog signalling. C3H10T1/2 cells 
were transfected with non-targeting siCon or siRNA against Gpc1 or Gli1 for 24h. Cells 
were then serum starved for 24h and either left unstimulated, stimulated with Ihh 
(2μg/ml) for 24h. Gli1 and 18S were assessed by real-time RT-PCR. Gli1 and Gapdh 
protein expression were assessed by Immunoblotting (validation of Gpc1 siRNA is 
shown in (Figure 5.14). (A) siGli1 and siGpc1 effect on basal and Ihh stimulated Gli1 
mRNA expression. Data combined form 4 independent experiments, each n=4 
Statistical differences were calculated using ANOVA followed by a Bonferroni post test 
where p<0.01=** and p<0.001=***. (B) siGli1 and siGpc1 effect on basal and Ihh 
stimulated Gli1 protein expression. Representative blot of 3 independent experiments. 
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Figure 6.4 siGpc1 on alkaline phosphatase and aclian blue 
 
Figure 6.4 Effect of Gpc1 depletion on osteoblastogenesis and chondrogenesis. (A) 
Alkaline phosphatase was used as a markers of bone formation, C3H10T1/2 cells were 
transfected with siCon, siGpc1 or siGli1, then stimulated with Ihh (2µg/ml) and BMP2 
(100ng/ml) for 5 days. P.Nitrophenol was measured to determine the level of alkaline 
phosphatase. Data are combined data from 3 independent experiments each n=4, 
SEM. (B) Alcian blue was used as a marker of cartilage formation. C3H10T1/2 cells 
were transfected with siCon, siGpc1 or siGli1 then plated into micromass cultures, 
stimulated with Bmp2 (100ng/ml) and/or Ihh (2µg/ml) alcian blue stain was extracted 
with GuHCl and quantified, data are combined data from 3 independent experiments 
each n=2, SEM. Statistical differences were calculated using ANOVA followed by a 
Bonferroni post test where p<0.05=*and p<0.01=**. 
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6.2.3  Gpc1 overexpression inhibits Hh signalling 
Because a reduction in Gpc1 (siGpc1) reduced Hh signalling, I hypothesised an increase 
in Gpc1 would increase Hh signalling. I therefore created a Gpc1 overexpression 
plasmid (see methods). Transfection of my Gpc1 overexpression plasmid increased 
Gpc1 protein, as detected by western blot (Figure 6.5B and C). In contrast to my 
hypothesis, overexpression of Gpc1 reduced basal Gli1 mRNA and slightly (not 
significantly) reduced Ihh and Pur induced Gli1 mRNA (Figure 6.5A). Overexpression of 
Gpc1 also reduced basal Gli1 protein (Figure 6.5C). This data indicated optimal levels of 
Gpc1 are required for Hh signalling. 
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Figure 6.5 Increased Gpc1 expression inhibits Hh signalling 
 
Figure 6.5 Increased Gpc1 expression inhibits Hh signalling. (A) Effect of Gpc1 
overexpression (OE) on Gli1 mRNA compared with Fugene HD transfection reagent 
alone (FHD), following serum starvation and stimulation with Ihh (2µg/ml) or Pur 
(2μM) for 24h. Data combined from two independent experiments each n=4. Statistical 
difference were calculated using Student’s t-test, where *p<0.05. (B) Example Western 
blot showing Gpc1 overexpression (OE) compared with Fugene HD transfection 
reagent alone (FGHD). (C) Representitive Western blot of 3 independent experiments 
showing Gpc1 overexpression increases Gpc1 protein expression and decreases Gli1 
protein compared with Fugene HD transfection reagent alone (FGHD). Blot also shows 
effect of Dharmafect transfection reagent (DF), siCon, siGpc1, miCon and miR-324-5p. 
At low exposure no Gli1 protein was detected. 
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6.3 Discussion 
As hypothesised, siRNA depletion of Gpc1 reduced Ihh induced Hh signalling (Figure 
6.3 and Figure 6.5C) and phenocopied the effect of miR-324-5p (Figure 4.14 and Figure 
6.5C). This suggested the mechanism by which miR-324-5p regulated Ihh induced Hh 
signalling in mouse was at least in part, by directly targeting Gpc1 (Figure 6.6). In 
contrast to siGli1, but similar to miR-324-5p (Figure 4.14), siGpc1 did not cause a 
reduction in basal Gli1 mRNA (Figure 6.3), suggesting Gpc1 was not involved in 
maintaining basal levels of Gli1 mRNA, but is involved in Ihh induction of Gli1 
expression. This further suggests the mechanism by which miR-324-5p regulated Hh in 
mouse is through targeting Gpc1 and not Gli1. In addition, siRNA against Gpc1 
phenocopied many of the downstream effects of miR-324-5p, where as siRNA against 
Gli1 did not, this reinforced the hypothesis that miR-324-5p functioned through Gpc1 
rather than Gli1 (Figure 6.6). 
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Figure 6.6 miR-324-5p regulation of Hh in mouse 
 
Figure 6.6 miR-324-5p regulation of Hh in mouse. Gpc1 plays a role in Hh signalling and 
is likely to act via its HS chains to effect the reception of Hh ligand. Gpc1 is a target of 
miR-324-5p in mouse, meaning miR-324-5p is likely to inhibit Hh signalling through its 
action on Gpc1. This model may also explain why siGli1 (Figure 6.3) but not miR-324-5p 
(Figure 4.14) or siGpc1 (Figure 6.3) can regulate basal Gli1 levels and why miR-324-5p, 
siGpc1 and Gli1 can all regulate Ihh induced Gli1. 
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6.3.1 Possible mechanisms by which Gpc1 depletion inhibits Hh signalling 
The mechanism by which reduced Gpc1 inhibited Hh signalling was not completely 
clear, however it is possible Gpc1 in this system acts in a similar way to dlp in 
Drosophila [252], or Gpc5 in mouse [247], which are involved in the internalisation of 
hh/Shh with ptc/Ptch respectively. This is supported by the data presented in Figure 
6.2B, where it is likely the miR-324-5p induced loss of Gpc1 is responsible for the loss 
of Ihh internalisation and the subsequent decrease in Ihh present in lysate, as 
measured in SILAC3. I hypothesised that the siGpc1/miR-324-5p reduction of Gpc1 
contributed to the reduction of Hh signalling by both decreasing the concentration of 
Ihh at the cell surface (there are fewer HS chains to bind Ihh (Figure 6.7A) and also 
preventing the internalisation of Ihh with Ptch (as there is no Gpc1 to facilitate the 
formation of a Hh:Gpc1:Ptch complex and mediate vesicle endocytosis (Figure 6.7B). 
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Figure 6.7 Decreased Gpc1/miR-324-5p reduces Hh signalling 
 
Figure 6.7 Schematic showing possible mechanisms by which decreased Gpc1/miR-
324-5p reduces Hh signalling. (A) Left; normal levels of Gpc1, Gpc1 increases the 
concentration of Hh ligand at the cell surface. Right; reduced levels of Gpc1 
(siGpc1/miR-324-5p), Hh ligand does not accumulate at the cell membrane and is lost 
in the media. (B) Left; normal levels of Gpc1, Gpc1 facilitates and stabilises the 
interaction between Hh ligand and Ptch. Gpc1 binds Hh ligand. Gpc1 is endocytosed 
with Hh ligand and Ptch (Hh:Gpc1:Ptch complex), meaning Ptch is removed from the 
membrane, leaving active Smo, to trigger downstream Hh signalling. Right; reduced 
levels of Gpc1 (siGpc1/miR-324-5p), Hh ligand has reduced binding to Ptch meaning Hh 
signalling remains inactive. 
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6.3.2 Possible mechanisms by which Gpc1 overexpression inhibits Hh 
signalling 
Unexpectedly, Gpc1 overexpression also reduced the level of Hh signalling (Figure 6.5), 
indicating excessive Gpc1 may act as a negative regulator of Hh signalling and 
illustrating the importance for tight Gpc1 regulation. I hypothesised this could be due 
to a number of reasons. 
Hypothesis A, the primary cilium is an essential cell organelle for Hh signalling [84], 
therefore I wanted to determine if the mechanism by which Gpc1 overexpression 
decreased Hh signalling is by regulation of the primary cilia. Gpc1 was overexpressed 
and the number of Gpc1 positive cells with primary cilia was compared to the number 
of Gpc1 negative cells with primary cilia. I found Gpc1 overexpression decreased the 
number of primary cilia, more precisely around 83% of cells not transfected had a 
detectable primary cilium, compared to around 27% of those transfected (Figure 6.8), 
perhaps suggesting Gpc1 overexpression reduced Hh signalling by decreasing the 
number of primary cilia, meaning Ihh was unable to activate signalling in these cells 
(Figure 6.9A). The reason why Gpc1 overexpression disrupted the primary cilia was not 
investigated, however Gpc1 maybe be involved in the correct localisation of the 
proteins required for ciliogenesis. Alternatively the lack of primary cilia may be due to 
increased cell stress, from transient transfection of the Gpc1 overexpression construct, 
or due to the cell being at different points in the cell cycle, both are yet to be 
examined. However, due to the low transfection efficiency and low number of cells 
which will lack primary cilia, it is unlikely primary cilia disruption alone can account for 
the reduction in Hh signalling following Gpc1 overexpression. 
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Figure 6.8 Gpc1 disrupts primary cilia 
 
Figure 6.8 Gpc1 disrupts the primary cilium. (A) Example immunoflourescence image 
showing Gpc1 overexpressing cells lack primary cilia. (B) Combined data from two 
independent experiments showing the number of Gpc1 overexpressing cells with a 
primary cilia is less than the number of cells not overexpressing Gpc1 with a primary 
cilia, 112/135 Gpc1 negative have primary cilia and 10/37 Gpc1 positive cells have 
primary cilia (fishers exact test, p=3.17x10-11). 
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Hypothesis B, the amount of morphogen, both in vivo and in vitro, is finite, therefore 
for every increase in morphogen there must also be a decrease in morphogen at other 
locations. The transfection efficiency to overexpress Gpc1 was low (Figure 6.8), 
meaning the majority of cells were not transfected and did not overexpress Gpc1. It 
was therefore possible almost all of the Ihh ligand accumulated at and activated Hh 
signalling in only the small number of transfected cells and was unavailable to the 
majority of cells. Then when cells were lysed and analysed together there was an 
apparent overall reduction in Hh signalling in the cells (Figure 6.9B-right) compared to 
mock transfected cells (Figure 6.9B-left). 
Hypothesis C, in the previous section I hypothesised Gpc1 facilitated the formation of a 
Hh:Gpc1:Ptch complex in vesicles to activate Hh signalling, however I had no evidence 
for this, it is therefore unknown if Gpc1 can endocytose Hh ligand with or without 
Ptch, meaning it is possible Gpc1 may actually endocytose Hh without Ptch (Gpc1:Hh 
complex) (Figure 6.9C). If this were the case it is likely overexpression of Gpc1 inhibited 
Hh signalling as Hh was unable to bind and activate Ptch, similar to the way Gpc3 
negatively regulates Hh in mice [246]. Both the second and third hypothesis suggest 
overexpressed Gpc1 acts as a sponge to either bind Hh on the ‘wrong cell’ or 
internalise it in the ‘wrong vesicle’. The type of complex formed with Gpc1 may be 
dependent on the level of Gpc1. It is possible basal levels Gpc1 promotes the 
formation and endocytosis of a ‘Gpc1:ptch:Hh’ complex (akin to Dlp model of Hh 
activation signal [252]) (Figure 6.7B-left), at high Gpc1 levels it promotes the formation 
and endocytosis of a ‘Gpc1:Hh’ complex (akin to Gpc3 inhibition of Hh signalling [246]) 
(Figure 6.9C-right) and when Gpc1 levels are reduced below basal no complex forms 
(Figure 6.7B-right). The reason for high levels of Gpc1 favouring a ‘Gpc1:Hh’ complex 
over a ‘Gpc1:ptch:Hh’ complex is unknown, casting doubt over this model. 
Hypothesis D, I have previously shown high levels of both Pur and SAG are inhibitory to 
the Hh pathway (Chapter 4). It is therefore possible Gpc1 overexpression actually 
increased Hh:Ptch interactions but, in doing so, activated negative feedback loops 
(Figure 6.9D), similar to those I hypothesised to explain high Pur/SAG being inhibitory 
in Chapter 4. 
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Figure 6.9 Increased Gpc1 reduces Hh signalling 
 
Figure 6.9 Schematic showing possible mechanisms by which increased Gpc1 reduces 
Hh signalling. (A) Gpc1 overexpression (O/E) reduces the number of primary cilia. (B) 
Left; normal levels of Gpc1, Gpc1 increases the concentration of Hh ligand at the cell 
surface. Right; Gpc1 overexpression, Hh ligand will accumulate at and activate Hh 
signalling in only the small number of transfected cells and is unavailable to the 
majority of cells, meaning there will be an apparent overall reduction in Hh signalling 
in the cells. (C) Left; normal levels of Gpc1, the lack of high Gpc1 allows Hh ligand and 
ptch to interact and are endocytosed, leaving active Smo, to trigger downstream Hh 
signalling. Right; increased levels of Gpc1, Hh ligand interacts and is endocytosed with 
Gpc1 meaning Hh ligand has reduced binding to Ptch and leaving Hh signalling inactive. 
(D) High Gpc1 increases Hh:ptch interactions but activates negative feedback loops. 
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6.3.3  miR-324-5p and Gpc1 have activator and repressor properties and 
may have differing roles in high and low Hh signalling 
Gpc1 depletion and overexpression reduces the level of Hh signalling, illustrating the 
importance of tight Gpc1 regulation. HSPGs have previously been shown to have 
positive and negative effects on cell signalling. Gpc3 can interact with Wnt to promote 
Wnt signalling [280], and also directly interact with Shh, to inhibit Hh signalling by 
influencing the endocytosis and lysosomal degradation of Shh [246]. In addition 
increased miR-324-5p also reduced Hh signalling (via decreased Gpc1). I therefore 
hypothesised decreased miR-324-5p would also inhibit Hh (due to increased Gpc1). 
Indeed preliminary data suggested miR-324-5p inhibition decreased Hh signalling 
(Figure 6.10A), although the effect of miR-324-5p inhibition on Gpc1 has not been 
examined. These data suggested miR-324-5p is likely to be inversely correlated with 
Gpc1 and both an increase and decrease in either miR-324-5p or Gpc1 leads to 
decreased Hh signalling (Figure 6.10B). 
As well as being both positive and negative regulators of signalling pathways, Glypicans 
can also have differing effects on high and low levels of Hh signalling [279], for 
example Dally and the GPI cleavage enzyme Notum are involved in high levels Hh 
signalling, but are dispensable for low levels of Hh signalling [279]. Similarly I have 
shown siGpc1 does not affect basal levels of Gli1 mRNA, but does effect Ihh induced 
Gli1 mRNA. I have however shown siGpc1 decreases both basal and Ihh induced Gli1 
protein (Figure 6.3B and Figure 6.5C). In contrast, Cui et al. have very recently shown 
Gpc1 depletion to promote basal Hh signalling in zebrafish [274], although the system I 
examined is obviously different. In addition, the Hh response genes of low, medium 
and high level signalling are different [279, 281], suggesting Gpc1 may control some Hh 
response genes and not others. For example dpp, which is the Drosophila homologue 
for Bmp, is responsive to low levels of Hh signalling [281], and as Gpc1 depletion does 
not appear to effect basal levels of Hh (Figure 6.3) this may partly explain the differing 
effects of siGpc1 on alkaline phosphatase and alcian blue. 
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Figure 6.10 miR-324-5p and Gpc1 have activator and repressor properties 
 
Figure 6.10 miR-324-5p and Gpc1 have activator and repressor properties. (A) miR-
324-5p inhibition decreases Hh signalling. C3H10T1/2 cells were transfected with 
Control hairpin inhibitor (Con HP) or miR-324-5p hairpin inhibitor (miR-324-5p HP) for 
24h. Cells were then serum starved for 24h and either left unstimulated, stimulated for 
with Ihh (2μg/ml) for 24h. Gli1 and 18s were assessed by real-time RT PCR, data from 
one n=6 experiment. Statistical difference were calculated using Student’s t-test, 
where *=p<0.05. (B) Possible mechanism by which decreased Gpc1 (due to miR-324-
5p) and increased Gpc1 (due to transfection of Gpc1 overexpression plasmid) can both 
lead to decreased Hh signalling. Left; loss of Gpc1 means Hh ligand does not 
accumulate at the cell membrane and is lost in the media (or may also involve reduced 
endocytosis). Middle; normal levels of Gpc1, Gpc1 acts as a key component of Hh 
signalling, by increasing the concentration of Hh ligand at the cell membrane and or 
promoting Hh binding to ptch and or facilitating endocytosis of ptch. Right; 
Overexpession of Gpc1 in some cells means the majority of cells do not receive a Hh 
signal and therefore results in a lower overall level of Hh activity (may also involve loss 
if primary cilia, incorrect endocytosis and activation of negative feedback loops). 
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6.3.4 Different mechanisms in human and mouse  
In humans miR-324-5p regulates SMO and GLI1 to regulate Hh signalling whereas in 
mouse miR-324-5p does not regulate Gli1, is unlikely to regulate Smo, and instead 
regulates Gpc1, which itself is a regulator of Hh signalling (Figure 6.11). To determine if 
GPC1 is a target in human I analysed the human GPC1 3’UTR. The Human GPC1 3’UTR 
also contains a miR-324-5p binding site (Figure 6.11), suggesting it may also be a miR-
324-5p target. If miR-324-5p can regulate human GPC1, it will mean miR-324-5p can 
regulate Hh in mouse through SMO, GLI1 and GPC1. Quite why miR-324-5p would 
need to regulate Hh by multiple mechanisms is unknown. However, the Hh pathway is 
still relatively poorly understood and regulation of all three molecules (GPC1, SMO and 
GLI1) may be required to ‘fine tune’ different types of Hh signalling. 
From an evolutionary perspective it is interesting that miR-324-5p regulates Hh in 
humans and mouse by differing mechanisms. This is either due to Hh requiring 
different regulation in human and mouse or because the regulation of miR-324-5p is 
different in human and mouse, the latter is unlikely as miR-324-5p is encoded from just 
downstream of Dvl2 in both species (Figure 7.1). It is more possible that the Hh 
pathway works in slightly different ways in humans and mouse and therefore requires 
slightly different regulation. Perhaps miR-324-5p functions in human is to completely 
shut down Hh, where as in mouse it only regulates Gpc1 dependent Hh signalling 
(Figure 6.11). On the other hand inhibition of Gpc1 in mice may contribute to the 
regulation of morphogens such as Bmps. In summary I have shown although miR-324-
5p regulates Hh in both mouse and human, the mechanism by which it does so is 
different, suggesting using mice to study the role of miR-324-5p in human OA is not 
the most appropriate model. 
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Figure 6.11 Different mechanisms by which miR-324-5p regulates Hh signalling in human and mouse 
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Figure 6.11 Different mechanisms by which miR-324-5p regulates Hh signalling in human 
and mouse. (A) miR-324-5p target sites differ in human and mouse Gpc1, alignment of 
human and mouse Gpc1 3’UTRs, full miR-324-5p binding sites are highlighted in bright 
green, miR-324-5p seed binding sites with single mismatch are highlighted with dull yellow 
(B) miR-324-5p complementarity to full miR-324-5p binding sites, Figure 5.14 of course 
showed only site 3 is function in mouse, mouse sites 1 and 2 are shown for completeness. 
(C) In humans miR-324-5p regulates SMO and GLI1. It remains to be determined if miR-
324-5p regulates GPC1 in human and if GPC1 is a regulator of Hh in human. (D) In mouse 
miR-324-5p does not regulate Smo or Gli1 and instead regulates Gpc1, which is a regulator 
of Hh signalling. 
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6.4 Summary 
In Chapter 5 I showed miR-324-5p directly targets the mouse Gpc1 3’UTR, and here 
(Chapter 6) I show that by doing so it is able to regulate Hh signalling. I have shown siRNA 
depletion of Gpc1 phenocopied miR-324-5p in its inhibition of Hh signalling and effect on 
alkaline phosphatase and alcian blue. I suggested the mechanism by which siGpc1/miR-
324-5p reduced Hh signalling was due to loss of Gpc1 HS chains, as global HS chain 
inhibition (sodium chlorate) decreased Hh signalling and miR-324-5p transfection lead to 
decreased Ihh retention in cell lysate as detected by SILAC MS. Interestingly, I also showed 
Gpc1 overexpression inhibited Hh signalling and suggested a number of theories for this, 
including effects on the primary cilia, Ihh localisation and activation of negative feedback 
loops. Preliminary data shows reduced miR-324-5p may also inhibit Hh signalling, 
suggesting optimal levels of both Gpc1 and miR-324-5p are required for active Hh 
signalling. Taken together with Chapter 4, this work illustrates a miRNA function can be 
conserved between species yet the mechanism by which it works is potentially not. 
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Chapter 7 Additional functions of miR-324-5p 
7.1 Introduction 
miR-324-5p is increased in OA cartilage (Figure 4.1) and regulates Hh signalling by 
targeting GLI1 and SMO in human (Chapter 4) and Gpc1 in mouse (Chapter 6). miRNAs 
have many targets and functions, in C3H10T1/2 cells I have estimated miR-324-5p has 
~185 targets (Chapter 5). In addition to regulation of Hh, these targets are likely to have a 
number of downstream functions. The main aim of this chapter is to investigate these 
additional functions. 
Specific aims 
Aim 1: Use pathway analysis of genes whose expression decreased following miR-324-5p 
transfection to predict additional functions 
Aim 2: Further investigate the additional functions identified in Aim 1, namely miR-324-5p 
regulation of Wnt signalling. 
7.2  Results 
7.2.1 Pathway analysis of genes decreased by miR-324-5p 
As well as identifying specific miR-324-5p targets, analysis of genes differentially regulated 
by miR-324-5p can be used to predict further pathways regulated by the miRNA. Genes 
whose expression decreased more than log2 0.2 in Array1 (unstim) were input into the 
online pathway analysis tool, DAVID [211], to search for enrichment of pathways or 
common gene functions. My results indicated a significant enrichment for a number of GO 
(Gene Ontology http://www.geneontology.org/) terms (Table 7.1), biological process GO 
terms (Table 7.2) and Kegg signalling pathways (Table 7.3). These included Wnt signalling, 
TLR signalling, TGFβ signalling, actin cytoskeleton, development, cancer and brain 
diseases. 
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Table 7.1 GO terms enriched for following miR-324-5p overexpression.  
 
Table 7.1 GO terms enriched for following miR-324-5p overexpression. 3000 (maximum 
for DAVID pathway analysis) gene whose expression were decreased following miR-324-5p 
transfection were input into DAVID pathway functional annotation chart. Table shows 50 
most enriched GO terms.  
Term Count PValue
Golgi apparatus 143 2.21209E-11
proteinaceous extracellular matrix 73 3.73872E-09
extracellular matrix 74 9.50518E-09
organelle lumen 200 1.55491E-08
intracellular organelle lumen 199 2.02717E-08
membrane-enclosed lumen 203 5.05597E-08
extracellular matrix structural constituent 17 1.09742E-07
cell cycle 121 2.67275E-07
extracellular matrix part 30 6.74597E-07
skeletal system development 66 9.76055E-07
regulation of transcription from RNA polymerase II promoter 119 1.26925E-06
Wnt receptor signaling pathway 37 2.74489E-06
metal ion binding 571 2.92749E-06
cation binding 574 4.42565E-06
actin cytoskeleton organization 43 4.60382E-06
DNA binding 287 5.99061E-06
embryonic organ development 56 6.40928E-06
positive regulation of nitrogen compound metabolic process 102 6.74822E-06
enzyme linked receptor protein signaling pathway 61 8.73781E-06
blood vessel development 56 9.43455E-06
vasculature development 57 9.56492E-06
nucleotide binding 341 1.04613E-05
actin filament-based process 44 1.09262E-05
regulation of transcription 343 1.24755E-05
embryonic development ending in birth or egg hatching 85 1.31013E-05
ion binding 576 1.3699E-05
platelet-derived growth factor binding 8 1.51564E-05
chordate embryonic development 84 1.65828E-05
intracellular non-membrane-bounded organelle 290 1.68812E-05
non-membrane-bounded organelle 290 1.68812E-05
cell division 61 2.20698E-05
cytoskeletalprotein binding 83 2.3053E-05
small GTPase mediated signal transduction 57 2.51441E-05
positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 97 2.62248E-05
intracellular signaling cascade 157 2.99017E-05
extracellular structure organization 38 2.99987E-05
organelle membrane 137 3.14166E-05
positive regulation of gene expression 93 3.53932E-05
positive regulation of transcription 91 3.55922E-05
mitotic cell cycle 54 4.01647E-05
cell cycle process 78 4.08242E-05
structure-specific DNA binding 24 4.37356E-05
chromosome 73 5.43135E-05
negative regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 78 5.74883E-05
small conjugating protein ligase activity 33 6.65439E-05
Golgi apparatus part 49 7.14567E-05
transition metal ion binding 392 7.65778E-05
negative regulation of nitrogen compound metabolic process 78 8.24603E-05
chromosomal part 63 8.83022E-05
negative regulation of gene expression 79 0.00010145
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Table 7.2 Biological process GO terms enriched for following miR-324-5p overexpression.  
 
Table 7.2 Biological process GO terms enriched for following miR-324-5p overexpression. 
3000 (maximum for DAVID pathway analysis) gene whose expression was decreased 
following miR-324-5p transfection were inputted into DAVID pathway functional 
annotation chart. Table shows 50 most enriched biological process GO terms.
Term Count PValue
cell cycle 121 2.67275E-07
skeletal system development 66 9.76055E-07
regulation of transcription from RNA polymerase II promoter 119 1.26925E-06
Wnt receptor signaling pathway 37 2.74489E-06
actin cytoskeleton organization 43 4.60382E-06
embryonic organ development 56 6.40928E-06
positive regulation of nitrogen compound metabolic process 102 6.74822E-06
enzyme linked receptor protein signaling pathway 61 8.73781E-06
blood vessel development 56 9.43455E-06
vasculature development 57 9.56492E-06
actin filament-based process 44 1.09262E-05
regulation of transcription 343 1.24755E-05
embryonic development ending in birth or egg hatching 85 1.31013E-05
chordate embryonic development 84 1.65828E-05
cell division 61 2.20698E-05
small GTPase mediated signal transduction 57 2.51441E-05
positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 97 2.62248E-05
intracellular signaling cascade 157 2.99017E-05
extracellular structure organization 38 2.99987E-05
positive regulation of gene expression 93 3.53932E-05
positive regulation of transcription 91 3.55922E-05
mitotic cell cycle 54 4.01647E-05
cell cycle process 78 4.08242E-05
negative regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 78 5.74883E-05
negative regulation of nitrogen compound metabolic process 78 8.24603E-05
negative regulation of gene expression 79 0.00010145
negative regulation of transcription, DNA-dependent 63 0.000101558
negative regulation of transcription 73 0.000107003
respiratory tube development 30 0.000112425
cell cycle phase 66 0.000112959
heart development 49 0.00011496
negative regulation of RNA metabolic process 63 0.000123016
negative regulation of cell differentiation 42 0.000125401
phosphate metabolic process 146 0.000138184
phosphorus metabolic process 146 0.000138184
negative regulation of macromolecule metabolic process 93 0.000142492
tissue morphogenesis 51 0.000157824
mitosis 43 0.000162741
nuclear division 43 0.000162741
modification-dependent protein catabolic process 93 0.000162909
modification-dependent macromolecule catabolic process 93 0.000162909
cytoskeleton organization 65 0.000168014
positive regulation of transcription from RNA polymerase II 
promoter 70 0.000168141
cartilage development 23 0.000170983
transmembrane receptor protein serine/threonine kinase signaling 
pathway 23 0.000170983
embryonic morphogenesis 70 0.000183206
negative regulation of macromolecule biosynthetic process 79 0.000193342
lung development 29 0.000200887
blood vessel morphogenesis 44 0.000207409
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Table 7.3 Kegg pathways enriched for following miR-324-5p overexpression.  
 
Table 7.3 Kegg pathways enriched for following miR-324-5p overexpression. 3000 
(maximum for DAVID pathway analysis) gene whose expression were decreased following 
miR-324-5p transfection were inputted into DAVID pathway functional annotation chart. 
Table shows all (41) of the enriched (default DAVID pathway cut off of p=0.1) Kegg 
pathways. 
Term Count PValue
Focal adhesion 51 1.16E-06
Ubiquitin mediated proteolysis 37 1.23E-05
Cell cycle 35 1.98E-05
Pathways in cancer 67 5.87E-05
Pancreatic cancer 23 6.11E-05
Valine, leucine and isoleucine degradation 17 1.13E-04
Colorectal cancer 25 1.43E-04
Oocyte meiosis 30 2.16E-04
GnRH signaling pathway 26 4.06E-04
Alzheimer's disease 40 7.50E-04
Glioma 19 8.57E-04
Neurotrophin signaling pathway 31 8.60E-04
ECM-receptor interaction 22 0.001488
Small cell lung cancer 22 0.00205
Wnt signaling pathway 33 0.002097
p53 signaling pathway 19 0.002197
ErbB signaling pathway 22 0.002783
Chronic myeloid leukemia 20 0.002848
Axon guidance 29 0.004166
Prostate cancer 22 0.004285
Renal cell carcinoma 18 0.006359
Melanoma 18 0.007389
Propanoate metabolism 10 0.010736
Bladder cancer 12 0.014762
Dorso-ventral axis formation 8 0.016979
Apoptosis 19 0.026425
TGF-beta signaling pathway 19 0.026425
MAPK signaling pathway 46 0.028951
Ether lipid metabolism 10 0.029459
Keratan sulfate biosynthesis 6 0.034673
Citrate cycle (TCA cycle) 9 0.038313
Phosphatidylinositol signaling system 16 0.05257
Chondroitin sulfate biosynthesis 7 0.054331
Regulation of actin cytoskeleton 37 0.062861
Progesterone-mediated oocyte maturation 17 0.0738
T cell receptor signaling pathway 22 0.07477
Circadian rhythm 5 0.075266
Inositol phosphate metabolism 12 0.079725
Toll-like receptor signaling pathway 19 0.079749
RIG-I-like receptor signaling pathway 14 0.091037
Huntington's disease 31 0.094498
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7.2.2 miR-324-5p is a regulator Wnt signalling 
Interestingly, one of the most enriched pathways was the Wnt signalling pathway (Table 
7.1, Table 7.2 and Table 7.3). The Wnt pathway is an important player in cartilage 
homeostasis and osteoarthritis (see Chapter 1). In addition, miR-324-5p is encoded from 
just downstream (or within one identified transcript- ENSMUST00000102575) of the 
Dishevelled (Dvl2) gene (Figure 7.1), an important molecule for Wnt signalling [282]. 
miRNAs have previously been shown to be involved in similar signalling pathways to their 
host gene [283]. Therefore due to their close proximity I hypothesised miR-324-5p and 
Dvl2 were controlled by similar mechanisms and involved in similar processes. 
There were many genes altered by miR-324-5p which were involved in Wnt signalling. The 
cumulative fraction plot (Figure 7.2A) and normalised fraction plot (Figure 7.2C) show 
there is a significant (Figure 7.2B and Figure 7.2D) enrichment of Wnt signalling related 
genes (Kegg Wnt pathway), in genes whose expression decreased following miR-324-5p 
overexpression. Figure 7.3 shows the relative positions of these genes (green) within the 
kegg Wnt signalling pathway. Some of these decreased genes are also predicted to be 
direct targets of miR-324-5p (yellow). 
To test if miR-324-5p is a regulator of canonical Wnt signalling I used the TOP/FOP FLASH 
luciferase reporter assay system. This is a luciferase based assay containing TCF/LEF 
binding sites (TOP) or mutant TCF/LEF binding sites (FOP). Canonical Wnt signalling signals 
through β-Catenin, which binds TCF/LEF binding sites meaning TOP/FOP flash is a good 
read out canonical Wnt signalling. Transfection of miR-324-5p inhibited Wnt3a induced 
TOP/FOP FLASH luciferase activity (Figure 7.4A), suggesting miR-324-5p is a regulator of 
canonical Wnt signalling. 
In Chapter 6 I showed miR-324-5p regulated Hh signalling by targeting Gpc1. Glypicans 
have been shown to be involved in Wnt signalling as well as Hh signalling [246, 280]. To 
test if Gpc1 is a regulator of Wnt signalling I co-transfected siGpc1 with TOP/FOP flash and 
stimulated with Wnt3a. siGPC1 caused reduced TOP FLASH luciferase activity (Figure 
7.4B). 
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Bmp2 + Wnt3a has previously been shown to regulate chondrogenesis (as measured by 
alcian blue) [284], I therefore hypothesised Gpc1 may also regulate Bmp2 + Wnt3a 
induced alcian blue by inhibition of Wnt signalling. Preliminary data suggested Gpc1, is 
involved in Bmp2 + Wnt3a induced alcian blue (Figure 7.4). Similar to the results in 
Chapter 4, where miR-324-5p did not affect Bmp2 + Ihh induced alcian blue (Figure 4.17), 
it also did not regulate Bmp2 + Wnt3a induced alcian blue (Figure 7.4). 
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Figure 7.1 miR-324-5p and DVL2 
 
Figure 7.1 miR-324-5p is encoded from within one mouse Dvl2 transcript and ~2kb 
downstream of most common Dvl2 transcripts. Human DVL2 transcript 
ID=ENST00000005340, mouse Dvl2 transcript-short (Dvl2-001) ID=ENSMUST00000019362, 
mouse Dvl2 transcript-long (Dvl2-006) I =ENSMUST00000102575. Question mark indicates 
it is unknown if a long human DVL2 transcript exists or if miR-324-5p is under the control 
of the same promoter as DVL2. 
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Figure 7.2 miR-324-5p decreases Wnt signalling genes 
 
Figure 7.2 miR-324-5p decreases Wnt signalling genes. List of Wnt signalling genes were 
determined from Wnt signalling Kegg pathway. (A) Cumulative fraction plot showing a 
higher fraction of Wnt signalling genes are decreased following miR-324-5p 
overexpression than fraction of non-Wnt signalling genes. (B) Fishers p value for 
cumulative fraction plot. (C) Normalised fraction plot showing a higher fraction of Wnt 
signalling genes are decreased following miR-324-5p overexpression than fraction of non-
Wnt signalling genes. (D) Fishers p value for normalised fraction plot. 
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Figure 7.3 Kegg Wnt pathway components are decreased following miR-324-5p transfection 
 
Figure 7.3 Schematic showing the position of miR-324-5p decreased genes (Chapter 4 -
microarray 1) in the Kegg Wnt pathway. Gene names shown are from the Kegg Wnt 
pathway and not necessarily the exact genes decreased. All predicted genes are in the 
Kegg pathway list of genes (not shown) and are orthologs of the genes shown. Green 
indicates genes decreased following miR-324-5p transfection. Yellow indicates genes 
decreased following miR-324-5p transfection and which are predicted miR-324-5p targets. 
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Figure 7.4 miR-324-5p regulates Wnt signalling 
 
Figure 7.4 Effect of miR-324-5p and siGpc1 on Wnt signalling and chondrogenesis. (A and 
B) miR-324-5p and siGpc1 decrease Wnt3a induced TOP FLASH. C3H10T1/2 cells were 
transfected with either FOP or TOP flash luciferase constructs, then after incubation 
period were transfected with either miCon, miR-324-5p, miR-125b, siCon or siGpc1 for 
24hr, cells were then serum starved and stimulated with Wnt3a (100ng/ml) or left 
unstimulated, luciferase values for TOP FLASH were then normalised to the respective 
values for FOP FLASH. TOP/FOP values were then normalised to either miCon or siCon. 
(Data combined from 3 independent experiments, each n=6) (C and D) Alcian blue was 
used as a marker of cartilage formation and extracted with GuHCl and quantified. 
C3H10T1/2 cells were transfected with siCon siGpc1, miCon or miR-324-5p then plated 
into micromass cultures, stimulated with Bmp2 (100ng/ml) and Wnt3a (100ng/ml) (n=6). 
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7.2.3 miR-324-5p is regulated by Wnt3a 
In Chapter 4 I showed miR-324-5p regulated Hh signalling, therefore I tested if Hh 
signalling could regulate miR-324-5p. I found neither Ihh nor Pur regulated miR-324-5p 
expression (Figure 4.15B). Here I demonstrated that miR-324-5p regulated Wnt3a induced 
canonical Wnt signalling, therefore I tested if Wnt3a can regulate miR-324-5p expression. 
Preliminary data shows miR-324-5p expression was increased following Wnt3a stimulation 
of C3H10T1/2 (Figure 7.5). 
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Figure 7.5 miR-324-5p is regulated by Wnt signalling 
 
Figure 7.5 Wnt3a alter miR-324-5p expression. C3H10T1/2 cells were stimulated with 
Wnt3a (100ng/ml) for 24h. miR-324-5p, was then assessed with real-time RT-PCR and 
normalised to 18s. Data combined from 2 independent experiments, each n=4. 
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7.3 Discussion 
7.3.1 Pathway analysis of genes decreased by miR-324-5p 
Pathway analysis of genes whose expression decreased following miR-324-5p 
overexpression suggested miR-324-5p was involved in a number of pathways in addition 
to Hh, including Wnt signalling, TLR signalling, TGFβ signalling, actin cytoskeleton, 
development, cancer and brain diseases. A number of these pathways were also enriched 
following DAVID pathway analysis of predicted mouse miR-324-5p targets (Figure 4.7D-
right), suggesting pathway analysis of predicted targets is a good indicator of miRNA 
function. More specifically of the 41 Kegg pathways enriched (Table 7.3), 23 (57%) were 
also enriched following DAVID pathway analysis of predicted mouse miR-324-5p targets 
(Figure 4.7D-right and Figure 7.6), which is over 5 times than that expected by chance 
(p=2.4 x10-23). In addition, of the 576 GO terms enriched following DAVID pathway 
analysis of genes decreased with miR-324-5p transfection (Table 7.3), 256 (44.4%) were 
also enriched following DAVID pathway analysis of predicted mouse miR-324-5p targets 
(Figure 4.7D-right). Taken together with Figure 5.17 (no single online target prediction 
algorithm predicted more than 5 times the expected number of decreased genes), this 
possibly suggests pathway analysis of predicted targets is better at predicting the function 
of a miRNA than online algorithms are at predicting which genes will decrease following 
overexpression of that miRNA. 
The pathway analysis did not distinguish between positive and negative regulators of a 
pathway, nor did it distinguish between the genes negatively or positively regulated by the 
pathway, possibly suggesting genes increased by miR-324-5p should also be considered 
when investigating miRNA function. 
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Figure 7.6 Venn diagram of predicted target pathway analysis vs. actual decreased genes pathway analysis 
 
Figure 7.6 Venn diagrams showing crossover of number of enriched pathways following 
DAVID pathway analysis of predicted targets (Predicted) and DAVID pathway analysis of 
3000 genes (DAVID max) whose expression decrease >log2 0.2. (A) Number of enriched 
Kegg pathways, (Fishers p-value=2.4 x10-23 based on the total number of possible Kegg 
pathways being 445). (B) Number of enriched GO pathways. 
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7.3.2 Role of miR-324-5p in Wnt signalling 
Here I have shown miR-324-5p is a negative regulator of canonical Wnt signalling 
(regulator of TOP/FOP flash), this was in agreement with a screen from a previous study 
where miR-324-5p was shown to regulate the STF19 reporter (canonical Wnt signalling 
reporter) [285]. siRNA depletion of miR-324-5p target Gpc1, also reduced Wnt pathway 
activity (Figure 7.4), suggesting the mechanism by which miR-324-5p regulates Wnt 
signalling also involves Gpc1. siGpc1 regulated Bmp2 + Wnt3a induced alcian blue (Figure 
7.4), probably due to Gpc1 regulation of Wnt signalling. 
Glypicans have previously been implemented in the regulation of Wnt signalling. For 
example, the HSPG gene dally-like (dly), a drosophila glypican, can regulate Wnt gradients 
[286] and Gpc3 can interact with Wnt to promote Wnt signalling [280]. 
A number of studies have shown miRNAs form parts of feedback loops. As I have shown 
miR-324-5p regulates Wnt signalling, I postulated that miR-324-5p may actually be 
regulated by Wnt signalling. Additionally miR-324-5p is encoded from just downstream (or 
within one identified transcript) of DVL2, a gene important in Wnt signalling. miR-324-5p 
expression was found to be Wnt3a responsive, indicating miR-324-5p forms part of a 
negative feedback loop in the Wnt signalling pathway, and can also regulate Hh. 
As siGpc1 decreased Bmp2 + Wnt3a induced alcian blue (Figure 7.4C), it is unclear why 
miR-324-5p did not (Figure 7.4D). The role of miR-324-5p on Bmp signalling is unknown, 
meaning it is possible miR-324-5p could act via other targets to positively regulate Bmp 
signalling, potentially compensating for the inhibitory effects on Hh and Wnt. 
This work shows a novel mechanism by which a miRNA links two important signalling 
pathways, as well as illustrating how a single miRNA can regulate the same pathway, in 
two species by two distinct mechanisms. 
Interestingly, the antisense miRNA, miR-324-3p, has recently been shown to regulate Wnt 
signalling by directly targeting WNT2B [287]. 
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7.3.3 Role of miR-324-5p in TLR signalling 
In Chapter 5 I hypothesised miR-324-5p may be able to regulate Hh signalling by activating 
TLRs. Interestingly, TLR signalling pathway genes were enriched for in genes decreased 
following miR-324-5p overexpression (Table 7.3) and is only one of 12 Kegg pathways also 
enriched for in genes whose expression increased following miR-324-5p overexpression. 
This possibly suggests miR-324-5p is able to activate TLR signalling as suggested in Chapter 
5. 
7.3.4 Role of miR-324-5p in TGFβ signalling 
TGFβ signalling was also enriched for in decreased genes following overexpression of miR-
324-5p (Table 7.3). TGFβ signalling is important for cartilage with its deregulation being an 
attributing factor to OA [288]. More specifically a switch from Smad2/3 signalling to 
Smad1/5/8 signalling is thought to play a role in OA, partly via the induction of MMP13 
[289]. The Wnt signalling pathway and MAPK signalling pathway have been shown to 
regulate this switch [288]. Interestingly, the MAPK signallng pathway is another of the 
enriched pathways in decreased genes following miR-324-5p transfection (Table 7.3). 
7.3.5 Role of miR-324-5p in actin cytoskeleton 
Pathway analysis also indicated miR-324-5p has a possible role in the actin cytoskeleton 
(Table 7.2). The actin cytoskeleton plays an important role in primary cilium organization 
[290], perhaps suggesting an additional mechanism by which miR-324-5p regulates Hh 
signalling, although no differences were observed in primary cilia following miR-324-5p 
overexpression (Figure4.14). In addition the actin cytoskeleton is important for 
maintaining chondrocyte phenotype [291]. 
7.3.6 Role of miR-324-5p in development 
There are a number of enriched development pathways (Table 7.2), reinforcing miR-324-
5p plays a role in development. This is also consistent with the role of miR-324-5p in the 
Hh and Wnt development pathways. Of particular interest to this study is the enrichment 
of genes involved in the cartilage development pathway (Table 7.2), BMP1, FGFR3, CYTL1, 
HSPG2, COL2A1, ZEB1, SOX9, TGFB2, ATP7A, DLX2, COL9A1, HIF1A, LECT1, MAPK14, 
FBXW4, CHST11, PKD1, ROR2, GNAS, COL1A1 and BMPR1B are all genes whose expression 
decreased following miR-324-5p overexpression and are part of the ‘GO’ cartilage 
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development pathway. In addition, my SILAC data indicated miR-324-5p can decrease type 
II collagen expression, a major constituent of articular cartilage. None of the online 
databases predict the mouse type II collagen gene, Col2a1, to have a miR-324-5p binding 
site in its 3’UTR, 5’UTR or coding sequence, suggesting it is not a direct target of miR-324-
5p. 
7.3.7 Role of miR-324-5p in vascularisation 
Healthy cartilage resists vascularisation by secretion of  anti-angiogenic proteins, these 
anti-angiogenic proteins are lost during OA [292], leading to the vascularisation of 
cartilage [293]. Here I have shown miR-324-5p is a possible regulator of vascularisation 
(Table 7.1 and Table 7.2), suggesting an addition mechanism by which miR-324-5p may be 
involved in OA pathogenesis. 
7.3.8 Role of miR-324-5p in cancer 
There was also an enrichment of a number of cancer pathways (Table 7.1, Table 7.2 and 
Table 7.3), suggesting miR-324-5p may play a role in some cancers. In addition miR-324-5p 
has previously been found to be aberrantly expressed in a number of cancers [294]. Some 
cancers also involve aberrant activation of Hh and Wnt signalling, suggesting modulation 
of miR-324-5p expression may form part of an effective cancer treatment. 
7.3.9 Role of miR-324-5p in brain diseases 
A number of studies have profiled miRNA expression in different tissues, one such study 
showing miR-324-5p was most highly expressed in Brain tissue. More specifically miR-324-
5p was most highly expressed in the cortex and cerebellum [206]. 
Interestingly, according to DAVID pathway analysis some of the most enriched pathways 
following miR-324-5p transfection were associated with the brain. These include 
Parkinson’s, Alzheimer’s, neuron development, Glioma and ErbB signalling (Table 7.1, 
Table 7.2 and Table 7.3). One of my validated targets of miR-324-5p was APP (Amyloid 
precursor protein) (Chapter 5), a gene involved in plaque formation and degenerative 
brain diseases, illustrating an important role for miR-324-5p in brain. In unpublished work, 
APP has been validated as miR-324-5p target in human [295]. Embryos deficient in Hh 
signalling often have neurological defects, possibly suggesting some of the effects of miR-
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324-5p on brain pathways are due to inhibition of Hh signalling. Further to this, Gpc1 has 
also been show to play a role in prion metabolism, suggesting there may be a number of 
mechanisms by which miR-324-5p can regulate brain function and disease [296]. Gpc1 is 
also found to be increased in glioma [297]. 
Recently, Stappert et al. has shown miR-324-5p (and miR-324-3p) regulates neural 
differentiation, but they do not show a mechanism by which miR-324-5p works, they also 
comment on the need to identify bonefied miR-324 targets involved in neural 
differentiation [298]. My research may lead to the identification of some of these targets. 
7.4 Summary 
In this chapter I have shown miR-324-5p regulates a number of pathways in addition to Hh 
signalling. I have further investigated the role miR-324-5p plays in Wnt signalling. I have 
also discussed how many of these additional pathways may be involved in development, 
cartilage maintenance and OA pathogenesis. miR-324-5p may also play key roles in other 
diseases such as cancer and diseases of the brain. 
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Chapter 8 General discussion 
The Hh and Wnt signalling pathways are important in development and diseases of many 
tissues, particularly cartilage, where their deregulation can lead to OA [48, 299-301]. 
miRNAs are important regulators of gene expression, and have also been implemented in 
the regulation of signalling pathways, development and diseases [142, 155, 301]. I 
hypothesised miRNAs are involved in OA progression and can regulate developmental 
pathways such as Hh and Wnt signalling. This study investigated the function of two 
miRNAs upregulated in OA; miR-125b-5p and miR-324-5p (Chapter 4), but focused on miR-
324-5p in Hh and Wnt signalling (Chapter 4-7). I also investigated SNPs which may affect 
the function of the most abundant and extensively studied miRNA in cartilage (miR-140) 
(Chapter 3). 
Focusing on miR-324-5p I have shown it is increased in end-stage OA cartilage and has 
previously been shown to regulate the Hh signalling pathway in human neural progenitor 
and tumour cells by targeting the Hh pathway activator SMO and transcription factor GLI1 
[127]. I demonstrated miR-324-5p regulation of Hh is conserved in mouse, yet the 
mechanism by which it does so is not. miR-324-5p has no full potential binding site in the 
mouse Smo 3’UTR and does not regulate the mouse Gli1 3’UTR, but instead regulates the 
mouse Gpc1 3’UTR in order to regulate Hh signalling (Chapter 4). I performed SILAC 
proteomics and microarray analysis following miR-324-5p overexpression to identify Gpc1 
as a direct miR-324-5p target in mouse (Chapter 5). Gpc1 is a HSPG and my data shows it 
is required for Hh signalling, probably by presenting Hh ligand via its HS chains to the Hh 
receptor Ptch (Chapter 6). I went on to show miR-324-5p also regulates Wnt signalling by 
a mechanism also likely to involve Gpc1 (Chapter 7). I finally demonstrated that miR-324-
5p is a Wnt responsive miRNA (Chapter 7). In summary miR-324-5p is Wnt responsive, 
increased in OA, and is a regulator of the Hh and Wnt signalling pathways, both important 
signalling pathways in cartilage biology. In addition I identified other novel miR-324-5p 
targets such as App, Anxa4 and Serpine2, illustrating the complexity of miRNA biology. 
In the general discussion I will; 1) Explain why miR-324-5p is a potent inhibitor of Hh 
signalling; 2) Discuss how miR-324p-5p links the Hh and Wnt signalling pathways; 3) 
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Discuss the importance of miRNA regulation of HSPGs, focusing on miR-324-5p regulation 
of Gpc1; 4) Discuss the role miR-324-5p is likely to have in vivo; and 5) finally I will 
summarise and comment on the wider implications of this work.  
8.1 miR-324-5p is a potent inhibitor of Hh signalling 
My data show miR-324-5p is an effective inhibitor of Hh signalling. In addition a recent 
paper actually uses miR-324-5p as an inhibitor of Hh rather than using pathway specific 
siRNAs to study the effect of oxidative stress [302]. I also found miR-324-5p is more 
potent than siGpc1 at inhibiting Hh signalling, which suggests miR-324-5p may target 
multiple components of the Hh signalling pathway.  
Drosophila smo mutant clones, which have abolished Hh signalling have reduced dlp 
(drosophila glypican homologue)  and ptc mutant clones which have increased Hh have 
increased dlp, suggesting glypicans in drosophila may actually be regulated by Hh 
signalling [252]. If conserved in mammals this mechanism may explain why both miR-324-
5p and siGpc1 are potent inhibitors of Hh signalling. For example the miR-324-5p induced 
reduction of Gpc1 and subsequent reduction of the Hh pathway may further reduce 
glypican expression, reinforcing the miR-324-5p reduction of Hh. A similar feedback, 
involving the Hh receptor Ptch, is already known and as expected the expression of Ptch1 
in my study was Hh dependent (Figure 4.10). Evidence from my studies does not suggest 
Gpc1 is under the control of Hh signalling in mammals (Figure 8.1), and is actually under 
the control of p53, the human tumour suppressor [303]. My microarray data did however 
indicate Gpc4 expression may be regulated by Hh signalling (Figure 8.1). Gpc4 does not 
have a miR-324-5p seed binding site suggesting its reduction is indirect, probably due to 
the miR-324-5p mediated reduction of Hh. If Gpc4 is similarly like Gpc1 and required for 
Hh signalling, this data may suggest part of the reason why miR-324-5p was a potent Hh 
inhibitor was because of the miR-324-5p mediated reduction of Hh (via Gpc1 inhibition) 
caused a reduction in the expression of Gpc4, which further potentiated the reduction of 
Hh signalling. 
In addition to glypicans there are a number of other HSPGs, including Syndecans and 
Perlecan. In mammals there are 4 different syndecans (Sdc1-4) and one perlecan (Hspg2). 
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Similar to glypicans, perlecan predominantly has HS chains, whereas syndecans have a mix 
of HS and CS chains. Similar to glypicans, syndecans are normally membrane bound, 
however unlike glypicans, they contain their own membrane spanning domain, rather 
than attaching via a GPI anchor. Perlecan is normally secreted from the cell. Sdc3 
(Syndecan 3) and Hspg2 are also reduced with the addition of miR-324-5p (Figure 8.1A), 
suggesting miR-324-5p may also act through these HSPGs to regulate Hh signalling (Figure 
8.1B). Neither Sdc3 nor Hspg2 have miR-324-5p seed binding sites or are Hh responsive 
indicating miR-324-5p regulates their expression by an indirect, Hh independent, 
mechanism (Figure 8.1). 
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Figure 8.1 miR-324-5p regulates many membrane proteins to regulates Hh 
 
Figure 8.1 miR-324-5p regulates many HSPGs to regulates Hh. In addition to Gpc1 miR-
324-5p also regulates a number of other HSPGs which may or may not play a role in Hh 
signalling. (A) Microarray data for all identified glypicans, Sydecans and Perlecan (Hspg2). 
(B) Schematic showing miR-324-5p can directly regulate Gpc1, can regulate Hspg2, Sdc3 
and Gpc4 via an unknown Hh independent mechanism and can regulate Gpc4, probably 
via inhibition of Hh signalling. 
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8.2 miR-324-5p links Hh and Wnt 
I have shown miR-324-5p is a regulator of Hh (Figure 4.14) and Wnt (Figure 7.4) signalling, 
and is Wnt3a (Figure 7.5), but not Ihh responsive (Figure 4.18), indicating miR-324-5p 
forms a negative feedback loop in the Wnt signalling pathway, and can also inhibit Hh 
signalling. This is perhaps unsurprising as miR-324-5p is encoded from just downstream of 
DVL2 (Figure 7.1), a gene involved in Wnt signalling [282]. Wnt ligands can lead to the 
activation of the canonical, the non-canonical Ca2+ and the non-canonical planar cell 
polarity (PCP) Wnt signalling pathways (Chapter 1). The non-canonical Ca2+ pathway has 
been shown to inhibit the canonical pathway by an unknown mechanism [102]. I know 
miR-324-5p inhibits canonical Wnt signalling (miR-324-5p decreased TOP/FOP flash 
expression). Without further investigation it remains unclear if miR-324-5p is canonical or 
non-canonical responsive, but if it is non-canonical responsive, it may form part of the 
mechanism by which non-canonical Wnt signalling inhibits canonical Wnt signalling. 
Wnt3a activates the canonical and non-canonical pathway [102]. Separate inhibition of 
the canonical and non-canonical Wnt pathways with Dkk1 and CaMKII inhibitor KN93 
respectively will determine if miR-324-5p is either canonical or non-canonical responsive 
The Hh and Wnt signalling pathways are closely linked and have many interactions. They 
are both involved in osteogenesis with Ihh being required for Wnt signalling activation 
[97]. In addition Sufu, which is a Hh regulator, is also involved in Wnt signalling [304]. 
Likewise GSK3 which is known to regulate Wnt can also regulate Hh signalling [70, 305]. 
miR-324-5p regulation of both the Hh and Wnt signalling pathways adds to this 
complexity. From an evolutionary perspective miR-324-5p appears relatively recently 
(around 100million years ago) in comparison to the Hh and Wnt pathways, which are 
largely conserved in all vertebrates meaning they are more than 100million years old. This 
suggests miR-324-5p may function in order to satisfy the differential needs of the Hh and 
Wnt signalling pathways without major alteration of the core Hh and Wnt signalling 
molecules. This can also been seen at a more general level where the 3’UTRs are less 
conserved than the coding sequence, meaning miRNAs may contribute to the evolution of 
these pathways and allow them to function in many different organisms, without changing 
the core proteins of the pathways. This makes sense as mutations in 3’UTRs are far more 
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likely benefit the organism than mutation in the coding sequence. This work shows a novel 
mechanism by which a miRNA links two important signalling pathways and regulates at 
least one of these pathways by potentially differing mechanisms. 
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8.3 The importance of miRNA:HSPG interactions  
8.3.1 The importance of GAG chains in ‘signalling hub’ and other signalling 
pathways 
In agreement with previous publications [306], I showed sodium chlorate can decrease 
Ihh induced Hh signalling, suggesting part of the mechanism by which Ihh induces Hh 
signalling involved HS chains. In addition to binding morphogens, HSPGs bind other 
molecules involved in Hh signalling, including lipoproteins which allows the release of 
morphogen with HSPGs [307]. Shifted [308] and Ihog (Hh co-receptor) [309], are 
thought to be involved in the interaction of Hh with HS chains and play roles in long 
and short range Hh signalling respectively. Another protein in Drosophila, 
Crossveinless2, allows the interaction of HS chains with Bmp receptors [310]. These 
interactions mean morphogens, their receptors, and their co receptors, are brought 
together in a ‘signalling hub’, each having the potential to regulate one another and 
ultimately regulate morphogen signalling. Depending on the molecules present in the 
signalling hub it will either act to promote signalling or as a decoy. Here I have shown 
miR-324-5p regulation of Gpc1 may play a role in these interactions and the generation 
of a ‘signalling hub’. 
8.3.2 HSPGs may explain aspect of Hh biology  
An interesting aspect of Hh signalling is Shh, Ihh and Dhh all a have similar capacity to 
bind the Hh receptor Ptch, yet have different potencies on cells (generally 
Shh>Ihh>Dhh) [67], indicating there must be accessory molecules in these cells binding 
differentially to each ligand. The loss of the Shh HSPG interacting domain decreases its 
potency [311, 312], suggesting HSPGs are responsible for the high Shh potency. 
Perhaps, each ligand binds differently to each HSPG, explaining the different potencies 
of Ihh, Shh and Dhh and suggesting the potency in dependent on the HSPG expression 
profile. Here I show Gpc1 is required for Ihh signalling, it would be of interest to 
examine if Gpc1 is also required for Shh and Dhh signalling. 
8.3.3 HSPGs are important for morphogen gradient regulation 
HSPGs, receptors and co-receptors all play major roles in regulating morphogen 
movement and a cells response to morphogen. To date much of the work looking at 
morphogen gradient regulation has been performed in Drosophila, with some of the 
mechanisms being able to be translated to vertebrates. Secreted morphogens interact 
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with the ECM, particularly HSPGs in order for them to properly from gradients prevent 
loss to the extracellular space and prevent aberrant signalling to the wrong cells. Baeg 
et al. showed GAG synthesis is required for organisation and extracellular distribution 
of wingless gradients, more specifically they showed a role for the HSPG gene, dally-
like (dly), a drosophila glypican in regulation of Wg (Wnt) morphogen gradient 
regulation [286]. HSPGs can interact with morphogens to produce many different 
types of morphogen gradient, for review see [267]. In mice which lack the ability to 
sulphate CS chain on CSPGs there are defects in Ihh morphogen gradient formation 
[313]. Both HSPGs and CSPGs are involved in Ihh morphogen gradient formation, 
illustrating how complex these processes can be. 
8.3.4 miR-324-5p regulates morphogen through regulation of Gpc1 
My data illustrates miR-324-5p inhibition of Gpc1 is likely to play a role a morphogen 
gradient generation, regulating both the movement and reception of morphogens. 
Interestingly, miR-324-5p is encoded from within a transcript variant of DVL2 (part of 
the Wnt signalling pathway) and miR-324-5p also regulates Gpc1 (also possibly part of 
the Wnt signalling pathway), this is an example of a miRNA which is encoded from, or 
co regulated with, a signalling pathway gene which regulates a glypican. The opposite 
of this may also be true in that miRNAs that are encoded from, or are co-regulated 
with, the glypicans, regulate other components of the morphogen signalling pathways. 
8.3.5 Other miRNA glypican interactions 
Interestingly, the GPC5/6 and the GPC3/4 cluster of glypicans are in close proximity 
(just downstream) of the miR-17~92 and miR-106a~363 miRNA clusters respectively. 
miR-17~92 is a group of polycistronic miRNAs encoding 6 mature miRNAs (miR-17, 
miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1). The miR-17~92 cluster has 
been suggested to play a role with Hh signalling [314] and their deletion leads to 
developmental phenotypes including skeletal defects in mice and humans [167, 315, 
316]. The miR-106a~363 is also group of polycistronic miRNAs also encoding 6 mature 
miRNAs (miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-1 and miR-363). The miR-
17~92 and miR-106a~363 clusters of miRNAs have themselves arisen from a genomic 
duplication of a precursor miRNA cluster [317]. It is possible the functions of these 
miRNA clusters and the glypican clusters are intimately linked. In an experiment where 
miR-17~92 cluster expression was induced by provirus integration, an induction of 
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GPC5 expression was also observed [318], indicating they are under the control of a 
common promoter. Indeed UCSC ENCODE data shows there is an active promoter at 
the start site of miR-17~92 and also an ‘inhibitor’ site between the miR-17~92 cluster 
and Gpc5, perhaps indicating why Gpc5 expression is not always increased with a miR-
17~92 increase [318]. The expression level of the miR-106a~363 cluster is lower than 
the miR-17~92 cluster [315], and is encoded from further upstream of GPC3 than miR-
17~92 is in relation to GPC5. This indicates GPC3 and miR-106a~363 are potentially 
more independently controlled than Gpc5 and miR-17~92. There is also a third miR 
cluster prologue (to the miR-17~92, miR-106a~363 clusters), the miR-106b~25 cluster, 
which is encodes three miRs (miR-106b, miR-93 and miR-25) it is located in an intron of 
MCM7, and appears unrelated to glypicans [316]. 
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8.4 miR-324-5p in development, and OA 
I have shown miR-324-5p regulates Hh and Wnt signalling, and as glypicans (which I 
have shown miR-324-5p can target) can regulate many morphogens it is plausible miR-
324-5p may also act on other morphogens such as BMPs, FGFs and TGFβ to exert its 
effects (including BMP2 in the alkaline phosphatase experiments), reinforcing the role 
of miR-324-5p in skeletogenesis and OA, although this was not tested directly in this 
study.  
Canonical Wnt signalling is increased in OA [319], where it is thought contribute to the 
loss of cartilage by controlling cartilage degrading enzymes called MMPs [320] and to 
the formation of osteophytes and thickening of subchondral bone by reactivation of 
genes involved in development [299]. Both over-activation and inhibition of Wnt 
signalling can lead to skeletal deformities and an early onset OA [299-301], illustrating 
how tightly regulated Wnt needs to be in cartilage homeostasis.  
Camk2, which is involved in non-canonical Wnt signalling, is involved in skeletal 
development [321]. miR-324-5p induction in OA may be due to non-canonical Wnt 
signalling. I show miR-324-5p inhibits canonical Wnt signalling. Interestingly, Nalesso et 
al. have shown there is reciprocal inhibition of canonical and non-canonical Wnt 
signalling pathways [102]. If my finding are reproducible in human it is possible miR-
324-5p may act as the mechanism for non-canonical Wnt signalling to inhibit canonical 
Wnt signalling in human chondrocytes. 
Hh signalling plays a role in anterior-posterior patterning, left-right patterning, 
patterning of the mammalian limb, limb bud development and endochondral 
ossification. If miR-324-5p is expressed in these tissues it is likely it will also have a role 
in these developmental processes. As miR-324-5p inhibits Hh it is likely overexpression 
of miR-324-5p will have similar effects to reduced Hh. However due to the other 
actions of miR-324-5p there are likely to be a number of differences between reducing 
Hh and increasing miR-324-5p expression. 
The Hh signalling pathway is thought to contribute to the loss of cartilage by 
controlling cartilage degrading MMPs [320] and to the formation of osteophytes and 
thickening of subchondral bone by reactivation of genes involved in development 
[299]. Similar to Wnt, mouse models have shown both over activation and inhibition of 
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Hh signalling can lead to OA [48]. Illustrating how tightly regulated both Wnt and Hh 
are in cartilage homeostasis. Similarly both increases and decreases in miR-324-5p and 
its target Gpc1 cause decrease Hh signalling, perhaps suggesting intricate links 
between miR-324-5p, Gpc1, Hh, Wnt and OA. A better understanding of miR-324-5p 
regulation of these pathways may provide a way to pharmacologically alter Wnt or Hh 
in such a way which is beneficial to cartilage. 
In vivo studies have shown the importance of HSPGs in Hh signalling. The reduction of 
an enzyme involved in the extension of the HS chains (Ext1) in mice, increased the 
range of Ihh signalling [322]. In mice which lack the ability to sulphate CS chain on 
CSPGs there are defects in Ihh morphogen gradient formation [313]. Mice which are 
mutant for Gpc3 (negative regulator of Hh) have increased size [323], similar to mice 
which are heterozygous for ptch (and have increased Hh signalling) [324], suggesting 
Gpc3 mutant mice have increased Hh signalling. In humans, EXT1 and EXT2 mutations 
can cause hereditary multiple exostoses (multiple osteochondromatosis), a condition 
involving the growth of multiple spurs consisting of bone and cartilage in children [325-
328]. All of these other studies involve a lack of regulation of morphogen gradients. 
Gpc1 has been genetically associated with Biliary atresia [274], a disease involving the 
liver. In terms of OA, a study has shown SDC4 is up regulated in OA [329]. Deletion of 
Sdc4 in mice shows Sdc4 has a role in bone repair [330]. 
Interestingly, GPC1 gene has previously been identified as a possible candidate for 
causing Brachydactyly Type E, an inherited condition causing skeletal deformities 
[331]. Genotype-phenotype correlations show GPC1 can be a cause of skeletal 
deformities in rodents, and is most highly expressed in developing and mature 
osteoblasts [332]. Also in two patients which have a loss of the GPC1 encoding region 
(part of chromosome 2q), there are skeletal deformities and also mental retardation. 
Additionally Gpc1 is most highly expressed in the developing nervous system in 
rodents [331], perhaps highlighting a duel role of miR-324-5p/ Gpc1 in the skeleton 
and the nervous system, also as indicated by pathway analysis following miR-324-5p 
overexpression (Chapter7). miR-324-5p inhibition of Gpc1 may result in both skeletal 
and central nervous system abnormalities. However, I do not suggest inhibition of 
Gpc1 is the sole mechanism by which miR-324-5p exerts its effects (Chapter 7), for 
example I have shown miR-324-5p can also inhibit App an important gene for brain 
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disease pathogenesis. Recently, a paper has shown miR-324-3p and miR-324-5p have a 
role in differentiation of neural cells [298]. 
8.5 Summary and future direction  
Due to the important roles Hh and Wnt play during development it is likely miR-324-5p 
will also play a role in development. In situ hybridisation of miR-324-5p in developing 
tissues may shed light on it role during development. The creation of miR-324-5p 
depleted and miR-324-5p overexpressing mice, both global and cartilage restricted, to 
investigate the overall role of miR-324-5p and its role in skeletal development 
respectively will also take this work forward. This work shows a novel mechanism by 
which a miRNA links two important signalling pathways, as well as illustrating how a 
single miRNA can regulate the same pathway, in two species by two distinct 
mechanisms. It also increases understanding of Hh and Wnt signalling, which may lead 
to new therapeutics for the many diseases in which these pathways are deregulated. 
Taken together this body of work demonstrates how miRNAs, their targets and their 
functions can be linked in their expression and association with OA.  
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Chapter 9 Appendix 
Appendix A  Inhibiting components of the Hh pathway  
As expected, siRNA against Smo reduced Smo mRNA (Figure 4.11G). However siRNA 
against Gli1 did not cause a reduction in Gli1 mRNA (Figure 4.11A) and siRNA against 
Ptch did not cause a reduction in Ptch mRNA (Figure 4.11D), possibly as these two 
genes are Hh responsive as well as being part of the pathway. The reduction in mRNA 
due to the action of the siRNA will be compensated by increased transcription of Ptch. 
Depletion of Hh signalling proteins Ptch, Smo and Gli1, prevents Ihh induced Gli1 
expression showing, all three molecules are required for Ihh signalling. One might 
expect depletion of Ptch to further activate the pathway, as its classical function is to 
prevent Smo localisation to the primary cilia, but this was not observed. Depletion of 
Smo and Gli1 did not affect basal levels of Gli1, probably due to the very low 
detectable levels of Gli1, however depletion of Ptch in unstimulated cells significantly 
increases Gli1 mRNA, presumably by releasing Smo (to the cilia) and allowing 
downstream Hh activity (Figure 4.11). As anticipated, depletion of both Smo and Gli1 
prevented Pur induction of Gli1 mRNA and protein expression (Figure 4.11C and E). 
Unexpectedly, depletion of Ptch also caused the loss of Pur induced Gli1 induction 
(Figure 4.11C and E), indicating Ptch, which is thought to act as a negative regulator 
upstream of Smo (which is the suggested site of Pur action), is actually required for Pur 
induction of Hh signalling. Similarly Ptch, Smo and Gli1 are also all required for Pur 
induction of Ptch (Figure 4.11F). siSmo, but not siPtch or siGli1, reduced Smo mRNA in 
unstimulated (Figure 4.11G), Ihh stimulated (Figure 4.11H) and Pur stimulated (Figure 
4.11I) cells. Interestingly, in contrast to Smo mRNA, siSmo, siPtch and siGli all prevent 
expression of Smo protein (Figure 4.11D and E), perhaps indicating why ptch depletion 
can prevent Pur induction of Gli1 (Figure 4.11) and indicates Smo localisation is 
dependent on Ptch and Gli1.  
In summary, all three molecules are involved in Hh signalling and their role can differ 
depending on the type of Hh activation.  
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Appendix B  How the cumulative fraction and normalised fraction 
plots were created 
To illustrustrate the level enrichment of different miRNA seed binding sites in genes 
whose expression decreased, I created ‘cumulative fraction’ (Figure 9.1) and 
‘normalised fraction’ (Figure 9.1) plots using Microsoft Excel.   
Figure 9.1 How the cumulative fraction and normalised fraction plots were created 
 
Figure 9.1 How the cumulative fraction and normalised fraction plots were created. (A) 
Cumulative fraction is calculated, by an increasing window of 1, starting with the most 
decreased genes. The sum of ‘seed type of interest’ in each calculated list (represented 
by arrow) was divided by the sum of ‘seed of interest’ in whole data set, to give the 
cumulative fraction and plotted against the respective log2 fold change. Where 
significance plots are shown (Appendix C), Fishers p-value was calculated at 
increments of every 5 of the original calculated cumulative fraction values (comparing 
the site type of interest to the appropriate control e.g. no seed). (B) Normalised 
fraction is calculated by a moving window of 500, at increasing increments of 1. The 
window moved outwards from genes whose expression did not change bi-directionally 
to increased and decreased genes. The sum of ‘seed type of interest’ in the calculated 
in each list (represented by arrow) is then divided by the sum of ‘seed type of interest’ 
in whole data set, giving the ‘fraction’ of the ‘seed of interest’. This fraction is then 
normalised to the average of this fraction in the whole data set and plotted against the 
respective log2 fold change.  
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Appendix C  Reason why log2 0.2 cut off was chosen 
Log2 0.2 cut off was chosen was because it allowed the most significant enrichment of 
miR-324-5p seeds in all experiments Figure 9.2.  
Figure 9.2 Reason why log2 0.2 cut off was chosen 
 
 
Figure 9.2 Reason why log2 0.2 cut off was chosen. Fishers p-value of the enrichment 
of non-conserved cumulative frequency plots for each of the target identification 
experiments (Figure 5.4E, Figure 5.5E, Figure 5.7E, Figure 5.10E and Figure 5.11E). See 
Appendix B for how this plot was made.  
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Appendix D Purmorphamine studies 
There were three unexpected results concerning HS regulation of Hh and Hh regulation 
of alkaline phosphatase. 
Firstly, sodium chlorate also decreased Pur induced Hh signalling (Figure 9.3A), 
suggesting the mechanism by which Pur induces Hh signalling also involves HS chains. 
It is known Pur acts directly on Smo, suggesting HS chains are also involved in Smo 
localisation or involved in Hh signalling downstream of Smo, strengthening the 
argument of HS controlling a ‘signalling hub’. 
Secondly, and consistent with above, siGpc1 decreased Pur induced Gli1 (Figure 9.3B) 
meaning it is likely HS chains on Gpc1 are involved in Pur induced Hh. Site directed 
mutagenesis of HS chain attachment sites within the Gpc1 overexpression plasmid 
could be used to specifically determine the role of Gpc1 HS chains in Hh signalling. 
Alternatively, HS may also interact with morphogens of other signalling pathways 
which may have effects on downstream Hh signalling. 
Thirdly, and again unexpectedly, siGli1 did not decrease Ihh + Bmp2 induced alkaline 
phosphatase (Figure 6.4A). The reason for this was unclear, however Bmp2 alone was 
not included in these experiments, making it possible the addition of Ihh did not 
actually cause any further increase in Bmp2 induced alkaline phosphatase, meaning 
siGli1 would have no effect. However, in the same experiments siGpc1 was able to 
affect the level of alkaline phosphatase (Figure 6.4), perhaps via an as yet untested 
effect on Bmp signalling. Alternatively, the effect of adding Ihh to Bmp2 on alkaline 
phosphatase could have been Gli1 independent with the effect of Hh activation on 
Bmp2 being downstream of Gpc1 but upstream of Gli1. 
In contrast to the above, and probably as expected siGli1 does and siGpc1 does not 
affect Pur and Bmp2 induced alkaline phosphatase (Figure 6.4). If Hh signalling is able 
to affect Bmp2 signalling independent of Gli1, it is possible regulation of Gpc1 may 
form an effective mechanism to regulate all effects of Hh. Whereas regulation of Gli1 
would only function to regulate Gli1 dependent Hh signalling. Further work may show 
switching between Gli1 dependent and Gli1 independent may form an effective 
mechanism to regulate cartilage and bone during development and OA (similar to that 
shown for the canonical and non-canonical Wnt signalling pathways [102]). 
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Figure 9.3 Purmorphamine studies 
 
Figure 9.3 Purmorphamine studies. (A) C3H10T1/2 cells were pre-treated with sodium 
chlorate (SC) for 48h at the concentration shown then serum starved and stimulated with 
Purmorphamine (Pur) (2μM) for 24h. Data combined from 2 independent experiments, 
each n=3. (B) C3H10T1/2 cells were transfected with non-targeting siCon or siRNA against 
Gpc1 or Gli1 for 24h. Cells were then serum starved for 24h and either left unstimulated, 
stimulated for with Pur (2μM) for 24h. Gli1 and 18s were assessed by real-time RT-PCR. 
Data combined from 4 independent experiments, each n=4. (C) C3H10T1/2 cells were 
transfected with siCon, siGpc1 or siGli1, then stimulated with Pur (2μM) and BMP2 
(100ng/ml) for 5 days. P.Nitrophenol was measured to determine the level of alkaline 
phosphatase. Data combined from 3 independent experiments, each n=3. All data are 
presented as mean + SEM, statistical difference were calculated using Student’s t-test, 
where, *p<0.05, **<0.01, ***p<0.001. Data combined from 5 independent experiments, 
each n=6. 
 
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
0.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
2
3
Pur + Bmp2
ns
**
R
e
la
ti
v
e
 A
lk
a
lin
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
0.0
0.5
1.0
1.5
**
PurUnstim
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A.
C.
B.
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
0.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
2
3
Pur + Bmp2
ns
**
R
e
la
ti
v
e
 A
lk
a
lin
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
0.0
0.5
1.0
1.5
**
PurUnstim
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A.
C.
B.
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
2
3
Pur + Bmp2
ns
**
R
e
la
ti
v
e
 A
lk
a
lin
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
.0
0.5
1.0
1.5
**
PurUnstim
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A.
C.
B.
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
0.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
2
3
Pur + Bmp2
ns
**
R
e
la
ti
v
e
 A
lk
a
lin
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
0.0
0.5
1.0
1.5
**
PurUnstim
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A.
C.
B.
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
0.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li
1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
2
3
Pur + Bmp2
ns
**
R
e
la
ti
v
e
 A
lk
a
li
n
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
0.0
0.5
1.0
1.5
**
PurUnstim
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A.
C.
B.
s
iC
o
n
s
iG
P
C
1
s
iG
li
1
 
0.0
0.5
1.0
1.5
Pur
***
***
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
U
n
s
ti
m
s
iC
o
n
 s
iG
p
c
1
s
iG
li
1
0
1
Pur + Bmp2
R
e
la
ti
v
e
 A
lk
a
lin
e
 P
h
o
s
p
h
a
ta
s
e
C
o
n
C
o
n
1
m
M
 S
C
1
0
m
M
 S
C
1
0
0
m
M
 S
C
0.0
0.5
1.0
1.5
**
rti
R
e
la
ti
v
e
 G
li1
 m
R
N
A
 /
1
8
s
A. B.
234 
 
References  
1. Arden, N. and M.C. Nevitt, Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol, 
2006. 20(1): p. 3-25. 
2. Altman, R., et al., Development of criteria for the classification and reporting of 
osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic 
Criteria Committee of the American Rheumatism Association. Arthritis Rheum, 1986. 29(8): 
p. 1039-49. 
3. Goldring, S.G., MB., Clinical aspects, pathology and pathophysiology of osteoarthritis. J 
Musculoskelet Neuronal Interact, 2006. 6: p. 376-378. 
4. Goldring, M.B. and S.R. Goldring, Osteoarthritis. J Cell Physiol, 2007. 213(3): p. 626-34. 
5. Lin, E.H., Depression and osteoarthritis. Am J Med, 2008. 121(11 Suppl 2): p. S16-9. 
6. Nuesch, E., et al., All cause and disease specific mortality in patients with knee or hip 
osteoarthritis: population based cohort study. BMJ, 2011. 342: p. d1165. 
7. Reginster, J.Y., The prevalence and burden of arthritis. Rheumatology (Oxford), 2002. 41 
Supp 1: p. 3-6. 
8. Fung, H.B. and H.L. Kirschenbaum, Selective cyclooxygenase-2 inhibitors for the treatment 
of arthritis. Clin Ther, 1999. 21(7): p. 1131-57. 
9. Dohme, M.S. Merck Announces Voluntary Worldwide Withdrawal of VIOXX(R).  2004  
[cited. 
10. Baragi, V.M., et al., A new class of potent matrix metalloproteinase 13 inhibitors for 
potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without 
musculoskeletal toxicity in rat models. Arthritis Rheum, 2009. 60(7): p. 2008-18. 
11. Alvarez-Soria, M.A., et al., Diacerein has a weak effect on the catabolic pathway of human 
osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes. 
Rheumatology (Oxford), 2008. 47(5): p. 627-33. 
12. Sawitzke, A.D., et al., Clinical efficacy and safety of glucosamine, chondroitin sulphate, 
their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year 
results from GAIT. Ann Rheum Dis, 2010. 69(8): p. 1459-64. 
13. Wieland, H.A., et al., Osteoarthritis - an untreatable disease? Nat Rev Drug Discov, 2005. 
4(4): p. 331-44. 
14. Qi, Y., G. Feng, and W. Yan, Mesenchymal stem cell-based treatment for cartilage defects 
in osteoarthritis. Mol Biol Rep, 2012. 39(5): p. 5683-9. 
15. Ronn, K., et al., Current surgical treatment of knee osteoarthritis. Arthritis, 2011. 2011: p. 
454873. 
16. Martel-Pelletier, J., et al., Cartilage in normal and osteoarthritis conditions. Best Pract Res 
Clin Rheumatol, 2008. 22(2): p. 351-84. 
17. Goldring, M.B., Update on the biology of the chondrocyte and new approaches to treating 
cartilage diseases. Best Practice & Research Clinical Rheumatology, 2006. 20(5): p. 1003-
1025. 
18. Knudson, C.B. and W. Knudson, Cartilage proteoglycans. Semin Cell Dev Biol, 2001. 12(2): 
p. 69-78. 
19. Wong, M., et al., Zone-specific cell biosynthetic activity in mature bovine articular 
cartilage: a new method using confocal microscopic stereology and quantitative 
autoradiography. J Orthop Res, 1996. 14(3): p. 424-32. 
20. Thomas, R.S., et al., Effects of Wnt3A and mechanical load on cartilage chondrocyte 
homeostasis. Arthritis Res Ther, 2011. 13(6): p. R203. 
235 
 
21. Cawston, T.E. and A.J. Wilson, Understanding the role of tissue degrading enzymes and 
their inhibitors in development and disease. Best Pract Res Clin Rheumatol, 2006. 20(5): p. 
983-1002. 
22. Cawston, T.E., Metalloproteinase inhibitors and the prevention of connective tissue 
breakdown. Pharmacol Ther, 1996. 70(3): p. 163-82. 
23. Verbruggen, G., et al., Influence of aging on the synthesis and morphology of the 
aggrecans synthesized by differentiated human articular chondrocytes. Osteoarthritis 
Cartilage, 2000. 8(3): p. 170-9. 
24. Guilak, F., et al., The role of biomechanics and inflammation in cartilage injury and repair. 
Clin Orthop Relat Res, 2004(423): p. 17-26. 
25. Blagojevic, M., et al., Risk factors for onset of osteoarthritis of the knee in older adults: a 
systematic review and meta-analysis. Osteoarthritis Cartilage, 2010. 18(1): p. 24-33. 
26. Grotle, M., et al., Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological 
study in the general population with 10 years follow-up. BMC Musculoskelet Disord, 2008. 
9: p. 132. 
27. Hui, W., et al., Leptin produced by joint white adipose tissue induces cartilage degradation 
via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis, 2012. 71(3): 
p. 455-62. 
28. Srikanth, V.K., et al., A meta-analysis of sex differences prevalence, incidence and severity 
of osteoarthritis. Osteoarthritis Cartilage, 2005. 13(9): p. 769-81. 
29. Cooley, H.M., J. Stankovich, and G. Jones, The association between hormonal and 
reproductive factors and hand osteoarthritis. Maturitas, 2003. 45(4): p. 257-65. 
30. Maleki-Fischbach, M. and J.M. Jordan, New developments in osteoarthritis. Sex differences 
in magnetic resonance imaging-based biomarkers and in those of joint metabolism. 
Arthritis Res Ther, 2010. 12(4): p. 212. 
31. Zhang, Y., et al., Lower prevalence of hand osteoarthritis among Chinese subjects in Beijing 
compared with white subjects in the United States: the Beijing Osteoarthritis Study. 
Arthritis Rheum, 2003. 48(4): p. 1034-40. 
32. Nevitt, M.C., et al., Very low prevalence of hip osteoarthritis among Chinese elderly in 
Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study. 
Arthritis Rheum, 2002. 46(7): p. 1773-9. 
33. Zhang, Y., et al., Comparison of the prevalence of knee osteoarthritis between the elderly 
Chinese population in Beijing and whites in the United States: The Beijing Osteoarthritis 
Study. Arthritis Rheum, 2001. 44(9): p. 2065-71. 
34. Spector, T.D., et al., Genetic influences on osteoarthritis in women: a twin study. BMJ, 
1996. 312(7036): p. 940-3. 
35. Miyamoto, Y., et al., A functional polymorphism in the 5' UTR of GDF5 is associated with 
susceptibility to osteoarthritis. Nat Genet, 2007. 39(4): p. 529-33. 
36. Loughlin, J., et al., Linkage analysis of chromosome 2q in osteoarthritis. Rheumatology 
(Oxford), 2000. 39(4): p. 377-81. 
37. Loughlin, J., et al., Stratification analysis of an osteoarthritis genome screen-suggestive 
linkage to chromosomes 4, 6, and 16. Am J Hum Genet, 1999. 65(6): p. 1795-8. 
38. Chapman, K., et al., Osteoarthritis-susceptibility locus on chromosome 11q, detected by 
linkage. Am J Hum Genet, 1999. 65(1): p. 167-74. 
39. arcOGEN, Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-
wide association study. Lancet, 2012. 380(9844): p. 815-23. 
40. Nakajima, M., et al., New sequence variants in HLA class II/III region associated with 
susceptibility to knee osteoarthritis identified by genome-wide association study. PLoS 
One, 2010. 5(3): p. e9723. 
236 
 
41. Kerkhof, H.J., et al., A genome-wide association study identifies an osteoarthritis 
susceptibility locus on chromosome 7q22. Arthritis Rheum, 2010. 62(2): p. 499-510. 
42. Little, C.B., et al., Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic 
cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis 
Rheum, 2009. 60(12): p. 3723-33. 
43. Glasson, S.S., et al., Deletion of active ADAMTS5 prevents cartilage degradation in a 
murine model of osteoarthritis. Nature, 2005. 434(7033): p. 644-8. 
44. Fukui, N., et al., Zonal gene expression of chondrocytes in osteoarthritic cartilage. Arthritis 
Rheum, 2008. 58(12): p. 3843-53. 
45. Pearle, A.D., R.F. Warren, and S.A. Rodeo, Basic science of articular cartilage and 
osteoarthritis. Clin Sports Med, 2005. 24(1): p. 1-12. 
46. Aigner, T., et al., Large-scale gene expression profiling reveals major pathogenetic 
pathways of cartilage degeneration in osteoarthritis. 2006. p. 3533-3544. 
47. Blanco, F.J., et al., Osteoarthritis chondrocytes die by apoptosis. A possible pathway for 
osteoarthritis pathology. Arthritis Rheum, 1998. 41(2): p. 284-9. 
48. Lin, A.C., et al., Modulating hedgehog signaling can attenuate the severity of 
osteoarthritis. Nat Med, 2009. 15(12): p. 1421-1425. 
49. Shortkroff, S. and K.E. Yates, Alteration of matrix glycosaminoglycans diminishes articular 
chondrocytes' response to a canonical Wnt signal. Osteoarthritis Cartilage, 2007. 15(2): p. 
147-54. 
50. Goldring, M.B., Are bone morphogenetic proteins effective inducers of cartilage repair? Ex 
vivo transduction of muscle-derived stem cells. Arthritis Rheum, 2006. 54(2): p. 387-9. 
51. Sandell, L.J. and T. Aigner, Articular cartilage and changes in arthritis. An introduction: cell 
biology of osteoarthritis. Arthritis Res, 2001. 3(2): p. 107-13. 
52. Wang, B., J.F. Fallon, and P.A. Beachy, Hedgehog-regulated processing of Gli3 produces an 
anterior/posterior repressor gradient in the developing vertebrate limb. Cell, 2000. 100(4): 
p. 423-34. 
53. Zuzarte-Luis, V. and J.M. Hurle, Programmed cell death in the embryonic vertebrate limb. 
Semin Cell Dev Biol, 2005. 16(2): p. 261-9. 
54. Dong, Y., et al., Wnt-mediated regulation of chondrocyte maturation: modulation by TGF-
beta. J Cell Biochem, 2005. 95(5): p. 1057-68. 
55. Bi, W., et al., Sox9 is required for cartilage formation. Nat Genet, 1999. 22(1): p. 85-9. 
56. Komori, T., Regulation of skeletal development by the Runx family of transcription factors. 
J Cell Biochem, 2005. 95(3): p. 445-53. 
57. Onyekwelu, I., M.B. Goldring, and C. Hidaka, Chondrogenesis, joint formation, and articular 
cartilage regeneration. J Cell Biochem, 2009. 107(3): p. 383-92. 
58. Lefebvre, V., R.R. Behringer, and B. de Crombrugghe, L-Sox5, Sox6 and Sox9 control 
essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage, 2001. 
9 Suppl A: p. S69-75. 
59. Mackie, E.J., et al., Endochondral ossification: How cartilage is converted into bone in the 
developing skeleton. The International Journal of Biochemistry & Cell Biology, 2008. 40(1): 
p. 46-62. 
60. Minina, E., et al., BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte 
proliferation and differentiation. Development, 2001. 128(22): p. 4523-34. 
61. Yoon, B.S., et al., BMPs regulate multiple aspects of growth-plate chondrogenesis through 
opposing actions on FGF pathways. Development, 2006. 133(23): p. 4667-78. 
62. Ducy, P., et al., Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell, 
1997. 89(5): p. 747-54. 
237 
 
63. Nakashima, K., et al., The novel zinc finger-containing transcription factor osterix is 
required for osteoblast differentiation and bone formation. Cell, 2002. 108(1): p. 17-29. 
64. Nusslein-Volhard, C. and E. Wieschaus, Mutations affecting segment number and polarity 
in Drosophila. Nature, 1980. 287(5785): p. 795-801. 
65. Chen, X., et al., Regulation of articular chondrocyte proliferation and differentiation by 
indian hedgehog and parathyroid hormone-related protein in mice. 2008. p. 3788-3797. 
66. Colnot, C., et al., Indian hedgehog synchronizes skeletal angiogenesis and perichondrial 
maturation with cartilage development. 2005. p. 1057-1067. 
67. Pathi, S., et al., Comparative biological responses to human Sonic, Indian, and Desert 
hedgehog. Mech Dev, 2001. 106(1-2): p. 107-17. 
68. Rohatgi, R., L. Milenkovic, and M.P. Scott, Patched1 regulates hedgehog signaling at the 
primary cilium. Science, 2007. 317(5836): p. 372-6. 
69. Haycraft, C.J., et al., Gli2 and Gli3 localize to cilia and require the intraflagellar transport 
protein polaris for processing and function. PLoS Genet, 2005. 1(4): p. e53. 
70. Jia, J., et al., Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus 
interruptus. Nature, 2002. 416(6880): p. 548-52. 
71. Incardona, J.P., et al., Receptor-mediated endocytosis of soluble and membrane-tethered 
Sonic hedgehog by Patched-1. Proc Natl Acad Sci U S A, 2000. 97(22): p. 12044-9. 
72. Chen, Y. and G. Struhl, Dual roles for patched in sequestering and transducing Hedgehog. 
Cell, 1996. 87(3): p. 553-63. 
73. Sinha, S. and J.K. Chen, Purmorphamine activates the Hedgehog pathway by targeting 
Smoothened. Nat Chem Biol, 2006. 2(1): p. 29-30. 
74. Chen, J.K., et al., Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S 
A, 2002. 99(22): p. 14071-6. 
75. Chung, U.I., et al., Indian hedgehog couples chondrogenesis to osteogenesis in 
endochondral bone development. J Clin Invest, 2001. 107(3): p. 295-304. 
76. Mak, K.K., et al., Indian hedgehog signals independently of PTHrP to promote chondrocyte 
hypertrophy. Development, 2008. 135(11): p. 1947-56. 
77. Kronenberg, H.M., Developmental regulation of the growth plate. Nature, 2003. 
423(6937): p. 332-6. 
78. Long, F., et al., Ihh signaling is directly required for the osteoblast lineage in the 
endochondral skeleton. Development, 2004. 131(6): p. 1309-18. 
79. Maeda, Y., et al., Indian Hedgehog produced by postnatal chondrocytes is essential for 
maintaining a growth plate and trabecular bone. Proc Natl Acad Sci U S A, 2007. 104(15): 
p. 6382-7. 
80. St-Jacques, B., M. Hammerschmidt, and A.P. McMahon, Indian hedgehog signaling 
regulates proliferation and differentiation of chondrocytes and is essential for bone 
formation. 1999. p. 2072-2086. 
81. Long, F., et al., Genetic manipulation of hedgehog signaling in the endochondral skeleton 
reveals a direct role in the regulation of chondrocyte proliferation. 2001. p. 5099-5108. 
82. Laurell, T., et al., A novel 13 base pair insertion in the sonic hedgehog ZRS limb enhancer 
(ZRS/LMBR1) causes preaxial polydactyly with triphalangeal thumb. Hum Mutat, 2012. 
33(7): p. 1063-6. 
83. Swingler, T.E., et al., Degradome expression profiling in human articular cartilage. Arthritis 
Res Ther, 2009. 11(3): p. R96. 
84. Huangfu, D., et al., Hedgehog signalling in the mouse requires intraflagellar transport 
proteins. Nature, 2003. 426(6962): p. 83-7. 
85. Corbit, K.C., et al., Vertebrate Smoothened functions at the primary cilium. Nature, 2005. 
437(7061): p. 1018-21. 
238 
 
86. Beisson, J. and M. Wright, Basal body/centriole assembly and continuity. Curr Opin Cell 
Biol, 2003. 15(1): p. 96-104. 
87. Marshall, W.F. and S. Nonaka, Cilia: tuning in to the cell's antenna. Curr Biol, 2006. 16(15): 
p. R604-14. 
88. Praetorius, H.A. and K.R. Spring, Bending the MDCK cell primary cilium increases 
intracellular calcium. J Membr Biol, 2001. 184(1): p. 71-9. 
89. Praetorius, H.A. and K.R. Spring, Removal of the MDCK cell primary cilium abolishes flow 
sensing. J Membr Biol, 2003. 191(1): p. 69-76. 
90. Jensen, C.G., et al., Ultrastructural, tomographic and confocal imaging of the chondrocyte 
primary cilium in situ. Cell Biol Int, 2004. 28(2): p. 101-10. 
91. Pedersen, L.B., S. Geimer, and J.L. Rosenbaum, Dissecting the molecular mechanisms of 
intraflagellar transport in chlamydomonas. Curr Biol, 2006. 16(5): p. 450-9. 
92. Scholey, J.M. and K.V. Anderson, Intraflagellar transport and cilium-based signaling. Cell, 
2006. 125(3): p. 439-42. 
93. McGlashan, S.R., et al., Primary cilia in osteoarthritic chondrocytes: from chondrons to 
clusters. Dev Dyn, 2008. 237(8): p. 2013-20. 
94. Wann, A.K. and M.M. Knight, Primary cilia elongation in response to interleukin-1 mediates 
the inflammatory response. Cell Mol Life Sci, 2012. 69(17): p. 2967-77. 
95. Zhang, Q., et al., Loss of the Tg737 protein results in skeletal patterning defects. Dev Dyn, 
2003. 227(1): p. 78-90. 
96. Monroe, D.G., et al., Update on Wnt signaling in bone cell biology and bone disease. Gene, 
2012. 492(1): p. 1-18. 
97. Hu, H., et al., Sequential roles of Hedgehog and Wnt signaling in osteoblast development. 
Development, 2005. 132(1): p. 49-60. 
98. Spater, D., et al., Wnt9a signaling is required for joint integrity and regulation of Ihh during 
chondrogenesis. Development, 2006. 133(15): p. 3039-49. 
99. Rodda, S.J. and A.P. McMahon, Distinct roles for Hedgehog and canonical Wnt signaling in 
specification, differentiation and maintenance of osteoblast progenitors. Development, 
2006. 133(16): p. 3231-44. 
100. Kim, W., M. Kim, and E.H. Jho, Wnt/beta-catenin signalling: from plasma membrane to 
nucleus. Biochem J, 2013. 450(1): p. 9-21. 
101. Rao, T.P. and M. Kuhl, An updated overview on Wnt signaling pathways: a prelude for 
more. Circ Res, 2010. 106(12): p. 1798-806. 
102. Nalesso, G., et al., WNT-3A modulates articular chondrocyte phenotype by activating both 
canonical and noncanonical pathways. J Cell Biol, 2011. 193(3): p. 551-64. 
103. Gong, Y., et al., LDL receptor-related protein 5 (LRP5) affects bone accrual and eye 
development. Cell, 2001. 107(4): p. 513-23. 
104. Little, R.D., et al., A mutation in the LDL receptor-related protein 5 gene results in the 
autosomal dominant high-bone-mass trait. Am J Hum Genet, 2002. 70(1): p. 11-9. 
105. Cui, Y., et al., Lrp5 functions in bone to regulate bone mass. Nat Med, 2011. 17(6): p. 684-
91. 
106. Oldridge, M., et al., Dominant mutations in ROR2, encoding an orphan receptor tyrosine 
kinase, cause brachydactyly type B. Nat Genet, 2000. 24(3): p. 275-8. 
107. Afzal, A.R. and S. Jeffery, One gene, two phenotypes: ROR2 mutations in autosomal 
recessive Robinow syndrome and autosomal dominant brachydactyly type B. Hum Mutat, 
2003. 22(1): p. 1-11. 
108. DeChiara, T.M., et al., Ror2, encoding a receptor-like tyrosine kinase, is required for 
cartilage and growth plate development. Nat Genet, 2000. 24(3): p. 271-4. 
239 
 
109. Takeuchi, S., et al., Mouse Ror2 receptor tyrosine kinase is required for the heart 
development and limb formation. Genes Cells, 2000. 5(1): p. 71-8. 
110. Bartel, D.P., MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 2004. 
116(2): p. 281-297. 
111. Lee, R.C., R.L. Feinbaum, and V. Ambros, The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell, 1993. 75(5): p. 843-854. 
112. Kozomara, A. and S. Griffiths-Jones, miRBase: integrating microRNA annotation and deep-
sequencing data. Nucleic Acids Res, 2011. 39(Database issue): p. D152-7. 
113. Lee, Y., et al., The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003. 
425(6956): p. 415-9. 
114. Yi, R., et al., Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin 
RNAs. Genes Dev, 2003. 17(24): p. 3011-6. 
115. Czech, B. and G.J. Hannon, Small RNA sorting: matchmaking for Argonautes. Nat Rev 
Genet, 2010. 12(1): p. 19-31. 
116. Liu, X., K. Fortin, and Z. Mourelatos, MicroRNAs: biogenesis and molecular functions. Brain 
Pathol, 2008. 18(1): p. 113-21. 
117. Griffiths-Jones, S., et al., MicroRNA evolution by arm switching. EMBO Rep, 2011. 12(2): p. 
172-7. 
118. Su, H., et al., Essential and overlapping functions for mammalian Argonautes in microRNA 
silencing. Genes Dev, 2009. 23(3): p. 304-17. 
119. Grimson, A., et al., MicroRNA targeting specificity in mammals: determinants beyond seed 
pairing. Mol Cell, 2007. 27(1): p. 91-105. 
120. Chang, T.C. and J.T. Mendell, microRNAs in vertebrate physiology and human disease. 
Annu Rev Genomics Hum Genet, 2007. 8: p. 215-39. 
121. Guo, H., et al., Mammalian microRNAs predominantly act to decrease target mRNA levels. 
Nature, 2010. 466(7308): p. 835-40. 
122. Huntzinger, E. and E. Izaurralde, Gene silencing by microRNAs: contributions of 
translational repression and mRNA decay. Nat Rev Genet, 2011. 12(2): p. 99-110. 
123. Tang, R., et al., Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the 
posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell 
Res, 2012. 22(3): p. 504-15. 
124. Seitz, H., Redefining microRNA targets. Curr Biol, 2009. 19(10): p. 870-3. 
125. Salmena, L., et al., A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell, 
2011. 146(3): p. 353-8. 
126. Stark, A., et al., Identification of Drosophila MicroRNA targets. PLoS Biol, 2003. 1(3): p. E60. 
127. Ferretti, E., et al., Concerted microRNA control of Hedgehog signalling in cerebellar 
neuronal progenitor and tumour cells. Embo J, 2008. 27(19): p. 2616-27. 
128. Lewis, B.P., et al., Prediction of mammalian microRNA targets. Cell, 2003. 115(7): p. 787-
98. 
129. Lewis, B.P., C.B. Burge, and D.P. Bartel, Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005. 
120(1): p. 15-20. 
130. Friedman, R.C., et al., Most mammalian mRNAs are conserved targets of microRNAs. 
Genome Res, 2009. 19(1): p. 92-105. 
131. Lall, S., et al., A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol, 
2006. 16(5): p. 460-71. 
132. Kiriakidou, M., et al., A combined computational-experimental approach predicts human 
microRNA targets. Genes Dev, 2004. 18(10): p. 1165-78. 
133. John, B., et al., Human MicroRNA targets. PLoS Biol, 2004. 2(11): p. e363. 
240 
 
134. Hsu, S.D., et al., miRTarBase: a database curates experimentally validated microRNA-
target interactions. Nucleic Acids Res, 2011. 39(Database issue): p. D163-9. 
135. Bernstein, E., et al., Dicer is essential for mouse development. Nat Genet, 2003. 35(3): p. 
215-7. 
136. Harfe, B.D., et al., The RNaseIII enzyme Dicer is required for morphogenesis but not 
patterning of the vertebrate limb. Proc Natl Acad Sci U S A, 2005. 102(31): p. 10898-903. 
137. Kobayashi, T., et al., Dicer-dependent pathways regulate chondrocyte proliferation and 
differentiation. Proc Natl Acad Sci U S A, 2008. 105(6): p. 1949-54. 
138. Wienholds, E., et al., MicroRNA expression in zebrafish embryonic development. Science, 
2005. 309(5732): p. 310-1. 
139. Tuddenham, L., et al., The cartilage specific microRNA-140 targets histone deacetylase 4 in 
mouse cells. FEBS Lett, 2006. 580(17): p. 4214-7. 
140. Miyaki, S., et al., MicroRNA-140 is expressed in differentiated human articular 
chondrocytes and modulates interleukin-1 responses. Arthritis Rheum, 2009. 60(9): p. 
2723-30. 
141. Yang, J., et al., MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to 
target Sp1 in maintaining the chondrocyte proliferation. FEBS Lett, 2011. 585(19): p. 2992-
7. 
142. Miyaki, S., et al., MicroRNA-140 plays dual roles in both cartilage development and 
homeostasis. 2010. p. 1173-1185. 
143. Song, B., et al., Mechanism of chemoresistance mediated by miR-140 in human 
osteosarcoma and colon cancer cells. Oncogene, 2009. 28(46): p. 4065-74. 
144. Nicolas, F.E., et al., Experimental identification of microRNA-140 targets by silencing and 
overexpressing miR-140. Rna, 2008. 14(12): p. 2513-20. 
145. Butz, H., et al., MicroRNA profile indicates downregulation of the TGFbeta pathway in 
sporadic non-functioning pituitary adenomas. Pituitary, 2011. 14(2): p. 112-24. 
146. Nakamura, Y., et al., Chondrocyte-specific microRNA-140 regulates endochondral bone 
development and targets Dnpep to modulate bone morphogenetic protein signaling. Mol 
Cell Biol, 2011. 31(14): p. 3019-28. 
147. Ye, W., et al., The effect of central loops in miRNA:MRE duplexes on the efficiency of 
miRNA-mediated gene regulation. PLoS One, 2008. 3(3): p. e1719. 
148. Song, J., D. Kim, and E.J. Jin, MicroRNA-488 suppresses cell migration through modulation 
of the focal adhesion activity during chondrogenic differentiation of chick limb 
mesenchymal cells. Cell Biol Int, 2011. 35(2): p. 179-85. 
149. Kim, D., et al., MicroRNA-34a regulates migration of chondroblast and IL-1beta-induced 
degeneration of chondrocytes by targeting EphA5. Biochem Biophys Res Commun, 2011. 
415(4): p. 551-7. 
150. Yang, B., et al., MicroRNA-145 regulates chondrogenic differentiation of mesenchymal 
stem cells by targeting Sox9. PLoS One, 2011. 6(7): p. e21679. 
151. Guan, Y.J., et al., MiR-365: a mechanosensitive microRNA stimulates chondrocyte 
differentiation through targeting histone deacetylase 4. Faseb J, 2011. 25(12): p. 4457-66. 
152. Dudek, K.A., et al., Type II collagen expression is regulated by tissue-specific miR-675 in 
human articular chondrocytes. J Biol Chem, 2010. 285(32): p. 24381-7. 
153. Yan, C., et al., MicroRNA regulation associated chondrogenesis of mouse MSCs grown on 
polyhydroxyalkanoates. Biomaterials, 2011. 32(27): p. 6435-44. 
154. Sumiyoshi, K., et al., Identification of miR-1 as a micro RNA that supports late-stage 
differentiation of growth cartilage cells. Biochem Biophys Res Commun, 2010. 402(2): p. 
286-90. 
241 
 
155. Swingler, T.E., et al., The expression and function of microRNAs in chondrogenesis and 
osteoarthritis. Arthritis Rheum, 2012. 
156. Iliopoulos, D., et al., Integrative MicroRNA and Proteomic Approaches Identify Novel 
Osteoarthritis Genes and Their Collaborative Metabolic and Inflammatory Networks. PLoS 
ONE, 2008. 3(11): p. e3740. 
157. Jones, S.W., et al., The identification of differentially expressed microRNA in osteoarthritic 
tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage, 
2009. 17(4): p. 464-72. 
158. Abouheif, M.M., et al., Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat 
osteoarthritis model in vitro. Rheumatology (Oxford), 2010. 49(11): p. 2054-60. 
159. Akhtar, N., et al., MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in 
human osteoarthritis chondrocytes. Arthritis Rheum, 2010. 62(5): p. 1361-71. 
160. Liu, Y., et al., MicroRNAs modulate the Wnt signaling pathway through targeting its 
inhibitors. Biochem Biophys Res Commun, 2011. 408(2): p. 259-64. 
161. Davis, N., E. Mor, and R. Ashery-Padan, Roles for Dicer1 in the patterning and 
differentiation of the optic cup neuroepithelium. Development, 2011. 138(1): p. 127-38. 
162. Andl, T., et al., The miRNA-processing enzyme dicer is essential for the morphogenesis and 
maintenance of hair follicles. Curr Biol, 2006. 16(10): p. 1041-9. 
163. Harris, K.S., et al., Dicer function is essential for lung epithelium morphogenesis. Proc Natl 
Acad Sci U S A, 2006. 103(7): p. 2208-13. 
164. Watanabe, T., et al., Dnm3os, a non-coding RNA, is required for normal growth and 
skeletal development in mice. Dev Dyn, 2008. 237(12): p. 3738-48. 
165. Flynt, A.S., et al., Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell 
fate. Nat Genet, 2007. 39(2): p. 259-63. 
166. Lin, E.A., et al., miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates 
chondrogenesis via direct targeting to Smad1. J Biol Chem, 2009. 284(17): p. 11326-35. 
167. de Pontual, L., et al., Germline deletion of the miR-17 approximately 92 cluster causes 
skeletal and growth defects in humans. Nat Genet, 2011. 43(10): p. 1026-30. 
168. Thatcher, E.J., et al., MiRNA expression analysis during normal zebrafish development and 
following inhibition of the Hedgehog and Notch signaling pathways. Dev Dyn, 2007. 
236(8): p. 2172-80. 
169. Mott, J.L., et al., Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, 
hedgehog, and NF-kappaB. J Cell Biochem, 2010. 110(5): p. 1155-64. 
170. Radzikinas, K., et al., A Shh/miR-206/BDNF cascade coordinates innervation and formation 
of airway smooth muscle. J Neurosci, 2011. 31(43): p. 15407-15. 
171. Razumilava, N., et al., miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death 
receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology, 2012. 
55(2): p. 465-75. 
172. Friggi-Grelin, F., L. Lavenant-Staccini, and P. Therond, Control of antagonistic components 
of the hedgehog signaling pathway by microRNAs in Drosophila. Genetics, 2008. 179(1): p. 
429-39. 
173. Fareh, M., et al., The miR 302-367 cluster drastically affects self-renewal and infiltration 
properties of glioma-initiating cells through CXCR4 repression and consequent disruption of 
the SHH-GLI-NANOG network. Cell Death Differ, 2012. 19(2): p. 232-44. 
174. Hornstein, E., et al., The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb 
development. Nature, 2005. 438(7068): p. 671-4. 
175. Jopling, C.L., S. Schütz, and P. Sarnow, Position-Dependent Function for a Tandem 
MicroRNA miR-122-Binding Site Located in the Hepatitis C Virus RNA Genome. Cell Host & 
Microbe, 2008. 4(1): p. 77-85. 
242 
 
176. Lanford, R.E., et al., Therapeutic silencing of microRNA-122 in primates with chronic 
hepatitis C virus infection. Science, 2010. 327(5962): p. 198-201. 
177. Lanford, R.E., et al., Therapeutic Silencing of MicroRNA-122 in Primates with Chronic 
Hepatitis C Virus Infection. 2010. p. 198-201. 
178. Reznikoff, C.A., D.W. Brankow, and C. Heidelberger, Establishment and characterization of 
a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. 
Cancer Res, 1973. 33(12): p. 3231-8. 
179. Nakamura, T., et al., Induction of Osteogenic Differentiation by Hedgehog Proteins. 
Biochemical and Biophysical Research Communications, 1997. 237(2): p. 465-469. 
180. Denker, A.E., et al., Chondrogenic differentiation of murine C3H10T1/2 multipotential 
mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density 
micromass cultures. Differentiation, 1999. 64(2): p. 67-76. 
181. Zhang, Q., et al., Differential Toll-like receptor-dependent collagenase expression in 
chondrocytes. 2008. p. 1633-1641. 
182. Cox, J., et al., A practical guide to the MaxQuant computational platform for SILAC-based 
quantitative proteomics. Nat Protoc, 2009. 4(5): p. 698-705. 
183. Stanton, H., et al., ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in 
vitro. Nature, 2005. 434(7033): p. 648-52. 
184. Shigeru, M., et al., MicroRNA-140 is expressed in differentiated human articular 
chondrocytes and modulates interleukin-1 responses. 2009. p. 2723-2730. 
185. Abelson, J.F., et al., Sequence variants in SLITRK1 are associated with Tourette's syndrome. 
Science, 2005. 310(5746): p. 317-20. 
186. Clop, A., et al., A mutation creating a potential illegitimate microRNA target site in the 
myostatin gene affects muscularity in sheep. Nat Genet, 2006. 38(7): p. 813-8. 
187. Wang, G., et al., Variation in the miRNA-433 binding site of FGF20 confers risk for 
Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet, 2008. 82(2): p. 
283-9. 
188. Simon, D., et al., A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-
transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-
linked chondrodysplasia. Hum Mol Genet, 2010. 19(10): p. 2015-27. 
189. Gong, J., et al., Genome-wide identification of SNPs in microRNA genes and the SNP effects 
on microRNA target binding and biogenesis. Hum Mutat, 2012. 33(1): p. 254-63. 
190. Ling, L., et al., Single nucleotide polymorphism associated with nonsyndromic cleft palate 
influences the processing of miR-140. 2009. p. 856-862. 
191. Chen, K. and N. Rajewsky, Natural selection on human microRNA binding sites inferred 
from SNP data. Nat Genet, 2006. 38(12): p. 1452-6. 
192. Saunders, M.A., H. Liang, and W.H. Li, Human polymorphism at microRNAs and microRNA 
target sites. Proc Natl Acad Sci U S A, 2007. 104(9): p. 3300-5. 
193. Eberhart, J.K., et al., MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis. 
Nat Genet, 2008. 40(3): p. 290-8. 
194. Nakamura, Y., et al., Wwp2 is essential for palatogenesis mediated by the interaction 
between Sox9 and mediator subunit 25. Nat Commun, 2011. 2: p. 251. 
195. Forster, T., et al., Finer linkage mapping of primary osteoarthritis susceptibility loci on 
chromosomes 4 and 16 in families with affected women. Arthritis Rheum, 2004. 50(1): p. 
98-102. 
196. Xu, Y., et al., Identification of the pathogenic pathways in osteoarthritic hip cartilage: 
commonality and discord between hip and knee OA. Osteoarthritis Cartilage, 2012. 20(9): 
p. 1029-38. 
243 
 
197. Loughlin, J., et al., Functional variants within the secreted frizzled-related protein 3 gene 
are associated with hip osteoarthritis in females. Proc Natl Acad Sci U S A, 2004. 101(26): 
p. 9757-62. 
198. Li, L., et al., Biological and epidemiological evidence of interaction of infant genotypes at 
Rs7205289 and maternal passive smoking in cleft palate. Am J Med Genet A, 2011. 
155A(12): p. 2940-8. 
199. Li, L., et al., Single nucleotide polymorphism associated with nonsyndromic cleft palate 
influences the processing of miR-140. Am J Med Genet A, 2010. 152A(4): p. 856-62. 
200. Johnson, A.D., et al., SNAP: a web-based tool for identification and annotation of proxy 
SNPs using HapMap. Bioinformatics, 2008. 24(24): p. 2938-9. 
201. Mestdagh, P., et al., A novel and universal method for microRNA RT-qPCR data 
normalization. Genome Biol, 2009. 10(6): p. R64. 
202. Lagos-Quintana, M., et al., Identification of tissue-specific microRNAs from mouse. Curr 
Biol, 2002. 12(9): p. 735-9. 
203. Landgraf, P., et al., A mammalian microRNA expression atlas based on small RNA library 
sequencing. Cell, 2007. 129(7): p. 1401-14. 
204. Weber, M.J., New human and mouse microRNA genes found by homology search. Febs J, 
2005. 272(1): p. 59-73. 
205. Cai, X., et al., Kaposi's sarcoma-associated herpesvirus expresses an array of viral 
microRNAs in latently infected cells. Proc Natl Acad Sci U S A, 2005. 102(15): p. 5570-5. 
206. Kim, J., et al., Identification of many microRNAs that copurify with polyribosomes in 
mammalian neurons. Proc Natl Acad Sci U S A, 2004. 101(1): p. 360-5. 
207. Poy, M.N., et al., A pancreatic islet-specific microRNA regulates insulin secretion. Nature, 
2004. 432(7014): p. 226-30. 
208. Ahn, H.W., et al., MicroRNA transcriptome in the newborn mouse ovaries determined by 
massive parallel sequencing. Mol Hum Reprod, 2010. 16(7): p. 463-71. 
209. Chiang, H.R., et al., Mammalian microRNAs: experimental evaluation of novel and 
previously annotated genes. Genes Dev, 2010. 24(10): p. 992-1009. 
210. Sievers, F., et al., Fast, scalable generation of high-quality protein multiple sequence 
alignments using Clustal Omega. Mol Syst Biol, 2011. 7: p. 539. 
211. Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009. 4(1): p. 44-57. 
212. Vortkamp, A., et al., Regulation of rate of cartilage differentiation by Indian hedgehog and 
PTH-related protein. Science, 1996. 273(5275): p. 613-22. 
213. Nakamura, T., et al., Induction of osteogenic differentiation by hedgehog proteins. 
Biochem Biophys Res Commun, 1997. 237(2): p. 465-9. 
214. Kinto, N., et al., Fibroblasts expressing Sonic hedgehog induce osteoblast differentiation 
and ectopic bone formation. FEBS Lett, 1997. 404(2-3): p. 319-23. 
215. Shea, C.M., et al., BMP treatment of C3H10T1/2 mesenchymal stem cells induces both 
chondrogenesis and osteogenesis. J Cell Biochem, 2003. 90(6): p. 1112-27. 
216. Wu, X., et al., Purmorphamine induces osteogenesis by activation of the hedgehog 
signaling pathway. Chem Biol, 2004. 11(9): p. 1229-38. 
217. Kevorkian, L., et al., Expression profiling of metalloproteinases and their inhibitors in 
cartilage. Arthritis Rheum, 2004. 50(1): p. 131-41. 
218. Saetrom, P., et al., Distance constraints between microRNA target sites dictate efficacy and 
cooperativity. Nucleic Acids Res, 2007. 35(7): p. 2333-42. 
219. Hon, L.S. and Z. Zhang, The roles of binding site arrangement and combinatorial targeting 
in microRNA repression of gene expression. Genome Biol, 2007. 8(8): p. R166. 
244 
 
220. Matsukawa, T., et al., MicroRNA-125b regulates the expression of aggrecanase-1 
(ADAMTS-4) in human osteoarthritic chondrocytes. Arthritis Res Ther, 2013. 15(1): p. R28. 
221. Xu, N., et al., MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits 
cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol 
Chem, 2012. 287(35): p. 29899-908. 
222. Stecca, B. and I.A.A. Ruiz, Context-dependent regulation of the GLI code in cancer by 
HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol, 2010. 2(2): p. 84-95. 
223. Boissart, C., et al., miR-125 potentiates early neural specification of human embryonic 
stem cells. Development, 2012. 139(7): p. 1247-57. 
224. Vinther, J., et al., Identification of miRNA targets with stable isotope labeling by amino 
acids in cell culture. Nucleic Acids Res, 2006. 34(16): p. e107. 
225. Lim, L.P., et al., Microarray analysis shows that some microRNAs downregulate large 
numbers of target mRNAs. Nature, 2005. 433(7027): p. 769-73. 
226. Baigude, H., et al., miR-TRAP: a benchtop chemical biology strategy to identify microRNA 
targets. Angew Chem Int Ed Engl, 2012. 51(24): p. 5880-3. 
227. Yoon, J.H., S. Srikantan, and M. Gorospe, MS2-TRAP (MS2-tagged RNA affinity 
purification): tagging RNA to identify associated miRNAs. Methods, 2012. 58(2): p. 81-7. 
228. Krutzfeldt, J., et al., Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005. 
438(7068): p. 685-9. 
229. Xu, G., et al., Transcriptome and targetome analysis in MIR155 expressing cells using RNA-
seq. Rna, 2010. 16(8): p. 1610-22. 
230. Selbach, M., et al., Widespread changes in protein synthesis induced by microRNAs. 
Nature, 2008. 455(7209): p. 58-63. 
231. Jacobson, E.L., et al., Effect of nicotinamide analogues on recovery from DNA damage in 
C3H10T1/2 cells. Cancer Res, 1984. 44(6): p. 2485-92. 
232. Kaller, M., et al., Genome-wide characterization of miR-34a induced changes in protein and 
mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell 
Proteomics, 2011. 10(8): p. M111 010462. 
233. Baek, D., et al., The impact of microRNAs on protein output. Nature, 2008. 455(7209): p. 
64-71. 
234. Geiger, T., et al., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat 
Methods, 2010. 7(5): p. 383-5. 
235. Zanivan, S., M. Krueger, and M. Mann, In vivo quantitative proteomics: the SILAC mouse. 
Methods Mol Biol, 2012. 757: p. 435-50. 
236. Ingolia, N.T., et al., Genome-wide analysis in vivo of translation with nucleotide resolution 
using ribosome profiling. Science, 2009. 324(5924): p. 218-23. 
237. Landthaler, M., et al., Molecular characterization of human Argonaute-containing 
ribonucleoprotein complexes and their bound target mRNAs. Rna, 2008. 14(12): p. 2580-
96. 
238. Orom, U.A. and A.H. Lund, Experimental identification of microRNA targets. Gene, 2011. 
451(1-2): p. 1-5. 
239. Hsu, R.J., H.J. Yang, and H.J. Tsai, Labeled microRNA pull-down assay system: an 
experimental approach for high-throughput identification of microRNA-target mRNAs. 
Nucleic Acids Res, 2009. 37(10): p. e77. 
240. Beitzinger, M., et al., Identification of human microRNA targets from isolated argonaute 
protein complexes. RNA Biol, 2007. 4(2): p. 76-84. 
241. Tan, L.P., et al., A high throughput experimental approach to identify miRNA targets in 
human cells. Nucleic Acids Res, 2009. 37(20): p. e137. 
245 
 
242. Chi, S.W., et al., Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature, 
2009. 460(7254): p. 479-86. 
243. Hafner, M., et al., Transcriptome-wide identification of RNA-binding protein and microRNA 
target sites by PAR-CLIP. Cell, 2010. 141(1): p. 129-41. 
244. Alexiou, P., et al., Lost in translation: an assessment and perspective for computational 
microRNA target identification. Bioinformatics, 2009. 25(23): p. 3049-55. 
245. Xiao, Y., et al., Prioritizing cancer-related key miRNA-target interactions by integrative 
genomics. Nucleic Acids Res, 2012. 40(16): p. 7653-65. 
246. Capurro, M.I., et al., Glypican-3 Inhibits Hedgehog Signaling during Development by 
Competing with Patched for Hedgehog Binding. Developmental Cell, 2008. 14(5): p. 700-
711. 
247. Li, F., et al., Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating 
Hedgehog signaling. 2011. p. 691-704. 
248. Djuranovic, S., A. Nahvi, and R. Green, miRNA-mediated gene silencing by translational 
repression followed by mRNA deadenylation and decay. Science, 2012. 336(6078): p. 237-
40. 
249. Bazzini, A.A., M.T. Lee, and A.J. Giraldez, Ribosome profiling shows that miR-430 reduces 
translation before causing mRNA decay in zebrafish. Science, 2012. 336(6078): p. 233-7. 
250. Desbordes, S.C. and B. Sanson, The glypican Dally-like is required for Hedgehog signalling 
in the embryonic epidermis of Drosophila. Development, 2003. 130(25): p. 6245-55. 
251. Han, C., et al., Drosophila glypicans control the cell-to-cell movement of Hedgehog by a 
dynamin-independent process. Development, 2004. 131(3): p. 601-11. 
252. Gallet, A., L. Staccini-Lavenant, and P.P. Therond, Cellular trafficking of the glypican Dally-
like is required for full-strength Hedgehog signaling and wingless transcytosis. Dev Cell, 
2008. 14(5): p. 712-25. 
253. Yan, D., et al., The cell-surface proteins Dally-like and Ihog differentially regulate Hedgehog 
signaling strength and range during development. Development, 2010. 137(12): p. 2033-
44. 
254. Wang, Y., et al., Mechanism of microRNA-target interaction: molecular dynamics 
simulations and thermodynamics analysis. PLoS Comput Biol, 2010. 6(7): p. e1000866. 
255. Jalvy-Delvaille, S., et al., Molecular basis of differential target regulation by miR-96 and 
miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65. 
256. Hu, H.Y., et al., Evolution of the human-specific microRNA miR-941. Nat Commun, 2012. 3: 
p. 1145. 
257. Kedde, M., et al., RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell, 
2007. 131(7): p. 1273-86. 
258. Rajewsky, N., microRNA target predictions in animals. Nat Genet, 2006. 38 Suppl: p. S8-13. 
259. Bethune, J., C.G. Artus-Revel, and W. Filipowicz, Kinetic analysis reveals successive steps 
leading to miRNA-mediated silencing in mammalian cells. EMBO Rep, 2012. 13(8): p. 716-
23. 
260. Staton, A.A. and A.J. Giraldez, Use of target protector morpholinos to analyze the 
physiological roles of specific miRNA-mRNA pairs in vivo. Nat Protoc, 2011. 6(12): p. 2035-
49. 
261. Place, R.F., et al., MicroRNA-373 induces expression of genes with complementary 
promoter sequences. Proc Natl Acad Sci U S A, 2008. 105(5): p. 1608-13. 
262. Lehmann, S.M., et al., An unconventional role for miRNA: let-7 activates Toll-like receptor 7 
and causes neurodegeneration. Nat Neurosci, 2012. 15(6): p. 827-35. 
263. Fabbri, M., et al., MicroRNAs bind to Toll-like receptors to induce prometastatic 
inflammatory response. Proc Natl Acad Sci U S A, 2012. 109(31): p. E2110-6. 
246 
 
264. Yaddanapudi, K., et al., Toll-like receptor 3 regulates neural stem cell proliferation by 
modulating the Sonic Hedgehog pathway. PLoS One, 2011. 6(10): p. e26766. 
265. Filmus, J., M. Capurro, and J. Rast, Glypicans. Genome Biol, 2008. 9(5): p. 224. 
266. Traister, A., W. Shi, and J. Filmus, Mammalian Notum induces the release of glypicans and 
other GPI-anchored proteins from the cell surface. Biochem J, 2008. 410(3): p. 503-11. 
267. Rogers, K.W. and A.F. Schier, Morphogen gradients: from generation to interpretation. 
Annu Rev Cell Dev Biol. 27: p. 377-407. 
268. McCarthy, R.A., et al., Megalin functions as an endocytic sonic hedgehog receptor. J Biol 
Chem, 2002. 277(28): p. 25660-7. 
269. Gritli-Linde, A., et al., The whereabouts of a morphogen: direct evidence for short- and 
graded long-range activity of hedgehog signaling peptides. Dev Biol, 2001. 236(2): p. 364-
86. 
270. The, I., Y. Bellaiche, and N. Perrimon, Hedgehog movement is regulated through tout velu-
dependent synthesis of a heparan sulfate proteoglycan. Mol Cell, 1999. 4(4): p. 633-9. 
271. Lum, L., et al., Identification of Hedgehog pathway components by RNAi in Drosophila 
cultured cells. Science, 2003. 299(5615): p. 2039-45. 
272. Yan, D., et al., The cell-surface proteins Dally-like and Ihog differentially regulate Hedgehog 
signaling strength and range during development. Development. 137(12): p. 2033-44. 
273. Torroja, C., N. Gorfinkiel, and I. Guerrero, Patched controls the Hedgehog gradient by 
endocytosis in a dynamin-dependent manner, but this internalization does not play a major 
role in signal transduction. Development, 2004. 131(10): p. 2395-408. 
274. Cui, S., et al., Evidence from Human and Zebrafish that GPC1 is a Biliary Atresia 
Susceptibility Gene. Gastroenterology, 2013. 
275. Bergeron, S.A., et al., Expression profiling identifies novel Hh/Gli-regulated genes in 
developing zebrafish embryos. Genomics, 2008. 91(2): p. 165-77. 
276. Lin, X., Functions of heparan sulfate proteoglycans in cell signaling during development. 
Development, 2004. 131(24): p. 6009-21. 
277. Keller, K.M., P.R. Brauer, and J.M. Keller, Modulation of cell surface heparan sulfate 
structure by growth of cells in the presence of chlorate. Biochemistry, 1989. 28(20): p. 
8100-7. 
278. Leong, J.M., et al., Hemagglutination and proteoglycan binding by the Lyme disease 
spirochete, Borrelia burgdorferi. Infect Immun, 1995. 63(3): p. 874-83. 
279. Ayers, K.L., et al., Dally and Notum regulate the switch between low and high level 
Hedgehog pathway signalling. Development, 2012. 139(17): p. 3168-79. 
280. Capurro, M.I., et al., Glypican-3 promotes the growth of hepatocellular carcinoma by 
stimulating canonical Wnt signaling. Cancer Res, 2005. 65(14): p. 6245-54. 
281. Ogden, S.K., et al., Regulation of Hedgehog signaling: a complex story. Biochem 
Pharmacol, 2004. 67(5): p. 805-14. 
282. Gao, C. and Y.G. Chen, Dishevelled: The hub of Wnt signaling. Cell Signal, 2010. 22(5): p. 
717-27. 
283. Nakamura, Y., et al., Unique roles of microRNA140 and its host gene WWP2 in cartilage 
biology. J Musculoskelet Neuronal Interact, 2008. 8(4): p. 321-2. 
284. Fischer, L., G. Boland, and R.S. Tuan, Wnt-3A enhances bone morphogenetic protein-2-
mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells. J Biol Chem, 2002. 
277(34): p. 30870-8. 
285. Anton, R., et al., A systematic screen for micro-RNAs regulating the canonical Wnt 
pathway. PLoS One, 2011. 6(10): p. e26257. 
286. Baeg, G.H., et al., Heparan sulfate proteoglycans are critical for the organization of the 
extracellular distribution of Wingless. Development, 2001. 128(1): p. 87-94. 
247 
 
287. Li, G., et al., MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by 
directly targeting WNT2B. Eur J Cancer, 2013. 
288. van der Kraan, P.M., et al., TGF-beta signaling in chondrocyte terminal differentiation and 
osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. 
Osteoarthritis Cartilage, 2009. 17(12): p. 1539-45. 
289. Blaney Davidson, E.N., et al., Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 
expression in osteoarthritis in humans and mice. J Immunol, 2009. 182(12): p. 7937-45. 
290. Kim, J., et al., Functional genomic screen for modulators of ciliogenesis and cilium length. 
Nature, 2010. 464(7291): p. 1048-51. 
291. Blain, E.J., Involvement of the cytoskeletal elements in articular cartilage homeostasis and 
pathology. Int J Exp Pathol, 2009. 90(1): p. 1-15. 
292. Hayami, T., et al., Expression of the cartilage derived anti-angiogenic factor 
chondromodulin-I decreases in the early stage of experimental osteoarthritis. J Rheumatol, 
2003. 30(10): p. 2207-17. 
293. Suri, S. and D.A. Walsh, Osteochondral alterations in osteoarthritis. Bone, 2012. 51(2): p. 
204-11. 
294. Salim, H., et al., miRNA-214 modulates radiotherapy response of non-small cell lung cancer 
cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer, 2012. 107(8): 
p. 1361-73. 
295. Patel, N., microRNA mediated regulation of APP gene expression. 2010, Drexel University. 
296. Hooper, N.M., Glypican-1 facilitates prion conversion in lipid rafts. J Neurochem, 2011. 
116(5): p. 721-5. 
297. Su, G., et al., Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 
signaling in glioma cells. Am J Pathol, 2006. 168(6): p. 2014-26. 
298. Stappert, L., et al., MicroRNA-Based Promotion of Human Neuronal Differentiation and 
Subtype Specification. PLoS One, 2013. 8(3): p. e59011. 
299. Zhu, M., et al., Activation of beta-catenin signaling in articular chondrocytes leads to 
osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone 
Miner Res, 2009. 24(1): p. 12-21. 
300. Zhu, M., et al., Inhibition of beta-catenin signaling in articular chondrocytes results in 
articular cartilage destruction. Arthritis Rheum, 2008. 58(7): p. 2053-64. 
301. Chen, M., et al., Inhibition of beta-catenin signaling causes defects in postnatal cartilage 
development. J Cell Sci, 2008. 121(Pt 9): p. 1455-65. 
302. Peterson, R. and J. Turnbull, Sonic hedgehog is cytoprotective against oxidative challenge 
in a cellular model of amyotrophic lateral sclerosis. J Mol Neurosci, 2012. 47(1): p. 31-41. 
303. Jin, L., et al., MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic 
regulator in human melanoma. Proc Natl Acad Sci U S A, 2011. 108(38): p. 15840-5. 
304. Meng, X., et al., Suppressor of fused negatively regulates beta-catenin signaling. J Biol 
Chem, 2001. 276(43): p. 40113-9. 
305. Price, M.A. and D. Kalderon, Proteolysis of the Hedgehog signaling effector Cubitus 
interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. 
Cell, 2002. 108(6): p. 823-35. 
306. Pallerla, S.R., et al., Heparan sulfate Ndst1 gene function variably regulates multiple 
signaling pathways during mouse development. Dev Dyn, 2007. 236(2): p. 556-63. 
307. Eugster, C., et al., Lipoprotein-heparan sulfate interactions in the Hh pathway. Dev Cell, 
2007. 13(1): p. 57-71. 
308. Glise, B., et al., Shifted, the Drosophila ortholog of Wnt inhibitory factor-1, controls the 
distribution and movement of Hedgehog. Dev Cell, 2005. 8(2): p. 255-66. 
248 
 
309. McLellan, J.S., et al., Structure of a heparin-dependent complex of Hedgehog and Ihog. 
Proc Natl Acad Sci U S A, 2006. 103(46): p. 17208-13. 
310. Serpe, M., et al., The BMP-binding protein Crossveinless 2 is a short-range, concentration-
dependent, biphasic modulator of BMP signaling in Drosophila. Dev Cell, 2008. 14(6): p. 
940-53. 
311. Chang, S.C., et al., Two distinct sites in sonic Hedgehog combine for heparan sulfate 
interactions and cell signaling functions. J Biol Chem, 2011. 286(52): p. 44391-402. 
312. Chan, J.A., et al., Proteoglycan interactions with Sonic Hedgehog specify mitogenic 
responses. Nat Neurosci, 2009. 12(4): p. 409-17. 
313. Cortes, M., A.T. Baria, and N.B. Schwartz, Sulfation of chondroitin sulfate proteoglycans is 
necessary for proper Indian hedgehog signaling in the developing growth plate. 
Development, 2009. 136(10): p. 1697-706. 
314. Uziel, T., et al., The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in 
medulloblastoma. Proc Natl Acad Sci U S A, 2009. 106(8): p. 2812-7. 
315. Ventura, A., et al., Targeted deletion reveals essential and overlapping functions of the 
miR-17 through 92 family of miRNA clusters. Cell, 2008. 132(5): p. 875-86. 
316. Mendell, J.T., miRiad roles for the miR-17-92 cluster in development and disease. Cell, 
2008. 133(2): p. 217-22. 
317. Guo, L., et al., Dynamic evolution of mir-17-92 gene cluster and related miRNA gene 
families in vertebrates. Mol Biol Rep, 2013. 40(4): p. 3147-53. 
318. Wang, C.L., et al., Activation of an oncogenic microRNA cistron by provirus integration. 
Proc Natl Acad Sci U S A, 2006. 103(49): p. 18680-4. 
319. Dell'Accio, F., C. De Bari, and F.P. Luyten, Molecular markers predictive of the capacity of 
expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis Rheum, 
2001. 44(7): p. 1608-19. 
320. Wei, F., et al., Activation of Indian hedgehog promotes chondrocyte hypertrophy and 
upregulation of MMP-13 in human osteoarthritic cartilage. Osteoarthritis Cartilage. 20(7): 
p. 755-63. 
321. Taschner, M.J., et al., Ca2+/Calmodulin-dependent kinase II signaling causes skeletal 
overgrowth and premature chondrocyte maturation. Dev Biol, 2008. 317(1): p. 132-46. 
322. Koziel, L., et al., Ext1-dependent heparan sulfate regulates the range of Ihh signaling 
during endochondral ossification. Dev Cell, 2004. 6(6): p. 801-13. 
323. Pilia, G., et al., Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel 
overgrowth syndrome. Nat Genet, 1996. 12(3): p. 241-7. 
324. Milenkovic, L., et al., Mouse patched1 controls body size determination and limb 
patterning. Development, 1999. 126(20): p. 4431-40. 
325. Cook, A., et al., Genetic heterogeneity in families with hereditary multiple exostoses. Am J 
Hum Genet, 1993. 53(1): p. 71-9. 
326. Ahn, J., et al., Cloning of the putative tumour suppressor gene for hereditary multiple 
exostoses (EXT1). Nat Genet, 1995. 11(2): p. 137-43. 
327. Wu, Y.Q., et al., Assignment of a second locus for multiple exostoses to the pericentromeric 
region of chromosome 11. Hum Mol Genet, 1994. 3(1): p. 167-71. 
328. Stickens, D., et al., The EXT2 multiple exostoses gene defines a family of putative tumour 
suppressor genes. Nat Genet, 1996. 14(1): p. 25-32. 
329. Echtermeyer, F., et al., Syndecan-4 regulates ADAMTS-5 activation and cartilage 
breakdown in osteoarthritis. Nat Med, 2009. 15(9): p. 1072-6. 
330. Bertrand, J., et al., Syndecan 4 supports bone fracture repair, but not fetal skeletal 
development, in mice. Arthritis Rheum, 2013. 65(3): p. 743-52. 
249 
 
331. Syrrou, M., et al., Glypican 1 gene: good candidate for brachydactyly type E. Am J Med 
Genet, 2002. 108(4): p. 310-4. 
332. Litwack, E.D., et al., Expression of the heparan sulfate proteoglycan glypican-1 in the 
developing rodent. Dev Dyn, 1998. 211(1): p. 72-87. 
 
  
